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ABSTRACT 
Chronic liver infection by hepatitis B virus (HBV) may lead to devastating clinical 
conditions that include hepatocellular carcinoma and cirrhosis. Approved antiHBV drugs 
do not completely eradicate the infection, leading to continued viral persistence in infected 
individuals. Inhibition of HBV replication using synthetic activators of RNA interference 
(RNAi) may provide a feasible strategy of developing superior antiviral drugs. The aim of 
this study was to evaluate the therapeutic utility of novel 2’-O-guanidinopropyl (GP) 
modified synthetic small interfering RNAs (siRNAs) to counter HBV replication in 
cultured mammalian cells and mice. Initially, single GP moieties were placed at different 
nucleotide positions of the guide strand of a potent antiHBV siRNA. Some GP-modified 
siRNAs enhanced antiHBV activity in vitro following transient transfection of Human 
hepatoma 7 (Huh7) cells with siRNAs and pCH-9/3091, a replication competent HBV 
target plasmid. These siRNAs inhibited the secretion of Hepatitis B surface antigen 
(HBsAg) by up to 95% in Huh7 cells. The level of knockdown exhibited by some modified 
siRNAs was statistically significant relative to that displayed by unmodified siRNA3 
which achieved HBsAg silencing of 73%. Additionally, modified siRNAs were also 
capable of reducing RNA containing the X sequence in vitro by 88-93%. Impressively, 
some of these knockdown levels were statistically significant when compared to 
unmodified siRNA3, which achieved HBx knockdown of 83%. Quantitation of interferon 
(IFN) response genes by reverse transcription quantitative polymerase chain reaction (RT-
qPCR) and evaluation of cell viability by 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay revealed no evidence of innate immune 
stimulation or cytotoxicity in cultured cells, respectively. 
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Modified siRNAs also displayed moderate stability in 80% foetal calf serum (FCS). Target 
specificity was markedly improved by GP-modified siRNAs, especially those with seed 
modifications (comprising nucleotide position 2 to 8 from the 5’ end of the guide strand). 
The siRNA-mediated mRNA cleavage product was detected from transfected cells using 5’ 
Rapid Amplification of cDNA ends (5’ RACE).  
 
In the hydrodynamic mouse model, co-injection of GP-modified siRNAs and HBV 
plasmid vector led to HBsAg suppression of approximately 80-92% at day 3 and 77-96% 
at day 5 post-administration. The HBV knockdown levels observed at day 3 were 
statistically significant when compared to those displayed by unmodified siRNA3 which 
achieved HBsAg silencing of 58% during the same time frame. Furthermore, both sets of 
siRNAs also suppressed the number of circulating viral particle equivalents (VPEs) by 88-
90% at day 3 post-injection. HBV silencing efficacy of 70-75% and 65% was achieved by 
modified and unmodified siRNAs, respectively at day 5 post-administration.   
 
Finally, antiHBV efficacy of GP-modified siRNAs was tested in HBV transgenic mice 
following delivery of these RNAi effectors using cationic polyglutamate (PG) adjuvant 
liposomes. Both groups of antiHBV siRNAs effected HBsAg knockdown that ranged from 
70-86% at day 3 to 7 post-administration as siRNA lipoplexes in HBV transgenic mice. In 
contrast to the unmodified siRNA3, GP-containing siRNAs achieved durable HBsAg 
silencing of 70% at day 14 post-administration, while the unmodified siRNA3 displayed a 
shorter duration of activity. As with HBsAg data, the GP-modified siRNAs also displayed 
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silencing efficacy that was similar to the unmodified siRNA, reducing the number of 
circulating VPEs by 95% from day 3 to 7 post-injection. However, the unmodified siRNA3 
lost efficacy by day 14 post-administration, while the GP-modified siRNAs displayed 
prolonged suppression by reducing the number of circulating VPEs by 75% during the 
same time interval. Intrahepatic RNA levels were also assessed in transgenic mice, in 
which GP3 siRNA3 significantly suppressed surface and core RNA levels by 40 and 42%, 
respectively at day 18 post-injection. The unmodified siRNA3 suppressed surface RNA 
levels by 20% and core RNA levels by 25% at day 21 post-administration. Furthermore, 
GP4 siRNA3 silenced both surface and core RNA levels by 42% during the same time 
period. Additionally, intrahepatic RNA quantitation revealed no induction of IFN response 
genes by either unmodified or GP-modified siRNAs. In contrast to mice that had received 
GP-modified siRNAs, significant induction of proinflammatory cytokine release was 
observed in mice treated with unmodified siRNAs. The siRNA-mediated mRNA cleavage 
product was also detected from liver samples following 5’ RACE analysis. Neither GP-
modified nor unmodified siRNAs significantly induced toxicity in injected mice. 
Collectively, our data provide evidence that utilisation of GP-modified siRNAs and an 
efficient hepatotropic non-viral delivery system may be used as a strategy to counter 
chronic HBV infection. 
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Chapter 1: Introduction and literature review 
1.1. Hepatitis B virus prevalence, transmission and geographical 
distribution 
Hepatitis B virus (HBV) is a member of the viral family called Hepadnaviridae [1]. This 
family consists of partially double-stranded DNA viruses capable of infecting the liver of 
humans [2-4], woodchucks [5], woolly monkeys [6, 7], ducks [8], herons [9] and other 
animals. Specifically, members of this family infect the liver resulting in chronic or acute 
liver infection. A patient’s acute or chronic HBV state depends mainly on HBV virulence 
factors and host immune competence [10-14]. Approximately 240 million people 
worldwide are infected with chronic HBV and a large number of these individuals die 
annually due to liver complications (http://www.who.int/mediacentre/factsheets/fs204/en/). 
In most adults, acute HBV infection does not usually require treatment as the infection is 
cleared spontaneously [15]. However, individuals who acquire infection at a young age 
have a greater risk of developing devastating liver complications [16, 17]. These include 
hepatocellular carcinoma (HCC) and cirrhosis [18, 19] and the majority of chronically 
infected individuals are located in East Asia and sub-Saharan Africa 
(http://www.who.int/mediacentre/factsheets/fs204/en/). 
 
In Black Africans, the asymptomatic stage is established during the early years of life [20] 
and rarely persists until adulthood. As a result, an estimated 1-14% of the adult population 
remain positive for Hepatitis B e antigen (HBeAg), an indicator of active HBV replication 
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in infected individuals. Conversely, about 40% of the Chinese population remain HBeAg-
positive during early adulthood [21]. The asymptomatic phase is characterised by absence 
or low detection of markers of HBV replication and acute inflammation [22]. An increase 
in the levels of liver enzymes such as alanine aminotransferase (ALT) [22, 23] and 
aspartate transaminase (AST) [22] may be observed from the necrotic hepatocytes. The 
virus may be spread from mother to child from about 28 weeks of gestation up to 7 days 
after birth (perinatal transmission) [24], contact with an infected individual (horizontal 
transmission) [25], exposure to contaminated blood products or infected fluids (parenteral 
transmission) [26] or by sexual contact [27]. A patient is described as having chronic HBV 
infection when hepatitis B surface antigen (HBsAg, an indicator of recent HBV infection) 
remains detectable in the serum for more than six months. 
 
To date, ten genotypes of HBV have been described. Global distribution of these 
genotypes is as follows: genotype A is mainly found in central, eastern and southern Africa 
(reviewed in [28]), genotypes B and C are dominant in Asia [29],  D is common in 
northern Africa, E is widespread in western Africa [29], F is the dominant genotype in 
Alaska, El Salvador and parts of South America (reviewed in [30]), G is widespread in 
France, Germany and the United States  [29], H dominates central and South America, I 
has been commonly identified in Laos and Vietnam, while J has been reported in  the 
Ryukyu islands in Japan [29]. Furthermore, subgenotypes have been identified within 
genotypes A-D, F and I. Coinfections also exist in countries where two different HBV 
genotypes are prevalent (reviewed in [28]). In countries like Cameroon and Nigeria 
coinfection with genotypes A and E have been observed in HIV positive patients [31]. 
Chapter 1 
 
3 
 
Sequence analysis of African genotype A strains revealed that many isolates in this group 
belong to subgenotype A1 (reviewed in [28]). This HBV subgenotype is prevalent in 
eastern and southern Africa and includes countries such as Somalia, Tanzania, Democratic 
Republic of Congo, Uganda, Malawi and South Africa (reviewed in [28]). 
 
1.2. Biology and replication of HBV 
HBV consists of a circular, partially double-stranded DNA genome [32] (Fig. 1.1) and 
replicates in the liver to cause hepatitis B infection [33]. HBV has a compact genome that 
is composed of a relaxed circular DNA (rcDNA). This rcDNA is produced following 
reverse transcription of a pre-genomic RNA (pgRNA) replication intermediate [34-36]. In 
infected hepatocytes, the rcDNA is repaired to produce covalently closed circular DNA 
(cccDNA). The cccDNA is important for the transcription of viral RNAs, production of 
pgRNA and is also essential for HBV replication and persistence [32, 37].  
 
The genome of HBV has four overlapping open reading frames (ORFs) namely 
precore/core, surface (composed of pre-S2, pre-S1 and S), polymerase (Pol) and hepatitis 
B x (HBx) [32].  The four RNAs code for seven viral proteins: polymerase, core, Hepatitis 
B core antigen (HBcAg), HBx and three surface (pre-S1, preS-2 and S) proteins. Viral 
gene expression is controlled by four separate promoters: the basic core promoter (BCP), 
pre-S1, pre-S2 and X promoters (Fig. 1.1). In addition to the four promoters, transcription 
is also controlled by three cis-elements, namely: the negative regulatory element, Enhancer 
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I and Enhancer II elements. The negative regulatory element is situated upstream of the 
BCP and serves as an antagonist of BCP function [38]. Enhancer I domain is situated 
between the X promoter region and S ORF and is involved in recruiting liver-specific 
transcription factors [39, 40]. Enhancer II overlaps the BCP region and functions in 
conjunction with the Enhancer I domain to activate transcription in differentiated liver cells 
[41].  
 
The pgRNA codes for core and polymerase. The pre C RNA has the same nucleotide 
sequence as the pgRNA, but its 5’ end is longer compared to pgRNA [42, 43] and codes 
for precore/core protein. The precore/core gene codes for HBeAg [44]. The HBcAg is 
produced by liver cells following HBV infection [45]. The upstream start codon of pre C 
sequence results in the incorporation of a secretory signal peptide in the synthesised 
protein. This secreted HBeAg has a different processing mechanism to that of the HBcAg, 
which remains in the cytoplasm and forms the viral capsid [46, 47]. Additionally, both 
these viral antigens are transcribed from the same ORF. The X and Pol genes code for HBx 
and polymerase proteins, respectively. The X protein has been shown to act as a 
transactivator [48] and is also thought to be involved in cell proliferation [49] and HBV 
replication in liver cells [49, 50]. The surface ORF comprises pre-S1 and pre-S2 genes. 
pre-S1 codes for the large surface protein, while pre-S2 codes for the middle and major 
surface proteins [51]. Collectively, these surface proteins are crucial in the generation of 
new viral envelopes which protect the nucleocapsid.  
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Figure 1.1. Genome organisation of HBV 
HBV consists of a circular, partially double-stranded DNA genome. In infected 
hepatocytes, the rcDNA is produced following reverse transcription of pgRNA, shown in 
the middle of the circular genome map. The four viral RNAs are depicted by outermost 
arrows, and code for polymerase, core, HBx, HBcAg and surface proteins. The inner 
arrows represent ORFs; position of regulatory elements is depicted by rectangles, while 
circles indicate location of promoters within the viral genome. This diagram has been 
adapted from Moolla et al., 2002 [52].  
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Although HBV mRNAs are transcribed from different ORFs, they share a single 
polyadenylation signal situated downstream of the BCP. New infections are as a result of 
transmission of viral particles that contain the rcDNA. Translation of viral mRNA occurs 
in the ribosomes to produce precore/core, core, S, Pol and X proteins (Fig. 1.2). The 
pgRNA is encapsidated into the nucleocapsid and the rcDNA is formed within the viral 
capsids. Subsequently, each capsid is surrounded by an envelope with large, middle and 
major surface proteins. The large surface protein has been shown to be essential for 
receptor binding and production of infectious HBV particles. As a result, liver-specificity 
of HBV is conferred by the large surface protein [53-56].  
 
Viral entry into host cells is facilitated by attachment of glycosaminoglycan residues of the 
heparan sulfate proteoglycans to the pre-S region of HBV [57] (Fig. 1.2). The receptor 
responsible for HBV interaction remained elusive for a long period of time. Recent 
advancements led to the discovery of a receptor responsible for HBV infection [58, 59]. It 
has been demonstrated and confirmed that sodium taurocholate cotransporting polypeptide 
(NTCP) is responsible for viral entry into host hepatocytes [58, 59] by interacting with the 
pre-S1 surface protein of HBV [58]. The entry step is followed by internalisation of the 
capsid which may occur via clathrin-mediated endocytosis [60, 61]. In the cytoplasm, the 
mature capsid containing the rcDNA associates with nucleoporin 153 protein located in the 
nuclear membrane [62].  
 
The association between the mature capsid and nucleoporin 153 promotes capsid 
dissociation and facilitates transport of the rcDNA to the nucleus. The pgRNA plays a 
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critical role in the synthesis of the viral polymerase enzyme (Fig. 1.2). Viral reverse 
transcription is initiated by interaction between the polymerase and stem-loop epsilon (ε), a 
structural RNA sequence located near the 5’ end of the pgRNA. Binding of viral 
polymerase to ε leads to pgRNA encapsidation [63, 64]. A 3 to 4 base DNA 
oligonucleotide is produced from the bulge of the epsilon sequence and is subsequently 
subjected to reverse transcription. A covalent bond links the polymerase to the 5’ end of 
the DNA oligonucleotide. The oligonucleotide is then translocated to the 3’ end of the 
pgRNA. Since a strong covalent bond connects the polymerase to the oligonucleotide, both 
molecules are translocated to the 3’ end of the pgRNA. Polymerase facilitates binding of 
the oligonucleotide to a complementary sequence located at the 3’-proximal direct 
repeat1* (DR1*).  
 
Thereafter, the oligonucleotide acts as a primer and reverse transcription of the DNA 
negative strand progresses [65, 66]. The polymerase degrades most of the pgRNA template 
by virtue of its RNaseH activity, leaving a short residual 5’ capped oligonucleotide. The 5’ 
end of the negative strand is then exchanged for the 3’ end to enable circularisation and 
results in the formation of new rcDNA [65].  The nucleocapsid may be transported to the 
nucleus, thus, maintaining the cccDNA pool [67] (Fig. 1.2). Alternatively, nucleocapsids 
may be introduced into the secretory pathway and interact with surface proteins found in 
the endoplasmic reticulum to be released from the cells as new virions [67].  
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Figure 1.2. HBV replication cycle 
The virions recognise and bind to the cell surface receptor. Following infection in target 
hepatocytes, the rcDNA is repaired to generate cccDNA which is important for viral 
replication and persistence. Synthesis of viral mRNA occurs in the ribosomes to produce 
precore/core, core, S, Pol and X proteins, followed by pgRNA encapsidation. The rcDNA 
is produced after reverse transcription of pgRNA and the resulting nucleocapsids are 
transported to the endoplasmic reticulum, enveloped and exported from the cell. 
Alternatively, nucleocapsids may be recycled into the nucleus and converted into cccDNA. 
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1.3. Current HBV prevention and treatment 
A universal and effective HBV vaccine is available and provides protection in about 90-
95% of vaccinated individuals [68].  Furthermore, the vaccine may be taken together with 
hepatitis B immune globulin (HBIG) to inhibit mother to child transmission during 
gestation and after birth [69]. To date, licensed HBV therapies include nucleotide and 
nucleoside analogues. These antiHBV chemotherapeutics block the reverse transcription 
step of viral replication [70] and include drugs such as lamivudine (Epivir), telbivudine 
(Tyzeka), adefovir (Hepsera), tenofovir (Viread) and entecavir (Baraclude) [71, 72]. 
Treatment with nucleotide/side chemotherapeutics has generally failed to eliminate HBsAg 
antigen secretion in infected individuals [73, 74].  
 
Patients are advised to continue taking these analogues for life, as HBV replication may be 
re-established after stopping treatment [75]. The aim of this treatment regimen is to 
establish HBsAg seroconversion. Although seroconversion may lead to better prognosis, 
hepatocellular carcinoma and cirrhosis still pose a greater threat to chronically infected 
patients [76]. In general, the nucleotide/side drugs have few side effects and prolonged use 
of these regimens is necessary to sustain viral suppression.  
 
Lamivudine is a reverse transcriptase inhibitor and results in decreased levels of rcDNA 
and cccDNA being produced [77-79]. Unfortunately, tyrosine-methionine-aspartate-
aspartate (YMDD) escape mutants may arise as a result of long-term lamivudine 
monotherapy, thus, compromising the antiHBV activity of this drug [80].  
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Adefovir has also been administered for HBV therapy, but displayed decreased efficacy 
relative to lamivudine. Moreover, nephrotoxicity has been observed after administering a 
high dosage of this antiviral agent [81]. Adefovir is capable of achieving effective HBV 
therapy in strains that are resistant to lamivudine [82, 83] and the number of escape 
mutants is also decreased [84]. In comparison to lamivudine, entecavir displays improved 
antiHBV activity [85, 86]. Furthermore, prolonged use of this drug improves liver 
histology [87, 88] and escape mutants are negligible [87, 89]. Recently approved 
nucleotide/side drugs for HBV therapy are telbivudine and tenofovir [90, 91]. These agents 
also display antiHIV activity [92] and may be conveniently used to treat HBV/HIV co-
infections [93].  
 
Relative to lamivudine [94, 95] and adefovir [96], telbivudine has superior antiviral 
efficacy. Unfortunately, administration of this drug is compromised by development of 
myalgia, drug-induced myopathy and emergence of escape mutants [97, 98]. Tenofovir is 
the most effective antiviral agent and the drug of choice for HBV monotherapy [99]. To 
date, escape mutants to tenofovir have not been identified; however, long-term mutational 
studies are required for detailed analysis. Currently, tenofovir and entecavir are the 
preferred regimens for chronic HBV therapy because of their superior antiviral efficacy 
and high barrier to viral resistance. Although these agents are capable of inhibiting HBV 
replication and improving liver histology, the major limitation is that they are unable to 
clear established cccDNA pools in chronically infected patients. Moreover, prolonged use 
of these drugs may lead to viral mutagenesis and HBV rebound is generally observed in 
patients that stop treatment.  
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Furthermore, immunomodulators which act by activating the host immune system to 
combat infection have also been approved for treating chronic HBV infection. These 
include interferon alpha (IFN-α), interferon alpha-2a (IFN-α 2a), PEGylated IFN-α2a, 
PEGylated IFN-α2b and interferon beta (IFN-β). Previously, IFN-α and PEGylated IFN-α 
have been employed for short-term therapy, in which durable viral suppression was 
achieved in patients with chronic HBV infection [100-103]. However, side-effects were 
observed and antiHBV activity of immunomodulators depends mainly on the starting HBV 
viral load, genotype, host immune competence and the extent of liver damage. In a clinical 
setting, it has been demonstrated that IFN-α displays superior antiviral efficacy in 
individuals infected with HBV genotype A than genotype C, D, or E [104-106].  
 
Efficacy of immunomodulators is generally unsatisfactory and not advisable for patients 
with HIV co-infection or cirrhosis [107]. Similarly, the levels of HBsAg seroconversion is 
also unsatisfactory in patients taking IFN therapeutics, and side effects such as 
autoimmune diseases and severe flu-like symptoms are common (reviewed in [108]). 
Although nucleotide/side analogues and immunomodulators can abrogate viral replication, 
they are unable to completely eradicate cccDNA, thus, allowing viral persistence. 
Consequently, there is still no effective cure for chronically infected individuals. Licensed 
therapeutic modalities are unable to convincingly clear chronic HBV infection and relapse 
is common after treatment withdrawal. Therefore, development of new and effective HBV 
therapy thus remains a priority. 
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1.4. RNA interference  
RNA interference (RNAi) is a naturally occurring mechanism which regulates target gene 
expression in various eukaryotic organisms [109-113] (Fig. 1.3). This gene silencing 
mechanism is activated by primary microRNAs (pri-miRNAs) [114]. Cleavage of pri-
miRNAs by the nuclear microprocessor complex comprising Drosha and DiGeorge 
syndrome critical region gene 8 (DGCR8) produces precursor miRNA (pre-miRNA) 
hairpins. Subsequently, exportin-5 transports the newly processed pre-miRNA molecules 
to the cytoplasm and additional processing of these hairpins by Dicer and transactivation 
response RNA binding protein (TRBP) leads to the formation of microRNAs (miRNAs). 
These miRNA duplexes are about 23 bp in length and their 3’ ends contain 2 nucleotide 
overhangs. The two miRNA strands are incorporated into the RNA Induced Silencing 
Complex (RISC). This is followed by selection of one miRNA strand to effect target gene 
silencing [115] (Fig. 1.3). 
 
The most frequently retained strand by the RISC is known as miRNA, while the less 
frequently retained strand is called miRNA*. The miRNA serves as the guide strand after 
incorporation into RISC, while the miRNA* assumes the role of a passenger strand. 
Similarly, selection of miRNA* by RISC allows it to be the leading strand, while the 
miRNA serves as a passenger strand. The leading strand is responsible for directing RISC 
to the target mRNA, while the passenger is removed and has no effect on subsequent RNAi 
stages. Incomplete base-pairing between target mRNA and guide strand results in 
translational suppression, while complete base-pairing results in degradation of target 
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mRNA. When artificial sequences resembling miRNA, pre-miRNA or pri-miRNA (i.e. 
exogenous RNAi activators) are introduced into a cell, the RNAi pathway is 
reprogrammed, leading to target gene silencing [116-119] (Fig. 1.3). RNAi-based 
approaches may be conveniently used to silence HBV replication. This is because HBV 
has several favourable features that are ideal for RNAi therapy and include:  
 The overlapping nature of the ORFs contributes to HBV having a low mutation rate, as 
opposed to RNA viruses.  
 Transcripts produced by viral genes overlap and possess similar 3’ sequences that have 
a single transcription termination signal. 
  The pgRNA is involved in the synthesis of rcDNA during reverse transcription and 
may be a convenient therapeutic target [120]. 
 
Consequently, a single RNAi effector molecule can target and silence many viral RNAs 
simultaneously. A number of HBV target sites have been silenced using expressed [118, 
121-123] and synthetic RNAi activators [124-127]. These RNAi activators possess 
sequences that resemble naturally occurring molecules that participate in the RNAi 
pathway, thus, enabling them to be introduced into cells to effect target gene silencing.  
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Figure 1.3. Schematic representation of the RNAi mechanism 
Pri-miRNAs are processed by the Drosha/DGCR8 complex to form pre-miRNA 
molecules. Exportin-5 transports the newly processed pre-miRNA molecules to the 
cytoplasm and additional processing of these hairpins by Dicer and TRBP leads to the 
formation of miRNAs. The two miRNA strands are incorporated into RISC and the guide 
strand selected to effect target mRNA degradation or translational suppression. 
Introduction of exogenous activators of RNAi that resemble miRNA, pre-miRNA or pri-
miRNA triggers the RNAi mechanism leading to target gene silencing. Diagrammatic 
illustration from Arbuthnot, 2010 [128].  
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1.5. Expressed RNAi activators 
Expressed RNAi activators are typically transcribed from RNA pol III to produce short 
hairpin RNA (shRNA) sequences. These sequences resemble pre-miRNA molecules, 
enabling them to participate in the RNAi pathway leading to target gene silencing. Most 
studies focusing on the utility of shRNA have mainly employed Pol III transcription 
regulatory elements, particularly U6 or H1 promoters [123, 129-131]. Advantages of 
employing these promoters include: (1) the ease of cloning and packaging into delivery 
systems, owing to their small size, and (2) effective construction of shRNAs may be 
achieved as the precise position of transcription and termination sites is known [132]. 
Limitations associated with the use of these promoters include: (1) lack of specificity as 
Pol III promoters are constitutively expressed in many cell types, (2) the promoters fail to 
offer spatial control required for the treatment of certain diseases [132], and (3) it is 
important to optimise the dosage of shRNAs expressed from U6 promoters, as over-
expression may result in toxicity from saturation of the endogenous RNAi pathway [133]. 
As a result, various strategies have been investigated to counter these shortcomings [134-
136]. Additionally, studies investigating the advantage of using inducible Pol III promoter 
systems have also been conducted with the aim of circumventing the undesirable effects 
associated with the use of Pol III promoters [134, 137-139].  
 
Pol II promoters optimised to achieve moderate shRNA expression levels may also be 
employed to avoid toxicity associated with the use of powerful Pol III promoters [132, 
140]. In contrast to Pol III promoters that are constitutively expressed across many cell 
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lines, Pol II promoters may be tissue specific [141]. The utility of Pol II promoters that 
express pri-miRNAs has also been investigated. This led to generation of effective pri-
miRNAs being expressed from Pol II promoters. These therapeutic agents have 
subsequently been employed to target and suppress HBV replication [121, 142]. Since 
some pri-miRNAs are polycistronic, exogenous pri-miRNA mimics that are polycistronic 
have been evaluated [118]. Additionally, polycistronic expression has been achieved by a 
single Pol II [141] or Pol III promoter when interfering RNAs were designed to mimic 
miRNAs [131]. In some instances, multimerisation of these therapeutic agents allows 
simultaneous silencing of different HBV sites. This increases antiHBV efficacy and 
minimises the emergence of viral escape mutants [131, 132, 141, 142]. Importantly, 
treatment of chronic HBV infection necessitates prolonged half-life of the therapeutic 
agents to achieve a sustained antiHBV effect. Therefore, stable DNA templates encoding 
RNAi expression cassettes may be used to achieve durable antiHBV activity [143], a 
characteristic which is often lacking when using synthetic RNAi activators to achieve 
target gene knockdown.  
 
1.6. Synthetic activators of RNAi and chemical modification of 
siRNAs 
Synthetic RNAi activators have been explored for their ability to target and suppress 
replication of HBV in cell culture and in vivo [144-147]. Synthetic small interfering RNAs 
(siRNAs) are composed of RNA duplexes of approximately 21 bp (Fig. 1.4). Additionally, 
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these synthetic RNAi activators also possess 2-base 3’ overhangs which improve RISC 
processing and target gene silencing. These features enable them to mimic miRNA 
duplexes and can then be applied to induce RNAi-based silencing following RISC 
processing [148]. Factors that contribute to siRNAs being ideal therapeutics for RNAi-
based approaches include:  
 The siRNA chemical synthesis process and quality control can be easily monitored.  
 Dosage may be more easily regulated than with expressed RNAi activators.  
 siRNAs may be delivered to mammalian cells using efficient non-viral vectors owing 
to their small size and cytoplasmic site of action.  
 Favourable “drug-like properties” may be conferred to these RNAi effectors by 
incorporating chemical modifications [149, 150].  
 
Despite these favourable properties, unfavourable qualities that impede therapeutic 
application of siRNA exist and include: (1) off-targeting effects [151], (2) innate immune 
stimulation [152, 153], (3) unsatisfactory biodistribution patterns, and (4) susceptibility of 
siRNAs to degradation by serum nucleases [154]. Improved stability of siRNAs against 
nuclease degradation results in increased half-life of these RNAi effectors in the 
circulation, which in turn, promotes sustained target gene silencing. Specificity implies that 
the administered siRNAs would result in decreased non-specific or off-target effects. Non-
specific effects arise when siRNAs target and silence genes other than the gene of interest 
leading to unintended inactivation of other cellular mRNAs [151, 155, 156]. Immune 
stimulation may also manifest as a result of off-targeting of siRNAs and is generally 
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induced by Toll-like receptors (TLRs) e.g. TLR3, TLR7 and TLR8 [157]. These immune 
receptors function by identifying various RNA molecules and stimulate IFN response 
genes such as IFN-β, IFN-γ, interferon-induced protein with tetratricopeptide repeats 1 
(IFIT1), oligoadenylate synthetase-1 (OAS-1), interleukin 6 (IL-6), IL-10, IL-12p70, 
monocyte chemoattractant protein-1 (MCP-1) and tumour necrosis factor (TNF). However, 
innate immune stimulation varies and mainly depends on the nature of the administered 
RNA and necessitates screening for activation of various IFN genes. 
 
To circumvent the negative attributes associated with siRNA delivery, chemical 
modification of siRNAs has been employed. Indeed, incorporation of chemical groups into 
siRNAs generally renders them more potent, specific and stable, thus, improving the 
therapeutic utility of these RNAi effectors. Interestingly, siRNA specificity and activity 
have been demonstrated to be markedly enhanced particularly when the chemical groups 
are incorporated within the seed region (i.e. nucleotide 2 to 8 of the 5’ region of the guide 
strand) (Fig. 1.4) [156, 158, 159]. It is thought that introducing chemical moieties within 
the siRNA seed region reduces off-target effects by minimising the interaction between 
RISC and partially complementary sequences [156].  
 
The efficacy with which the seed region hybridises to cellular mRNAs determines target 
specificity [156] by reducing interaction with incomplete target sequences. Subsequently, 
this improves target specificity and decreases off-target effects. Off-target effects refer to 
silencing of genes other than the gene of interest. Therefore, in the application of antiHBV 
siRNAs, viral RNA is the on-target (i.e. desired target), while the host genes are off-
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targets. Incorporation of chemical moieties, particularly at the 2’ ribose position, changes 
the binding and thermodynamic properties of modified siRNAs [160-162]. Subsequently, 
this improves specificity of these RNAi effectors by minimising interaction between 
modified siRNAs and partial complementary targets without compromising the therapeutic 
efficacy of siRNAs [156]. It has been reported that some chemical modifications may 
decrease hybridisation between modified siRNAs and incomplete targets by reducing the 
free energy [156, 163] or thermostability of the seed region-mRNA complex [164]. 
Moreover, chemical modifications also introduce structural alterations to siRNAs. These 
conformational alterations may influence the efficiency of RISC processing whereby, weak 
hybridising targets (i.e. partial complementary targets) are removed from the guide strand 
before cleavage, while strong hybridising targets (i.e. complete complementary targets) are 
retained and efficiently processed by RISC [156]. Conformational changes and strong 
hybridisation of chemically modified siRNAs (as opposed to their unmodified 
counterparts),  may also be responsible for improved target gene silencing by allowing 
efficient processing of modified therapeutic sequences by the RISC machinery [165]. In 
addition to conformational changes, RISC processing and siRNA efficacy may be 
markedly improved by introducing chemical groups that enhance recognition of 3’ 
overhangs or alter the thermodynamic stability of siRNAs [166]. A diagram of the siRNA 
molecule is depicted in Fig. 1.4. 
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Figure 1.4. Graphical representation of the siRNA molecule 
The double-stranded siRNA molecule is comprised of the guide (in blue) and sense (in red) 
strands. These synthetic RNAi activators are about 21 bp in length and also possess 2-base 
3’ overhangs which enhance RISC processing and target gene silencing. The 5’ end of the 
RNA duplex consists of the phosphate group, while the hydroxyl moiety is present at the 3’ 
end. The seed region (in orange) is critical for target recognition and incorporation of 
chemical groups into this region improves siRNA activity and specificity.  
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However, only moderate thermodynamic alterations of the guide seed region are tolerated, 
as extensive destabilisation may decrease interaction between modified siRNAs and target 
mRNA, leading to reduced siRNA activity [166]. 
 
Importantly, chemical groups should not distort the A-form helix of the guide strand-
mRNA complex, as it prevents recognition by RISC and subsequently abolishes RNAi-
mediated gene silencing [149]. Alterations of the A-form helix may disrupt protein 
binding, hydrogen bonding and decrease interactions between RISC and modified siRNAs, 
thus, preventing target gene silencing [149]. Various studies have been carried out to 
evaluate the advantage of using chemically modified as opposed to unmodified siRNAs. 
To date, most of these strategies have focused on incorporating chemical groups at the 2’-
OH of ribose [166]. Addition of 2’-fluoro (2’-F), 2’-O-methyl (2’-O-Me) or 2’-
methoxyethyl (2’-O-MOE) groups to siRNAs enhances silencing efficacy and resistance to 
nuclease degradation [167, 168]. Furthermore, addition of a chemical group at the 2’-OH 
site, particularly 2’-O-Me also prevents innate immune stimulation [169] by avoiding 
interaction with TLRs. It is also thought that chemically modified siRNAs may prevent 
immune stimulation by causing internalisation of receptor molecules or antagonising 
pathways associated with innate immune signalling [157]. Additionally, 2’ modification 
with bulky chemical groups that do not alter the structure of the A-form helix [149] may 
prevent unwanted interaction between modified siRNAs and immune receptors, thereby, 
avoiding immune stimulation [170]. Other research groups also investigated the advantage 
of replacing ribose with sugars such as hexitol [164, 166, 171, 172]. Incorporation of 
chemical groups at different positions of the sense or guide strand may significantly 
Chapter 1 
 
22 
 
increase or decrease the silencing efficacy of siRNAs. This is true as addition of 
boranophosphate to the middle of the guide strand leads to poor activity, while 
incorporation of this chemical group to other positions results in improved silencing 
efficacy and resistance to nuclease degradation [173]. This illustrated that incorporation of 
chemical groups at key positions within the siRNA sense or guide strand is necessary to 
augment silencing efficacy.  
 
Chemically modified siRNAs targeting conserved regions of HBV RNA have been 
employed to abrogate viral replication in cell culture and mice [158]. These modifications 
included 2’-F, (2’-O-Me), 2’-deoxy sugars and phosphorothioate linkages. Incorporation of 
these chemical groups resulted in enhanced stability of modified siRNAs in serum relative 
to the unmodified group [158]. Significant suppression of markers of HBV replication was 
achieved by modified siRNAs while their unmodified counterparts displayed 
unsatisfactory activity in vitro. Antiviral activity was also observed in mice following 
hydrodynamic co-injection of modified or unmodified siRNAs and HBV plasmid vector 
[158]. A marked decline in markers of HBV replication was observed in mice treated with 
antiHBV siRNAs relative to animals injected with control siRNA or saline. As in cell 
culture studies, pronounced HBV silencing was achieved with modified as opposed to 
unmodified siRNAs, thus demonstrating the utility of chemical modifications in effecting 
enhanced antiHBV activity in cell culture and mice. This observation highlighted the 
importance of chemical modifications with regard to improving siRNA stability and 
activity in vitro and in vivo [158]. 
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In a separate study, the utility of employing lipoplexes containing altritol (ANA)-modified 
siRNAs was investigated [124]. These complexes were delivered to transgenic mice and 
targeted the conserved HBx ORF of HBV. Both unmodified and ANA-modified siRNAs 
were injected at a constant dose of 1 mg/kg mouse body weight and involved a maximum 
of four injections per week. The siRNAs were capable of silencing markers of HBV 
replication for 25 days without inducing hepatotoxicity [124]. Markers of innate immune 
stimulation were induced in mice treated with unmodified siRNA, but, this non-specific 
effect was abrogated in animals treated with modified siRNAs. Data from this study 
indicated that incorporation of the ANA chemical group into antiHBV siRNAs abrogates 
viral replication in transgenic mice without a substantial increase in hepatotoxicity and 
immune stimulation, and may potentially be utilised as effective antiHBV agents [124].   
 
1.7. Delivery methods 
1.7.1. Viral delivery methods 
There are two types of delivery systems used to deliver RNAi effectors to target cells: viral 
and non-viral delivery systems. Viral systems are employed to deliver expressed RNAi 
activators, while non-viral vectors are usually used for the delivery of synthetic RNAi 
activators. Recombinant viruses such as Adenoviruses (Ads), Adeno-associated viruses 
(AAVs) and lentiviruses (LVs) achieve efficient transduction of liver cells, have broad 
tissue tropism and are capable of effecting long-term transgene expression in target 
hepatocytes. Consequently, viral systems have been widely used for basic research and 
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clinical studies [174-176]. However, drawbacks of utilising viral vectors to deliver 
therapeutic RNAi sequences include induction of the innate and adaptive immune response 
[177-180], cytotoxicity [181] and insertional mutagenesis [182].  
 
1.7.2. Non-viral delivery methods 
To circumvent the devastating manifestations associated with utilising viral vectors, 
several non-viral strategies have been invented and utilised for the delivery of therapeutic 
sequences to target cells. These include the use of cationic liposome-containing nucleic 
acids (lipoplexes) [124, 159, 183] and cationic polymer-containing nucleic acids 
(polyplexes) [184-186]. Both RNA and DNA molecules can be formulated with cationic 
liposomes or polymers to achieve efficient transgene delivery and target gene silencing in 
target tissues. The siRNA molecules are smaller in size compared to RNAi expression 
cassettes. Moreover, siRNAs have a cytoplasmic site of action, while DNA molecules need 
to be delivered to the nucleus. Collectively, these features enable siRNA administration 
and dose regulation easier to achieve relative to expressed RNAi activators. Furthermore, 
delivery of siRNAs to the cytoplasm encounters fewer challenges than administration of 
DNA to the nucleus. Favourable properties that advance the use of non-viral vectors 
include:  
 Safe and regulated production process.  
 Decreased immunogenicity and cytotoxicity. 
 Integration into the host cell genome is greatly reduced. 
 Versatility in accommodating small and large nucleic acids.  
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siRNA molecules may be formulated with liposomes to form siRNA lipoplexes, which can 
then be used to transport these therapeutic molecules to target cells in vivo. In such 
formulations, the siRNA molecules are linked to liposomal components by electrostatic 
interactions [187]. In vivo delivery of siRNA using liposomes is generally unsatisfactory, 
due to various shortcomings that need to be countered if efficient transgene delivery is to 
be realised. The drawbacks of this delivery system include unspecific tissue targeting, 
inefficient delivery of RNAi effectors, unsatisfactory circulation profile [188] and 
aggregation of liposomal components [189].  
 
These limitations may be abolished by: (1) optimisation of siRNA and vector 
concentrations, (2) formulation of uniform small particle sizes of approximately 50-100 nm 
in diameter, (3) addition of molecules that have enhanced affinity for the cellular receptor 
and, (4) conjugation of liposomal components to polymers that mask the lipoplexes from 
the immune system. Incorporation of polyethylene glycol (PEG), for example enhances the 
half-life of lipoplexes in vivo. This is because PEG is capable of forming a water shell, 
leading to decreased adhesion of opsonin molecules that promote phagocytosis. Poor 
adhesion leads to masking of lipoplexes which subsequently prevents activation of liver 
immune cells and the mononuclear phagocyte system [188, 190, 191]. Addition of PEG 
into lipoplexes also improves the biodistribution and amount of siRNAs being delivered 
into target cells, relative to unPEGylated lipoplexes [188].  
 
In addition to PEG, other essential liposomal components include 1,2-dioleoyl-sn-Glycero-
3-Phosphoethanolamine (DOPE) which is commonly used as a helper fusion lipid and also 
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decreases toxicity of the lipoplex formulation [124, 192-197]. 3β-[N(N',N'-
Dimethylaminoethane carbamoyl cholesterol] (DC-Chol) is a cationic lipid [196-201] 
which binds to the negatively charged siRNA molecule. Carbohydrate molecules (e.g. 
galactose) have high affinity for the asialoglycoprotein receptor (ASGPr), which is found 
on the surface of liver cells and may be conveniently used to confer liver-specific delivery 
of siRNA lipoplexes [185, 186, 192-195, 202]. In most cases, hepatocytes are the most 
commonly targeted cells due to their accessibility by both viral and non-viral delivery 
systems. Delivery of therapeutic agents using the receptor targeting strategy is 
advantageous as it may increase specificity and the amount of effector molecules being 
administered into target cells. It has been demonstrated that association between the 
receptor and targeting molecule promotes clustering, which improves the binding affinity 
between the targeting molecule and receptor [203-205]. It has also been shown that 
recognition of galactose by ASGPr in vivo is dependent on the amount of galactose in the 
lipoplex formulation [206]. Additionally, pharmacokinetic investigations revealed that the 
number of galactose molecules on the surface proteins determines the binding efficacy of 
galactose to ASGPr [206]. For this reason, both natural and synthetic compounds derived 
from galactose have been produced with the aim of targeting the ASGPr on the surface of 
hepatocytes [185, 202, 207].  
 
Following administration of siRNA lipoplexes, the complexes bind and gain access to the 
cells through clathrin-mediated endocytosis [208]. To ensure that the lipoplexes are 
released from the acidic endosomes before interacting with the lysosome, fusogenic lipids 
such as DOPE may be included in the lipoplex formulation. This prevents degradation of 
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the formulation as fusogenic lipids interact with the endosome, resulting in fusion between 
the endosome membrane and lipoplex membrane. This destabilises the endosome 
membrane [209] and allows siRNAs to be released into the cytoplasm, where they exert 
their therapeutic activity. In addition to fusogenic lipids, endosomolytic agents can also be 
used to prevent lysosomal degradation [209, 210]. This includes the use of haemagglutinin 
subunit 2 (HA2) and glutamic acid-alanine-leucine-alanine (GALA) [209]. Both peptides 
are pH-sensitive and undergo a conformational change under acidic conditions of the 
endosome [209]. This promotes fusion between the endosomolytic agent and the endosome 
membrane. Subsequently, this leads to destabilisation of the endosome membrane, thus, 
triggering the delivery of therapeutic agents into target tissues [209, 211, 212]. 
 
Various cationic liposomes have been employed to deliver siRNAs to target cells. 
Previously, stable nucleic acid lipid particle (SNALP) formulations were employed to 
facilitate delivery of 2’-OMe, 2’-F, phosphorothioate and 3’, 5’ inverted deoxy abasic 
modified siRNAs [159]. Following efficient antiviral activity in mammalian cells, these 
formulations were employed to inhibit viral replication in vivo. In this study, chemically 
modified SNALP-siRNAs displayed enhanced half-life in the plasma and liver compared 
to unformulated siRNA. Serum HBV DNA levels in mice were substantially reduced after 
administration of three daily injections at a dose of 3 mg/kg [159]. This antiHBV activity 
persisted for seven days and was dose-dependent. Additionally, a weekly administration of 
SNALP-siRNAs reduced serum HBV DNA levels for up to six weeks. Although there was 
in general no significant difference in antiHBV efficacy between modified and unmodified 
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siRNAs, administration of 3 mg/kg unmodified siRNA induced toxicity and innate immune 
stimulation in mice [159]. Conversely, toxicity and immune stimulation were abrogated 
after administering the same dose of modified siRNAs. Collectively, data gathered from 
this study demonstrated that the SNALP formulations are capable of delivering chemically 
modified antiHBV siRNAs to exert a sustained RNAi effect in target hepatocytes without a 
marked increase in toxicity or markers of innate immune stimulation [159].  
 
Similarly to cationic liposomes, cationic polymers bind to effector molecules (e.g. siRNA 
or DNA) resulting in charge neutralisation, which facilitates delivery into target cells 
following endocytosis (reviewed in [213]). In contrast to lipoplexes that utilise clathrin-
mediated endocytosis, polyplexes gain access into target cells by employing both the 
clathrin and caveolae-mediated endocytosis [208]. Lipoplexes require destabilisation of the 
endosome membrane to achieve endosomal release, while polyplexes utilise the “proton 
sponge” effect to accomplish endosomal escape. Indeed, cationic polymers such as 
polyethyleneimine (PEI) employ this mechanism to augment nucleic acid delivery. With 
this approach, the buffering capability of PEI inhibits nuclease enzymes in the lysosome 
and creates an osmolaric change of acidic vesicles. This causes the endosome to burst, 
thus, allowing the release of therapeutic agents into target cells [184, 214-216]. 
 
In a study conducted using a cationic polymer system, Dynamic PolyConjugates (DPCs) 
were employed to deliver 2’-OMe or 2’-F (2’-F) modified siRNAs to target hepatocytes 
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[186]. This formulation was composed of N-acetylgalactosamine that conferred liver-tropic 
delivery of particles.  Co-injection of these vectors with 1-6 mg/kg anti coagulation factor 
VII (F7) siRNA significantly suppressed gene expression in HBV transient and transgenic 
mice as well as non-human primates, and the level of gene silencing was dose-dependent 
[186]. This impressive antiF7 activity was achieved without evidence of toxicity or an 
innate immune response in injected animals, even after four injections. Furthermore, a 
single injection of chemically modified siRNAs targeting conserved HBV regions effected 
simultaneous and prolonged silencing of viral DNA, RNA and proteins in injected mice, 
thus reinforcing the notion that DPCs have potential as therapeutic agents against chronic 
HBV infection [186]. 
 
Therapeutic properties of siRNAs may be enhanced by using chemical modifications and 
an efficient delivery system. Collectively, strategic incorporation of chemical groups at key 
positions within the guide or sense strand of siRNAs and development of a robust, 
competent and efficient non-viral delivery system are critical for improving specificity, 
stability and target gene silencing, while minimising unintended manifestations such as 
toxicity and innate immune stimulation in target cells. This will go a long way to 
promoting application of siRNA-mediated RNAi as therapy for chronic HBV infection in a 
clinical setting.  
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Our current study was aimed at building on previous investigations that exploited 
chemically modified siRNA molecules and efficient non-viral delivery systems to achieve 
target gene silencing without a marked increase in toxicity and non-specific effects. 
Specifically, our study was aimed at assessing the utility of introducing novel 2’-O-
guanidinopropyl (GP) moieties into the potent antiHBV siRNA (i.e. siRNA3) previously 
employed by Hean et al., 2010 [124]. Initially, single GP groups were incorporated into the 
guide strand and modified siRNAs were named based on the location of the GP moiety 
from the 5’ end. The rationale for using a single siRNA, as opposed to multiple effector 
molecules include: (1) dose may be easily optimised with a single as opposed to multiple 
siRNA molecules, and (2) since all siRNAs targeted the HBx ORF of HBV, application of 
more than one RNAi effector molecule would potentially result in saturation of the natural 
RNAi system and non-specific effects such as innate immune stimulation. 
 
Various chemical residues have already been employed to improve the therapeutic 
properties of siRNAs. However, this study was conducted because it introduces the novel 
GP-modification of antiHBV siRNAs. This modification is unique in that the amino 
moieties of the GP group and the carbon propyl linker may allow efficient charge 
neutralisation [217]. Additionally, charge neutralisation is also achieved by interaction 
between the cationic amine groups of GP residues and the anionic phosphate moieties of 
siRNAs. Therefore, this efficient charge neutralisation may improve therapeutic efficacy of 
modified siRNAs by facilitating delivery of therapeutic sequences into target hepatocytes. 
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These useful properties triggered the prospect of investigating RNAi-mediated gene 
silencing in cell culture and mice using GP-modified siRNAs.  
 
Prior to conducting this study, 2’-O-aminoethyl modifications were utilised to enhance the 
utility of siRNAs [166]. This strategy was improved by subjecting the four ribonucleosides 
to alkylation using phalimidoethyltriflate [218]. However, the setbacks of this new 
approach included insufficient yields and challenges pertaining to the scaling up process. 
This led to the development of the novel GP modification as an alternative method of 
conferring useful therapeutic properties into siRNAs without compromising the yield of 
the chemical synthesis procedure [217]. To improve the yield, the crude 2’-O-aminopropyl 
served as the source of guanidino groups while N,N’-di-Boc-N’’-triflyguanidine was used 
as a guanidinylation agent. This strategy significantly improved the production of all four 
GP nucleosides, namely adenosine (A), cytidine (C), guanosine (G) and uridine (U) [217]. 
Additionally, this modification provides several favourable characteristics that are not 
offered by previous 2’-OH modifications. The chemical synthesis procedure comprised 
cyanoethylation which involves addition of acrylonitrile to protected nucleosides. 
Subsequent Raney-Nickel reduction reaction produces propylamino molecules which are 
guanidinylated using triflyguanidine. This approach presents a novel strategy in which all 
four phosphoramidites are modified with the GP moiety, placed at the 2’ position and 
incorporated into antiHBV siRNAs. Versatility of this chemical synthesis process is that it 
allows alterations at the 2’-O-aminopropyl position, while the amino moieties of the GP 
group and the carbon propyl linker may allow efficient charge neutralisation [217]. 
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Although several non-viral delivery strategies have been devised for the administration of 
antiHBV siRNAs in vivo, only a limited number of delivery systems are capable of 
achieving efficient transgene delivery into target hepatocytes of various animal models. 
Collectively, our current study was focused on testing the use of novel GP-modified 
siRNAs in conjunction with an effective, competent, hepatotropic non-viral delivery 
system as an alternative strategy to combat chronic HBV infection.  
 
 1.8. Aims and objectives: 
The aim of this study was to investigate the therapeutic advantage of utilising novel GP-
modified siRNAs to counter HBV replication in cultured cells and mice. The siRNAs were 
designed to target the viral HBx ORF of genotype A (coordinates 1693 to 1711), as it is 
conserved and its sequence is common in all HBV transcripts. Efficient charge 
neutralisation between the amino groups of the GP residue and carbon propyl linker as well 
as the cationic amine groups of GP moieties and the anionic phosphate groups of siRNAs 
may facilitate delivery of therapeutic sequences into target hepatocytes. 
 
The objective of this study was to assess the activity, specificity, stability, toxicity and to 
detect the siRNA-mediated cleavage product in cultured mammalian cells and mice 
following delivery of GP-modified siRNAs. Markers of viral replication were evaluated 
from cell culture and animal sera, and were indicative of the effect of siRNAs on HBV 
replication. Animal experimentations entailed preliminary assessment of antiHBV activity 
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of modified siRNAs in a hydrodynamic injection (HDI) mouse model. Subsequent animal 
studies involved interrogation of antiHBV activity, specificity, toxicity and detection of the 
siRNA-mediated cleavage product in HBV transgenic mice following liposome-mediated 
delivery of GP-modified siRNAs. 
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Chapter 2: Materials and methods 
Methods will be discussed in each result chapter. 
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Recent advances in developing nucleic acid-based HBV therapy 
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This review article discusses milestones achieved in the field of gene therapy. Additionally, it 
details some of the challenges associated with the application of therapeutic RNAi sequences 
and gene editing technologies, reviews current developments and evaluates potential 
application of gene therapy in the treatment of chronic HBV infection. 
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HBV infects the liver to result in acute or chronic 
hepatitis [1,2]. It has been estimated that 350 mil-
lion people suffer from chronic HBV infection, 
and these carriers are at increased risk for compli-
cating cirrhosis and hepatocellular carcinoma. An 
effective preventative vaccine is available, but is of 
little use to individuals who are already infected 
with the virus. As a result, problems associated 
with HBV infection are likely to remain a signifi-
cant public health problem for many years. Most 
infections in adults clear spontaneously; however, 
infection in children frequently leads to chronic-
ity. Current therapies approved for HBV infec-
tion include nucleotide and nucleoside analogs, 
which act by inhibiting the reverse transcription 
step of viral replication [3,4]. Immunomodulators, 
such as IFN-a and polyethylene glycol (PEG)
ylated IFN-a, are also licensed HBV therapies. 
The available therapeutics rarely eradicate HBV 
and re-establishment of replication often occurs 
after treatment withdrawal [5]. Consequently, 
development of new and more effective therapies 
is required to combat HBV infection.
HBV is a small, enveloped virus with a par-
tially dsDNA genome of 3.2 kb (Figure 1) [6]. The 
viral genome is composed of relaxed circular 
DNA, which is formed after reverse transcrip-
tion of a pregenomic RNA (pgRNA) intermedi-
ate. Conversion of relaxed circular DNA to cova-
lently closed circular DNA (cccDNA) occurs in 
infected hepatocytes [7,8]. cccDNA is a very stable 
replication intermediate and serves as a template 
for transcription of pgRNA and mRNAs. More-
over, cccDNA persistence is responsible for chro-
nicity of HBV infection and modest curative 
efficacy of current therapies [9,10]. During virion 
formation, HBV core particles are assembled in 
the cytosol after pgRNA encapsidation [11]. The 
viral surface proteins are produced in the rough 
endoplasmic reticulum and transported to the 
Golgi. Budding and secretion of the capsids 
occurs via the Golgi to release HBV virions [12].
Discovery of the RNAi pathway [13] was an 
important development in the field of gene 
therapy and presented an opportunity for 
silencing of pathology-causing genes, such as 
those expressed by HBV. This pathway is trig-
gered by primary miRNAs (pri-miRNAs), pre-
cursor miRNAs (pre-miRNAs), miRNAs and 
the mimics of these molecules (Figure 2) [14,15]. 
Naturally, endogenous pri-miRNAs are cleaved 
by the nuclear microprocessor complex, Drosha 
and DGCR8, to produce pre-miRNA hairpins. 
The pre-miRNAs are subsequently exported 
to the cytoplasm and further processed by the 
Dicer RNase III enzyme to form short duplex 
miRNAs of approximately 23 bp. The miRNA 
duplex is incorporated into the RNA induced 
silencing complex (RISC), after which one of 
the two RNA strands is selected as the mature 
miRNA and serves as an antisense guide to target 
mRNA. The passenger strand, named miRNA*, 
is degraded and plays no further part in RNAi. 
Complete base-pairing between the guide strand 
and its cognate mRNA leads to target cleavage 
by Ago 2, while partial base-pairing leads to 
translational suppression. The RNase H activity, 
PAZ and PIWI domains of Ago2 provide critical 
function to the slicing component of the RNAi 
machinery [16]. The mechanism of translational 
suppression mainly involves mRNA destabiliza-
tion in processing bodies (P-bodies) [17] and, to a 
lesser extent, inhibition of ribosome function [18]. 
P-bodies are cytoplasmic foci containing mRNA 
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targeted by miRNAs that are complexed to Ago1 
and Ago2 from the RISC, and also include the 
scaffold protein GW182. Evidence indicates that 
complementarity between the seven nucleotides 
of the seed region of the guide strand, which 
comprise nucleotides 2–8 from the 5´ end, 
and the target are all that is required to affect 
silencing and degradation in P-bodies [19].
The HBV genome is well suited to RNAi-
based targeting. The pgRNA, which is greater 
than genome length, is an essential replication 
intermediate that may be disabled using RNAi-
based methods [20–24]. There are four major 
overlapping open reading frames of the compact 
viral genome: preC/core, polymerase, surface and 
X (Figure 1). HBV transcripts also overlap with 
each other and have common 3´ sequences that 
are defined by the single transcription termina-
tion signal. Single RNAi effector molecules may 
therefore have cognates in more than one of the 
viral RNAs. Supporting the idea that HBV is a 
suitable target for RNAi-based therapy, many 
sites of the viral genome have been successfully 
targeted by engineered synthetic and expressed 
RNAi activators [20,25]. Interestingly, the HBV e 
packaging signal, which is a highly structured 
sequence with duplex stem and loop regions that 
are bound to viral and cellular proteins, was found 
to be a good RNAi target sequence [20]. Overall, 
results suggest that no particular sequence of the 
HBV genome is particularly sensitive to silenc-
ing; rather it is the sequence-specific properties 
of the RNAi activators themselves that influence 
their effectiveness.
Synthetic anti‑HBV activators of RNAi
Synthetic activators of RNAi have been used 
to silence HBV replication in vitro and in vivo 
[26–29]. siRNAs typically comprise dsRNAs 
of approximately 21 bp that have two nucleo-
tide overhangs at their 3´ ends. They therefore 
resemble mature miRNA duplexes and activate 
RNAi at the stage of guide strand incorpora-
tion into RISC [30]. As with all gene therapies, 
synthetic siRNAs have limitations in their 
application to treating HBV. Susceptibility to 
serum nuclease degradation [31], unfavorable bio-
distribution, nonspecific immune stimulation 
[32,33] and silencing of host genes through par-
tial hybridization to cellular mRNA, are some 
of the limiting factors. These undesirable effects 
may be attenuated by chemical modification of 
siRNAs, and this type of alteration has there-
fore been widely used to improve therapeutic 
properties of siRNAs. Initially, modifications to 
siRNAs included incorporation of 2 -´O-methyl, 
2 -´fluoro or 2-methoxyethyl moieties, to increase 
durability of silencing by siRNAs and prolong 
Figure 2. The RNAi pathway. Pri-miRNA sequences that are processed by the Drosha/DGCR8 
microprocessor complex produce pre-miRNAs. Processing of pre-miRNAs yield miRNA duplexes. One 
of the strands from the miRNA duplex is selected within RNA induced silencing complex and guides 
the complex to target mRNA. Exogenous RNAi activators mimic pri-miRNA, pre-miRNA or mature 
miRNA and enter the pathway where indicated. 
Pre-miRNA: Precursor miRNA; Pri-miRNA: Primary miRNA. 
Reproduced with permission from [139] © 2010–2013 Prous Science, S.A.U. or its licensors.  All rights 
reserved.
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their plasma stability [34,35]. Addition of moi-
eties to the 2´ and 4´ positions of the ribose [36], 
changes to the natural phosphodiester linkages, 
and substitution of the ribose for sugars, such 
as hexitol, were subsequently used [37–40]. Inter-
estingly, positioning of modifications at spe-
cific nucleotides within the sense or antisense 
strands of siRNAs influences their efficacy. 
For example, boranophosphonate-modified 
siRNAs show improved resistance to nucleases; 
however, incorporation of this modification at 
the center of the guide strand results in loss of 
silencing efficacy [41]. There are several chemical 
modifications to siRNAs that have resulted in 
improved therapeutic properties; however, only 
recent developments and those that are perti-
nent to advancing use of potentially therapeutic 
anti-HBV siRNAs will be discussed here.
One of the first studies to demonstrate enhanced 
anti-HBV activity of chemically modified siRNAs 
in a murine model was conducted by Morrissey 
et al. [42]. The siRNAs contained numerous modi-
fications: inverted abasic residues at the 5´  and 3´ 
ends; phosphorothioate linkages; and substitu-
tion of 2´ hydroxyl groups with fluoro, methyl 
or H groups. After administration as naked mol-
ecules, these siRNAs inhibited HBV replication 
in vivo; however, the high dose that was neces-
sary to be effective was impractical for therapy. 
Stable nucleic acid lipid particle (SNALP) formu-
lations, which assemble into uniform small size 
particles, were then used as a means for delivery. 
SNALP-delivered siRNAs resulted in the suppres-
sion of markers of HBV replication over a 6-week 
period in mice subjected to hydrodynamic injec-
tion (HDI) with an HBV replication-competent 
plasmid. Attenuation of siRNA-mediated immu-
nostimulation, affected by chemical modification, 
was also demonstrated in this study.
Other chemical modifications to anti-HBV 
siRNAs that have recently been investigated 
include altritol-containing nucleic acids, which 
are distinguished by containing six-membered 
sugar moieties (Figure 3) [43]. Helix stability and 
maintenance of RNA-like A-form structures are 
enhanced by the presence of the altritol moiety 
and may improve siRNA-mediated silencing 
[40]. Altritol nucleic acid (ANA) modifications 
were introduced at the 3´ ends of the sense and 
antisense strands, and also at the 5´  end of the 
sense strand of an anti-HBV siRNA, then com-
plexed with liposomal vectors [43]. The ANA-
modified siRNA-lipoplexes generally displayed 
increased anti-HBV efficacy when compared 
with their unmodified counterparts; however, 
they did cause minor hepatotoxicity. Analysis 
of immunostimulation using a cytometric bead 
array revealed that unmodified siRNA induced 
release of proinflammatory cytokines which 
was markedly attenuated in mice receiving the 
ANA-modified siRNA-lipoplexes.
To assess the efficacy of a different class of 
chemical modification, 2 -´O-guanidinopropyl 
(GP) residues were incorporated into anti-HBV 
siRNAs (Figure 4) [44]. These alterations were 
included at each nucleotide position from 
two to 21 of the guide strand. In transfected 
liver-derived human Huh7 cells, GP-modified 
siRNAs were more effective than unmodified 
siRNAs and decreased gene expression by up to 
95% [45]. Both unmodified and GP-modified 
siRNAs did not stimulate interferon-associated 
pathways or decrease cellular viability, but sta-
bility was improved by incorporation of the GP 
modification. GP-modified siRNAs also caused 
significant knockdown of markers of viral rep-
lication (HBsAg and circulating viral particle 
equivalents) in vivo using a murine HDI model.
Expressed RNAi activators against HBV 
infection
Treatment of chronic HBV infection by har-
nessing RNAi will require sustained presence 
of silencing molecules. Utilization of stable DNA 
templates encoding RNAi expression cassettes 
has the potential to enable prolonged inhibition 
of HBV replication [46]. Expression cassettes 
comprising DNA also have the advantage of 
HO
HO
OH
O
Base
4´
4´
5´
5´
6´ 1´
2´
3´
ANA
siRNA
Figure 3. Structure of altritol nucleic acid containing two six-membered 
hexitol sugars incorporated into the sense and antisense strands of an 
anti-HBV siRNA. Structure of the six membered hexitol sugar is shown. 
ANA: Altritol nucleic acid.
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compatibility with highly efficient viral delivery 
vectors. Exogenously expressed RNAi interme-
diates vary, and may enter the RNAi pathway 
at different stages as mimics of pri-miRNAs, 
pre-miRNAs and miRNA-like structures 
(Figure 2). Typically anti-HBV RNAi expression 
cassettes contain a Pol II or Pol III promoter, a 
template encoding the RNAi activator sequence 
and a transcription termination sequence. Pol III 
transcription regulatory elements, usually U6 
or H1 promoters, have been widely used for 
expression of shRNA that act as mimics of 
pre-miRNA. An advantage of these transcrip-
tion regulatory elements is that they are capable 
of efficiently generating short transcripts with 
defined 5´  and 3´ ends [24]. Furthermore, they are 
active in a wide range of tissues, are small in size 
and contain most required regulatory elements 
upstream of the transcription initiation site [47].
To date, a variety of highly effective anti-HBV 
RNAi activators have been expressed from both 
Pol II and Pol III promoters. McCaffrey was 
the first to demonstrate the anti-HBV potential 
of expressed shRNAs in a murine model [48]. 
This observation was subsequently supported 
by other studies in which silencing in cultured 
cells and in vivo has been reported for Pol III-
expressed shRNAs [24,49], long hairpin RNAs 
targeting the X open reading frame [50] and other 
HBV mRNA sequences [51–53]. As a substitute 
for the powerful U6 transcription regulator, H1 
and tRNALys3 Pol III promoters have also been 
used successfully in anti-HBV expression cas-
settes [54]. In an alternative approach, Blazquez 
et al. demonstrated the advantage of utilizing 
both RNAi and U1 small nuclear RNA ribo-
nucleoprotein-based inhibition as a therapeu-
tic strategy against HBV [55,56]. Combinatorial 
approaches have also been used to improve HBV 
silencing, in which RNAi activators were used in 
conjunction with lamivudine, a licensed HBV 
drug [57]. In addition to the targeting of HBV 
genes, silencing of host dependency factors that 
are required for viral replication, such as heat 
shock cognate 70, may be used to limit risk of 
escape mutation occurring in the virus [58].
In 2006, Grimm et al. revealed that the high 
level of transcription of anti-HBV shRNAs from 
the U6 Pol III promoter resulted in toxicity in vivo 
from saturation of the endogenous RNAi pathway 
[59]. This important observation emphasized the 
need for controlled expression of RNAi activators, 
and led to investigating use of Pol II and weaker 
Pol III transcriptional elements to produce exog-
enous RNAi intermediates. Although inducible 
expression of Pol III promoters has been described 
[60], Pol II regulators offer more versatility. Natural 
expression of pri-miRNAs from Pol II promoters 
has been harnessed to aid the design of artificial 
pri-miRNA Pol II expression sequences that tar-
get HBV genes [21], and multimerization of artifi-
cial pri-miRNAs to simulate natural pri-miRNAs 
allows for simultaneous targeting of several viral 
sites [61]. This approach improves efficacy and 
diminishes risk of viral escape. The exact number 
of simultaneously acting HBV-silencing RNAi 
activators required to prevent escape remains to 
be determined; however, it is likely that a trimeric 
cassette will be sufficient. Four silencing com-
ponents of an artificial polycistronic pri-miRNA 
cassette, targeting the larger, more flexible HIV 
genome, were adequate to prevent emergence of 
viral escape [62,63]. A further advantage of using 
artificial pri-miRNAs over sh- or si-RNAs relates 
to the notion that exogenous sequences intro-
duced at earlier steps of the RNAi pathway are 
processed more efficiently. It is thought that each 
stage of the pathway is functionally linked to the 
preceding event during miRNA biogenesis. Intro-
ducing exogenous pri-miRNAs into cells should 
therefore improve silencing, since their natural 
counterparts are produced at the initial stages of 
miRNA biogenesis.
Alternatives to RNAi‑based HBV gene 
therapies
A recent alternative approach to inhibiting HBV 
replication using gene therapy entailed use of 
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Figure 4. 2´-O-guanidinopropyl modifications at a single nucleotide of the 
guide strand of an anti-HBV siRNA.
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an external guide sequence (EGS) to direct 
RNase P to cleave HBV RNA [64]. The EGS 
was designed to hybridize with HBV to form a 
secondary structure that mimics that of a tRNA 
precursor. RNase P naturally cleaves tRNA pre-
cursors and, using the EGS to create an artificial 
substrate, caused efficient degradation of HBV 
RNA. Good efficacy in cell culture and in vivo, 
using an attenuated Salmonella bacterial strain 
as vector, was demonstrated.
Failure to effectively treat chronic HBV 
infection has largely been ascribed to the per-
sistence of the episomal cccDNA replication 
intermediate [65,66]. As cccDNA is epigenetic, 
it may serve as a dormant viral reservoir in the 
nucleus of hepatocytes. Although RNAi acti-
vators have shown promise as novel therapies, 
they inhibit viral replication post-transcrip-
tionally. This mechanism of action is similar 
to that of licensed nucleoside and nucleotide 
analogs, which are incapable of eliminating 
cccDNA. Inability of RNAi activators to target 
the cccDNA directly is potentially a limitation, 
and reactivation of viral replication may occur 
after withdrawal of gene silencing sequences. 
Sequence-specific DNA-binding proteins, such 
as those derived from the zinc finger eukaryotic 
transcription factors, have been investigated as 
potential inhibitors of HBV gene expression 
[67]. Each zinc finger is capable of binding a spe-
cific nucleotide triplet and zinc finger proteins 
(ZFPs), comprising modules of fingers, may be 
designed to bind intended target DNA [68]. The 
ability of several ZFPs to inhibit gene expres-
sion from duck HBV (DHBV) cccDNA has 
been reported [67]. Arrays were designed to bind 
to either 9 or 18 bp target sequences within the 
enhancer region of DHBV and inhibit binding 
of transcription factors to viral regulatory ele-
ments. When tested in vitro, the ZFPs inhibited 
pgRNA expression by 32–42%. This resulted 
in a decrease in expression of core and surface 
proteins, with concomitant reduction in viral 
particle production.
Zinc finger arrays have also been successfully 
fused to nuclease domains to generate engi-
neered DNA ‘molecular scissors’. Zinc finger 
nucleases (ZFNs), comprising ZFPs coupled to 
the nuclease domain of the FokI endonuclease, 
act as obligate dimers and are capable of intro-
ducing double-strand breaks at specific DNA 
target sequences [69,70]. Site-directed mutagene-
sis may result if the error prone, nonhomologous 
end joining pathway is activated to repair the 
double-stranded breaks. Cradick et al. investi-
gated the ability of modularly assembled ZFNs 
to cleave and disrupt HBV DNA targets [71]. 
ZFN pairs were designed to bind DNA of the 
core gene, particularly at the region encoding 
the overlapping common polyadenylation site. 
Each monomer ZFN component of the dimer 
comprised a three-finger array. A 6 bp spacer 
region was positioned between the left and 
right nucleases, and the dimer targeted an HBV 
sequence of 18 nucleotides. Using a replication-
competent HBV target expression plasmid to 
test efficacy of the ZFNs in vitro, it was demon-
strated that 36% of DNA targets were cleaved. 
In addition, activation of nonhomologous end 
joining resulted in mutations occurring in 6% 
of these cleaved sites. Out of the insertions and 
deletions identified, 81% produced frameshift 
mutations, which should cause disruption of 
translation of the core protein. This was the first 
study to explore designer nucleases as a potential 
anti-HBV gene therapy; however, the ability of 
these ZFNs to disable cccDNA has yet to be 
determined.
Other designer nucleases, the transcription 
activator-like effector nucleases (TALENs) [72,73] 
and the RNA-guided endonucleases (RGENs) 
[74,75], have recently been described. As with 
ZFNs, TALENs act as obligate dimers and 
comprise a transcription activator-like effector 
DNA-binding sequence fused to a FokI endo-
nuclease domain. Sequence-specif ic DNA-
binding domains are generated by concatamer-
ization of transcription activator-like effector 
monomers, where each monomer confers indi-
vidual nucleotide specificity through base rec-
ognition by distinct repeat variable diresidues. 
TALENs have advantages over ZFNs in that 
they are more specific to their intended cog-
nates and are compatible with modular design. 
A major drawback of ZFN engineering is that 
the sequence context of the subunits often has 
a profound influence on target binding [76,77]. 
Unlike ZFNs, TALENs can easily be assembled 
by modular cloning techniques without the need 
for context-dependent selection [78]. In addition, 
TALENs have shown reduced cytotoxicity and 
off-target cleavage when compared with ZFNs 
[79]. While ZFNs and TALENs rely on protein-
based DNA-binding domains, the RGENs use 
an RNA-guide of clustered regularly interspaced 
short palindromic repeats (CRISPRs) to recruit 
Cas9 (CRISPR-associated protein) which acts 
as an endonuclease. Although RGENs have 
recently been exploited for genome engineer-
ing [80–85], further investigation into cleavage 
activity and specificity is needed. TALENs and 
RGENs may therefore provide a promising 
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new approach to treating HBV and other viral 
infections [86].
Cell culture & animal models of HBV 
infection
To date, surrogate models of HBV infection 
have been used to establish the silencing effi-
cacy of RNAi activators. These models imitate 
various stages of viral infection; however, none 
have the capacity to simulate all stages of the 
virus’ life cycle. Only recently has the HepaRG 
cell line been developed to achieve HBV infec-
tion of cells in culture [87]. As an alternative to 
infection of these cells, HBV has been intro-
duced into cultured cells by transient or stable 
transfection of replication-competent plasmids. 
These plasmid-based systems have been widely 
used to assess the antiviral efficacy of the gene 
silencers against HBV. Recent developments 
have revealed a receptor that may be involved in 
natural HBV infection [88]. Sodium taurocholate 
cotransporting polypeptide has been associated 
with the uptake of HBV in hepatocytes. Ectopic 
expression of sodium taurocholate cotransport-
ing polypeptide facilitated the infection of cells 
that are usually not permissive to HBV; further-
more, transfer of this gene to cells in culture 
and in vivo may enable improvement of current 
models of HBV infection [89].
Murine models are currently the most widely 
utilized to assess efficacy of RNAi activators 
in vivo. HDI is a convenient method of achiev-
ing HBV replication in vivo. The procedure 
entails the introduction of a replication-com-
petent HBV plasmid into the liver, which then 
recapitulates viral gene expression, replication 
and release of virus and virus-like particles into 
the circulation [90,91]. Although this model does 
not result in a productive infection in mice, it 
is convenient to establish knockdown in vivo. 
In contrast to the transient expression of HBV 
plasmids in mice subjected to HDI, constitu-
tive and stable virus replication occurs in HBV 
transgenic mice [92]. Therefore, these animals 
are suited to long-term studies on the efficacy of 
HBV gene silencers. However, HBV replication 
in transgenic mice does not mimic all the stages 
of natural HBV infection, such as viral entry and 
cccDNA formation. A third murine model is 
available, in which urokinase plasminogen acti-
vator severe combined immunodeficiency mice 
are xenografted with human hepatocytes [93]. 
Successful infection by HBV has been shown in 
these grafted animals. All stages of the HBV life 
cycle, including formation of the HBV cccDNA 
intermediate, are recapitulated in the animals. 
Drawbacks of the urokinase plasminogen acti-
vator severe combined immunodeficiency xeno-
graft model are that the immune response to 
HBV infection is compromised, and working 
with these animals is technically demanding. 
Consequently, their use for assessing efficacy 
of RNAi-based therapy has not been widely 
employed.
There are two naturally occurring Hepadna­
virus infections that may be used as models 
to develop anti-HBV therapies. Woodchuck 
hepatitis virus [94] and DHBV [95]: both result 
in chronic hepatitis, and have been used to 
model human HBV pathogenesis. Woodchucks 
infected with woodchuck hepatitis virus have 
successfully been used to assess anti-HBV effi-
cacy, of both antiviral drugs and immunostimu-
lators, prior to clinical evaluation (reviewed in 
[96–98]). However, despite similarities in patho-
genesis, differences in immune response and 
viral biology complicate the interpretation of 
efficacy of antiviral drugs tested in woodchucks.
Delivery of HBV‑targeting RNAi activators
Although significant progress has been made in 
developing anti-HBV RNAi activators, in vivo 
delivery of potentially therapeutic sequences 
remains a major hurdle. To date, viral vectors for 
gene therapy have shown the most promise for 
delivery of expressed sequences and represent the 
most commonly used vector in clinical trials. By 
contrast, synthetic siRNAs have typically been 
incorporated into lipoplexes or conjugated to 
various molecules to achieve hepatocyte delivery 
after systemic administration.
siRNA delivery
Delivery of siRNAs to the liver is typically 
achieved through the use of various polymers, 
conjugates and lipoplexes as vectors. The syn-
thetic nature of these carriers means that they 
are conveniently amenable to scalable synthesis, 
which is useful for clinical application. Obstacles 
that restrict efficient delivery of siRNAs to liver 
cells in vivo include susceptibility of the cargo 
to nuclease degradation, an innate immune 
response, sequestration by the reticuloendothe-
lial system, inadequate tissue targeting, aggre-
gation and instability of vectors. Some of these 
challenges may be addressed by optimizing vec-
tor formulations, employing different methods 
that enhance uptake of siRNAs by target cells, 
achieving siRNA protection from serum nucle-
ase degradation and coupling of ‘stealth’ mol-
ecules to enable evasion of innate and adaptive 
immune responses [99].
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A large variety of siRNA-containing lipid 
vector formulations have been designed for use 
in vivo, including liposomes, micelles, emul-
sions and SNALPs [100]. Assembly with siRNAs 
occurs through electrostatic interactions of lipids 
containing amines that bind negatively charged 
RNA and form lipid bilayer complexes [101]. 
Critical parameters that need to be controlled 
include optimization of the ratio of siRNA to 
lipid, a uniform small particle size, appropriate 
pharmacokinetics, tissue targeting, prevention 
of siRNA degradation and minimizing toxicity 
[100]. Selection of lipids for incorporation into 
the lipoplexes is also crucially important [102–104].
SNALPs are made up of cationic and fuso-
genic lipids, which facilitate delivery to target 
cells and endosomal release of the siRNA car-
gos. These vectors have been employed to deliver 
siRNAs in guinea pigs [105], nonhuman primates 
[106] and mice [42]. In a study aimed at developing 
RNAi therapy for HBV, Morrissey et al. used 
SNALPs covered with PEG to provide a neutral, 
hydrophilic environment and to enhance par-
ticle stability [42]. Anti-HBV siRNAs formulated 
with SNALPs were injected intravenously fol-
lowing HDI of mice. siRNA–SNALPs improved 
HBV silencing compared with unformulated 
siRNA, and this was thought to be as a result 
of prolonged half-life in vivo. Administration of 
siRNA–SNALPs also suppressed serum levels 
of HBV DNA for up to 6 weeks when using a 
weekly dosing regimen [42].
In another study, Hean et al. employed a 
cationic lipoplex comprising a helper fusion 
lipid dioleoylphosphatidyl ethanolamine, liver-
targeting cholesterol galactoside component 
and ANA-modified anti-HBV siRNAs. HBV 
silencing was achieved in transgenic mice with-
out triggering the innate immune response or 
inducing toxicity in injected mice [43]. Other 
studies reported anti-HBV efficacy of unmodi-
fied siRNAs in lipoplex formulations [107,108]. 
Complexes included a polyamine-conjugated 
cholesterol [108] or an aminoxy cholesterol lipid 
to enable postcoupling of ‘stealth’ PEG moi-
eties [107]. The vectors achieved passive hepato-
tropism, and silencing of HBV replication in 
HBV transgenic mice was observed over a period 
of 4 weeks [107].
Many polymer-based siRNA vectors achieve 
gene delivery by encapsulating and condensing 
nucleic acids into small particles that are taken 
up into cells by endocytosis [109]. Polymers have 
been used to administer plasmid DNA; however, 
the in vivo efficiency of this type of gene deliv-
ery system is modest. Understandably, interest 
has shifted to focusing on use of polymers to 
deliver smaller siRNAs to their more accessible 
cytoplasmic site of action. As with lipid-based 
vectors, a RNA-binding cationic group of poly-
mer carriers is an important feature. These cat-
ionic polymers may be divided into synthetic 
(e.g., polyethylenimine and poly-l-lysine) and 
natural (e.g., chitosan and cationic polypeptides) 
groups.
In a recent study, dynamic polyconjugates 
were designed to deliver siRNAs to hepatocytes 
of HBV transgenic mice and nonhuman pri-
mates [110]. This dynamic polyconjugates com-
plex was targeted to liver cells using N-acetyl-
galactosamine-conjugated melittin-like peptide 
(NAG-MLP) as a ligand. In transgenic mice and 
nonhuman primates, HBV silencing efficacy of 
siRNAs was assessed by determining the concen-
tration of the product of an endogenous hepatic 
target gene, coagulation factor VII (F7), in the 
plasma. In mice, administration of 0.01 mg/kg 
cholesterol–siRNA reduced F7 expression by 
approximately 50%, while a higher dose of 
0.1 mg/kg cholesterol–siRNA suppressed F7 
expression by approximately 97% at 48 h after 
injection. Additionally, HBsAg secretion was 
suppressed by approximately 80% for 4 weeks 
after coinjecting a combination of cholesterol 
and anti-HBV siRNA, while the level of viral 
particle eqivalents decreased by approximately 
90% for 4 weeks following single administration. 
Importantly, serum activities of liver-derived 
ALT, AST and alkaline phosphatase were not 
increased, even when a high dose of NAG-MLP 
was administered [110]. In nonhuman primates 
(cynomolgus monkeys), expression of F7 in the 
plasma was reduced by approximately 30–60% 
after coinjection with 1 mg/kg NAG-MLP and 
2 mg/kg cholesterol–siRNA, while coinjec-
tion with 3 mg/kg NAG-MLP and 2 mg/kg 
cholesterol–siRNA resulted in approximately 
97–99% knockdown in F7 expression. Inter-
estingly, F7 expression in the plasma decreased 
by approximately 80% for at least 4 weeks 
without evidence of toxicity. Collectively, data 
from this study demonstrated that codelivery of 
NAG-MLP with cholesterol–siRNA suppresses 
HBV replication and expression of an endog-
enous gene in murine and nonhuman primate 
models, respectively. These observations suggest 
that the approach could be exploited to advance 
RNAi-based HBV therapy.
In a study conducted by Kim et al., apoA-I, a 
high-density lipoprotein, was utilized in the lipo-
somal formulation for siRNA administration to 
hepatocytes of transgenic HBV mice [111]. apoA-I 
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was formulated on the lipid bilayer surface of 
the cationic lipid 1,2-dioleoyl-3-trimethylam-
monium-propane. Additionally, the cholesterol 
moiety was included to confer liver tropism. Data 
from this study revealed that administration of a 
single dose of apolipoprotein-siRNAs (≤2 mg/kg) 
resulted in decreased expression of viral protein 
in injected mice for up to 8 days [111].
In the only Phase I clinical trial reported to 
date, a formulation termed NUC B1000 was 
evaluated for its safety and anti-HBV activity 
in individuals with chronic HBV infection [112]. 
Four different HBV-targeting shRNAs, encoded 
in a plasmid and complexed to cholesteryl sper-
midine nanoparticles, were administered to 
patients. Recipients displayed side effects, such 
as pharyngitis, chills, muscle pain and fever, 
after approximately 4–7 h post-NUC B1000 
administration (5 mg of a single DNA dose); 
however, these effects were attenuated after treat-
ment with antipyretics. Furthermore, induction 
in IFN-g and IL-10 was observed in two recipi-
ents, while an induction in IL-8 was observed in 
a single participant after NUC B1000 adminis-
tration. Decreased concentrations of HBsAg and 
HBV DNA were not reported in this study and 
suggest that dose increment may be required to 
suppress markers of viral replication.
Viral vectors for HBV gene therapy
The three main types of recombinant viral 
vectors that have been used for delivery of 
anti-HBV-expressed sequences are adenoviruses 
(Ads), adeno-associated viruses (AAVs) and len-
tiviruses (reviewed in [113]). To date, ana lysis of 
efficacy has progressed to a stage of testing in 
murine models and currently there are no gene 
therapy clinical trials that use viral vectors 
against HBV infection.
Globally, Ads have been used in the majority 
of clinical trials that rely on viral vector deliv-
ery (over 430 trials, constituting 23% of viral 
vector trials) [201]. Ads have several features that 
are useful for delivery of anti-HBV expression 
cassettes. They are: 
n	Naturally hepatotropic; 
n	Capable of transducing dividing and non-
dividing cells;
n	Amenable to high titer preparation; 
n	Capable of packaging large DNA inserts of up 
to 32 kb in length; 
n	Compatible with modification by polymers;
n	Rarely integrated into host chromo somes 
[114–117]. 
A drawback of the therapeutic use of Ads is 
their powerful stimulation of innate and adap-
tive immune responses. This property may result 
in serious toxicity and attenuation of transgene 
delivery to target tissues. Countering immuno-
stimulation by Ads may be achieved by conjuga-
tion to polymers such as PEG [118], in addition 
to the removal of virus protein-coding sequences 
from first generation, Ads to propagate second 
generation Ads and third generation Ads (gutless 
or helper dependent [HD] Ads) [119]. To date, 
five studies have been reported that demon-
strate the utility of Ads for delivering anti-HBV 
sequences [53,120–123]. Early results demonstrated 
that first generation Ads are capable of efficient 
delivery of RNAi expression cassettes to the 
liver, to cause >90% knockdown of markers of 
HBV replication [53,120]. However, the effect was 
limited by the transient nature of suppression. 
Subsequently, it was shown that the PEG-ylation 
of first generation Ads carrying Pol III shRNA 
expression cassettes improved vector safety and 
efficacy [121]. HD Ads have delivered HBV-
silencing sequences, and differences in HBV 
replication inhibition are largely ascribed to vari-
able antiviral efficacy of the transduced RNAi 
expression cassette [122,123]. Nevertheless, the 
prolonged expression of transgenes that may be 
achieved with HD Ads is an important feature 
that is potentially useful for the treatment of 
chronic HBV infection.
In contrast to Ad vectors, AAVs have far 
smaller ssDNA genomes of 4.7 kb [124]. Recom-
binant AAVs are attractive vectors for RNAi 
therapy as they: 
n	Are not associated with pathology; 
n	Have low immunostimulatory properties;
n	Have broad tissue tropism;
n	Are capable of transducing dividing and non-
dividing cell lines;
n	Persist episomally with low risk of integration 
into the host genome [125,126]. 
AAVs, like other viral vectors, are amenable 
to the combination of viral serotypes to produce 
chimeras (pseudotypes) with desired tissue tro-
pism and immunoevasive properties. This may 
entail the combination of one AAV genome (typ-
ically AAV2), with the capsid of another AAV 
serotype. Chen et al. produced a self-comple-
mentary double-stranded AAV2/8 pseudotyped 
vector for the hepatotropic delivery of anti-HBV 
RNAi-activating sequences in vivo [127]. Signifi-
cant knockdown was achieved that peaked at 
21 days after vector administration. The silenc-
ing effect then waned over 4 months, and was 
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thought to have resulted from an immune 
response to the vector [127,128]. The group then 
went on to show that changing the vector cap-
sid pseudotype to that of AAV2/9 overcame 
the immune response and re-established HBV 
silencing [128]. AAVs are gaining in popularity 
and have shown promise for liver gene therapy 
to treat hemophilia B [129]. Although AAVs are 
used in only 5% of worldwide gene therapy tri-
als [201], this proportion is likely to increase in 
the near future.
Recombinant retroviral vectors (lentiviruses 
and g-retroviruses) were the first vectors to be 
used to transduce hepatocytes [130] and the first 
to be used in clinical trials [131]. Proviruses 
derived from these vectors integrate into the 
host genome to enable long-term transgene 
expression [132]. Although stable transgene 
expression is a significant benefit of transduc-
tion by lentiviral vectors, modest efficiency of 
hepatocyte transduction following systemic 
administration has limited their use for HBV 
therapy. As a result, lentiviral vectors have been 
favored for gene therapy of inherited diseases 
and HIV-1 infection [133]. An application for 
these vectors to RNAi-based treatment of HBV 
infection may, however, be found with ex vivo 
delivery. This would entail transduction of 
hepatocytes in culture, followed by their rein-
fusion to repopulate HBV-infected livers with 
hepatocytes that express anti-HBV expression 
cassettes. Constitutive production of the HBV-
silencing sequences should make the hepato-
cytes refractory to HBV infection and provide a 
selective growth advantage. Ex vivo engraftment 
of hepatocytes has been achieved in nonhuman 
primates [134,135] and in the treatment of hyper-
bilirubinemic Gunn rats [136]. The remarkable 
progress that has recently been made with prop-
agating hepatocyte-like cells from induced plu-
ripotent stem cells [137] suggests that an ex vivo 
approach to RNAi-based HBV therapy may be 
feasible in the near future.
An interesting alternative approach, termed a 
‘Trojan horse’, introduced RNAi activators tar-
geting HBV that were expressed from a recom-
binant HBV vector [138]. Successful knockdown 
of HBV gene expression in cultured hepato-
cytes was observed. The vector may be afforded 
immunoprotection by the Dane particles in an 
infected patient’s blood; however, the clinical 
utility of this approach remains to be established.
Conclusion
Since the landmark discovery of RNAi-based 
gene silencing in 1998 [13], several studies have 
reported on the successful harnessing of the 
pathway to inhibit pathology-causing genes. 
Since RNAi functions in metazoan cells and 
viruses are dependent on parasitizing cells for 
their gene expression and replication, silenc-
ing of viral mRNA is well-suited to countering 
viral infection. Dependence of HBV prolifera-
tion on a pgRNA replication intermediate, as 
well as viral protein-coding transcripts, make 
it a good candidate for RNAi-based therapy. 
However, despite the impressive pace at which 
development of RNAi-based HBV therapy has 
progressed, obstacles need to be overcome before 
this method of treatment becomes a reality. As 
nucleic acids, RNAi activators do not have the 
properties of traditional small molecule drugs, 
and they require vectors for delivery to target 
hepatocytes. This poses challenges for optimiz-
ing pharmacokinetics, dose regulation, efficacy 
following repeat vector administrations and 
evasion of immune stimulation. HBV silencing 
observed in vitro often does not correlate with 
inhibition of viral replication in vivo. Moreover, 
most cell culture and animal models of HBV 
replication that have been tested do not simu-
late all the steps of HBV infection in humans, 
and this complicates successful extrapolation to 
clinical trials [112].
Studies to date have reported on various 
approaches to countering replication of HBV, 
and different parts of the viral genome have 
been effectively targeted. It appears that there 
is no particularly favorable target within the 
viral genome. Synthetic and expressed RNAi 
activators have both been used successfully and 
each of the groups have their advantages and 
disadvantages. Although unmodified synthetic 
siRNAs achieve silencing of HBV replication in 
cultured cells and in vivo, inclusion of chemical 
moieties is useful to enhance their efficacy. Nev-
ertheless, since siRNAs are not renewable within 
cells, repeated administrations of siRNA-con-
taining nonviral vector formulations will be 
a requirement for their anti-HBV therapeutic 
utility. Expressed anti-HBV RNAi activators 
may provide more durable silencing than their 
synthetic counterparts, which is useful to inhibit 
HBV replication over a long period. However, 
the requirement for viral vectors to deliver 
anti-HBV expression cassettes poses additional 
problems. Safety is a particular concern and 
this has been highlighted by past experiences 
of using adenoviral and retroviral vectors for 
treatment of inherited diseases. Difficulties with 
large scale preparation of recombinant viral vec-
tors pose another obstacle to clinical application.
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Executive summary
Harnessing RNAi for therapeutic gene silencing
	n RNAi is a conserved gene silencing pathway that is present in metazoan cells.
	n Synthetic or expressed exogenous intermediates of the RNAi pathway may be introduced into cells to achieve silencing of 
pathology-causing genes.
Inhibiting HBV replication with synthetic activators of RNAi
	n Incorporation of chemical modifications into anti-HBV siRNAs improves their silencing efficacy, specificity, stability and limits off-target 
effects in vivo.
	n Anti-HBV siRNAs containing a combination of different chemical modifications was one of the first demonstrations of the therapeutic 
potential of RNAi-based gene silencing.
	n Recently it has been shown that altritol nucleic acid-modified siRNAs attenuate immunostimulation without compromising efficacy 
in vivo.
	n Incorporation of a 2´-O-guanidinopropyl moiety within siRNAs results in improved activity, stability and specificity in cell culture and 
in vivo.
Expressed RNAi activators against HBV infection
	n RNAi activators can be expressed from both Pol II and Pol III promoters.
	n Pol II expression cassettes may provide the advantage of regulated, tissue-tropic expression.
	n RNAi is unlikely to remove covalently closed circular DNA (cccDNA), the replication intermediate responsible for reactivation of HBV 
replication following treatment withdrawal.
Alternatives to RNAi-based gene therapies
	n Latent cccDNA pools may cause reactivation of viral replication after cessation of therapy.
	n Targeted mutation of cccDNA with transcription activator-like effector nucleases or zinc finger nucleases in combination with anti-HBV 
RNAi-based therapies may provide synergy for treating the chronic infection.
In vitro & in vivo models of HBV infection
	n Only the HepaRG cell line can be infected with HBV.
	n Murine hydrodynamic injection and transgenic models simulate HBV replication, but not infection of hepatocytes and formation of 
cccDNA.
	n The urokinase plasminogen activator severe combined immunodeficiency humanized mouse model is able to maintain cccDNA, thereby 
providing the most accurate murine HBV infection disease model currently available.
siRNA delivery systems
	n Both lipid- and polymer-based vectors allow efficient delivery of siRNAs to target tissues.
	n The cationic group is a critical component in both these approaches.
	n Most siRNA delivery studies have utilized cationic liposomes as they have:
– High transfection efficiency;
– Improved pharmacokinetic properties;
– Low immunostimulation and toxicity;
– Well-established protocols for formulation.
Viral vectors for gene therapy
	n Adenoviruses (Ads) are widely used in clinical trials, but are associated with powerful immunostimulation.
	n Ads are efficiently hepatotropic, and have been used successfully to deliver HBV gene silencers to HBV transgenic mice.
	n The small adeno-associated virus genome size may accommodate RNAi cassettes. 
	n Adeno-associated viruses are also less immunogenic than Ads and display liver tropism.
	n Lentiviral vectors are not suitable for HBV therapy in vivo, but have potential use for ex vivo treatment strategies.
Conclusion
	n Use of chemically modified siRNAs, RNAi expression cassettes and cccDNA-disabling engineered nucleases have potential for 
developing more effective HBV therapies.
	n Efficient and safe delivery vectors are required to achieve the sustained HBV gene silencing required to treat the virus infection.
	n Recent improvements in delivery vector design and models of HBV infection should fast track in vivo studies of gene therapy-based 
anti-HBV efficacy.
It is unclear whether RNAi-based drugs will 
be capable of eradicating the troublesome HBV 
cccDNA replication intermediate. Advancing use 
of engineered nucleases is therefore particularly 
appealing. The specificity and efficiency of tar-
get sequence cleavage by TALENs may well find 
useful application to disabling HBV cccDNA. 
Investigating synergies between gene silencing 
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and other HBV therapeutic approaches will be 
interesting. Combination of RNAi-based treat-
ment with sequence-specific nucleases may well 
provide the means for effectively eliminating 
the virus.
Future perspective
The EMA approved the f irst human gene 
therapy for commercial use in 2012. If this 
treatment of lipoprotein lipase def iciency 
proves successful, it is likely to pave the way 
for an upsurge of gene therapies for a wide 
variety of diseases. An anti-HBV gene ther-
apy for chronically infected patients would 
be important to a large demographic in sub-
Saharan Africa and parts of Asia, and poten-
tially could diminish serious morbidity and 
mortality associated with the infection. The 
significant advances in nucleic acid vectorol-
ogy, together with improvements in efficacy of 
antiviral sequences, are providing momentum 
to the field. Moreover, the availability of animal 
models that simulate human persistent HBV 
infection more closely should facilitate progress 
to evaluation in a clinical setting. Both inter-
feron and nucleotide/side analogs are expected 
to remain the primary HBV therapies for the 
foreseeable future. However, clinical applica-
tion of gene therapy for HBV will no doubt 
lead to changes in treatment regimens, and 
future protocols may include combinations of 
the different treatment modalities.
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20-O-GuanidinopropylSilencing hepatitis B virus (HBV) gene expressionwith exogenous activators of the RNA interference (RNAi)
pathway has shown promise as a newmode of treating infection with the virus. However, optimizing efﬁ-
cacy, speciﬁcity, pharmacokinetics and stability of RNAi activators remains a priority before clinical appli-
cation of this promising therapeutic approach is realised. Chemical modiﬁcation of synthetic short
interferingRNAs (siRNAs) provides themeans to address these goals. This study aimed to assess thebeneﬁts
of incorporating nucleotides with 20-O-guanidinopropyl (GP) modiﬁcations into siRNAs that target HBV.
Single GP residues were incorporated at nucleotide positions from 2 to 21 of the antisense strand of a pre-
viously characterised effective antiHBV siRNA. When tested in cultured cells, siRNAs with GP moieties at
selected positions improved silencing efﬁcacy. Stability of chemically modiﬁed siRNAs in 80% serum was
moderately improved and better silencing effectswere observedwithout evidence for toxicity or induction
of an interferon response. Moreover, partially complementary target sequences were less susceptible to
silencing by siRNAswith GP residues located in the seed region. Hydrodynamic co-injection of siRNAswith
a replication-competentHBVplasmid resulted inhighly effective knockdownofmarkers of viral replication
in mice. Evidence for improved efﬁcacy, reduced off target effects and good silencing in vivo indicate that
GP-modiﬁcations of siRNAs may be used to enhance their therapeutic utility.
 2013 Elsevier Ltd. All rights reserved.1. Introduction
Hepatitis B virus (HBV) infects the liver and may cause acute or
chronic hepatitis. (reviewed in1,2) Infection during early life, which
may occur perinatally or as a result of horizontal spread in chil-
dren, carries a high risk for chronicity. Globally it is now estimated
that 350 million people are chronically infected with HBV. These
individuals have an increased likelihood of developing complicat-
ing cirrhosis and hepatocellular carcinoma. Current drugs that
have been approved for HBV treatment include the nucleotide
and nucleoside analogues, which act by inhibiting the viral reverse
transcriptase, as well as the immunomodulators, interferon alpha-
2a and PEGylated interferon alpha-2a.3 Although these drugs are
capable of suppressing viral replication to reduce liver damage, a
limitation is that they rarely clear the infection. Development ofmore effective drugs that are capable of eliminating HBV therefore
remains an important priority.
Harnessing the RNA interference (RNAi) pathway has been
shown to inhibit HBV gene expression effectively and is believed
to have therapeutic potential. (reviewed in4,5) RNAi is a natural
gene silencing mechanism that occurs in cells of a variety of organ-
isms including mammals, fungi and plants. (reviewed in6,7) Natu-
rally, expression of primary microRNAs (pri-miRNAs) initiates
activation of this pathway. Cleavage of pri-miRNAs by the nuclear
microprocessor complex, comprising Drosha and DGCR8, then re-
sults in formation of precursor miRNA (pre-miRNA) hairpins. After
transport of these hairpins to the cytoplasm, they are processed by
Dicer to form short duplex microRNAs (miRNAs) of about 23 base
pairs. Incorporation of a miRNA into the RNA Induced Silencing
Complex (RISC) is followed by selection of one of the two RNA
strands to serve as a guide sequence for mRNA inactivation. Com-
plete base-pairing between a guide and its cognate leads to mRNA
degradation, while partial base-pairing leads to translational sup-
pression. To silence HBV gene expression, the RNAi pathway can
be reprogrammed with exogenous mimics that encode HBV-tar-
geting guides. DNA cassettes that express antiHBV pri-miRNAs8,9
6146 M. D. Marimani et al. / Bioorg. Med. Chem. 21 (2013) 6145–6155and pre-miRNAs,10,11 as well as synthetic miRNA analogues12–14
have been used successfully to inhibit replication of the virus.
Synthetic small interfering RNAs (siRNAs) resemble miRNA du-
plexes and activate RNAi at the stage of guide strand incorporation
into RISC. (reviewed in6) siRNAs are considerably smaller than
pri-miRNA- or pre-miRNA-encoding DNA cassettes. As a result
efﬁcient delivery to target cells and better dose regulation are
easier to achieve with siRNAs. However, susceptibility of siRNAs
to serum nuclease degradation, problems with delivery and non-
speciﬁc gene silencing remain problematic. Studies have shown
that these difﬁculties may be mitigated by chemical modiﬁcation
of siRNA.15–19 Modiﬁcations have included addition of moieties
to the 20 and 40 positions of the ribose,20 changes to the natural
phosphodiester linkages, and also substitution of naturally
occurring ribose for other sugars such as hexitol.21,22 Importantly,
introduction of chemical modiﬁcations into siRNAs may inﬂuence
several steps leading from their administration to incorporation
into RISC. Predicting efﬁcacy is therefore difﬁcult and empirical
characterization of siRNA actions is necessary.
Synthetic siRNAs have successfully been used to target different
regions of the HBV genome and results support the notion that
RNAi-based gene silencers have therapeutic potential against the
virus.5 In one study, a combination of chemical modiﬁcations to
antiHBV siRNAs was used to inhibit HBV replication in a murine
hydrodynamic injection model of HBV replication.12 These effec-
tive antiHBV siRNAs were modiﬁed by addition of 20-O-methyl
(20-O-Me) and 20-ﬂuoro (20-F) moieties to the ribose, incorporation
of phosphorothioate linkages and inverted deoxy abasic sites. Use
of antiHBV siRNAs containing the hexitol six carbon sugar has also
been used successfully in cultured cells and in vivo.14 In an earlier
study, our groups have shown that incorporation of 20-O-guanidi-
nopropyl (GP) moieties at some positions of an antiHBV siRNAs im-
prove stability and antiviral efﬁcacy in cultured cells.23 The
positive charge of this modiﬁcation also potentially neutralizes
overall negative charge of the siRNAs to facilitate delivery to target
cells. To characterize the utility of this siRNA chemical modiﬁca-
tion more fully, we have undertaken detailed analysis of GP-mod-
iﬁcations that have been incorporated at different sites of a
previously described effective antiHBV siRNA.14 Our data provide
evidence for improved efﬁcacy, reduced off target effects and good
silencing in vivo by GP-modiﬁed siRNAs.
2. Results
2.1. Synthesis of 20-O-guanidinopropyl-
nucleosidephosphoramidites and their incorporation into
antiHBV siRNAs
Procedures employed for the synthesis of 20-O-guanidinopro-
pyl-nucleosidephosphoramidites have previously been de-Scheme 1. Improved method of synthesis of the 20-O-guanidinopropyl-N2-dmf-guanosin
butyl alcohol, rt; (ii) formic acid (70%), dioxane/water; (iii) Raney-Ni/H2 (30 bar), NH
(30 min) to rt (30 min); (v) N,N-dimethylformamide dimethyl acetal, methanol, rt (12
cyanoethyl N,N,N0 ,N0-tetraisopropyl phosphane, 4,5-dicyanoimidazole, CH2Cl2, rt.scribed.23 However, to circumvent the problem of a product
mixture upon introduction of the isobutyryl group to the N2-posi-
tion of guanosine, we developed a different protection strategy,
which entailed incorporation of a dimethylformamidine group
(Scheme 1). The earlier synthesis procedure yielded a mixture of
mono- and di-isobutyryl compounds. Although desired RNA oligo-
nucleotides were formed after complete deprotection, yields and
purity of the 20-O-GP-guanosine phosphoramidite were consider-
ably improved when using dimethylformamidine protection. Stan-
dard phosphoramidite synthetic procedures with a prolonged
coupling time of 30 min were employed to incorporate GP-con-
taining nucleotides into the antisense guide strand of an effective
antiHBV siRNA. This RNAi activator, siRNA3, targets the HBx open
reading frame (ORF) of HBV genotype A from coordinates 1693
to 1711.14 Control siRNA3 without GP moieties is referred to in this
study as being unmodiﬁed. It does however contain two dT resi-
dues at the 30 end of the sense strand to improve stability. Naming
of the panel of twenty siRNA3 derivatives was according to the
nucleotide position of the GP moiety. That is starting from the sec-
ond nucleotide (GP2 siRNA3) and ending at the twenty ﬁrst nucle-
otide (GP21 siRNA3) from the 50 end of the guide strand. Melting
point studies of selected GP-modiﬁed antisense strands in combi-
nation with the unmodiﬁed sense strand resulted in very small
destabilising effects considering the accuracy of the UV-method
used (see Supplementary data).
2.2. Effective target silencing by GP-modiﬁed siRNAs following
transfection of liver-derived cultured cells
Liver-derived Human hepatoma 7 (Huh7) cells were initially
used to assess inhibition of markers of HBV replication. Target
silencing was measured after co-transfection of each of the panel
of siRNAs with either a dual luciferase reporter containing the
HBV siRNA3 target (psiCHECK-HBx)24 or a replication competent
HBV target plasmid (pCH-9/3091)25 (Fig. 1). Unmodiﬁed siRNA3
was included in all studies as a positive control, while the scram-
bled siRNA was used as a negative control.14
After co-transfecting Huh7 cells with the panel of siRNAs and the
psiCHECK-HBx dual luciferase reporter plasmid, the ratio of Renilla
to Fireﬂy luciferase activity was measured (Fig. 1B). The HBV target
sequence in this vector is located on the same transcript but down-
stream of the Renilla luciferase ORF. Since Fireﬂy luciferase is sepa-
rately and constitutively expressed on the same plasmid, the ratio
of Renilla to Fireﬂy luciferase activity was used conveniently as a
normalized indicator of silencing efﬁcacy. When compared to the
scrambled siRNA control, GP-modiﬁed siRNAs decreased the ratio
of Renilla to Fireﬂy luciferase activity by up to 93% (GP10 siRNA3,
GP17 siRNA3, GP 18 siRNA3 and GP21 siRNA3). GP-modiﬁed siRNAs
with weakest activity inhibited Renilla luciferase activity with
approximately similar efﬁcacy to that of the unmodiﬁed siRNA3.e phosphoramidite for oligoribonucleotide synthesis. (i) acrylonitrile, Cs2CO3, tert-
3, methanol, 30–60 min, rt; (iv) N,N0-di-Boc-N00-triﬂylguanidine, Et3N, CH2Cl2, 0 C
h); (vi) Et3N3HF, THF, rt; (vii) 4,40-dimethoxytrityl chloride, pyridine, rt; (viii) 2-
Figure 1. HBV target sequences and assessment of knockdown in transfected cultured cells. psiCHECK-HBx plasmid, with relevant sequences schematically illustrated in A,
was used to co-transfect Huh7 cells. Dual-luciferase reporter gene assay was performed 48 h after transfection with the indicated unmodiﬁed or GP-modiﬁed siRNAs (B).
Results are given as mean ratios of Renilla to Fireﬂy luciferase activity. To assess effects on HBV replication in cultured cells, the pCH-9/3091 vector that contains replication
competent HBV sequences (C) was used to transfect Huh7 cells. Surface antigen (HBsAg) concentrations in cell culture supernatants were measured by ELISA at 48 h after co-
transfecting with pCH-9/3091 plasmid and indicated siRNAs (D). Values represent the means and standard deviation of three replicate transfections. Differences were
considered statistically signiﬁcant when analysis using the student t-test showed p <0.05.
M. D. Marimani et al. / Bioorg. Med. Chem. 21 (2013) 6145–6155 6147In a complementary experiment, transfection of Huh7 cells
with siRNAs and the pCH-9/3091 replication competent plasmid,
then measurement of HBV surface antigen (HBsAg) concentration
in culture supernatants was used as an indicator of knockdown
(Fig. 1D). Modiﬁed siRNAs effectively inhibited secretion of this
marker of HBV replication. Compared to the scrambled siRNA
control, inhibition of HBsAg secretion of about 90% was observed
with GP2 siRNA3, GP3 siRNA3, GP4 siRNA3, GP5 siRNA3, GP6
siRNA3, GP7 siRNA3 and GP8 siRNA3, while about 95% inhibition
was achieved with GP10 siRNA3, GP17 siRNA3, GP18 siRNA3 and
GP21 siRNA3. Lowest target silencing was observed when cells
were co-transfected with siRNAs containing modiﬁcations in
the central region (GP9 siRNA3, GP11 siRNA and GP12 siRNA
3) of the guide strand and may be a result of a destabilizing ef-
fect at the site of Ago2 target cleavage. Interestingly, GP10 siR-
NA3 had good silencing efﬁciency. The reasons for this are not
clear, but modiﬁcation at position 10 may facilitate Ago2-medi-
ated cleavage of the target. As with inhibition Renilla luciferase
activity after psiCHECK-HBx transfection, the most effective GP-
modiﬁed siRNAs inhibited HBsAg secretion signiﬁcantly more
effectively than did unmodiﬁed siRNA3. There was however
some variation between the silencing efﬁcacy of the siRNAs after
transfecting with either pCH-9/3091 or psiCHECK-HBx vectors.
This may be a result of differences in accessibility of the targets
to the siRNAs within the different sequence contexts. Neverthe-
less, the data demonstrate that GP modiﬁcations confer
improved silencing by the antiHBV siRNAs, and the efﬁcacy is
dependent on the positions of the modiﬁcations within the guide
strand.2.3. No evidence for activation of the interferon response or
toxicity in cultured cells following transfection with
GP-modiﬁed siRNAs
To assess whether GP-modiﬁed siRNAs stimulate an innate
interferon (IFN) response, concentrations of mRNA transcribed
from some IFN response genes were measured in HEK293 cells
after transfection with each of the panel of siRNAs. Innate immu-
nostimulation is attenuated in Huh7 liver-derived cells,26 which
is the reason for electing to assess the IFN response in the
HEK293 line. Immunostimulatory effects of double stranded RNA
are activated mainly by Toll-like receptor 3 (TLR3), TLR7 and
TLR8.27 These receptors recognise different forms of double
stranded RNA and activate transcription of interferon response
genes that encode a variety of proteins such as interferon-beta
(IFN-b), Interferon-induced protein with tetratricopeptide repeats
1 (IFIT1) and Oligoadenylate synthetase-1(OAS-1). Immunostimu-
latory effects vary depending on the nature of the synthetic double
stranded RNA,28 which makes it desirable to screen for induction of
different IFN genes. Results from using reverse transcriptase quan-
titative PCR (RT-qPCR) to measure IFN-b, IFIT1 and OAS-1mRNA are
shown in Figure 2A. IFN-b, IFIT1 and OAS-1 mRNA concentrations
measured after treatment of cells with poly(I:C), a positive control
for IFN response induction, were normalized and used for compar-
ison. IFN gene expression was signiﬁcantly elevated in positive
control cells that had been transfected with poly(I:C). However
both unmodiﬁed and GP-modiﬁed siRNAs did not induce expres-
sion of IFN response genes, and their concentrations were similar
to those detected in untransfected cells.
Figure 2. Assessment of stimulation of the innate IFN response and toxicity of siRNAs following transfection of cells. mRNA from IFN-b, IFIT1, OAS-1 and GAPDH genes was
reverse transcribed and ampliﬁed using qRT-PCR. Data, presented as a ratio of the concentrations of IFN response genes to the GAPDH housekeeping gene, was determined at
24 h after transfection (A). Cell viability was assessed using the MTT assay and determined at 48 and 72 h after transfection (B). Data analysis was carried out by calculating
the ratio of optical density of transfected and untransfected cells at 570 and 650 nm. Values of data presented in A and B represent the means and standard deviation of 3
replicate transfections. Differences were considered statistically signiﬁcant when analysis using the student t-test showed p <0.05.
6148 M. D. Marimani et al. / Bioorg. Med. Chem. 21 (2013) 6145–6155The sensitive MTT assay was conducted to investigate whether
siRNAs caused toxicity to cultured cells (Fig. 2B). Compared to con-
trol cells the data showed that unmodiﬁed or GP-containing siR-
NAs did not cause signiﬁcant toxicity in Huh7 cells at 48 and
72 h after transfection. Collectively, these observations indicate
that GP-modiﬁed siRNAs did not cause toxicity or induction of an
innate IFN immune response in cultured cells.
2.4. Inﬂuence of the position of the GPmodiﬁcation on silencing
of complete and partial HBV targets
A panel of dual luciferase reporter plasmids was generated in
which the HBV target sequences included variable numbers of
nucleotides that were complementary to the siRNA3 guide strand.
Different target sequences were inserted downstream of the Renilla
luciferase ORF of psiCHECK and structures of the dual luciferase
reporters are illustrated schematically in Figure 3A. The reporter
plasmids with their targets were the following:
1. psiCHECK-siRNA3 complete target (psiCHECK-siRNA3 CT),
complete base complementarity between target HBV and siR-
NA3 guide.
2. psiCHECK-siRNA3 incomplete target 1 (psiCHECK-siRNA3
IT1), three nucleotide mismatch at the 50 end of siRNA3 guide
target site.
3. psiCHECK-siRNA3 incomplete target 2 (psiCHECK-siRNA3
IT2), ﬁve nucleotide mismatch at the 50 end of siRNA3 guide
target site.4. psiCHECK-siRNA3 seed only target (psiCHECK-siRNA3 SO), the
HBV target sequence is complementary to the guide seed
region, comprisingnucleotides 1 to 8 fromthe50 endof siRNA3.
Huh7 cells were co-transfected with various unmodiﬁed or GP-
containing siRNAs, together with a reporter gene plasmid contain-
ing completely or partially complementary guide targets (Fig. 3B).
As before, the siRNAs differed with respect to location of the GP
modiﬁcations, and the ratio of Renilla to Fireﬂy luciferase activity
was used to assess knockdown efﬁcacy of the modiﬁed siRNAs.
Compared to a scrambled siRNA control, analysis showed that
the Renilla luciferase activity was diminished by at least 85% when
the reporter plasmid containing the complete target was co-trans-
fected with the unmodiﬁed or GP-modiﬁed siRNA. These results
are in accordance with the data shown in Figure 1, where knock-
down efﬁciency was assessed against the complete HBx target.
Silencing of the reporter gene that included SO and IT2 targets
was attenuated when GP modiﬁcations were located at nucleotides
2 to 7. This suggests that the GP modiﬁcations within the seed-tar-
geting region diminish the interaction of the siRNA guide with an
incompletely matched cognate. Importantly, efﬁcient knockdown
of Renilla luciferase activity derived from psiCHECK-siRNA3 CT
was achieved by siRNAs containing modiﬁcations within the
seed-targeting region. GP13 siRNA3 also demonstrated diminished
silencing of incomplete targets. The reason for this is unclear but
may be a result of an effect of the GP13 modiﬁcation on interaction
of RISC components with target mRNA. Silencing of cellular targets
caused by their complementarity to guide strands’ seed sequences
Figure 3. Silencing of complete and partial targets by GP-modiﬁed and control siRNAs. Four different target sequences of siRNA3 were cloned into psiCHECK 2.2 (A).
psiCHECK-siRNA3 CT contained a sequence that was completely complementary to siRNA3. Partially complementary targets contained a three nucleotide mismatch at the 30
end (psiCHECK-siRNA3 IT1), a 5 nucleotide mismatch at the 30 end (psiCHECK-siRNA3 IT2) and the seed region alone (psiCHECK-siRNA3 SO). A dual-luciferase reporter gene-
based assay was performed 48 h after co-transfection of each of the target plasmids with the panel of siRNAs (B). Data are presented as mean ratios of Renilla to Fireﬂy
luciferase activity and standard deviations are indicated by the error bars.
M. D. Marimani et al. / Bioorg. Med. Chem. 21 (2013) 6145–6155 6149is widespread.34,35 This unintended effect is similar to the natural
target regulation that is mediated by miRNAs interacting with their
cellular targets. Resulting unintended inhibition of gene expression
may cause toxicity and minimizing this effect is important for
therapeutic use of siRNAs. Our ﬁndings suggest that siRNAs with
GP modiﬁcations within the seed targeting region interact less
efﬁciently with partially complementary targets to effect more
speciﬁc silencing of intended complete targets.
2.5. Serum stability of GP-modiﬁed siRNAs
To assess whether GP modiﬁcation affected siRNAs stability,
control and GP-modiﬁed siRNAs were incubated in the presence
of 80% foetal calf serum (FCS) for up to 48 h. As an indicator of deg-
radation, siRNA bands detected after polyacrylamide gel electro-
phoresis and ethidium bromide staining were quantiﬁed using
densitometry (Fig. 4). Employing this assay, control siRNA had a
half-life of approximately 5 h. Importantly the control siRNA3 used
in our study included two dT residues at the 30 end of the sense
strand, which should confer protection against 30–50 exonuclease
activity. In general, GP-modiﬁed siRNAs were slightly more stable
than the control siRNA3. As reported previously,23 siRNAs with a
GP moiety further from seed region (i.e., GP13 siRNA3andGP19 siR-
NA3) displayed slightly increased stability.
2.6. Efﬁcient silencing of HBV replication in vivo using GP-
modiﬁed siRNAs
The murine hydrodynamic tail vein injection (HDI) method29
was employed to determine the effects of control and GP-modiﬁedsiRNAs on HBV replication in vivo. The procedure initially involved
co-transfection of siRNAs with pCH-9/3091 HBV replication com-
petent plasmid,25 and was followed by measurement of serum
markers of HBV replication (Fig. 5). The siRNAs with GP modiﬁca-
tions within the seed region at position 3, 4 or 5 were selected for
in vivo studies. Selection was based on antiHBV efﬁcacy in vitro
(Fig. 1) and evidence for good target speciﬁcity (Fig. 3). As with
studies on cultured cells, unmodiﬁed and scrambled siRNAs were
used as positive and negative controls. AntiHBV effects of these
siRNAs were assessed by measuring serum HBsAg concentrations
(Fig. 5A) and qRT-PCR to determine circulating virus particle equiv-
alents (VPEs) (Fig. 5B). The unmodiﬁed and GP-modiﬁed antiHBV
siRNAs each effected knockdown of the viral antigen by 70–98%.
This was observed when measurements were taken at days 3
and 5 after HDI. Of the siRNAs, GP4 siRNA3 and GP5siRNA3 were
the most efﬁcient. HBsAg concentration in the serum of mice in-
jected with these siRNAs was approximately 2% of the controls.
The numbers of circulating VPEs in the same mice were also mea-
sured using qPCR. The results corroborate observations made on
HBsAg determinations in that unmodiﬁed and GP-modiﬁed siRNAs
effected highly efﬁcient knockdown of the number of circulating
VPEs at both time points. At days 3 and 5, the numbers of VPEs
were approximately 1.8  104 and 8  103/mL of serum respec-
tively in the negative control animals. The circulating VPEs in anti-
HBV siRNA-treated animals were generally more than 100-fold
lower and ranged from 0.5 to 2.5  103/mL of serum. GP-modiﬁed
and unmodiﬁed siRNAs had approximately equal efﬁcacy in knock-
ing down this marker of replication. Collectively, these data show
that GP-modiﬁed siRNAs are highly efﬁcient silencers of HBV gene
expression in vivo. Moreover, based on the assessment of HBsAg
Figure 4. Stability of siRNAs in 80% FCS. Stability of unmodiﬁed siRNA, siRNAs containing GP-moieties within the seed region (GP2 siRNA3 and GP7 siRNA3) or siRNAs with
GP-moieties outside seed region (GP13 siRNA3 and GP19 siRNA3) was determined after incubation in 80% FCS. Aliquots were collected during a time course from 0 to 48 h,
subjected to polyacrylamide gel electrophoresis and bands corresponding to siRNA were quantiﬁed densitometrically. Values below each of the lanes represent the
percentages of siRNAs, relative to the amount determined at time point of 0 h, calculated to be remaining at each time point.
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is better than that of the unmodiﬁed siRNA3.
3. Discussion
Use of chemical modiﬁcations to enhance properties of oligonu-
cleotides that are intended for therapeutic silencing application
has been widely investigated. (reviewed in30) Early studies were
aimed at improving efﬁcacy of antisense sequences, and since dis-
covery of the RNAi pathway, similar approaches have been ex-
tended to advance use of synthetic siRNAs. Although useful
guidelines have been drafted, predicting the effects of particular
chemical modiﬁcations on siRNA efﬁcacy is difﬁcult. Empirical
assessment of alteration to natural siRNA structure is therefore
critically important for their optimization for a particular applica-
tion. Incorporation of modiﬁcations into siRNAs essentially aims to
enhance their function by improving:
1. silencing efﬁcacy,
2. speciﬁcity for a particular target mRNA,
3. avoidance of innate immunostimulation,
4. stability and
5. delivery to target tissue.
In this study, the potential utility of GP-modiﬁcations at the 20
position of ribose moieties within all four nucleotides at positions
2–21 of an siRNA that targets HBV has been analysed. Our ﬁndings
indicate that this GP modiﬁcation improves efﬁcacy, speciﬁcity of
guide interaction with its target and stability without causing tox-
icity or induction of an IFN response.
Good silencing efﬁcacy of GP-modiﬁed siRNAs was demon-
strated using dual luciferase and HBV replication models that were
carried out on cells in culture. When assessed with the reporter
gene assay, silencing efﬁcacy of all GP-containing siRNAs was
similar to that of unmodiﬁed siRNA. Although silencing of HBVreplication revealed an overall improved silencing efﬁciency of
the GP-modiﬁed siRNAs, modiﬁcations positioned in the central
region of the siRNA antisense strand had attenuated silencing efﬁ-
ciency. This observation is likely to be a result of the requirement
for complete hybridization to occur at this region to enable target
cleavage by Ago2 within RISC. Interestingly GP10 siRNA3, with GP
modiﬁcation at position 10, effected efﬁcient silencing in cell
culture. Ago2-mediated cleavage of target mRNA occurs at the site
opposite this nucleotide.31 Facilitation of the cleavage reaction by a
GP residue opposite the site of Ago2 action is an interesting possi-
bility and will be the topic of future investigation. Good efﬁcacy of
the selected GP-modiﬁed siRNAs was corroborated by analysis
carried out in vivo. This effective silencing in vivo is an important
feature that indicates that GP modiﬁcations may have utility in a
clincical context.
Successful advancement of therapeutic RNAi-based gene
silencing is largely dependent on achieving minimal off target ef-
fects. In a clinical setting, these undesirable consequences may
lead to toxicity. Non-speciﬁc interaction of guide strands with
partially complementary cellular mRNA targets, and resultant
inhibition of gene expression, is widespread and of particular
concern.32–34 Modiﬁcation with 20-O-methyl residues at position
2 of the seed sequence has been reported to attenuate unin-
tended silencing.35 Our results support the notion that chemical
modiﬁcation of siRNA seed regions can be used to improve spec-
iﬁcity. Moreover, we demonstrate that GP residues included at
most of the seed region positions of antiHBV siRNA3 limit micr-
oRNA-like off-target silencing. These observations are also in line
with the demonstration that non-bulky chemical modiﬁcations
in the seed region are well tolerated.22 Importantly, overall
silencing of the complete target by GP-modiﬁed siRNAs was
not compromised.
In addition to off-target silencing of cellular mRNA, cellular tox-
icity and non-speciﬁc activation of the innate IFN response by
siRNAs are also potentially problematic. Inclusion of chemical
Figure 5. AntiHBV effects of siRNAs on markers of HBV replication in vivo. Mice
were co-injected with 15 lg HBV target plasmid pCH-9/3091 together with 1 nmol
of GP-modiﬁed or unmodiﬁed control siRNAs. Serum concentrations ofHBsAg (A)
and circulating VPEs (B)were detected at days 3 and 5 after siRNA administration.
Values represent the means and standard deviation of 5 replicate injections (p
<0.05).
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response.19,30 Our data indicate that the unmodiﬁed siRNA3 does
not induce the innate IFN response, and it is therefore difﬁcult to
assess whether the GP moieties ameliorate this innate immuno-
stimulatory effect. Nevertheless, mRNA from IFN response genes
were not increased following transfection of GP-containing siRNAs,
which indicates that this chemical modiﬁcation is not immuno-
stimulatory per se. Moreover, since GP modiﬁcations at all of the
positions from 2 to 21 showed a similar effect, the position of
the moiety does not inﬂuence siRNA immunostimulation. The ab-
sence of toxicity, measurable using the sensitive MTT assay, also
suggests that the chemical modiﬁcation is also not directly toxic
to cells.
Poor stability of naked siRNAs in serum may be a factor that
diminishes efﬁcacy of these silencing molecules. Enhancing dura-
tion of activity of siRNAs may be achieved through encapsulation
within protecting nanoparticles or through chemical modiﬁcation
to confer resistance to nuclease degradation. The mechanism of
degrading naked siRNA in serum is thought to result from activity
of the 30–50 exoribonuclease 1 (ERI1) enzyme,36 and protection of
naked siRNAs through modiﬁcation at the 30 end improves stability
of siRNAs.19 A commonly employed method of modifying 30 ends
has been through incorporation of two dT residues at the 30 ends
of siRNAs. In this study, dT residues were present at the 30 end ofthe sense strand of the control siRNA3 as well as in each of the pa-
nel of siRNAs containing the GP modiﬁcations. Control siRNA3 had
a half-life in 80% serum of approximately 5 h. This is longer than
what is expected for completely unmodiﬁed siRNAs, and may re-
sult from the presence of the two dT residues at the 30 dinucleotide
overhangs of the sense strand of siRNA3. A further, although mod-
est, increase in the siRNAs half-life in 80% serum was achieved by
incorporation of GP residues. This observation is in accordance
with ﬁndings that we have previously reported,23 and indicates
that GP residues have a beneﬁcial stabilizing effect on siRNAs.
Synthetic siRNAs with chemical modiﬁcations have previously
been used successfully to silence replication of HBV.12,14 Morrissey
et al. compared extensively modiﬁed with unmodiﬁed antiHBV
siRNAs.12 Improved potency, speciﬁcity and stability was observed
with siRNAs that included (1) substitution of all 20-OH residues on
the RNA with 20F, 20O-Me or 20H residues, (2) phosphorothioate
linkages at selected sites and (3) terminal inverted ribose moieties.
In mice that had been subjected to HDI with a HBV replication
competent plasmid, administration of the modiﬁed siRNAs in sta-
ble nanoparticle lipid particle (SNALP) vectors resulted in efﬁcient
knockdown of viral replication. There have however been few
studies to follow up on this report and the clinical utility of these
extensively modiﬁed siRNAs has not been fully assessed.
siRNAs with therapeutic utility would be required to interact
with several intra- andextracellular proteinsduring the events lead-
ing from their administration to contact of the guide strand with its
target within RISC. Since many of these interactions are likely to be
sensitive to chemical modiﬁcations, simpliﬁcation of the chemical
modiﬁcations may facilitate the drug development process. Our
observation that siRNAs incorporating singleGPmoieties at selected
sites improves their efﬁcacy, speciﬁcity and stability without caus-
ing toxicity and innate immunostimulation is therefore promising.
To advance use of GP-modiﬁed siRNAs for therapeutic use, current
investigations are aimed at incorporating GP-modiﬁed siRNAs into
non-viral vector formulations, assessing pharmacokinetic proper-
ties and optimizing efﬁcacy against HBV in vivo.
4. Materials and methods
4.1. Chemical synthesis of GP-modiﬁed nucleosides
Synthesis of oligonucleoside precursors of the HBV-targeting
siRNAs has previously been described.23 However, to circumvent
the problem of obtaining a product mixture upon introduction of
the isobutyryl group to the N2-position of guanosine, we estab-
lished a different protection strategy, using the dimethylformami-
dine group (Scheme 1).
4.1.1. Synthesis of the O6-(2,4,6-Triisopropylbenzenesulfonyl)-
30,50-O-di-tert-butylsilanediylguanosine (1)
O6-(2,4,6-Triisopropylbenzenesulfonyl)-30,50-O-di-tert-buty-
lsilanediylguanosine (1) was synthesised according to a previously
described procedure.37
4.1.2. 20-O-(2-Cyanoethyl)-30,50-O-di-tert-
butylsilanediylguanosine (2)
Compound 1 (2.28 g, 3.3 mmol) was dissolved in tert-butanol
(17 mL). Freshly distilled acrylonitrile (4.25 mL, 66 mmol) and ce-
sium carbonate (1.16 g, 3.3 mmol) were added to the solution.
After vigorous stirring at room temperature for 2–3 h, the mixture
was ﬁltered through celite. The solvent and excess reagents were
removed in vacuo. The crude material was used for the next reac-
tion without further puriﬁcation. The residue was dissolved in
4 mL of a mixture of formic acid/dioxane/water (70:24:6, v/v/v).
After stirring at room temperature for 1 h, water (150 mL) was
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methane. The organic layer was dried over Na2SO4 and the solvent
was evaporated. The residue was puriﬁed using silica gel column
chromatography with dichloromethane/methanol (9:1, v/v) to give
1.1 g (70% over 2 steps) of 2 as a colourless foam. 1H NMR
(250 MHz, DMSO-d6) d [ppm] 10.71 (br s, 1H, NH), 7.89 (s, 1H,
H8), 6.45 (br s, 2H, NH2), 5.81 (s, 1H, H10), 4.45–4.33 (m, 3H),
4.05–3.81 (m, 4H), 2.83–2.76 (m, 2H, O–CH2–CH2–CN), 1.06 (s,
9H, C(CH3)3), 1.01 (s, 9H, C(CH3)3); 13C NMR (63 MHz, DMSO-d6)
d [ppm] 156.51, 153.69, 150.50, 135.36, 118.71, 116.53, 87.25,
80.31, 76.35, 73.80, 66.64, 65.14, 27.12, 26.80, 22.07, 19.82,
18.29; MS (ESI) was calculated to be 477.2 for C21H33N6O5Si
(M+H+), and found to be 477.5.
4.1.3. 20-O-(2-Aminopropyl)-30,50-O-di-tert-
butylsilanediylguanosine (2a)
Compound 2 (500 mg, 1.06 mmol) was dissolved in dry metha-
nol (5 mL). Raney nickel (ca. 0.5 mL of the methanol-washed sedi-
ment) and methanol (5 mL) saturated with ammonia were then
added. The mixture was hydrogenated at 30 bar hydrogen-pres-
sure for 1 h at room temperature. Thereafter the mixture was ﬁl-
tered through a glass ﬁlter and the catalyst was washed several
times with methanol and a methanol/water mixture. The solvents
were evaporated from the ﬁltrate and the residue was used with-
out further puriﬁcation for the next reaction. MS (ESI) was calcu-
lated to be 481.3 for C21H37N6O5Si (M+H+), and found to be 481.8.
4.1.4. 20-O-(N,N0-Di-tert-butoxycarbonylguanidinopropyl)-30,50-
O-di-tert-butylsilanediylguanosine (3)
N,N0-Di-boc-N00-triﬂylguanidine (163 mg, 0.415 mmol) was dis-
solved in dichloromethane (2.1 mL) and triethylamine (54 lL) was
then added. The solution was cooled in an ice bath and then 20-O-
(2-Aminopropyl)-30,50-O-di-tert-butylsilanediylguanosine (2a)
(200 mg, 0.42 mmol) was added. After 30 min the reaction mixture
was removed from the ice bath then stirred for an additional
30 minat roomtemperature. The reaction solutionwaswashedwith
saturated sodium bicarbonate solution and brine. After drying over
Na2SO4 the solventwas evaporated. The residuewas puriﬁed by col-
umnchromatographyusingdichloromethane/methanol (9:1, v/v) to
give 270 mg (89%) of 3. 1H NMR (400 MHz, DMSO-d6)d [ppm] 11.49
(br s, 1H,NH), 10.66 (br s, 1H,NH), 8.56–8.53 (m, 1H,NH–CH2–), 7.87
(s, 1H, H8), 6.39 (br s, 2H, NH2), 5.86 (s, 1H, H10), 4.42–4.38 (m, 1H,
H30), 4.30–4.27 (m, 2H, H20, H50), 4.06–3.93 (m, 3H, H40, H50,
½  O–CH2–CH2–CH2–NH–), 3.72–3.67 (m, 1H, ½  O–CH2–CH2–
CH2–NH–), 3.51–3.30 (m, 2H, O–CH2–CH2–CH2–NH–), 1.84–1.77
(m, 2H, O–CH2–CH2–CH2–NH–), 1.46 (s, 9H, –CO–C(CH3)3), 1.39 (s,
9H, –CO–C(CH3)3), 1.06 (s, 9H, –Si–C(CH3)3), 0.97 (s, 9H, –Si–
C(CH3)3); HRMS (MALDI) was calculated to be 723.3856 for
C32H55N8O9Si (M+H+), and found to be 723.3880.
4.1.5. N2-Dimethylformamidine-20-O-(N,N0-di-tert-
butoxycarbonylguanidinopropyl)-30,50-O-di-tert-
butylsilanediylguanosine (3a)
Compound 3 (1.12 g, 1.55 mmol) was dissolved in 25 mL dry
methanol. N,N-Dimethylformamide dimethyl acetal (1.0 mL,
7.76 mmol) was added and the solution was stirred at room tem-
perature overnight. After a reaction time of 12 h the solvents were
removed in vacuo and the residue was puriﬁed by silica gel column
chromatography using dichloromethane/methanol (19:1, v/v) to
give 1.14 g (94%) of the dmf-protected derivative. 1H NMR
(400 MHz, DMSO-d6) d [ppm] 11.51 (s, 1H, N1H), 11.40 (s, 1H,
NH-boc), 8.54 (s, 1H, –N@CH–N(CH3)2), 8.47 (m, 1H, 20-O–CH2–
CH2–CH2–NH–), 7.99 (s, 1H, H-8), 5.98 (s, 1H, H10), 4.48–4.45 (m,
1H, H50), 4.41–4.39 (m, 1H, H20), 4.33–4.30 (m, 1H, H50), 4.07–
3.99 (m, 2H, H30 und H40), 3.98–3.77 (m, 2H, 20-O–CH2–CH2–CH2–
NH–), 3.48–3.37 (m, 2H, 20-O–CH2–CH2–CH2–NH–), 3.14 (s, 3H,N–CH3), 3.04 (s, 3H, N–CH3), 1.87–1.78 (m, 2H, 20-O–CH2–CH2–
CH2–NH–), 1.47 (s, 9H, –CO–C(CH3)3), 1.37 (s, 9H, –CO–C(CH3)3),
1.06 (s, 9H, –Si–C(CH3)3), 1.00 ppm (s, 9H, –Si–C(CH3)3); 13C NMR
(75 MHz, DMSO-d6) d [ppm] 163.00, 157.60, 157.39, 157.35,
154.98, 151.95, 149.21, 136.96, 119.86, 88.07, 82.78, 80.59, 77.90,
76.48, 73.83, 69.64, 66.77, 44.41, 40.58, 34.54, 28.61, 27.86,
27.44, 27.08, 26.70, 22.06, 19.76; HRMS (MALDI) was calculated
to be 800.4097 for C35H59N9O9SiNa (M+Na+), and found to be
800.4124.
4.1.6. N2-Dimethylformamidine-20-O-(N,N0-di-tert-
butoxycarbonylguanidinopropyl)-guanosine (3b)
Compound 3a (1.24 g, 1.59 mmol) was dissolved in dry tetrahy-
drofurane (17 mL). Triethylamine (470 lL, 3.18 mmol) and
Et3N3HF (943 lL, 5.79 mmol) were then added. After stirring at
room temperature for 1 h the solvent was evaporated. The residue
was puriﬁed using silica gel column chromatographywith dichloro-
methane/methanol (9:1, v/v) to give 840 mg (83%) of compound 3b
as white foam. 1H NMR (400 MHz, DMSO-d6) d [ppm] 11.50 (s, 1H,
N1H), 11.34 (s, 1H, NH–boc), 8.54 (s, 1H, –N@CH–N(CH3)2), 8.35
(m, 1H, 20-O–CH2–CH2–CH2–NH–), 8.10 (s, 1H, H8), 5.95–5.94 (m,
1H, H10), 5.14–5.12 (m, 1H, 30-OH), 5.08–5.05 (m, 1H, 50-OH), 4.31–
4.30 (m, 2H, H20, H30), 3.95–3.93 (m, 1H, H40), 3.67–3.56 (m, 4H,
2  H50, O–CH2–CH2–CH2–NH–), 3.36–3.33 (m, 2H, O–CH2–CH2–
CH2–NH–), 3.16 (s, 3H, N–CH3), 3.04 (s, 3H, N–CH3), 1.77–1.74 (m,
2H, O–CH2–CH2–CH2–NH–), 1.47 (s, 9H, –CO–C(CH3)3), 1.37 (s, 9H,
–CO–C(CH3)3); 13C NMR (75 MHz, DMSO-d6) d [ppm] 162.98,
157.84, 157.44, 157.24, 155.10, 151.89, 149.61, 136.41, 119.77,
85.26, 85.23, 82.75, 81.36, 78.00, 68.51, 67.87, 60.81, 40.54, 37.86,
34.53, 28.65, 27.85, 27.50; HRMS (MALDI) was calculated to be
660.3076 for C27H43N9O9Na (M+Na+), and found to be 660.3087.
4.1.7. N2-Dimethylformamidine-20-O-(N,N0-di-tert-
butoxycarbonylguanidinopropyl)-50-O-(4,40-dimethoxytrityl)-
guanosine (3c)
Compound 3b (840 mg, 1.32 mmol) was dissolved in dry pyri-
dine (30 mL). 4,40-Dimethoxytrityl chloride (670 mg, 1.98 mmol)
was added and the solution was stirred for 3 h at room tempera-
ture. After the reaction was complete according to TLC, the reaction
was quenched with methanol and the solvents were evaporated.
The residue was puriﬁed by silica gel column chromatography
using dichloromethane/methanol (100:0 to 95:5, v/v; the column
was packed with dichloromethane containing 0.5% triethylamine)
to give 1.08 g (87%) of the tritylated compound 3c. 1H NMR
(400 MHz, DMSO-d6) d [ppm] 11.51 (s, 1H, N1H), 11.38 (s, 1H,
NH-boc), 8.50 (s, 1H, –N@CH–N(CH3)2), 8.40 (m, 1H, 20-O–CH2–
CH2–CH2–NH–), 7.94 (s, 1H, H8), 7.38–7.20 (m, 9H, DMTr),
6.86–6.82 (m, 4H, DMTr), 6.01–6.00 (m, 1H, H10), 5.16–5.13 (m,
1H, 30-OH), 4.35–4.30 (m, 2H, H20, H30), 4.08–4.05 (m, 1H, H40),
3.73 (s, 6H, 2  O–CH3), 3.71–3.61 (m, 2H, 20-O–CH2–CH2–CH2–
NH–), 3.40–3.35 (m, 2H, 20-O–CH2–CH2–CH2–NH–), 3.28–3.16 (m,
2H, 2  H50), 3.09 (s, 3H, N–CH3), 3.02 (s, 3H, N–CH3), 1.80–1.74
(m, 2H, 20-O–CH2–CH2–CH2–NH–), 1.44 (s, 9H, –CO–C(CH3)3),
1.34 (s, 9H, –CO–C(CH3)3); 13C NMR (100 MHz, DMSO-d6) d [ppm]
162.96, 157.97, 157.95, 157.72, 157.48, 157.20, 155.10, 151.89,
149.59, 144.71, 136.15, 135.43, 135.30, 129.59, 129.57, 127.67,
127.57, 126.55, 119.83, 113.02, 85.53, 85.37, 82.72, 82.69, 81,04,
77.96, 69.02, 68.22, 63.55, 54.90, 40.54, 37.99, 34.54, 28.66,
27.82, 27.49; HRMS (MALDI) was calculated to be 962.4383 for
C48H61N9O11Na (M+Na+), and found to be 962.4408.
4.1.8. N2-Dimethylformamidine-20-O-(N,N0-di-tert-
butoxycarbonylguanidinopropyl)-50-O-(4,40-dimethoxytrityl)-
guanosine 30-(cyanoethyl)-N,N-diisopropylphosphoramidite (4)
Compound 3c (1.08 g, 1.15 mmol) was dissolved in dichloro-
methane (25 mL), then 2-cyanoethyl-N,N,N0,N0-tetraisopropylami-
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(199 mg, 1.69 mmol) were added. After 4 h TLC showed complete
consumption of the starting material. The reaction solution was
then washed twice with saturated sodium bicarbonate solution
and once with brine. After drying over Na2SO4 the solvent was
evaporated and the residue was puriﬁed using silica gel column
chromatography with dichloromethane/acetone/methanol (4:0:1
to 3:0:2 to 2:1:2 to 2:2:1, v/v, the column was packed with eluent
containing 0.5% triethylamine). The residue was dissolved in a
small amount (5 mL) of dichloromethane. This solution was
dripped into a ﬂask with hexane (500 mL) to form a white precip-
itate. Two thirds of the solvent was evaporated and the residual
solvent was decanted carefully. The precipitate was redissolved
in benzene and lyophilised to give 1.01 g (77%) of the phospho-
ramidite (4). According to 31P NMR spectrum the product was still
containing a small amount of the hydrolysed phosphitylation re-
agent but this did not interfere with the oligonucleotide synthesis.
1H NMR (400 MHz, DMSO-d6) d [ppm] 11.50–11.48 (m, 1H, NH),
11.39 (s, 1H, NH), 8.44–8.42 (m, 1H, –N@CH–N(CH3)2), 8.39–8.34
(m, 1H, 20-O–CH2–CH2–CH2–NH–), 7.96 (s, 1H, H8), 7.37–7.19 (m,
9H, DMTr), 6.85–6.78 (m, 4H, DMTr), 6.07–6.05 (m, 1H, H10),
4.64–4.58 (m, 1H, H30), 4.48–4.44 (m, 1H, H20), 4.26–4.19 (m, 1H,
H40), 3.80–3.23 (m, 10H), 3.73–3.70 (m, 6H, 2  OCH3), 3.07 (s,
3H, N–CH3), 3.02 (s, 3H, N–CH3), 2.77–2.74 (m, 1H, –P–O–CH2–
CH2–CN), 2.55–2.52 (m, 1H, –P–O–CH2–CH2–CN),1.80–1.72 (m,
2H, 20–O–CH2–CH2–CH2–NH–), 1.44–1.34 (m, 18H, 2  –CO–
C(CH3)3), 1.20–0.93 (m, 12H, –N((CH(CH3)2)2); 31P NMR
(121 MHz, DMSO-d6) d [ppm] 149.21, 148.93.
4.2. AntiHBV siRNAs
The GP moieties were incorporated into the antisense strand of
a previously characterised antiHBV siRNA sequence, siRNA3, which
targets HBV genotype A from coordinates 1693 to 1711.14 Oligonu-
cleotides comprising unmodiﬁed and GP-modiﬁed antiHBV siRNAs
were synthesised on an Expedite 8909 synthesiser using phospho-
ramidite chemistry.23 5-Ethylthio-1H-tetrazole (0.35 M in acetoni-
trile) was used as activator. Commercially obtained unmodiﬁed
20-TBDMS-phorphoramidites were benzoyl-(A), isobutyryl-(G) or
acetyl-(C) protected. With a coupling time of 30 min the coupling
efﬁciency of the modiﬁed phosphoramidites was as good as for
the unmodiﬁed phorphoramidites. (Trityl-protocol diagrams of
the oligonucleotide syntheses wherein the new phosphoramidite
(4) was used, are depicted in the Supplementary data.) After com-
pletion of synthesis, 30 min of deprotection in 3% trichloroacetic
acid in dichloromethane was carried out to ensure complete cleav-
age of the boc groups. The RNA oligomers were cleaved from the
controlled-pore-glass (CPG) support by incubation at 40 C for
24 h using an ethanol:ammonia (32% in H2O) solution (1:3). The
20-TBDMS groups were deprotected by incubation for 90 min at
65 C with a triethylamine, N-methylpyrrolidinone and Et3N3HF
mixture. RNA oligomers were precipitated with BuOH at 80 C
for 60 min followed by centrifugation at 0 C and were puriﬁed
by anion exchange HPLC using a Dionex DNAPac PA-100 column.
The oligonucleotides were desalted in a subsequent reverse phase
HPLC step. Identity was conﬁrmed by mass spectroscopy on a Bru-
ker micrOTOF-Q II and the data are deposited in the supplement.
The purity of the oligos is about 90%. An exemplary chromatogram
of GP10 siRNA3 synthesised with the new phosphoramidite (4) can
be found in the Supplementary data. The intended guide, 50-UUG
AAG UAU GCC UCA AGG UCG-30, was modiﬁed at each of positions
2–21 from the 50end. Thermodynamic stability of these modiﬁed
strands in combination with the unmodiﬁed sense strand were
measured by temperature dependent UV spectroscopy and re-
ported as DTm, see supplement. The sense strand oligonucleotide,
with sequence 50-ACC UUG AGG CAU ACU UCA AdTdT-30, had twodT residues at the 30 end. siRNA with scrambled unmodiﬁed se-
quences comprised antisense, 50-UAU UGG GUG UGC GGU CAC
GGT-30, and sense, 50-CGU GAC CGC ACA CCC AAU ATT-30, strands
was used as a control.4.3. Target vectors
pCH-9/3091 is an HBV replication competent plasmid contain-
ing a greater than genome length HBV sequence.25 The pCI-eGFP
reporter plasmid, used in some cases to verify equivalent transfec-
tion efﬁciencies, produces enhanced green ﬂuorescent protein
from the CMV immediate early promoter/enhancer.38 The psi-
CHECK-HBx vector contains the HBx target sequence downstream
of the Renilla luciferase ORF and a separate constitutively active
Fireﬂy luciferase cassette.39 The complete, incomplete and seed
only targets of siRNA3 were generated by removing HBx from psi-
CHECK, then substituting this sequence with various annealed oli-
gonucleotides in the backbone. This backbone was prepared by
digesting psiCHECK-HBx with XhoI and NotI followed by puriﬁca-
tion of the 6.2 kb fragment. To generate the panel of siRNA3 target
insert sequences, pairs of forward and reverse oligonucleotides
(Integrated DNA Technologies, Iowa, USA) were heated to 95 C
for 5 min, then cooled to room temperature. Sequences of the oli-
gonucleotides were the following: complete target forward (CT F):
50-TCG AGC GAC CTT GAG GCA TAC TTC AAG TCG ACC AGC TGG C-
30, complete target reverse (CT R): 50-GGC CGC CAG CTG GTC GAC
TTG AAG TAT GCC TCA AGG TCG C-30, incomplete target 1 forward
(IT1 F): 50-TCG AGC GAC ACC GAG GCA TAC TTC AAG TCG ACC AGC
TGG C-30, incomplete target 1 reverse (IT1 R): 50-GGC CGC CAG CTG
GTC GAC TTG AAG TAT GCC TCG GTG TCG C-30, incomplete target 2
forward (IT2 F): 50-TCG AGA TCA ACC GAG GCA TAC TTC AAG TCG
ACC AGC TGG C-30, incomplete target 2 reverse (IT2 R): 50-GGC CGC
CAG CTG GTC GAC TTG AAG TAT GCC TCG GTT GAT C-30, seed only
target forward (SO F): 50-TCG AGA TCA ACC ACT AAC TAC TTC AAG
TCG ACC AGC TGG C-30, and seed only target reverse (SO R): 50-GGC
CGC CAG CTG GTC GAC TTG AAG TAG TTA GTG GTT GAT C-30. The
annealed oligonucleotides, which had sticky ends complementary
to those generated by NotI and XhoI restriction digestion, were
then ligated to the psiCHECK backbone fragment according to stan-
dard procedures and the sequences of positive clones were veriﬁed
(Inqaba Biotech Industries, South Africa). Resulting dual luciferase
target plasmids were psiCHECK-siRNA3 Complete Target
(psiCHECK-siRNA3 CT), psiCHECK-siRNA3 Incomplete Target 1
(psiCHECK-siRNA3 IT1), psiCHECK-siRNA3 Incomplete Target 2
(psiCHECK-siRNA3 IT2), and psiCHECK-siRNA3 Seed Only Target
(psiCHECK-siRNA3 SO).4.4. Transfections and HBV knockdown assessment in vitro by
ELISA and dual-luciferase assays
The Huh7 line was maintained in DMEM (Lonza, Basel, Switzer-
land) supplemented with 10% FCS (Gibco BRL,UK). One day before
transfection, cells were seeded in 24-well plates at a conﬂuency of
40%. To assess target knockdown, Lipofectamine 2000 (Invitrogen,
CA, USA) was employed to transfect cells with 100 ng of either
pCH-9/3091 or psiCHECK-HBx, 100 ng pCI-eGFP and 32.5 ng siRNA
(10 nM ﬁnal concentration). The ratio of Lipofectamine to target
plasmids was 1:1 (mL:mg), while that of Lipofectamine to siRNAs
was 1:3 (mL:mg). Unmodiﬁed and scrambled siRNAs were in-
cluded as positive and negative controls, respectively. Forty eight
hours after transfection, growth medium was collected and HBsAg
concentration was measured by ELISA using the MONOLISA HBsAg
ULTRA kit (Bio-Rad, CA, USA). Cells transfected with psiCHECK-HBx
were lysed and assessed for luciferase activity using the Dual-
Luciferase Reporter Assay System (Promega, WI, USA). The average
6154 M. D. Marimani et al. / Bioorg. Med. Chem. 21 (2013) 6145–6155ratio of Renilla luciferase to Fireﬂy luciferase activity was calcu-
lated from a minimum of three replicates.
4.5. Assessing induction of the interferon response by antiHBV
siRNAs
The HEK293 line was maintained in DMEM supplemented with
10% FCS, penicillin (50 IU/mL) and streptomycin (50 lg/mL) (Gibco
BRL, UK). On the day prior to transfection, wells of 2 cm diameter
were each seeded with 250 000 HEK293 cells. Transfection was
carried out with 800 ng of unmodiﬁed or GP-containing siRNAs
using Lipofectamine (Invitrogen, CA, USA) according to the manu-
facturer’s instructions. As a positive control for induction of the IFN
response, cells were also transfected with 800 ng poly (I:C) (Sigma,
MI, USA). Two days after transfection, RNA was extracted with Tri
Reagent (Sigma, MI, USA) according to the manufacturer0s
instructions.
To assess induction of the IFN response genes, IFN-b and GAPDH
cDNA preparation and qPCR ampliﬁcation where performed
according to the procedures described by Song et al.40 with minor
modiﬁcations. All qPCRs were carried out using the Roche Light-
cycler V.2. Controls included water blanks and RNA extracts that
were not subjected to reverse transcription. Taq readymix with
SYBR green (Sigma, MO, USA) was used to amplify and detect
DNA during the reaction. Thermal cycling parameters consisted
of a hotstart for 30 sec at 95 C, followed by 50 cycles of 58 C
for 10 sec, 72 C for 7 sec and then 95 C for 5 sec. Speciﬁcity of
the PCR products was veriﬁed by melting curve analysis and aga-
rose gel electrophoresis. The primer combinations used to amplify
IFN-b, OAS-1, IFIT1 and GAPDH mRNA were IFN-b forward: 50-TCC
AAA TTG CTC TCC TGT TGT GCT-30, IFN-b reverse: 50-CCA CAG GAG
CTT CTG ACA CTG AAA A-30, OAS-1 forward: 50-CGA GGG AGC ATG
AAA ACA CAT TT-30, OAS-1 reverse: 50-GCA GAG TTG CTG GTA GTT
TAT GAC – 30, IFIT1 forward: 50-CCC TGA AGC TTC AGG ATG AAG G
– 30, IFIT1 reverse: 50-AGA AGT GGG TGT TTC CTG CAA G-30, GAPDH
forward 50-AGG GGT CAT TGA TGG CAA CAA TAT CCA-30, GAPDH
reverse 50-TTT ACC AGA GTT AAA AGC AGC CCT GGT G-30.
4.6. Inﬂuence of GP modiﬁcations of siRNAs on cell viability
using the MTT assay
The MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazoli-
um bromide] reagent was purchased from Sigma (St. Louis, MO,
USA). Huh7 cells were seeded in 96-well plates at a conﬂuency of
40% a day before transfection and untransfected cells were used
as controls. To assess toxicity, Lipofectamine 2000 (Invitrogen,
CA, USA) was employed to transfect cells with 25 ng pCH-9/3091,
25 ng pCI-eGFP and 8.125 ngsiRNA (2.5 nM ﬁnal concentration).
Transfection ratios of Lipofectamine to plasmids and siRNAs were
1:1 and 1:3 (mL:mg), respectively. Twenty microliters of MTT solu-
tion (5 mg/mL dissolved in 1  Dulbecco‘s Phosphate Buffered Sal-
ine) was added into each well, gently mixed for 5 min and
incubated (37 C, 5% CO2) for 4 h. Culture medium from each well
was gently removed by aspiration and formazan (blue product of
MTT metabolism) was resupended in 200 ll DMSO with constant
mixing for 5 min. Data analysis, carried out in triplicate at time
points of 48 and 72 h after transfection, was performed by calculat-
ing the ratio of optical density at 570 nm and 650 nm.
4.7. Inﬂuence of the position of GP modiﬁcations on silencing of
complete and partial HBV targets using the dual luciferase
reporter assay
To measure knockdown efﬁciency of 20-O-guanidinopropyl-
modiﬁed siRNAs that were completely or partially complementary
to targets, Huh7 cells were co-transfected with 100 ng of eitherpsiCHECK-siRNA3 CT, psiCHECK-siRNA3 IT1, psiCHECK-siRNA3
IT2 or psiCHECK-siRNA3 SO, 100 ng pCI-eGFP and 32.5 ng siRNA
(10 nM ﬁnal concentration). Ratios of Lipofectamine to plasmids
and siRNAs were 1:1 and 1:3 (mL:mg), respectively. Detection of
Renilla and Fireﬂy luciferase activity was conducted 48 h after
transfection according to the procedures described above.
4.8. Assessment of siRNA stability in FCS
siRNAs were added to 80% FCS at a ﬁnal concentration of 10 nM,
then incubated at 37 C for 0, 1, 3, 5, 20, 24 and 48 h. Aliquots of
10 ll were loaded on a 15% denaturing polyacrylamide gel, sub-
jected to electrophoresis, visualised under UV transillumination
and RNA bands were quantiﬁed by densitometry (Syngene G-Box,
SYNGENE, UK).
4.9. AntiHBV effects of GP-modiﬁed and unmodiﬁed siRNAs
in vivo
The siRNAs with sense strand GP modiﬁcations in position 3, 4
or 5 were selected for studies in vivo. The murine hydrodynamic
tail vein injection model of HBV replication29 was employed to as-
sess antiHBV effects of siRNAs in mice. Experiments on animals
were conducted in accordance with protocols approved by the Uni-
versity of the Witwatersrand Animal Ethics Screening Committee.
A saline solution comprising 10% of the mouse’s body weight
was injected via the tail vein over 10 seconds. The saline solution
included a combination of 15 lg of HBV target plasmid (pCH-9/
3091), 15 lg of pCI-eGFP plasmid and 1 nmol of GP-modiﬁed or
unmodiﬁed siRNAs. At days 3 and 5 after injection, blood samples
were collected. HBsAg and circulating VPEs were measured accord-
ing to previously described methods.8,9
4.10. Statistical analysis
Data are expressed as the mean ± standard error of the mean.
Statistical variation was considered signiﬁcant when P < 0.05 and
was calculated using nonparametric student t-tests with the
GraphPad Prism software package (GraphPad Software, Inc., CA,
USA).
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Trityl protocols of the syntheses of modified oligonucleotides
S11
The red arrow marks the GP-modified nucleotide. Slightly reduced coupling efficiency in the synthesis corresponding to the trityl protocol in the upper left
might be a result of insufficient purging of the supply line of the synthesiser with the modified amidite solution.
5' - UUG AAG UAU GGP CC UCA 
AGG UCG - 3' 
5' - UUG AAG UAU GCC UCA 
AGGP G UCG - 3'
5' - UUG AAG UAU GCC UCA 
AGGGP  UCG - 3'
5' - UUG AAG UAU GCC UCA 
AGG UCGGP  - 3'
Analytical RP-Chromatogram of the sequence: 5' - UUG AAG UAU GGP CC UCA AGG UCG - 3' 
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Exemplary reverse phase chromatogram of the purified RNA (GP10 siRNA3, 400 pmol) using a Nucleosil 100-5 C18 column (4.6 x 250 mm, 
CS Chromatography) (acetonitrile, 0.1 M triethylammonium acetate solution pH = 7; prerun: 2 min 5 % acetonitril; gradient: 5 % to 35 % acetonitrile  
in 30 minutes, flow: 1 mL/min, detector: 254 nm).
 Name Sequence Mcalc. Mexp. 
GP2 siRNA3 5- UUGP G AAG UAU GCC UCA AGG UCG -3' 6809.0 6809.1 
GP3 siRNA3 5- UUGGP  AAG UAU GCC UCA AGG UCG -3' 6809.0 6809.5 
GP4 siRNA3 5- UUG AGP AG UAU GCC UCA AGG UCG -3' 6809.0 6809.4 
GP5 siRNA3 5- UUG AAGP G UAU GCC UCA AGG UCG -3' 6809.0 6809.4 
GP6 siRNA3 5- UUG AAGGP  UAU GCC UCA AGG UCG -3' 6809.0 6809.4 
GP7 siRNA3 5- UUG AAG UGP AU GCC UCA AGG UCG -3' 6809.0 6809.1 
GP8 siRNA3 5- UUG AAG UAGP U GCC UCA AGG UCG -3' 6809.0 6809.4 
GP9 siRNA3 5- UUG AAG UAUGP GCC UCA AGG UCG -3' 6809.0 6809.1 
GP10 siRNA3 5- UUG AAG UAU GGPCC UCA AGG UCG -3' 6809.0 6809.5 
GP11 siRNA3 5- UUG AAG UAU GCGPC UCA AGG UCG -3' 6809.0 6809.4 
GP12 siRNA3 5- UUG AAG UAU GCCGP UCA AGG UCG -3' 6809.0 6809.4 
GP13 siRNA3 5- UUG AAG UAU GCC UGP CA AGG UCG -3' 6809.0 6809.1 
GP14 siRNA3 5- UUG AAG UAU GCC UCGPA AGG UCG -3' 6809.0 6809.4 
GP15 siRNA3 5- UUG AAG UAU GCC UCAGP AGG UCG -3' 6809.0 6809.3 
GP16 siRNA3 5- UUG AAG UAU GCC UCA AGPGG UCG -3' 6809.0 6809.4 
GP17 siRNA3 5- UUG AAG UAU GCC UCA AGGPG UCG -3' 6809.0 6809.5 
GP18 siRNA3 5- UUG AAG UAU GCC UCA AGGGP UCG -3' 6809.0 6809.5 
GP19 siRNA3 5- UUG AAG UAU GCC UCA AGG UGPCG -3' 6809.0 6809.4 
GP20 siRNA3 5- UUG AAG UAU GCC UCA AGG UCGPG -3' 6809.0 6809.4 
GP21 siRNA3 5- UUG AAG UAU GCC UCA AGG UCGGP -3' 6809.0 6809.5 
MS data of the synthesised oligos measured on a Bruker microTOF QII 
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 Name Sequence Δ Tm (°C) 
GP4 siRNA3 5- UUG AGP AG UAU GCC UCA AGG UCG -3' - 1.9 
GP5 siRNA3 5- UUG AAGP G UAU GCC UCA AGG UCG -3' - 1.1 
GP8 siRNA3 5- UUG AAG UAGP U GCC UCA AGG UCG -3' - 0.9 
GP9 siRNA3 5- UUG AAG UAUGP GCC UCA AGG UCG -3' - 0.9 
GP11 siRNA3 5- UUG AAG UAU GCGPC UCA AGG UCG -3' - 1.6 
GP12 siRNA3 5- UUG AAG UAU GCCGP UCA AGG UCG -3' - 0.6 
GP14 siRNA3 5- UUG AAG UAU GCC UCGPA AGG UCG -3' - 0.8 
GP16 siRNA3 5- UUG AAG UAU GCC UCA AGPGG UCG -3' - 0.1 
GP19 siRNA3 5- UUG AAG UAU GCC UCA AGG UGPCG -3' - 0.4 
GP20 siRNA3 5- UUG AAG UAU GCC UCA AGG UCGPG -3' 0.3 
GP21 siRNA3 5- UUG AAG UAU GCC UCA AGG UCGGP -3' - 1.3 
Δ Tm values of modified oligos 
S14 
Melting point studies were accomplished on a JASCO V650 Spectrophotometer. A 1.15 µM solution of the duplex of the unmodified sense strand (5’ - 
ACC UUG AGG CAU ACU UCA AdTdT - 3’) and the appropriate modified antisense strand was prepared in PBS (phosphate buffered saline, pH = 7.4). 
The absorption was measured at 260 nm and the temperature was cycled from 90 °C to 50 °C and back to 90 °C. The experiment was done in triplicate for 
each siRNA combination. 
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SUPPLEMENTARY METHODS: 
4.1. Transfections and antiHBV activity of GP-modified siRNAs in vitro by ELISA and 
Dual-luciferase assays 
Huh7 cells were used to investigate antiviral activity of GP-modified siRNAs. Cells were 
maintained in Dulbecco’s Modified Eagle Medium (DMEM, Lonza, Basel, Switzerland) 
comprised of Penicillin (50 IU/ml, Gibco
®
, Life Technologies, CA, USA), Streptomycin (50 
µg/ml, Gibco
®
, Life Technologies, CA, USA) and 10% foetal calf serum (FCS, Gibco
®
, Life 
Technologies, CA, USA). Cells were maintained in 24-well plates at 40% confluence, a day 
prior to transfection. For transfections, Lipofectamine
® 
2000 (Life Technologies, CA, USA) 
was employed to deliver 100 ng of either psiCHECK-HBx or pCH-9/3091 target plasmid, 100 
ng pCI-eGFP and 10 nM siRNA (32.5 ng) and incubated at 37°C and 5% CO2. The ratio of 
Lipofectamine
®
 2000 to siRNAs was 3:1 (ml:mg), while that of Lipofectamine
®
 2000 to 
plasmid vectors was 1:1 (ml:mg). The scrambled or non-targeting siRNA and unmodified 
siRNA3 were employed as negative and positive controls, respectively. 
 
Two days post-transfection, culture medium was harvested from cells treated with pCH-
9/3091 and HBsAg concentration was assessed by Enzyme-Linked Immunosorbent Assay 
(ELISA) using the MONOLISA™ HBs Ag ULTRA kit (Bio-Rad, CA, USA). Briefly, 100 µl 
of harvested supernatant was added to each well of the ELISA plate. Additionally, 100 µl of 
the ELISA negative control (R3, in quadruplicate) and ELISA positive control (R4) were 
included as additional experimental controls. Fifty microlitres of the conjugate solution (R6 + 
R7) was dispensed into each well. The ELISA plate was covered with an adhesive film and 
incubated at 37°C for one and a half hours. Thereafter, the adhesive film was removed; wells 
emptied by aspiration and washed a minimum of 5 times using a Microplate Washer (Bio-
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Rad, CA, USA). One hundred microlitres of freshly prepared enzyme development solution 
(R8 + R9) was dispensed into each well and incubated at room temperature in the dark for 35 
minutes. Subsequently, 100 µl of stopping solution (R10) was added into all wells, gently 
mixed and incubated at room temperature for 4 minutes. Optical density was measured at 
450/620-700 nm using a plate reader (Bio-Rad, CA, USA) within 30 minutes of stopping the 
reaction. 
 
In a parallel experiment, luciferase activity was assessed from cells transfected with 
psiCHECK-HBx using the Dual-Luciferase
®
 Reporter Assay System (Promega, WI, USA), 
unless otherwise stated. Growth medium was removed from transfected cells by aspiration. 
Cell lysis was achieved by dispensing 100 µl of 1 × passive lysis buffer into each well of the 
24-well plate containing transfected cells and incubated with shaking at room temperature for 
15 minutes. Ten microlitres of each lysate was transferred into a Costar
®
 96-well assay plate 
(Corning Inc, NY, USA). In this assay, the activities of firefly (Photinus pyralis) and sea 
pansy (Renilla reniformis) luciferase were measured consecutively from a single sample 
using a luminometer (VERITAS Microplate Luminometer, TURNER BioSystems, MA, 
USA) equipped with reagent auto-injectors. The activity of firefly luciferase was measured 
first after adding 1 × Luciferase Assay Reagent II (LAR II) to produce a luminescent signal. 
After quantification, 1 × Stop & Glo
®
 Reagent was added into the same sample, quenched 
firefly luciferase reaction and initiated Renilla luciferase activity. The psiCHECK-HBx 
plasmid comprises an independent active Firefly luciferase cassette, while the HBx region is 
located downstream of the Renilla luciferase ORF. The ratio of Renilla to Firefly luciferase 
activity was utilised to indicate relativised silencing efficacy. 
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4.2. Assessment of innate immune stimulation of antiHBV siRNAs in vitro 
Human Embryonic Kidney 293 (HEK293) cells were employed to investigate 
immunostimmulatory effects of antiHBV siRNAs in vitro, since innate immune stimulation is 
attenuated in Huh7 cells. The HEK293 cells were maintaned in DMEM comprised of 
Penicillin (50 IU/ml), Streptomycin (50 µg/ml) and 10% FCS. Cells were maintained in 24-
well plates at 20% confluence, a day prior to transfection. Transfections were performed with 
100 ng of pCH-9/3091, 100 ng pCI-eGFP and 800 ng siRNA using Lipofectamine
®
 2000 and 
incubated at 37°C and 5% CO2. As a positive control for immune stimulation, cultured cells 
were treated with 100 ng pCH-9/3091, 100 ng pCI-eGFP and 800 ng 
polyinosinic:polycytidylic acid, Poly(I:C) (Sigma, MI, USA). The ratio of Lipofectamine
®
 
2000 to siRNAs was 3:1 (ml:mg),  while that of Lipofectamine
®
 2000 to plasmid vectors and 
Poly(I:C)  was 1:1 (ml:mg). 
 
Forty eight hours post-transfection, total RNA was extracted using Tri Reagent
®
 (Sigma, MI, 
USA). Growth medium was removed from all wells by aspiration and 250 µl of Tri Reagent
®
 
was added to each well and gently mixed. The mixtures were transferred to 1.7 ml 
microcentrifuge tubes and incubated at room temperature for 5 minutes. Fifty microlitres of 
chloroform was added into each sample, gently mixed by inverting tubes and centrifuged at 
12 000 × g at 4°C for 20 minutes. Subsequently, 100 µl of the upper aqueous phase was 
transferred to new 1.7 ml microcentrifuge tubes; an equal volume of isopropanol was added 
and mixed by inverting tubes. Samples were incubated at -70°C for 2 hours and centrifuged 
at 12 000 × g at 4°C for 20 minutes. The resulting supernatants were discarded, pellets 
washed with 200 µl 70% ethanol and centrifuged at 12 000 × g at 4°C for 5 minutes. The 
supernatants were discarded, pellets resuspended in 50 µl nuclease-free water (Thermo 
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Scientific, MA, USA) and stored at -70°C until use. One microgram of total RNA was 
reverse transcribed using the QuantiTect
®
 Reverse Transcription Kit (Qiagen, GmbH, 
Germany), according to manufacturer’s instructions. First, genomic DNA contamination was 
removed with gDNA Wipeout Buffer in a final volume of 14 µl. cDNA synthesis (reverse 
transcription) was carried out using 14 µl of RNA, 4 µl of Quantiscript RT Buffer (5 ×), 1 µl 
of Quantiscript
® 
Reverse Transcriptase and 1 µl of RT Primer Mix. The reaction mixture was 
incubated at 42°C for 30 minutes. 
 
To assess induction of IFN genes, IFN-β, IFIT1, OAS-1 and Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) reverse transcription quantitative polymerase chain reaction (RT-
qPCR) was performed. The RT-qPCR reaction mixtures (Sensimix
TM
 Capillary Kit, 
BIOLINE, MA, USA) were prepared using 10 pmol of each human primer pair (Integrated 
DNA Technologies, IA, USA) and 2 µl of cDNA template. The primer sequences employed 
for amplifications were: IFN-β forward: 5’-TCC AAA TTG CTC TCC TGT TGT GCT-3’, 
IFN-β reverse: 5’-CCA CAG GAG CTT CTG ACA CTG AAA A-3’, IFIT1 forward: 5’-CCC 
TGA AGC TTC AGG ATG AAG G-3’, IFIT1 reverse: 5’-AGA AGT GGG TGT TTC CTG 
CAA G-3’, OAS-1 forward: 5’-CGA GGG AGC ATG AAA ACA CAT TT-3’, OAS-1 
reverse: 5’-GCA GAG TTG CTG GTA GTT TAT GAC-3’, GAPDH forward 5’-AGG GGT 
CAT TGA TGG CAA CAA TAT CCA-3’ and GAPDH reverse: 5’-TTT ACC AGA GTT 
AAA AGC AGC CCT GGT G-3’. 
 
All amplification reactions were performed using the Roche Lightcycler V.2 (Roche 
Diagnostics, Germany) and controls included RNA samples that were not treated with reverse 
transcriptase as well as water blanks. Cycling conditions comprised: hotstart for 30 seconds at 
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95°C, followed by 50 cycles of denaturation at 95°C for 5 seconds, annealing at 58°C for 10 
seconds and extension at 72°C for 7 seconds. Additionally, specificity of the amplicons was 
confirmed by melting curve analysis. Crossing-point analysis was used to calculate relative 
mRNA concentrations. Data analysis was performed at 48 hours post-transfection and was 
calculated as the ratio to the GAPDH reference gene mRNA concentrations. 
 
4.3. AntiHBV effects of unmodified and GP-modified siRNAs in a hydrodynamic mouse 
model 
The siRNAs containing GP moieties in position 3, 4 and 5 were employed for preliminary 
animal investigations. Experiments on animals were conducted in accordance with protocols 
approved by the University of the Witwatersrand Animal Ethics Screening Committee 
(Appendix 7.1). The murine HDI model was used to investigate therapeutic efficacy of 
siRNAs in vivo and the experimental mice (NMRI strain) weighed between 20-22 g. 
Subsequently, mice were injected via the tail vein using a saline solution corresponding to 
10% of the animal’s body weight. This solution was comprised of 1 nmol siRNA, 15 µg pCI-
eGFP plasmid and 15 µg HBV replication plasmid (pCH-9/3091). At days 3 and 5 after 
injection, blood samples were collected from behind the eyes of injected animals using a retro 
orbital puncture and animals were humanely sacrificed after completion of the experiment. 
 
Blood samples were incubated at 4°C for 2 hours, centrifuged at 8 000 × g at 4°C for 10 
minutes and serum samples collected from the upper phase. Subsequently, serum samples 
were used to measure HBsAg by ELISA and circulating viral particle equivalents (VPEs) by 
quantitative polymerase chain reaction (qPCR). A 1:50 serum dilution in saline was 
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performed and 100 µl of each sample was used to perform ELISA, as described in 
Supplementary Methods Section 4.1. A 1:5 dilution of serum samples in saline was 
prepared and used for DNA extraction using the MagNA Pure LC Total Nucleic Acid 
Isolation Kit according to manufacturer’s instructions (Roche Diagnostics, Germany). 
Subsequently, qPCR was conducted by amplifying five microlitres of DNA with 10 pmol 
each of mouse HBV surface primers (Integrated DNA Technologies, IA, USA), forward 5’-
TGCACCTGTATTCCCATC-3’ and reverse 5’-CTGAAAGCCAAACAGTGG-3’. All 
amplification reactions were performed using the Roche Lightcycler V.2. Cycling conditions 
comprised: hotstart for 30 seconds at 95°C, followed by 50 cycles of denaturation at 95°C for 
5 seconds, annealing at 57°C for 10 seconds and extension at 72°C for 7 seconds. 
Additionally, HBV standard samples were included in the qPCR and run concurrently with 
experimental samples and melting curve analysis was used to confirm specificity of the 
amplification reaction. 
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unmodified siRNA was only active for up to 7 days. Our data indicate that application of 
novel GP-modified siRNAs in conjunction with a competent delivery system improves 
therapeutic utility of these RNAi effectors by enhancing antiHBV activity and specificity, 
while minimising toxicity and innate immune response. 
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RNAiChronic infectionwith hepatitis B virus (HBV) occurs commonly and complications that arise from persistence of
the virus are associated with highmortality. Available licensed drugs have modest curative efﬁcacy and advanc-
ing new therapeutic strategies to eliminate the virus is therefore a priority. HBV is susceptible to inactivation by
exogenous gene silencers that harness RNA interference (RNAi) and the approach has therapeutic potential. To
advance RNAi-based treatment for HBV infection, use in vivo of hepatotropic lipoplexes containing siRNAs
with guanidinopropyl (GP) modiﬁcations is reported here. Lipoplexes contained polyglutamate, which has pre-
viously been shown to facilitate formulation and improve efﬁciency of the non-viral vectors. GP moieties were
included in a previously described anti-HBV siRNA that effectively targeted the conserved viral X sequence. Par-
ticles had physical properties that were suitable for use in vivo: average diameterwas approximately 50–200 nm
and surface charge (zeta potential) was +65 mV. Efﬁcient hepatotropic delivery of labeled siRNA was observed
following systemic intravenous injection of the particles into HBV transgenic mice. Good inhibition of markers of
viral replication was observed without evidence of toxicity. Efﬁcacy of the GP-modiﬁed siRNAs was signiﬁcantly
more durable and formulations made up with chemically modiﬁed siRNAs were less immunostimulatory. An
RNAi-mediated mechanism was conﬁrmed by demonstrating that HBV mRNA cleavage occurred in vivo at the
intended target site. Collectively these data indicate that GP-modiﬁed siRNAs formulated in anionic polymer-
containing lipoplexes are effective silencers of HBV replication in vivo and have therapeutic potential.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Infection with hepatitis B virus (HBV) remains a health problem
of considerable importance. It is estimated that 350 million people are
chronically infected with the virus, and at high risk for the life-
threatening complications of cirrhosis and liver cancer [1,2]. Although
there is an effective vaccine to prevent transmission of HBV, immuniza-
tion is not administered to many populations where the infection is
endemic. Currently licensed treatments for HBV infection include nucleo-
side and nucleotide analogs, which function as inhibitors of the viral
reverse transcriptase. Immunomodulatory interferon-alpha (IFN-α),
modiﬁedwithpolyethylene glycol (PEG)or in its native form, is also avail-
able for treatment of the infection. Unfortunately the licensed drugs have
modest curative efﬁcacy against HBV [3] and tominimize risks for com-
plications from the infection, improvements in treatment is a priority.thnot).The genome of HBV has a compact arrangement with restricted
sequence plasticity. As a result, the virus has limited ability to generate
escapemutants and use of nucleic acids that have an inhibitory effect by
hybridization to viral targets is potentially a useful therapeutic strategy.
Replication of HBV has been shown to be susceptible to silencing by ex-
ogenous activators of the RNA interference (RNAi) pathway (reviewed
in [4]), and harnessing this gene silencing mechanism has potential
for therapeutic application. Speciﬁc silencing of intended targets may
be induced by introducing various artiﬁcialmimics of the RNAi pathway
into hepatocytes. Inhibition is dependent on the interaction of a guide
strand derived from RNAi activators with intended mRNA targets.
Both expressed and synthetic RNAi activators have been employed suc-
cessfully against HBV and each class of gene silencers has advantages.
Expressed RNAi activators may cause lasting inhibition of viral replica-
tion and are amenable to incorporation into recombinant viral vectors.
Although efﬁcient, dose regulation is difﬁcult to achieve and delivery
of RNAi activators with recombinant viruses may be complicated by
induction of an immune response to the vectors. Moreover, preparation
199M.D. Marimani et al. / Journal of Controlled Release 209 (2015) 198–206of recombinant viral vectors is costly and not easily scalable for wide-
spread clinical use.
Synthetic activators of RNAi typically comprise duplexes of RNA,
which resemble the products of Dicer. Short interfering RNAs (siRNAs)
may be prone to degradation, off target effects and immunostimulation.
To minimize these effects and improve silencing potency, a variety of
chemical modiﬁcations has been employed (reviewed in [5,6]). These
include alterations to the 2′OH group of the ribose moiety, changes to
the phosphodiester backbone and substitutions of ribose for alternative
sugars. Modiﬁcations to the 2′ OH group include incorporation of 2′-O-
methyl (2′OMe), 2′-ﬂuoro (2′-F), locked nucleic acids (LNAs), acyclic
unlocked nucleic acids (UNAs), 2′-O-methoxyethyl (2′MOE), and deoxy
residues. Recently we demonstrated that incorporating guanidinopropyl
(GP) groups into the ribose components of HBV-targeting siRNAs im-
proves their efﬁcacy [7]. Thesemoieties achieve some charge neutraliza-
tion of siRNAs, which is useful to facilitate delivery of nucleic acid-based
gene silencers. Importantly the modiﬁcations also improve stability and
speciﬁcity of target knockdown by attenuating off target interaction of
the seed with mRNA sequences.
siRNAs have a cytoplasmic site of action, which is convenient for de-
livery to target tissues. Various non-viral vector formulations have been
developed for therapeutic use of synthetic siRNAs. Stable nucleic acid
lipid particles (SNALPs) delivered gene silencers efﬁciently in vivo to in-
hibit HBV replication in murine models of the viral infection [8]. Other
lipoplex formulations have included polyamine-conjugated cholesterol
[9] or aminoxycholesterol lipid to facilitate post coupling of ‘stealth’
polyethylene glycol moieties [10]. Recently, synthetic anti-HBV siRNAs
have been delivered in vivo using Dynamic PolyConjugates (DPCs)
[11,12]. Promising results indicating effective inhibition of HBV replica-
tion have led to development of the technology to stage II of clinical trial
(http://www.arrowheadresearch.com/programs-overview). Although
these advances are encouraging, optimization of conveniently assem-
bled non-viral vectors and identifying the most suitable chemically
modiﬁed gene silencers for incorporation into the formulations con-
tinues to be important. Previously we have shown that improvement
in the efﬁciency of the non-viral vectors is brought about by addition
of polyglutamate [13,14]. Here we report on delivery of GP-modiﬁed
siRNAs using these novel polyanion-containing hepatotropic lipoplexes.
Evaluation in amodel that stringently simulates the human condition of
chronic HBV infection demonstrated that efﬁcient and safe silencing of
viral replication is achieved.2. Materials and methods
2.1. Preparation and characterization of siRNA-containing lipoplexes
Cationic liposomes were formed by combining equimolar amounts
of cationic lipid 2-{3-[Bis-(3-amino-propyl)-amino]-propylamino}-
Nditetradecylcarbamoyl methyl-acetamide (DMAPAP) [15] and 1,2-
dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) (Avanti Polar
Lipids, AL, USA). Procedures for preparation of the liposomes have pre-
viously been described [16]. siRNA-containing lipoplexes were formed
by combining equal masses of siRNA and polyglutamate (Poly-L-
glutamic acid sodium salt, Sigma-Aldrich, MO, USA), which were
made up in 150 mM NaCl. This solution was then added to the cationic
liposome suspension, also made up in 150 mM NaCl, then rapidly
mixed by vortexing. Typically, 15 μg siRNA (1.13 nmol) and 15 μg
polyglutamate (3 to 10 nmol) were diluted in 100 μl saline and mixed
with 100 μl saline containing 20 μl of a 20 mM suspension of
DMAPAP/DOPE (400 nmol each). Lipoplexes were allowed to form by
incubating at room temperature for 30 min before use. The charge
ratio was calculated as the molar ratio of positive charges from
DMAPAP to negative charges of siRNA and polyglutamate. Each mole-
cule of DMAPAP has 3 positive charges. siRNAs and polyglutamate
have 3.03 and 6.58 nmoles of negative charge per μg respectively.Size and zeta (ζ) potential measurements were performed using a
Malvern Zetasizer (Nano series) Nano ZS (Malvern, UK). Liposomes or
lipoplexes were prepared in 100 μl of NaCl (150 mM). Final lipid
concentrations were 0.4 mM for the liposomes and 0.334 μM for the
siRNA-containing lipoplexes. For ζ potential measurements, liposomes
(lipid 0.04 mM) and lipoplexes (siRNA 33.4 nM) were prepared in
15 mM NaCl.
A drop of the lipoplex suspension (siRNA concentration 400 nM)
was initially applied to a Formvar and carbon-coated copper grid of
200 mesh (Agar Scientiﬁc, UK), which had been pre-treated with 0.1%
bacitracine. The sample was allowed to adsorb for 2 min, blotted with
ﬁlter paper, stained with 4% aqueous uranyl acetate then viewed using
a JEM 100S transmission electron microscope.
2.2. Synthesis of siRNAs containing GP moieties
The GP-modiﬁed siRNAs were synthesized as previously described
[17]. One, two, three or four GP moieties were incorporated at different
positions of the antisense strand of a previously characterized anti-HBV
siRNA, called siRNA3 (antisense, 5′UUGAAGUAUGCCUCAAGGUCG3′)
[18]. The sense strand (5′ACCUUGAGGCAUACUUCAAdTdT3′) did not
possess any GP modiﬁcation, but instead contained two deoxyribonu-
cleotides (dTdT) at the 3′ end. The siRNA3 derivatives were named
according to the position of the nucleotide, determined from the 5′
end of the guide strand, that contained the GPmoiety [7,17]. The control
scrambled siRNA comprised the following complementary strands:
antisense, 5′GCGAAGUGACCAGCGAAUACdT3′ and sense, 5′UAUUCG
CUGGUCACUUCGUdTdT3′.
2.3. Plasmids and transfection
pCH-9/3091 is a viral replication competent plasmid that has a
greater than genome length HBV sequence [19]. The complete and par-
tial targets of siRNA3 were produced by inserting appropriate oligonu-
cleotide sequences into psiCHECK as has previously been described
[7]. The liver-derived human hepatoma (Huh7) cells were cultured in
DMEM (Lonza, Basel, Switzerland) containing 10% FCS (Life Technolo-
gies, CA, USA). Transfection, measurement of reporter activity and
HBsAg concentrations in culture supernatants were performed as has
been described [7,20,21].
2.4. Assessment of biodistribution of labeled siRNAs following intravenous
administration of lipoplexes to HBV transgenic mice
Animal studies were performed according to protocols approved by
the University of the Witwatersrand Animal Ethics screening Commit-
tee. To enable assessment of biodistribution, the sense strand of the
siRNAs was labeled with Alexa Fluor 750 at the 3′ end (Inqaba Biotech
Industries, South Africa). Lipoplexes were injected into the tail veins of
HBV transgenic mice at a dose of 1 μg of siRNA per g of the mouse's
body weight. Control mice were injected with an equivalent dose of
uncomplexed GP3 siRNA3 or saline. At 10 min after injection, mice
were killed and the kidneys, liver, lungs and spleen were taken for im-
aging ex vivo. Fluorescence in harvested organs, determined using a ﬁl-
ter set at 745 nm, wasmeasured using the IVIS Kinetic Bioluminescence
imager (PerkinElmer, MA, USA). Subsequently, tissues were processed
following overnight incubations at 4 °C in 20% paraformaldehyde then
in 30% sucrose. Sections (~5 μm) were stained with 4′,6-diamidino-2-
phenylindole (DAPI, Life Technologies, CA, USA) prior to viewing with
a confocal microscope (Zeiss, LSM 780, Oberkochen, Germany).
2.5. Anti-HBV effects in vivo of siRNA-containing lipoplexes
The HBV transgenic mice contain replication-competent viral se-
quences [22]. Blood samples were collected at days 0 (baseline), 3, 5,
7, 14, 18 and 21 after injections of the lipoplexes or control samples.
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using the Monolisa™ HBs Ag ULTRA assay kit (Bio-Rad, CA, USA) as de-
scribed previously [23]. Circulating viral particle equivalents (VPEs)
were assayed by quantitating viral DNA in serum samples using real-
time qPCR carried out using the Roche Lightcycler v.2. or the Bio-Rad
CFX96 Touch™ Real-Time PCR Detection System (Bio-Rad, CA, USA),
as has been described [20,24]. Alanine transaminase (ALT) activity
was measured in serum samples using the accredited facilities of the
South African National Health Laboratory Service (NHLS, Johannesburg,
South Africa). Extraction of RNA from the liver samples was carried out
using Tri Reagent®, andwas performed according to procedures recom-
mended by the supplier (Life Technologies, CA, USA). Total RNAwas re-
verse transcribed with the QuantiTect® Reverse Transcription Kit
(Qiagen GmbH, Germany) according to themanufacturer's instructions.
To amplify murine GAPDH, HBV surface and core mRNA, the following
primer sets were used: mGAPDH F (5′AGGGGTCATTGATGGCAACAAT
ATCCA3′) and mGAPDH R (5′TTTACCAGAGTTAAAAGCAGCCCTGGTG
3′), HBV Surface F (5′TGCACCTGTATTCCCATC3′) and HBV Surface R (5′
CTGAAAGCCAAACAGTGG3′), HBV Core F (5′ACCACCAAATGCCCCT
AT3′) and HBV Core R (5′TTCTGCGACGCGGCGA3′). PCR analysis was
performed using the SsoFast™ EvaGreen®Supermix (Bio-Rad, CA,
USA) with standard conditions for thermocycling. To identify RNAi-
mediated cleavage of HBV mRNA, total hepatic RNA was subjected to
analysis using the 5′ RACE procedure as has been described [25].
2.6. Evaluation of innate immune stimulation in vivo by siRNA-containing
lipoplexes
To investigate innate immune stimulation in mice, the animals re-
ceived intravenous injections of the lipoplex formulations, poly (I:C)Fig. 1. Formulation of siRNA-containing lipoplexes. A. The non-viral vectors comprised a cationic
acetamide, DMAPAP) and neutral lipid (1,2-dioleoyl-sn-glycero-3-phospho-ethanolamine, DO
molecules were combined with the liposomes to form lipoplexes. Formulations were generate
ratio 6. B. Representative particle size distribution of the GP siRNA-containing lipoplexes. C. Tr
that siRNAs were entrapped within the organized lipoplexes. Scale bar indicates 50 nm.or liposome alone. The doses of the siRNAs were consistently 1 μg per
g of a mouse's body weight. Six hours after injection, blood samples
were collected and livers harvested. Interleukin 6 (IL-6), interleukin
10 (IL-10), Monocyte Chemoattractant Protein-1 (MCP-1), interferon
gamma (IFN-γ), Tumor Necrosis Factor alpha (TNF-α) and interleukin
12p70 (IL-12p70) protein were measured in serum samples using the
Cytometric Bead Array (CBA) Mouse Inﬂammation Kit (BD Biosciences,
CA, USA) with minor previously described modiﬁcations [26–28]. Liver
samples were subjected to RNA extraction using Tri Reagent®, the
RNA reverse transcribed using the QuantiTect® Reverse Transcription
Kit (Qiagen GmbH, Germany) and resulting cDNA used to quantify
IFN-β and OAS-1mRNA levels by RT-qPCR using procedures that have
previously been described [21,29].
2.7. Statistical analysis
Data are represented as the mean ± standard error of the mean
(±SEM). Two-tailed Student's t tests were performed using GraphPad
Prism version 4.00 (GraphPad software, CA, USA). P values of b0.05
were regarded as statistically signiﬁcant.
3. Results
3.1. Non-viral lipoplexes for delivery of GP-modiﬁed siRNAs
To achieve hepatotropic delivery of GP-modiﬁed siRNAs, cationic
lipid-based formulations were employed (Fig. 1A). Polyglutamate, an
anionic polymer,was included in the complexes to limit toxicity and en-
hance efﬁcacy of the siRNA-containing vectors [14]. Polyethylene glycol
(PEG) was however omitted from the formulations as this polymerlipid (2-{3-[Bis-(3-amino-propyl)-amino]-propylamino}-N-ditetradecylcarbamoylmethyl-
PE), which were combined to form the cationic liposome. Polyglutamate and the siRNA
d after pre-association of siRNA with polyglutamate (1.5 kDa) (1/1, w/w) at a N/P charge
ansmission electron microscopy revealed a typical multilamellar arrangement suggesting
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lipoplexes [14]. A charge ratio (N/P) of 6 was used to complex the cat-
ionic lipids with siRNAs, and has been shown to be optimal for
hepatotropic delivery in vivo with these vectors. Lipoplexes had a uni-
form diameter that ranged from 50 to 200 nm for the GP-siRNA3-
containing lipoplexes (Fig. 1B) and was similar to the size of 45 to
180 nm for the lipolexes containing unmodiﬁed siRNA3. The ζ potential
was slightly more positive for the GP3-siRNA3-containing lipolexes
(65±1mV)when compared to that of the particles containing unmod-
iﬁed siRNA (57 ± 1 mV). The polydispersity index of the particle sizes,
which ranged between 0.5 and 1.1, was not inﬂuenced by inclusion of
polyglutamate. Transmission electron microscopy of the particles re-
vealed multilamellar structures (Fig. 1C), which are typical of cationic
lipid-based siRNA particles. These features of the lipoplexes were con-
sidered suitable for their assessment as vectors for delivery of HBV-
targeting chemically modiﬁed siRNAs.
3.2. Guanidinopropyl-modiﬁed HBV-targeting siRNAs
siRNAs that were delivered with hepatotropic non-viral vectors
were derived from a previously described HBV-targeting RNAi activator
called siRNA3 [18]. The intended guide strand of this gene silencer is
complementary to sequences in the viral X open reading frame (ORF)
(Fig. 2A). X is well conserved in genotypes of HBV and is present in allFig. 2. Schematic illustration ofHBV targets and guanidinopropyl (GP)-modiﬁed siRNAs. A.
Linear depiction of greater-than-genome length HBV DNA that is integrated into the ge-
nome of HBV transgenic mice. Coordinates of the viral genome are calculated relative to
the position of the single EcoRI site. The site targeted by siRNA3 (nucleotides 1693 to
1711) is depicted as a vertical arrow. The four groups of viral transcripts are indicated as
horizontal arrows. Precore (PC), core, preS1, preS2 (S2), surface, polymerase and X viral
open reading frames (ORFs) are indicated as the labeled rectangles. Transcriptional regu-
latory elements are indicated by the arrowheads below the ORF-encoding viral DNA. B.
siRNAs comprising duplexes of RNA with dinucleotide overhangs at the 3′ ends had GP
residues incorporated at positions 3 or 4 from the 5′ end of the antisense strand.of the viral transcripts, which makes it a good target to counter replica-
tion of the virus. The structure of the synthetic siRNAwas typical and in-
cluded a 19 bp duplex with additional overhangs of two nucleotides at
either 3′ end. To improve stability and antiviral efﬁcacy, GP moieties
were incorporated at positions 3 or 4 from the 5′ end of the antisense
strand of the siRNA (Fig. 2B) siRNAs [7]. Evaluation in transfected cul-
tured cells demonstrated that inclusion of additional GP modiﬁcations
did not improve speciﬁcity and efﬁcacy of the siRNAs (Supp. Figs. 1 & 2).
3.3. Biodistribution of labeled siRNAs following administration of lipoplex
formulations
To assess biodistribution of the siRNAs in mice, the gene silencers
were labeled at their 3′ ends with Alexa Fluor 750. Lipoplexes contain-
ing these labeled siRNAs were administered intravenously to mice.
Mice were killed 10 min after the injections and ﬂuorescence was de-
tected in the kidneys, liver, lungs and spleen (Fig. 3). After intravenous
injection,most of the naked labeledGP3 siRNA3 accumulated in the kid-
neys and lungs but ﬂuorescence in the liver and spleen was barely de-
tectable (Fig. 3A&D). When complexed to the liposomes delivery to
the liver was favored and diminished ﬂuorescence was detectable in
the kidneys, lungs and spleen (Fig. 3B&D). Microscopy conﬁrmed
hepatotropic delivery of the labeled siRNAs, andmost cells were labeled
with the ﬂuorescent siRNAs. Small amounts of the labeled siRNAs were
detectable in the kidneys, spleen and lungs. Fluorescence was not
detectable macro- and microscopically in in the control animal that
received saline (Fig. 3C). Based on the good efﬁciency of hepatotropic
delivery of siRNAs with the lipoplex vectors, these formulations
were tested for efﬁcacy against HBV replication in HBV transgenic
mice [30].3.4. Antiviral effects of GP-modiﬁed siRNAs following systemic
administration of lipoplexes to HBV transgenic mice
The HBV transgenic mice contain an integrated replication-
competent greater-than-genome-length viral sequence (Fig. 2A) [22].
Transcription and translation of the transgenic DNA results in HBV rep-
lication in hepatocytes in these animals. Although infection of murine
hepatocytes does not occur, long term replication of HBV in the trans-
genic animals approximates chronic HBV infection of humans [22,31].
A limitation of the transgenic model is that covalently closed circular
DNA (cccDNA) of HBV is not formed in murine hepatocytes [32]. Pro-
duction of the viral replication intermediate does occur following HBV
infection of severe combined immunodeﬁcient (SCID) mice that have
been xenografted with human hepatocytes [33]. Although this property
is advantageous, procedures required to generate the chimeric animals
are challenging. Also, the immunocompromised state of xenografted
SCID mice eliminates the role of host immune responses during a ther-
apeutic response. Based on convenience of HBV transgenic mice, status
of the immune system and stringent simulation of viral replication in
chronically infected individuals, we elected to use this murine model
to assess efﬁcacy of lipoplexes containing GP-modiﬁed siRNAs.
Following injection of the formulations, HBsAg and circulating VPEs
were measured as indicators of viral replication (Fig. 4). Administration
of formulated scrambled siRNAs or saline caused no signiﬁcant effect on
the markers of viral replication during the three week period of follow
up. Formulations containing the unmodiﬁed siRNA3 caused knockdown
of HBsAg concentrations by about 86% at days 3 and 5, and diminished
to 70% at day 7 after injection (Fig. 4A). The effect on circulating VPEs
was similar, and signiﬁcant inhibition was observed during the week
after the mice received the antiviral formulations (Fig. 4B). GP-
modiﬁed siRNAs caused similar early suppression of HBsAg concentra-
tions and circulating VPEs. However, GP-containing siRNAs achieved
more durable HBsAg silencing than their unmodiﬁed counterpart.
With formulations containing GP3 siRNA3 and GP4 siRNA3,
Fig. 3. Biodistribution of siRNAs in HBV transgenic mice. Representative ﬂuorescence images obtained from samples harvested 10min after injection of lipoplexes containing Alexa Fluor
750-labeled siRNAs. Three mice (i–iii) received intravenous injection of the uncomplexed naked labeled siRNA (A) and three mice (i–iii) received labeled siRNA within polyglutamate-
containing lipoplexes (B). One mouse, which received a saline injection, served as the negative control (C). Fluorescence detectable in livers (Li), lungs (Lu), kidneys (Ki) and spleen
(S) are shown in the top row of images. Microscopy of frozen sections from liver and kidney samples are also shown below. The scale bar indicates 50 μm. Quantitation of ﬂuorescence,
radiant efﬁciency,wasmeasured in the organs ofmice given nakedGP3-siRNA3or lipoplexed GP3-siRNA3 (D). Data are represented as themean radiant efﬁciency (±SEM) for each organ
from the three animals.
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diminished up to and including day 14 after administration of the
lipoplexes. Compared to the baseline values at this time point, the con-
centrations of HBsAg were reduced by approximately 70% and circulat-
ing VPEs were diminished by 75–80%. Concentrations of the markers
returned to baseline values at day 21 after receiving lipoplexes contain-
ing GP3 siRNA3 and GP4 siRNA3.
Transgenic mice receiving saline and GP3 siRNA3 were killed at day
18, while experiments with those treated with scrambled siRNA, un-
modiﬁed siRNA3 and GP4 siRNA3 were terminated on day 21 after ani-
mals were injected. Viral RNA concentrations in harvestedmouse livers
were determined using quantitative ampliﬁcation of viral surface and
core sequences (Supp. Fig. 3). Compared to themice that received saline,
intrahepatic concentrations of viral surface and coreRNA inmice treated
with GP3 siRNA3 were reduced by about 40% at the termination of the
experiments. Similarly when compared to mice treated with scrambled
siRNA, unmodiﬁed siRNA3 diminished intrahepatic viral RNA concen-
trations by 20–25%. However, the silencing efﬁcacy was higher in mice
treated with GP4 siRNA3. In these animals intracellular concentrations
of viral RNA sequences were signiﬁcantly suppressed by about 42%.
Collectively these data indicate that delivery of GP-modiﬁed siRNAs ef-
ﬁciently inhibits markers of HBV replication in transgenic mice. More-
over, since HBV gene expression predominates in hepatocytes of the
animals [22,31], inhibition of markers of viral replication is further
support of the hepatotropism of the formulations.3.5. Veriﬁcation of siRNA-mediated cleavage of HBV mRNA in vivo
Previouslywe showed that GP3 siRNA3 andGP4 siRNA3 caused sim-
ilar predicted HBV target cleavage in transfected liver-derived cells [25].
This indicates that target cleavage is not inﬂuenced by positioning of the
GP residue at the third or fourth nucleotide from the 5′ end of the guide.
The 5′ RACE technique was again employed here to verify an RNAi-
mediated intrahepatic effect of the GP-modiﬁed siRNAs. The expected
ampliﬁcation product of 217 bp was detected after analysis of RNA
extracts from mice that were treated with formulations containing un-
modiﬁed siRNA3 and GP3 siRNA3 (Fig. 5A). Conversely, no products of
PCR were detected in animals that had received the scrambled siRNA.
DNA sequencing conﬁrmed the presence of the ligated RNA oligonucle-
otide and predicted cleavedmRNAproducts (Fig. 5B). HBVmRNA cleav-
age occurred at position 10 from the 5′ end of the antisense strand,
which is in accordance with the canonical RNAi-mediated target cleav-
age by Ago2 [34,35].3.6. Assessment of toxic and immunostimulatory effects following adminis-
tration of siRNA-containing lipoplexes to HBV transgenic mice
To investigate effects of the formulations on release of pro-
inﬂammatory cytokines, a CBA was carried out (Fig. 6). Concentrations
of IL-6, IL-10, MCP-1, IFN-γ, TNF-α and IL-12p70 were measured in
Fig. 5.Detection of siRNA-mediated cleavage of HBVmRNA in vivo. A. A linker oligonucle-
otidewas ligated to hepatic RNA and then subjected to RT PCR (5′ RACE). Products obtain-
ed from samples of animals that were treated with lipoplexes containing either
unmodiﬁed siRNA3 or GP3 siRNA3 were subjected to agarose gel electrophoresis. B. Sim-
ilar sequences of ligated ampliﬁedproductswere obtained from samples ofmice thatwere
treated with siRNA3 or GP3 siRNA3 (bottom). For comparison, sequences of the HBV
target (top) and ligated oligonucleotide (middle) are shown.
Fig. 4. Anti-HBV effects of siRNAs on serummarkers of HBV replication in transgenic mice.
TheHBV transgenicmicewere injectedwith siRNA-containing lipoplexes. Guanidinopropyl
(GP) residues were positioned at the third (GP3 siRNA3) or fourth (GP4 siRNA3) nucleo-
tides from the 5′ end of the antisense strand of the siRNAs. Unmodiﬁed anti-HBV siRNA
(siRNA3) or scrambled siRNA were also administered after complexing to the liposome
and polyglutamate components. Control animals received intravenous saline or injection
of a formulated scrambled siRNA duplex. Serum concentrations of HBsAg (A) and circulat-
ing viral particle equivalents (VPEs) (B) were detected from day 3 to 21 after injection.
Values represent the means (± SEM) of replicate injections of four mice per group. Statis-
tically signiﬁcant differences between the samples, determined using the Student's two
tailed paired t test, are indicated.
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imals that received poly (I:C), a positive control for stimulation of the in-
nate immune response, serum concentrations of IL-6, MCP-1, IFN-γ and
TNF-αwere signiﬁcantly elevated. Secretion of pro-inﬂammatory cyto-
kines was not induced after injection of liposomes that did not contain
nucleic acids. However, systemic injection of mice with unmodiﬁed
siRNA3 resulted in signiﬁcantly elevated concentrations of IL-6, MCP-
1, IFN-γ and TNF-α at 6 h after the administration. Conversely formula-
tions containing GP-modiﬁed siRNAs caused only amodest induction of
MCP-1, and other markers of inﬂammation were not elevated.
Measurement of alanine aminotransferase (ALT) activity in serum
samples of mice revealed that this marker of hepatotoxicity was not el-
evated in mice that received the lipoplex formulations (Supp. Fig. 4).
Moreover, measurements for each of the groups were not statistically
signiﬁcantly different to those obtained from the control mice that re-
ceived a saline injection. To assess induction of the innate interferon re-
sponse following systemic injection of the siRNA-containing lipoplexes,
mRNA derived from IFN-β and OAS-1genes was quantiﬁed relative to
the amount of GAPDH mRNA (Supp. Fig. 5). mRNA concentrations of
the IFN response genes were similar in liver cells of mice that had re-
ceived the liposomes alone and the siRNA-containing lipoplexes.
These valueswere signiﬁcantly lower than those obtained from samples
extracted frommice that had received poly (I:C). The data thus indicate
that the liposomal component of the non-viral vectors was not
immunostimulatory andmodiﬁcation of siRNAswith GP residues atten-
uated an innate immune response.
4. Discussion
Studies have demonstrated that activators of the RNAi pathway ef-
fectively inhibit replication of HBV (reviewed in [4]). Since HBV has a
compact genome, ability of the virus to evade inhibitory effects ofhybridizing nucleic acids is constrained. Given the dependence of the
virus on pregenomic RNA, an essential replication intermediate, cleav-
age of target viral RNA by an RNAi-mediated mechanism is well suited
to therapeutic application. In this study, we used GP-modiﬁed siRNAs
to target the conserved X region of the viral pregenome that was com-
mon to all of the HBV transcripts. Liposome-based non-viral vectors
were employed to deliver GP-modiﬁed siRNAs. Formulations that are
made up entirely of synthetic constituents, such as have been described
here, have distinct advantages. Modular components are amenable to
large scale synthesis required for clinical application and chemicalmod-
iﬁcation enables alteration of biological properties to suit particular ap-
plications. Nevertheless, lipoplexes should have several important
features before they may be considered efﬁcient vehicles for
hepatotropic delivery of anti-HBV siRNAs. Complexes need to be stable,
enhance the half-life of siRNAs in the circulation, be positively charged
and ensure targeted delivery to the liver [9,36,37]. The size and charge
of lipoplexes are also critical for efﬁcient hepatotropic delivery. The fe-
nestrae of hepatic sinusoidal endothelial cells have diameters that
range in size between 150 and 175 nm [38]. To cross this barrier and
gain access to hepatocytes, siRNA-containing lipoplexes should there-
fore ideally have a diameter of less than 100 nm.
The anionic polymer- and GP siRNA-containing lipoplexes used here
had diameters ranging from 50–200 nm and ζ potentials of approxi-
mately +65 mV. These properties are expected to enhance stability
and facilitate siRNA delivery to hepatocytes [39–41]. Intended
hepatotropic transport of the lipoplexes was conﬁrmed by demonstrat-
ing localization of labeled siRNAs in hepatocytes of HBV transgenic
mice. Efﬁcient silencing was shown in this stringent model of HBV
Fig. 6. Assessment of cytokine induction in HBV transgenic mice following intravenous administration of lipoplexes containing siRNAs. A. Representative data from the assay using the
cytometric bead array to quantify interleukin 6 (IL-6), interleukin 10 (IL-10), monocyte chemoattractant protein-1 (MCP-1), interferon gamma (IFN-γ), tumor necrosis factor alpha
(TNF-α) and interleukin 12p70 (IL-12p70) concentrations. Measurements were made 6 h after injection of the indicated lipoplexes. Administration of equivalent amounts of liposome
or poly (I:C) were used as controls. Mean concentrations of IL-6 (B), MCP-1 (C), IFN-γ (D) and TNF-α (E) obtained at 6 h following administration of lipoplexes, liposome and poly
(I:C) are shown.Means (±SEM)were calculated from replicate injections of fourmice per group. Statistically signiﬁcant differences between the samples, determined using the student's
two tailed paired t test, are indicated.
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Inhibitory effects of the formulations containing GP-modiﬁed siRNAs
were more sustained than their unmodiﬁed counterparts. Veriﬁcation
of the expected cleavage of HBV mRNA targets, demonstrated using 5′
RACE, conﬁrmed an RNAi-mediated effect. The lipoplexes did not in-
duce an innate immune response and the GPmodiﬁcation of the siRNAs
attenuated release of pro-inﬂammatory cytokines.
Reduced immunostimulation is important to diminish toxicity, im-
prove duration of silencing and enable repeated administration of the
formulations. Previous work frommembers of our group demonstrated
that inclusion of polyglutamate in the lipoplexes improved safety by re-
ducing release of pro-inﬂammatory cytokines following administration
in vivo [13]. The complexes used in this study thus included two
immunoattenuating components: polyglutamate as part of the vector
and GP residues of the siRNA. Comparison to our earlier studies using
anti-HBV siRNAs in transgenic murine models of HBV replication
shows that the formulations used here have enhanced silencing efﬁcacy
and good safety [10,42]. The minimal immunostimulation by the
lipolexes containing GP-modiﬁed siRNAs suggests that repeat adminis-
tration of the formulations would be effective with minimal toxicity.
Themechanismbywhich theGPmoiety attenuates immunostimulation
is incompletely understood. Previous studies using chemically modiﬁed
siRNAs have established that changes to the 2′OH of the ribose limitstimulation of Toll-like receptors (TLRs) and other sensors of duplex
RNA such as OAS-1 (reviewed in [5]). Activation of downstream inter-
feron response genes is limited and immunostimulation is therefore re-
duced. It seems likely that GP-modiﬁed siRNAs would operate by a
similar mechanism. As the liposomal component of the lipoplexes is
also minimally immunostimulatory (Fig. 6), the combination with GP-
modiﬁed siRNAs imparts features that may have utility for therapeutic
application.
A useful strategy for silencing HBV gene expression has been dem-
onstrated here, which compares favorably to approaches to countering
HBV replication with siRNAs that have previously been reported [8,10,
11,18]. Demonstration of immune-attenuated effects, hepatotropism
of the lipoplexes, good durability of silencing, convenient methods for
synthesis and formulating the particles are advantageous. These fabrica-
tion procedures are amenable to large scale preparation which will be
required for therapeutic application to treatment of chronic HBV infec-
tion. Persistence of HBV in infected individuals remains an important
global health problem [1,2]. Whether the viral replication intermediate
comprising cccDNA can be eliminated after sustained gene silencing
remains to be established. Nevertheless, the lipoplex formulations
described here have useful features that may be exploited alone or in
combination with newly developed gene editing strategies [24] to
cure chronic HBV infection.
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GP-modiﬁed siRNAs, formulated in novel hepatotropic lipoplexes
containing anionic polymers, achieved efﬁcient inhibition of HBV repli-
cation in HBV transgenic mice. Moreover, GP-modiﬁed siRNAs
displayed improved anti-HBV efﬁcacy in vivo when compared to their
unmodiﬁed counterpart. Toxicity or induction of an innate immune
response was not observed after injection of lipoplexes containing the
GP-modiﬁed siRNAs. However, release of pro-inﬂammatory cytokines
occurred in mice that received the unmodiﬁed siRNAs. Analysis using
5′ RACE conﬁrmed that the RNAi pathwaywas activated to effect cleav-
age of HBV mRNA in vivo. These data indicate that delivery of GP-
modiﬁed siRNAs within polymer-containing lipoplexes may be useful
for therapeutic application.Acknowledgments
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Supplementary Figure 1. Silencing of HBV target sequences by siRNAs containing multiple 
GP residues. psiCHECK-HBx plasmid, which contains the HBx target downstream of the 
Renilla luciferase reporter, is schematically illustrated in A. Dual-luciferase reporter gene assay 
was performed 48 hours after transfection of Huh7 cells with the indicated unmodified or GP-
modified siRNAs (B). Results are given as mean ratios of Renilla to Firefly luciferase activity. 
To assess effects on HBV replication, the viral replication-competent plasmid, pCH-9/3091 was 
used to transfect Huh7 cells (C). Surface antigen (HBsAg) concentrations in cell culture 
supernatants were measured using ELISA that was carried out 48 hours after co-transfecting with 
the indicated siRNAs (D). Values represent the means and standard error of the mean of three 
replicate transfections. Differences were considered statistically significant when analysis using 
the Student’s t test showed p<0.05.  
  
 
 
 
 
 
 
 
 
Supplementary Figure 2. Silencing of complete and partial targets by siRNAs containing 
multiple GP moieties. Four different sequences of siRNA3 were cloned into the dual-luciferase 
reporter plasmid, psiCHECK 2.2 (A). psiCHECK-siRNA3 CT contained a completely 
complementary target to siRNA3. Partially complementary targets contained a 3 nucleotide 
mismatch at the 3’ end (psiCHECK-siRNA3 IT1), a 5 nucleotide mismatch at the 3’ end 
(psiCHECK-siRNA3 IT2) and the seed region alone (psiCHECK-siRNA3 SO). A dual-luciferase 
reporter gene-based assay was performed 48 hours after co-transfecting Huh7 cells with each of 
the target plasmids with the panel of siRNAs (B). Data are presented as mean ratios of Renilla to 
Firefly luciferase activity (±SEM) from three replicate transfection experiments. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 3. Effect of siRNAs on intrahepatic concentrations of viral RNA 
encoding surface and core open reading frames. HBV transgenic mice were injected with 
lipoplexes containing siRNAs that were unmodified or contained guanidinopropyl (GP) residues. 
Mouse livers were harvested at day 18 or 21 post-administration. Viral mRNAs, relative to 
GAPDH mRNA, were quantified using RT-qPCR with primers specific for surface (A) and core 
(B) viral sequences. Values represent the means (±SEM) from replicate injections of four 
animals. Statistically significant differences between the samples, determined using the Student’s 
two tailed paired t test, are indicated.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 4. Assessment of hepatotoxicity following intravenous 
administration of lipoplexes. HBV transgenic mice were injected with saline or formulations 
containing the indicated siRNAs. Blood samples were collected at day 3 and day 18 or 21 after 
administration. The threshold of the accepted normal range, < 100 IU/L, is indicated. Means 
(±SEM) were calculated from replicate injections of four different mice. 
  
  
 
 
 
 
 
 
 
Supplementary Figure 5. Assessment of stimulation of the innate IFN response in HBV 
transgenic mice following intravenous administration of the siRNA-containing lipoplexes. 
Hepatic mRNA was prepared 6 hours subsequent to intravenous injection of mice with poly 
(I:C), liposome or lipoplexes containing unmodified (siRNA3) or guanidinopropyl (GP) siRNAs 
(GP3 siRNA3 and GP4 siRNA3). After reverse transcription, the samples were subjected to 
quantitative PCR to measure concentrations of mRNA from OAS-1, IFN-β and GAPDH genes. 
Data are presented as a ratio of the concentrations of mRNA from the IFN response genes 
relative to concentration of the GAPDH mRNA. Values represent the means and standard error 
of the means following injection of four different animals. Statistically significant differences 
between the samples, determined using the student’s two tailed paired t test, are indicated. 
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SUPPLEMENTARY METHODS: 
5.1. Characterisation and biodistribution of PG adjuvant-siRNA lipoplexes in HBV 
transgenic mice 
The HBV transgenic mouse model was employed as it has the HBV sequence stably 
integrated into its genome and is capable of producing viral DNA, RNA and protein levels 
that mimic those of chronically infected individuals. These mice were generated by using the 
viral DNA sequence derived from HBV 1.3 [219]. This redundant DNA construct is located 
slightly upstream of HBV Enhancer I, and covers the whole HBV genome and ends 
downstream of the viral polyadenylation site. In these mice, viral mRNA expression is 
significantly higher in centrilobular liver cells relative to any other region in the hepatic 
lobule. Replication of viral DNA mainly occurs within the nucleocapsid particles that are 
formed in the cytoplasm of centrilobular liver cells. As a result, this mouse model is 
convenient for assessing the effect of antiHBV therapeutics on chronic HBV infection by 
examining markers of viral replication, pathogenesis and immune response [219]. 
 
The polyglutamate (PG) adjuvant liposomes were complexed with unmodified or GP-
modified siRNAs to form PG adjuvant-siRNA lipoplexes. To enable tracking of the delivered 
siRNAs in injected mice, a modified sense strand with an Alexa Flour 750 label at its 3’ end 
(Inqaba Biotech Industries, South Africa) was used. The lipoplexes were prepared by mixing 
15 µg of GP3 siRNA3 and 15 µg of PG adjuvant in 100 µl saline into a single tube (tube 1). 
The second tube (tube 2) contained 15 µl of liposome dissolved in 100 µl saline. The 
contents of tube 1 were transferred to tube 2 and vigorously vortexed for at least 1 minute. 
The mixture was incubated at room temperature for at least 30 minutes. The PG adjuvant-
siRNA lipoplexes were subjected to particle sizing and zeta potential was measured using the 
ZetaPALS Zeta Potential Analyzer (Brookhaven, NY, USA) using Dynamic Light Scattering 
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(DLS). Zeta potential was measured to determine the surface charge of the lipoplexes by 
Hückel analysis, after they were dissolved in 1 ml saline solution (pH 7.0). Three replicate 
measurements of particle sizing and zeta potential were performed (Appendix 7.2). The HBV 
transgenic mice were weighed and their body weight ranged between 20-22 g. Lipoplex 
samples were again briefly vortexed for 15 seconds before filling the injection syringe. 
Thereafter, 200 µl of PG adjuvant-GP3 siRNA3 lipoplex was injected into HBV transgenic 
mice via the tail vein and the total dose was 1 mg/kg (Table 5.1). Control mice were injected 
with 200 µl naked GP3 siRNA3 or saline. The injection scheme was as follows: 
 
Table 5.1: Experimental groups used for assessing biodistribution of siRNAs in HBV 
transgenic mice 
At 10 minutes post-injection, mice were sacrificed and the kidneys, liver, lungs and spleen 
were harvested for ex vivo imaging. Biodistribution of siRNAs in injected mice was assessed 
by measuring Alexa Flour 750 fluorescence at 745 nm in harvested organs using the IVIS 
Kinetic Bioluminescence imager (PerkinElmer, MA, USA). Subsequently, tissues were fixed 
in 20% paraformaldehyde at 4°C overnight, followed by suspension in 30% sucrose solution 
and kept at 4°C overnight. Thin sections (~5 µm) of harvested tissues were cut using an 
ultramicrotome (Thermo Scientific, MA, USA) and stained with 4’,6-diamidino-2-
Experimental groups Number of animals 
Group 1: 1 mg/kg naked GP3 siRNA3, single dose n=3 
Group 2: 1 mg/kg PG adjuvant-GP3 siRNA3 lipoplex, single dose n=3 
Group 3: Saline, single injection n=1 
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phenylindole (DAPI, Invitrogen™, Life Technologies, CA, USA) for 15 minutes. Sections 
were gently soaked in saline and placed on glass slides. Confocal microscopy (Zeiss, LSM 
780, Oberkochen, Germany) detecting both DAPI staining and Alexa Fluor 750 fluorescence 
was performed to verify biodistribution and cellular localisation of siRNAs in injected mice 
at 40 × and 63 × magnifications. 
 
5.2. AntiHBV effects and toxicity of PG adjuvant-siRNA lipoplexes in HBV transgenic 
mice 
A separate group of HBV transgenic mice was employed to investigate antiHBV efficacy and 
toxicity of PG adjuvant-siRNA lipoplexes in injected animals using the injection scheme 
illustrated in Table 5.2.  
 
Table 5.2: Experimental groups used for assessing activity and toxicity of siRNAs in 
transgenic mice 
Experimental groups Number of animals 
Group 1:  Saline, single injection n=4 
Group 2: 1 mg/kg PG adjuvant-scrambled siRNA lipoplex, single dose n=4 
Group 3: 1 mg/kg PG adjuvant-siRNA3 lipoplex, single dose n=4 
Group 4: 1 mg/kg PG adjuvant-GP3 siRNA3 lipoplex, single dose n=4 
Group 5: 1 mg/kg PG adjuvant-GP4 siRNA3 lipoplex, single dose n=4 
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At day 0 (baseline), 3, 5, 7, 14 and 18 or 21 post-administration blood samples were collected 
from injected mice and incubated at 4°C for 2 hours. Samples were centrifuged at 8 000 × g 
at 4°C for 10 minutes and serum collected from the upper phase. Subsequently, serum 
samples were used to measure HBsAg by ELISA and circulating VPEs by qPCR using mouse 
HBV surface primers, as described in Supplementary Methods Section 4.3.  
 
Serum samples were also used to perform the ALT toxicity test at day 3, 18 and 21 using the 
accredited diagnostic protocols of the South African National Health Laboratory Service 
(NHLS, Johannesburg, South Africa). The HBV transgenic mice injected with saline and PG 
adjuvant-GP3 siRNA3 lipoplex were sacrificed at day 18 post-injection, while those treated 
with scrambled siRNA, PG adjuvant-siRNA3 and PG adjuvant-GP4 siRNA3 were sacrificed 
at day 21 post-administration. Mouse livers were collected and subjected to DNA extraction 
using the QIAamp DNA Mini Kit (Qiagen, GmbH, Germany) with minor modifications. 
Briefly, harvested mouse livers were weighed, saline added (1 ml saline for every gram of 
liver) and the organs homogenised. Fifty microlitres of the homogenates were transferred to 
1.5 ml microcentrifuge tubes. One hundred microlitres of Buffer ATL was dispensed into 
each tube, followed by addition of 20 μl Proteinase K. Samples were mixed by vortexing and 
incubated at 56°C in a shaking water bath until the tissue was completely lysed. 
 
Samples were centrifuged at 13 000 × g for 1 minute to collect drops from the inside of the 
lid. Two hundred microlitres of Buffer AL was dispensed into each tube, mixed by pulse-
vortexing for 15 seconds followed by incubation at 70°C for 10 minutes. Samples were 
briefly centrifuged at 13 000 × g for 1 minute to collect drops from the inside of the lid. To 
each sample, 200 μl of 100% ethanol was dispensed and mixed by pulse-vortexing for 15 
seconds. After mixing, samples were briefly centrifuged at 13 000 × g for 1 minute to collect 
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drops from the inside of the lid. The resulting mixture was carefully applied to the QIAamp 
Spin Column (in a 2 ml collection tube) without wetting the rim. Samples were centrifuged at 
8 000 × g for 1 minute. The QIAamp Spin Column was placed in a clean 2 ml collection tube 
and the tube containing the flow-through was discarded. Thereafter, 500 μl Buffer AW1 was 
added to the QIAamp Spin Column without wetting the rim and centrifuged at 8 000 × g for 1 
minute. The QIAamp Spin Column was placed in a clean 2 ml collection tube and the tube 
containing the flow-through was discarded. Five hundred microlitres of Buffer AW2 was 
applied to the QIAamp Spin Column without wetting the rim, followed by centrifugation at 
13 000 × g for 3 minutes. The QIAamp Spin Column was placed in a new 2 ml collection 
tube and centrifuged at 13 000 × g for 1 minute to collect residual buffer. The QIAamp Spin 
Column was placed in a clean 1.5 ml microcentrifuge tube and the collection tube containing 
the flow-through was discarded. Two hundred microlitres of Buffer AE was added to the 
QIAamp Spin Column, incubated at room temperature for 1 minute and centrifuged at 8 000 
× g for 1 minute. Subsequently, the eluate was reapplied to the QIAamp Spin Column, 
incubated at room temperature for 1 minute and centrifuged at 8 000 × g for 1 minute. DNA 
samples were subjected to qPCR using mouse HBV surface primers as described in 
Supplementary Methods Section 4.3. 
 
Additionally, from the same liver samples, RNA extraction was performed using Tri 
Reagent
®
. Harvested mouse livers were weighed, Tri Reagent
® 
added (1 ml Tri Reagent
®
 for 
every gram of liver) and organs homogenised. Fifty microlitres of the homogenates were 
transferred into 1.7 ml microcentrifuge tubes. Ten microlitres of chloroform was added to 
each sample, gently mixed by inverting tubes and incubated for 3 minutes. Samples were 
centrifuged at 12 000 × g at 4°C for 20 minutes. Subsequently, the upper aqueous phase was 
transferred to new 1.7 ml microcentrifuge tubes; an equal volume of isopropanol was added 
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and mixed by inverting tubes. Samples were incubated at -70°C for 2 hours and centrifuged 
at 12 000 × g at 4°C for 20 minutes. The supernatants were discarded, pellets washed with 
200 µl 70% ethanol and centrifuged at 12 000 × g at 4°C for 5 minutes. The supernatants 
were discarded, pellets resuspended in 50 µl nuclease-free water and stored at -70°C until 
use. One microgram of total RNA was subjected to Genomic DNA Elimination and reverse 
transcription as described in Supplementary Methods Section 4.2. The resulting cDNA was 
subjected to RT-qPCR using 10 pmol of either mouse HBV core (Integrated DNA 
Technologies, IA, USA), BCP1: 5’-ACC ACC AAA TGC CCC TAT-3’ and BCP2: 5’-TTC 
TGC GAG GCG GCG A-3’ or surface primers, as described in Supplementary Methods 
Section 4.3. 
 
5.3. Innate immune stimulation of PG adjuvant-siRNA lipoplexes in HBV transgenic 
mice 
A separate group of HBV transgenic mice was employed to investigate innate immune 
stimulation following administration of PG adjuvant-lipoplexes. These mice were injected via 
the tail vein with Poly(I:C), PG adjuvant liposome, unmodified siRNA3, GP3 siRNA3 or 
GP4 siRNA3 (Table 5.3). At 6 hours post-injection, blood samples were collected and livers 
obtained after mice were sacrificed. Serum samples were obtained from animal blood as 
described in Supplementary Methods Section 4.3 to assess the release of proinflammatory 
cytokines using the CBA mouse inflammation kit (BD Biosciences, CA, USA), with minor 
modifications. Specifically, this assay was employed to measure IL-6, IL-10, MCP-1, IFN-γ, 
TNF and IL-12p70 protein levels after administration of PG adjuvant lipoplexes. 
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Table 5.3: Experimental groups used for assessing immunostimulatory effects of 
siRNAs in transgenic mice 
Briefly, serum samples were diluted 2-fold in saline. The “Top Standard” solution (5000 
pg/ml) was prepared by dissolving the Mouse Inflammation Standard in 2 ml assay diluent 
and incubated at room temperature for 15 minutes. The 12 × 75 mm Falcon
™
 Round-Bottom 
Polystyrene tubes (BD Biosciences, CA, USA) were labelled and arranged in the following 
order: 1:2 (2500 pg/ml), 1:4 (1250 pg/ml), 1:8 (625 pg/ml), 1:16 (312 pg/ml), 1:32 (156 
pg/ml), 1:64 (80 pg/ml), 1:128 (40 pg/ml) and 1: 256 (20 pg/ml). Additionally, one tube 
containing the assay diluent was used as a negative control (0 pg/ml). 
 
Three hundred microlitres of assay diluent was dispensed into each labelled tube. A serial 
dilution was performed by transferring 300 µl from the “Top Standard” to the 1:2 dilution 
tube and gently mixed. Subsequently, 300 µl from the 1:2 dilution tube was transferred to the 
1:4 dilution tube and so on up to the 1:256 dilution tube. Six Capture Bead suspensions 
(specific for each cytokine to be analysed) were mixed by vortexing for 15 seconds and 10 µl 
of each Bead was added into a single tube “mixed Capture Beads”. Fifty microlitres of the 
Experimental groups Number of animals 
Group 1: 2 ml saline and 100 µg Poly(I:C) (HDI), single dose n=4 
Group 2: 15 µg PG adjuvant liposome, single dose n=4 
Group 3: 1 mg/kg PG adjuvant-siRNA3 lipoplex, single dose n=4 
Group 4: 1 mg/kg PG adjuvant-GP3 siRNA3 lipoplex, single dose n=4 
Group 5: 1 mg/kg PG adjuvant-GP4 siRNA3 lipoplex, single dose n=4 
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“mixed Capture Beads” were transferred to each assay tube followed by addition of 50 µl 
Phycoerythrin (PE) detection reagent. All samples were incubated in the dark at room 
temperature for 2 hours, washed with 1 ml wash buffer and centrifuged at 200 × g for 5 
minutes. The wash buffer was gently removed and the beads resuspended in fresh 300 µl 
wash buffer solution. Samples were placed in the flow cytometry instrument (BD, 
LSRFortessa
TM
) and the BD CBA Software (BD Biosciences, CA, USA) was used to assess 
the levels of inflammatory cytokines in injected mice. Mouse livers were subjected to RNA 
extraction using Tri Reagent
®
 as described in Supplementary Methods Section 5.2. The 
extracted RNA was used to investigate immunostimulatory effects of PG adjuvant-siRNA 
lipoplexes in mouse livers following administration in transgenic mice. RNA was subjected 
to Genomic DNA Elimination and reverse transcription using the QuantiTect
®
 Reverse 
Transcription Kit, and RT-qPCR using mouse IFN-β, OAS-1 and GAPDH primers as 
described in Supplementary Methods Section 4.2. 
 
5.4. Detection of siRNA-mediated mRNA cleavage in vivo by 5’ RACE 
5.4.1. Ligation of RNA to GeneRacer
TM
 RNA Oligo 
All reagents used to perform 5’ Rapid Amplification of cDNA ends (5’ RACE) were from 
Life Technologies (GeneRacer
TM
 Kit, Life Technologies, CA, USA), unless otherwise stated. 
Specifically, the RNA ligase-mediated amplification of cDNA ends (RLM-RACE) technique 
was applied to detect the mRNA cleavage product in injected mice following siRNA 
administration. Total RNA extracted from mouse livers (Supplementary Methods Section 
5.2) was also ligated to the GeneRacer
TM
 RNA Oligo without prior dephosphorylation or 
removal of the mRNA cap structure. The ligation reactions were performed by adding 7 µl of 
RNA (100 ng/µl) to the tubes with the pre-aliquoted, lyophilised GeneRacer
TM
 RNA Oligo 
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(0.25 µg) and briefly centrifuged at 12 000 × g at 4°C for 1 minute. The reaction mixtures 
were transferred to 1.7 ml microcentrifuge tubes and incubated at 65°C for 5 minutes. 
Samples were placed on ice for 2 minutes and centrifuged at 12 000 × g at 4°C for 1 minute. 
To each tube, 1 µl of ligase Buffer (10 ×), 1 µl ATP (10 mM), 1 µl RNaseOut
TM
 (40 U/ µl) 
and 1 µl of T4 RNA ligase (5 U/µl) were added and incubated at 37°C for 1 hour. After 
incubation, the ligated RNA was precipitated using the phenol-chloroform protocol. Briefly, 
ninety microlitres of Diethylpyrocarbonate-treated water (DEPC water) and 100 µl of phenol-
chloroform were added to the RNA transcripts and mixed by vigorously vortexing for 30 
seconds. The mixtures were centrifuged at 13 000 × g for 5 minutes. 
 
One hundred microlitres of the top aqueous phase from each sample was transferred to a new 
1.7 ml microcentrifuge tube. Two microlitres of mussel glycogen (10 mg/ml) and 10 µl of 
sodium acetate (3M, pH 5.2) were dispensed into each tube and gently mixed. This was 
followed by addition of 220 µl 95% ethanol, briefly mixed by inverting tubes and incubated 
at -20°C overnight. Following incubation, samples were centrifuged at 13 000 × g at 4°C for 
20 minutes and the resulting supernatants discarded. Five hundred microlitres of 70% ethanol 
was dispensed into each tube, mixed by gently inverting tubes and centrifuged at 13 000 × g 
at 4°C for 2 minutes. The ethanol was gently removed and the pellets were air-dried at room 
temperature for 2 minutes. Subsequently, the RNA transcripts were resuspended in 10 µl 
DEPC water and stored at -70°C until use. 
 
5.4.2. Reverse transcription of ligated RNA 
To the tubes containing 10 µl of ligated RNA, the following reagents were added to initiate 
cDNA synthesis: 1 µl of the gene-specific RT primer (10 pmol) (5’-
AGGGTCGATGTCCATGCCCC-3’; Integrated DNA Technologies, IA, USA), 1 µl dNTP 
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mix (10 mM each) and 1 µl of nuclease-free water. The reaction mixtures were briefly 
centrifuged at 12 000 × g at 4°C for 20 seconds and incubated at 65°C for 5 minutes. Samples 
were placed on ice for 2 minutes and centrifuged at 12 000 × g at 4°C for 20 seconds. This 
was followed by addition of 4 µl First Strand Buffer (5 ×), 1 µl DTT (0.1 M), 1 µl 
SuperScript
TM
 III RT (200 U/µl) and 1 µl RNaseOut
TM
 (40 U/µl). Samples were centrifuged 
at 12 000 × g at 4°C for 20 seconds and incubated at 55°C for 1 hour. Reverse transcriptase 
was inactivated at 70°C for 15 minutes, samples placed on ice for 2 minutes and centrifuged 
at 12 000 × g at 4°C for 20 seconds. One microlitre of RNaseH (2 U) was added to the 
samples followed by incubation at 37°C for 20 minutes. Samples were recentrifuged at 
12 000 × g at 4°C for 20 seconds. Subsequently, 10 µl cDNA aliquots were prepared and 
stored at -20°C to prevent degradation from frequent freeze-thaw cycles. 
 
5.4.3. Amplification of cDNA by 5’ RACE-PCR, cloning and DNA sequencing 
cDNA was amplified by 5’ RACE-PCR using 2 × Phusion Master Mix (Thermo Scientific, 
MA, USA), 10 pmol each of the forward GeneRacer
TM
 5’ primer (5’-
CGACTGGAGCACGAGGACACTGA-3’, Life Technologies, CA, USA), reverse gene-
specific PCR primer (5’-CAAGAGATGATTAGGCAGAGGTG-3’, Integrated DNA 
Technologies, IA, USA) and 1.25 µl cDNA template (100 ng/µl). All PCR amplification 
reactions were performed in a thermocycler (T100
TM
 Thermal Cycler, Bio-Rad, CA, USA) 
using the following cycling conditions: one cycle of 98°C for 30 seconds (initial 
denaturation), 27 cycles of denaturation at 98°C for 10 seconds, annealing at 63°C for 30 
seconds and extension at 72°C for 30 seconds. The final extension step was performed at 
72°C for 10 minutes. Amplified PCR products were subjected to electrophoresis on a 2% 
agarose gel at 100 volts for 45 minutes and visualised under UV transillumination (G:Box, 
Syngene, Cambridge, UK) (Appendix 7.4.1) [220]. 
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The PCR products were purified using the MinElute Gel Extraction kit (Qiagen, GmbH, 
Germany). Briefly, the section of the gel containing the DNA of interest was excised using a 
clean sharp blade and transferred to 1.7 ml microcentrifuge tubes. The gel slices were 
weighed and 3 volumes of QG buffer were added. Gel slices were melted by incubating the 
tubes at 50°C for 10 minutes. A gel volume of isopropanol was added into each tube, mixed 
and applied to the spin columns. Samples were centrifuged for 1 minute at room temperature 
and the flow-through was discarded. Five hundred microlitres of QG buffer was applied to 
each column and centrifuged at 10 000 × g for 1 minute. The flow-through was discarded and 
the columns washed with 750 µl of PE buffer. Samples were centrifuged at 10 000 × g for 1 
minute and the flow-through was discarded. The columns were placed in clean 1.7 ml tubes 
and 20 µl of Buffer EB was added to the column matrix. Samples were incubated at room 
temperature for 2 minutes and the DNA was eluted by centrifugation at 10 000 × g for 1 
minute. 
 
The purified PCR products were ligated to the pTZ57R/T plasmid using the InsTAclone PCR 
cloning kit (Thermo Scientific, MA, USA). Ligation was performed using T4 DNA ligase (5 
U), pTZ57R/T plasmid (0.17 pmol ends) and 3 µl purified PCR product (200 ng/µl). Samples 
were incubated at 14°C overnight. One hundred microlitres of chemically competent bacteria 
(E. coli DH5α) was transformed with 10 µl of ligation reaction and spread on ampicillin-
containing Luria Bertani agar plates coated with 40 µl 5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside (X-gal, 20 mg/ml, Sigma, MI, USA) and 8 µl of Isopropyl β-D-1-
thiogalactopyranoside (IPTG, 100 mM, Sigma, MI, USA). Plates were inverted and incubated 
at 37°C overnight. Subsequently, ten individual white colonies were picked using sterile 
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procedures. Each colony was inoculated into 10 ml of ampicillin-containing Luria Bertani 
broth and incubated at 37°C overnight with shaking.  
 
Standard plasmid mini preparations were performed using the alkaline lysis method. Briefly, 
cultures were centrifuged at 2 500 × g for 15 minutes at 4°C and the supernatants were 
discarded. Three hundred microlitres Buffer P1 (10 mM EDTA, 50 mM Tris, pH 8.0 and 100 
µg/ml RNase A) was added to the pellets and transferred to sterile 2 ml microcentrifuge 
tubes. To each tube, 300 µl Buffer P2 (200 mM sodium hydroxide and 1% SDS) was 
dispensed, mixed and incubated at room temperature for 5 minutes. Three hundred 
microlitres of Buffer P3 (3 M potassium acetate, pH 5.5) was added into the samples and 
mixed by inverting the tubes. Samples were centrifuged at 13 000 × g for 10 minutes at 4°C, 
and approximately 800 µl of the resulting supernatant was transferred to a new 2 ml 
microcentrifuge tube. An equal volume of isopropanol was added, mixed by inverting tubes 
and incubated at -20°C for 2 hours. After incubation, samples were centrifuged at 13 000 × g 
at 4°C for 30 minutes. The resulting supernatants were discarded, pellets resuspended in 100 
µl of water and stored at -20°C until use. 
 
Positive clones were identified by digesting plasmid DNA (1 µg) with ApaLI (10 U, Thermo 
Scientific, MA, USA). Samples were incubated at 37°C for 1 hour and subjected to 
electrophoresis on a 2% agarose gel at 100 volts for 45 minutes and visualised under UV 
transillumination. Presence of two DNA fragments of approximately 1859 bp and 1246 bp 
indicated successful cloning of the PCR products into pTZ57R/T. Positive clones were 
verified by automated DNA sequencing (Inqaba Biotech Industries, South Africa) using the 
M13 reverse primer 5’-CAGGAAACAGCTATGAC-3’ (Inqaba Biotech Industries, South 
Africa). The expected 5’ RACE product was identified by the presence of sequences derived 
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from both the ligated GeneRacer
TM
 RNA oligonucleotide and predicted mRNA cleavage 
product (Appendix 7.4.2) [220]. 
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Chapter 6: General discussion and conclusion 
The goal of this study was to assess the advantage of using novel GP-modified siRNAs over 
unmodified siRNA3 to inhibit HBV replication in cultured Huh7 cells and mice. Data 
presented in this work provide novelty to the field of gene therapy as it demonstrates that 
incorporation of the GP moiety improves the specificity and silencing efficacy of the siRNAs, 
thus, enhancing their antiHBV effects in cultured mammalian cells [217, 221] (Chapter 4), 
HDI mouse model [221] (Chapter 4) and transgenic mice [220] (Chapter 5) relative to 
unmodified siRNA3. Moreover, these antiviral effects were enhanced without a marked 
induction of non-specific effects such as innate immune stimulation and cytotoxicity [220, 
221] (Chapter 4 and 5). Furthermore, this was consistent with previous studies which 
reported an increase in suppression of markers of HBV replication in vivo following 
liposome-mediated delivery of chemically modified siRNAs, without a marked induction of 
the innate immune response as opposed to the unmodified siRNAs [124, 159, 170].  
 
The pCH-9/3091 plasmid used for transient transfections in cell culture belongs to HBV 
genotype D. Genotype A differs from genotype D within the siRNA3 target site by one 
nucleotide, this discrepancy is unlikely to affect silencing efficiency. This is mainly because 
in the RNAi mechanism, incomplete base-pairing between target mRNA and guide strand 
results in translational suppression, while complete base-pairing results in degradation of 
target mRNA. Translational suppression results in decreased levels of proteins being 
manufactured which subsequently leads to reduced levels of mRNA being produced. 
Therefore, this would still allow the siRNAs to activate RNAi-mediated gene silencing, 
regardless of the single nucleotide mismatch. 
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It is not well-elucidated how incorporation of a GP moiety improves therapeutic properties of 
antiHBV siRNAs such as specificity and silencing efficacy. However, it has been 
demonstrated that incorporation of chemical groups into siRNAs, particularly in the seed 
region, decreases off-target effects by minimising the interaction between RISC and 
incomplete target sequences [156]. Modification of 2’ ribose has been shown to change the 
binding and thermodynamic properties of modified siRNAs [160-162]. This leads to 
improved specificity of modified siRNAs by reducing interaction with partial complementary 
targets without diminishing efficacy of these RNAi effectors [156]. It has also been 
postulated that modified siRNAs may prevent immune stimulation by triggering 
internalisation of receptor molecules or by antagonising pathways associated with innate 
immune signalling [157]. 
 
Furthermore, modification of the 2’ position with bulky chemical groups without altering the 
A-form helix of the guide strand-mRNA complex [149, 222] may also prevent interaction 
between modified siRNAs and immune receptors, thereby, avoiding immune stimulation 
[170]. The GP moiety constitutes a bulky chemical modification and was placed at the 2’ 
position without distorting the structure of the A-form helix. Therefore, these features may 
enhance specificity of GP-modified siRNAs, particularly those with seed modifications, by: 
(a) avoiding interactions with TLRs, (b) inhibiting pathways associated with innate immune 
stimulation or (c) altering thermodynamic properties of modified siRNAs. Consequently, 
these properties may have contributed to GP-modified siRNAs, as opposed to unmodified 
siRNA3, being able to discriminate between complete and incomplete targets by regulating 
the strength of seed region hybridisation to various target constructs, leading to improved 
specificity [221] (Chapter 4) and modest immune stimulation [220] (Chapter 5). 
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The mechanism with which the GP modification improves therapeutic activity is yet to be 
unravelled. It has previously been reported that chemical residues introduce structural 
alterations to siRNAs that may influence the efficiency of RISC processing [156]. The ability 
of GP-modified siRNAs to hybridise strongly to complete as opposed to incomplete targets 
coupled with conformational changes introduced by the GP moiety may be responsible for 
the superior therapeutic efficacy of modified siRNAs over the unmodified siRNA3 [217, 220, 
221] (Chapter 4 and 5). These attributes may increase interaction between GP-modified 
siRNAs and RISC components, leading to enhanced retention of the guide strand followed by 
improved target gene silencing.  
 
In addition to suppressing HBsAg expression and the number of circulating VPEs, both sets 
of antiHBV siRNAs also markedly reduced viral surface and core levels in transgenic mice 
[220] (Chapter 5). The HBsAg and VPEs levels were significantly suppressed in mice treated 
with unmodified siRNA for up to day 7 post-administration, while the GP-modified siRNAs 
displayed prolonged antiHBV activity that persisted for up to 14 days post-injection. 
However, at day 18 and 21 post-administration, the HBsAg and VPEs levels in mice treated 
with antiHBV siRNAs returned to baseline levels [220] (Chapter 5). In contrast, 
quantification of intrahepatic RNA levels from mouse livers revealed significant suppression 
of these markers of HBV replication in mice treated with unmodified and GP-modified 
siRNAs at day 18 and 21 post-administration [220] (Chapter 5). This discrepancy may be due 
to the fact that both ELISA and qPCR were used to measure HBsAg and VPEs levels, 
respectively from mice sera. In our study, sera were obtained from blood samples collected 
from behind the eyes of injected animals using a retro orbital puncture. Although serum 
samples are routinely used in diagnostic tests to evaluate various biomarkers, they do not 
provide accurate results compared to assessment from the site of interest (e.g. mouse liver). 
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Therefore, subsequent qPCR amplifications relied on quantification of intrahepatic RNA 
levels directly from mouse livers. This approach is more sensitive and accurate than 
evaluation from mice sera, as it relied on assessment of markers of HBV replication directly 
from infected mouse livers. 
 
The RNAi mechanism of action was confirmed after detecting the siRNA-mediated mRNA 
cleavage product in vitro (Appendix 7.3.1 and 7.3.2) [223] and in vivo (Appendix 7.4.1 and 
7.4.2) [220] (Chapter 5) using the sensitive 5’ RACE technique. This conclusively 
demonstrated that silencing of markers of HBV replication in cultured cells and injected 
animals was due to an RNAi effect. Importantly, the position or number of GP moieties 
incorporated into the siRNA guide strand did not change the site of cleavage, which 
consistently occurred at position 11 in vitro (Appendix 7.3.2) [223] and 10 in vivo (Appendix 
7.4.2) [220] (Chapter 5). The discrepancy in the position of target mRNA cleavage in vitro 
and in vivo can be accounted for, as previous studies demonstrated that following Argonaute 
loading into RISC, the RISC machinery uses the siRNA guide strand to recognise RNA 
comprising complementary sequences. This leads to direct cleavage of target mRNA 
occurring in nucleotides 10-11 from the 5’ end of the siRNA guide strand [224, 225]. It is 
also possible that physiological differences in cultured mammalian cells and injected animal 
cells may have contributed to the 5’ RACE discrepancy, with regard to the site of target 
mRNA cleavage occurring at position 10 or 11. Collectively, our data highlighted the 
importance of using GP-modified siRNAs coupled with a competent hepatotropic non-viral 
delivery system to achieve efficient and safe RNAi-based therapy against chronic HBV 
infection. Findings emanating from this study may be used as a platform for future studies 
that may focus on the effect of a second or third administration of GP-modified siRNA 
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lipoplexes into HBV transgenic mice, and their implications on silencing efficacy, 
sustainability, hepatotoxicity and immune stimulation. 
 
To advance this strategy to a clinical setting, several outstanding factors not covered by our 
study need to be satisfied. For example, the HBV transgenic mouse model [219] employed in 
our study is suitable for studying antiHBV activity of GP-modified siRNAs as it is capable of 
secreting high levels of viral DNA, RNA and proteins which closely resembles that of 
chronically infected individuals. Furthermore, these mice also possess a functional immune 
system which is well-suited for investigating non-specific effects following administration of 
modified siRNAs. However, the limitation is that this model does not contain human 
hepatocytes and is incapable of producing cccDNA. Moreover, the HBsAg levels vary greatly 
between mice, thus, necessitating screening of HBsAg concentrations before investigating 
antiHBV efficacy in vivo. 
 
To date, the urokinase plasminogen activator-severe combined immunodeficiency (uPA-
SCID) mouse is the only animal model capable of establishing human HBV infection [226]. 
These mice consist of engrafted human hepatocytes, thus, making the uPA-SCID system 
ideal for studying human HBV infection. The engrafted human cells populate the liver, 
resulting in the formation of chimaeric livers comprised of mouse and human hepatocytes. 
Extensive colonisation of mouse livers by human hepatocytes renders them susceptible to 
human HBV infection. Furthermore, these human hepatocytes produce cccDNA during 
infection, thus, allowing active viral replication to be established. Therefore, these features 
advance the use of uPA-SCID mice as a relevant model for investigating antiHBV activity of 
GP-modified siRNAs. However, the limitation is that these mice are immunocompromised, 
thus, making this model unsuitable for conducting rigorous analysis of therapeutic efficacy or 
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investigating immunostimulatory effects of GP-modified siRNAs. Depending on the antiviral 
activity of modified siRNAs in the uPA-SCID model, subsequent efficacy studies may be 
conducted in woodchucks, non-human primates and human subjects. Importantly, efficacy 
studies in these systems may require dose regulation, as an effective dose of 1 mg/kg in 
transgenic mice may not necessarily translate to the same amount of efficacy and durability in 
other animal models. 
 
For clinical application, the use of modified siRNAs and licensed antiHBV drugs (i.e. 
combination therapy) may provide a robust approach of eradicating chronic HBV infection. 
Additionally, application of gene therapy in conjunction with gene editing technologies may 
also be an effective strategy of accomplishing clinical success. Various HBV sites have been 
successfully targeted and disrupted using gene editing strategies such as zinc finger nucleases 
(ZFNs) [227], transcription activator-like effector nucleases (TALENs) [228, 229] and 
clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated 
protein 9 (Cas9) [230-232]. Impressively, these systems have also been employed to target, 
cleave and disrupt the cccDNA of HBV which is essential for viral replication and 
persistence [228, 229, 231].  
 
Cleavage of target DNA using gene editing strategies induces the formation of double-
stranded breaks in the target sequence. This is followed by DNA repair which allows 
subsequent binding and cleavage of viral DNA to occur. Homology directed repair (HDR) 
and non-homologous end joining (NHEJ) are responsible for DNA repair [227, 233-236]. The 
HDR mechanism uses homologous DNA sequences to achieve accurate repair of cleaved 
target DNA, while the NHEJ process is error prone and results in deletions and insertions 
being introduced at the cleavage site. Therefore, application of gene editing technologies may 
Chapter 6 
 
63 
 
weaken the virus following multiple cleavage events, leading to mutation of target cccDNA 
sequence [237]. The inability of the cccDNA pool to be re-established within the host cells 
may halt viral replication and persistence, thus allowing symptom alleviation and eradication 
of chronic HBV infection. 
 
In conclusion, GP-modified siRNAs generally displayed improved antiHBV activity relative 
to unmodified siRNA3 in cultured mammalian cells and mice. Incorporation of a GP-moiety 
within the seed region improves specificity of siRNAs (compared to unmodified siRNA3) by 
abolishing unwanted off-target effects, but this strategy does not seem to significantly 
improve stability of these RNAi effectors against serum nuclease degradation. Neither 
modified nor unmodified siRNAs significantly induce the innate IFN pathway or toxicity in 
cell culture and HBV transgenic mice. Conversely, the unmodified siRNA3 triggers the 
release of proinflammatory cytokines in transgenic mice. However, this immunostimulatory 
effect is generally attenuated in mice treated with siRNAs harbouring the GP-moiety, in 
which modest MCP-1 activation was observed. Silencing of markers of HBV replication in 
vitro and in vivo resulted from an RNAi effect exerted by both sets of siRNAs as confirmed 
by 5’ RACE analysis. Data from this particular investigation indicate that application of 
novel GP-modified siRNAs and an efficient liver-tropic non-viral delivery system improves 
therapeutic properties of these RNAi activators by achieving sustained antiHBV efficacy, 
while minimising toxicity and innate immune stimulation in cultured cells and transgenic 
mice, thus, augmenting the prospect of siRNA therapy against chronic HBV infection. 
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Chapter 7: Appendix 
7.1. Animal Ethics Clearance Certificate 
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Appendix 7.2: Particle sizing and zeta potential of siRNA-lipoplexes:  
7.2.1. Particle sizing of siRNA3-lipoplexes: 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2.1. Particle sizing of PG adjuvant-siRNA3 lipoplexes 
The negatively charged siRNAs were complexed to positively charged PG adjuvant 
liposomes to form siRNA3 lipoplexes and analysed by DLS. Particle size of unmodified 
siRNA3 lipoplexes ranged from 45-180 nm in diameter with a polydispersity index of 0.508-
1.098.  
 
Chapter 7 
 
66 
 
7.2.2. Zeta potential of siRNA3-lipoplexes: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2.2. Zeta potential of PG adjuvant-siRNA3 lipoplexes 
The negatively charged siRNA3 molecules were complexed to cationic PG adjuvant 
liposomes to form siRNA3 lipoplexes. The surface charge of unmodified siRNA3 lipoplexes 
was determined by Hückel analysis and ranged between +54 to +60 mV.  
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7.2.3. Particle sizing of GP3 siRNA3-lipoplexes: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2.3. Particle sizing of PG adjuvant-GP3 siRNA3 lipoplexes 
The negatively charged GP3 siRNAs were complexed to positively charged PG adjuvant 
liposomes to form GP3 siRNA3 lipoplexes and analysed by DLS. Particle size of GP3 
siRNA3 lipoplexes ranged between 50-200 nm in diameter with a polydispersity index of 
0.488-0.981.  
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7.2.4. Zeta potential of GP3 siRNA3-lipoplexes: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2.4. Zeta potential of PG adjuvant-GP3 siRNA lipoplexes 
The negatively charged GP3 siRNA3 molecules were complexed to cationic PG adjuvant 
liposomes to form GP3 siRNA3 lipoplexes. The surface charge of modified siRNA3 
lipoplexes was determined by Hückel analysis and ranged between +64 to +67 mV.  
Chapter 7 
 
69 
 
7.3. Detection of siRNA-mediated mRNA cleavage product in cultured cells by 5’ RACE  
7.3.1. Detection of cleavage product by 5’ RACE-PCR and DNA sequencing: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.3.1. Detection of siRNA-mediated mRNA cleavage product in vitro 
Agarose gel electrophoresis of amplified PCR products after reverse transcription of mRNA 
comprising the GeneRacer
TM
RNA oligo ligated to the 5’ end of the target RNA (A). 
Sequences of the ligated GeneRacer
TM
RNA oligo (in red), mRNA cleavage product (in blue) 
and a positive 5’ RACE product composed of sequences derived from the RNA oligo and 
mRNA cleavage product (B). 
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7.3.2. Representative sequencing data of siRNA samples used for the 5’ RACE experiment in vitro: 
Sequences of ligated RNA oligo (left panel) and amplified cleavage product in vitro (right panel): 
 
siRNA3          
  
 
 
 
 
 
GP3 siRNA3   
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GP4 siRNA3          
 
 
 
 
 
 
 
 
 
GP5 siRNA3 
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GP2.3 siRNA3 
 
 
 
 
 
 
 
 
 
GP2.3.17 siRNA3 
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GP2.5.17.20 
 
 
 
 
 
 
 
 
 
In vitro transcribed RNA (5’ RACE positive control) 
 
Chapter 7 
 
74 
 
7.4. Detection of siRNA-mediated mRNA cleavage in mice by 5’ RACE  
7.4.1. Detection of cleavage product by 5’ RACE-PCR and DNA sequencing: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.4.1. Detection of siRNA-mediated mRNA cleavage product in vivo 
Agarose gel electrophoresis of amplified PCR products after reverse transcription of mRNA 
comprising the GeneRacer
TM
RNA oligo ligated to the 5’ end of the target RNA (A). 
Sequences of the ligated GeneRacer
TM
RNA oligo (in red), mRNA cleavage product (in blue) 
and a positive 5’ RACE product comprised of sequences derived from the RNA oligo and 
mRNA cleavage product (B). 
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7.4.2. Representative sequencing data of siRNA samples used for 5’ RACE experiment in vivo: 
Sequences of ligated RNA oligo (left panel) and amplified cleavage product in vivo (right panel): 
 
siRNA3 
 
 
 
 
 
 
 
GP3 siRNA3 
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7.5. List of publications:  
The following are additional published journal articles emanating from work presented in this 
thesis. 
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E-mail address: Joachim.Engels@chemie.uni-frankfSynthetic RNAi activators have shown considerable potential for therapeutic application to silencing of
pathology-causing genes. Typically these exogenous RNAi activators comprise duplex RNA of approxi-
mately 21 bp with 2 nt overhangs at the 30 ends. To improve efﬁcacy of siRNAs, chemical modiﬁcation
at the 20-OH group of ribose has been employed. Enhanced stability, gene silencing and attenuated immu-
nostimulation have been demonstrated using this approach. Although promising, efﬁcient and controlled
delivery of highly negatively charged nucleic acid gene silencers remains problematic. To assess the
potential utility of introducing positively charged groups at the 20 position, our investigations aimed at
assessing efﬁcacy of novel siRNAs containing 20-O-guanidinopropyl (GP) moieties. We describe the for-
mation of all four GP-modiﬁed nucleosides using the synthesis sequence of Michael addition with acry-
lonitrile followed by Raney-Ni reduction and guanidinylation. These precursors were used successfully to
generate antihepatitis B virus (HBV) siRNAs. Testing in a cell culture model of viral replication demon-
strated that the GP modiﬁcations improved silencing. Moreover, thermodynamic stability was not
affected by the GP moieties and their introduction into each position of the seed region of the siRNA guide
strand did not alter the silencing efﬁcacy of the intended HBV target. These results demonstrate that
modiﬁcation of siRNAs with GP groups confers properties that may be useful for advancing therapeutic
application of synthetic RNAi activators.
 2011 Elsevier Ltd. All rights reserved.1. Introduction
Use of synthetic small interfering RNAs (siRNAs) to trigger RNA
interference- (RNAi-) mediated gene silencing has shown consider-
able potential for therapeutic application.1–3 Typically, siRNAs are
synthetic mimics of natural Dicer products and comprise 21–25 nt
duplexes with 2 nt 30 overhangs. Progress with use of synthetic siR-
NAs has proﬁted from vast experience gained from developing anti-
sense RNA molecules. Consequently advances have been rapid and
improving siRNA efﬁcacy has beneﬁted from valuable biological
and synthetic chemistry insights. Advantages of synthetic siRNAs
over expressed RNAi activators are that they are amenable to chem-
ical modiﬁcation to improve stability, safety and speciﬁcity.4,5 Also,
controlled large scale preparation necessary for clinical use is feasi-
ble with chemical synthetic procedures. Nevertheless, despite sig-
niﬁcant advances, the delivery of these polyanionic nucleic acids
across lipid-rich cellmembranes remains problematic. Vectors used
to transport synthetic RNAi activators to target cells have included
cationic lipid-containing lipoplexes,6 conjugations to peptides7 orll rights reserved.
x: +49 69 798 29148.
urt.de (J.W. Engels).oligocationic compounds such as spermidine.8 However, success
using these methods has been variable. To overcome difﬁculties of
the excessive negative charge of nucleic acids, while at the same
time improving thermal and serum stability, we previously
investigated an approach that entailed 20-modiﬁcation of ribose
with cationic groups.9,10 Initially we generated always 20-O-amino-
ethyl-adenosine and 20-O-aminoethyl uridine. Synthesis entailed
initial alkylation by methyl bromoacetate, which was followed by
a series of transformation reactions. Using a luciferase reporter as-
say tomeasure knockdown, it was demonstrated that the 20-O-ami-
noethyl modiﬁcations were at least as efﬁcient as 20-OMe siRNA
modiﬁcations. An important property of the 20-O-aminoethyl deriv-
atives was their ability to rescue less active siRNAs when the chem-
ical modiﬁcations were placed at the 30 end of the siRNA passenger
strand.11 Subsequently this approach was advanced by developing
methods that enabled successful alkylation of all four ribonucleo-
sides.12 This was achieved using phalimidoethyltriﬂate as an alkyl-
ating agent and with this methodology all four phosphoramidites
bearing 20-O-aminoethyl side chains were formed. Although
encouraging, a problem of using these siRNA reagents is that the
yields of the multistep chemical synthesis are typically low. More-
over scaling up the synthesis reaction is difﬁcult. To address these
J. Brzezinska et al. / Bioorg. Med. Chem. 20 (2012) 1594–1606 1595concerns, we have investigated utility of an alternative 20-O-guani-
dinopropyl (GP) nucleoside modiﬁcation method. Using the novel
approach reported here, we describe the formation of all four GP-
modiﬁed nucleosides using the synthesis sequence ofMichael addi-
tion with acrylonitrile13–15 followed by Raney-Ni reduction16 and
guanidinylation. Efﬁciency of the GP siRNAs was assessed in a cell
culture model of hepatitis B virus (HBV) replication using target se-
quences that have previously been shown to be suitable for RNAi-
based inhibition of viral replication.17–20 Results demonstrate more
effective silencing of markers of viral replication than unmodiﬁed
counterparts. Moreover, the GP-modiﬁed siRNAs were more stable
to serum conditions than the unmodiﬁed controls.
2. Results
2.1. Synthesis of the four 20-O-guanidinopropyl-nucleoside-
phosphoramidites
Each of the four 20-O-guanidinopropyl-nucleoside phospho-
ramidites was synthesised using essentially analogous methodol-
ogy. The synthesis of the adenosine (A), cytidine (C) and uridine
(U) derivatives is depicted in Scheme 1. Since a different protecting
group strategy was employed to synthesise the guanosine (G)
derivative, it is shown in a separate scheme (Scheme 2). Each
synthesis was initiated by simultaneous protection of 50- and the
30-OH-groups with 1,1,3,3-tetraisopropyldisiloxane-1,3-diyl (TIPS)
(for A,C and U) or di-tert-butylsilanediyl (DTBS) for guanosine.
DTBS was selected for protection of G as this group has been
reported to improve selectivity for the subsequent 2,4,6-tri-
isopropylbenzenesulfonyl (TPS) protection of O6-position of guano-
sine.21 The exocyclic amino functions of A and C were protectedScheme 1. Synthesis of the 20-O-guanidinopropyl adenosine-, cytidine- and uridine- pho
alcohol, rt; (ii) H2N–NH2H2O, methanol, rt (adenosine and cytidine derivative); no depro
N,N0-di-Boc-N00-triﬂylguanidine, Et3N, CH2Cl2, 0 C (30 min) to rt (30 min); (v) DMF-dime
(30 min) to rt (30 min) (cytidine derivative); no protection group was applied to the urid
(viii) 2-cyanoethyl N,N,N0 ,N0-tetraisopropyl phosphane, 4,5-dicyanoimidazole, CH2Cl2, rt.
Scheme 2. Synthesis of the 20-O-guanidinopropyl guanosine phosphoramidite for oligorib
(70%), dioxane/water; (iii) H2 (30 bar), NH3, methanol, 30–60 min, rt; (iv) N,N0-di-Boc-N0
pyridine, 0 C (1 h) to rt (1 h); (vi) Et3N3HF, THF, rt; (vii) 4,40-dimethoxytrityl ch
dicyanoimidazole, CH2Cl2, rt.with dimethylaminomethylene groups employing standard condi-
tions and a benzoyl group was attached to N3-position of U using
the two phase system reported by Sekine.22 The resulting nucleo-
tide precursors (1a–4a) were then subjected to the ﬁrst crucial step
of the 20-O-guanidinopropyl derivatisation. Employing the proce-
dure reported by Sekine et al.,23 a Michael addition under mild
conditions (Cs2CO3, tert-butanol, room temperature) was per-
formed using acrylonitrile to obtain the 20-O-cyanoethyl deriva-
tives. In a subsequent step the dimethylaminomethylene group
of the A and C derivatives was removed with hydrazine to form
the 20-O-cyanoethyl derivatives 1b and 2b. This additional depro-
tection step was necessary to avoid formation of a mixture of
dimethylaminomethylene protected and unprotected derivatives
that result from proceeding directly to the next reduction step.
For the uridine derivative 3b no intermediate deprotection of the
N3-benzoyl group was necessary. This is because the benzoyl group
was completely removed under the ammonia conditions of the fol-
lowing step. The O6-TPS group of the guanosine derivative was re-
moved without further puriﬁcation of the Michael reaction
product. This was achieved after ﬁltration and evaporation of sol-
vents using formic acid in a mixture of dioxane and water to yield
the 20-O-cyanoethyl-guanosine derivative 4b.
In the next step, the 20-O-cyanoethyl group was transformed
into a 20-O-aminopropyl group. Reduction with hydrogen (30 bar)
with Raney-nickel as catalyst in ammonia and methanol was used
to achieve this according to a procedure we previously described.24
The hydrogenation step was sensitive to reaction conditions such
as the ratio of amount of starting material to catalyst, the size of
the autoclave employed and reaction time. Under optimised condi-
tions, yields from reduction of each nucleotide derivative were
moderate (about 50%). A loss of the desired product was alsosphoramidites for oligoribonucleotide synthesis. (i) acrylonitrile, Cs2CO3, tert-butyl
tection of the uridine derivative; (iii) H2 (30 bar), NH3, methanol, 30–60 min, rt; (iv)
thyl diacetale, methanol, rt (adenosine derivative); benzoyl chloride, pyridine, 0 C
ine derivative; (vi) Et3N3HF, THF, rt; (vii) 4,40-dimethoxytrityl chloride, pyridine, rt;
onucleotide synthesis. (i) Acrylonitrile, Cs2CO3, tert-butyl alcohol, rt; (ii) formic acid
0-triﬂylguanidine, Et3N, CH2Cl2, 0 C (30 min) to rt (30 min); (v) isobutyryl chloride,
loride, pyridine, rt; (viii) 2-cyanoethyl N,N,N0 ,N0-tetraisopropyl phosphane, 4,5-
Table 1
Synthesised GP modiﬁed oligonucleotides
Name Sequence
GP2 siRNA3 5-UUGP G AAG UAU GCC UCA AGG UCG-30
GP3 siRNA3 5-UUGGP AAG UAU GCC UCA AGG UCG-30
GP4 siRNA3 5-UUG AGP AG UAU GCC UCA AGG UCG-30
GP5 siRNA3 5-UUG AAGP G UAU GCC UCA AGG UCG-30
GP6 siRNA3 5-UUG AAGGP UAU GCC UCA AGG UCG-30
GP7 siRNA3 5-UUG AAG UGP AU GCC UCA AGG UCG-30
GP8 siRNA3 5-UUG AAG UAGP U GCC UCA AGG UCG-30
GP13 siRNA3 5-UUG AAG UAU GCC UGP CA AGG UCG-30
Table 2
Effect of GP modiﬁcation on duplex stability with complementary RNA (50-GGCAU-
ACUUCAA-30)
Oligo Sequence Tm [C] DTm [C]
ON 1 50-UUG AAG UAU GCC-30 54.9 —
ON 2 50-UUGGP AAG UAU GCC-30 54.5 0.4
ON 3 50-UUG AAGGP UAU GCC-30 52.5 2.4
ON 4 50-UUG AAG UAUGP GCC-30 54.4 0.5
ON 5 50-UUGGP AAGGP UAU GCC-30 54.6 0.3
ON 6 50-UUGGP AAGGP UAUGP GCC-30 54.4 0.5
1596 J. Brzezinska et al. / Bioorg. Med. Chem. 20 (2012) 1594–1606conﬁrmed by the observation that part of the amino compound
was not released from the catalyst during ﬁltration, despite being
subjected to several washes with methanol. To minimise losses
the crude unpuriﬁed 20-O-aminopropyl compounds were used to
introduce the guanidino groups. N,N0-di-Boc-N00-triﬂylguanidine
was employed as guanidinylation agent. The procedure we em-
ployed was initially reported by Goodman et al. in 1998 and the re-
agent is now commercially available.25 Our previous studies
showed that the boc groups are cleaved under the repetitive depro-
tection conditions during oligonucleotide synthesis when employ-
ing the TBDMS-phosphoramidite method. Also, the guanidino
group undergoes no side reaction during the solid phase synthe-
sis.26 The guanidinylation took place with good yields (70% for 1c
(A), 60% for 2c (C), around 60% for 3c (U) and approximately 90%
for 4c (G)).
After successful guanidinylation, established reaction condi-
tions were applied to synthesize the desired phosphoramidites
(1d– 4d). This entailed use of protection groups that were suitable
for the TBDMS method of oligoribonucleotide synthesis. The A
derivative was protected with dimethylaminomethylene at the
N6-position, and the exocyclic amino function of the C derivative
was protected with a benzoyl group. The N2-position of the G
derivative was protected with an isobutyryl group. However, under
the reaction conditions we employed, a mixture of the desired G
derivative product, as well as a compound with an additional iso-
butyryl group on the non-boc-protected nitrogen of the guanidino
group, were obtained. It was very difﬁcult to separate this double
isobutyryl modiﬁed compound using chromatography. However,
since it would be cleaved during the ammonia deprotection step
at the completion of oligonucleotide synthesis, we utilised this
mixture of 4d and 4d⁄ for solid phase oligonucleotide synthesis.
To synthesise U derivatives, no further protection was necessary.
For synthesis of all of the 20-O-guanidinopropyl phosphoramidites,
removal of silyl protecting groups was achieved with Et3N3HF. The
50-OH-group was protected with a 4,40-dimethoxytrityl group and
in a last step the 30-OH group was converted to a phosphoramidite
using 2-cyanoethyl N,N,N0,N0-tetraisopropylamino phosphane and
4,5-dicyanoimidazole as activator. Starting with the adenosine,
cytidine and guanosine nucleosides, synthesis of the 20-O-guanidi-
nopropyl phosphoramidites took place in 10 steps and provided
overall yields of 15.4% (1d), 6.3% (2d) and 7.5% (4d). Synthesis ofthe 20-O-guanidinopropyl uridine phosphoramidite was performed
in eight steps with an overall yield of 11.8% (3d).
The obtained phosphoramidites were used for synthesis of the
GP-modiﬁed siRNA antisense strands depicted in Table 1 and the
GP-modiﬁed oligonucleotides for melting point studies depicted
in Table 2. For the modiﬁed phosphoramidites a prolonged cou-
pling step of 25 min was used. To ensure complete cleavage of
the boc groups, an additional deprotection step of 30 min with
3% trichloroacetic acid in dichloromethane was applied after com-
pletion of oligonucleotide synthesis. The boc group was chosen for
protection of the guanidine moiety due to its compatibility con-
cerning the protecting group strategy that was used for synthesis
of the monomers. Although partial cleavage of the boc groups dur-
ing RNA-synthesis is expected in consequence of the acidic depro-
tection step of each cycle, no side reaction of the free guanidino
groups was observed. According to the anion-exchange chromato-
grams of the deprotected RNA (an exemplary chromatogram is
shown in the Supplementary data), only one main product has
formed. After puriﬁcation the oligonucleotides were obtained with
10% to 40% yield (1 lmol synthesis scale).
2.2. Hybridization studies
The inﬂuence of GP-modiﬁed nucleosides on thermal stability
of different RNA duplexes was examined. For this purpose, the
GGP and UGP modiﬁed phosphoramidites were inserted into
12mer RNA (ON2–ON6) and the duplex melting point measured.
As shown in Table 2, the presence of GP group in oligoribonucleo-
tides did not signiﬁcantly affect the stability of duplexes, although
slightly destabilized them. Guanidinopropyl modiﬁed building
blocks give almost the same Tm value for single, double and triple
substituted oligonucleotides.
Interestingly, in the case when a GP modiﬁcation of G was
placed in a central position, the Tm decreased more signiﬁcantly
(DTm = 2.4 C).
The results indicate that the thermodynamic effect of GP group
is more or less independent on the placement of the modiﬁcation
and modiﬁed nucleoside. While more modiﬁcations were incorpo-
rated, substitutions were not adjacent, additional destabilizing ef-
fect was not observed (ON5 and ON6, Table 2). Moreover, for the
modiﬁed oligonucleotides bearing more than one GP residue, high
binding afﬁnity to the complementary strand was unaffected.
2.3. Inhibition of Fireﬂy luciferase activity in transfected cells
Initially, to measure knockdown efﬁciency of GP-modiﬁed siR-
NAs in situ, HEK293 cells were co-transfected with RNAi activators
together with a reporter gene plasmid (psiCHECK-HBx)20 (Fig. 1).
The siRNAs targeted a single sequence of the X open reading frame
(ORF) of HBV (HBx) that has previously been shown to be an effec-
tive cognate for RNAi-based silencing.27 Each of the siRNAs differed
with respect to location of the GP modiﬁcation, and these were
within the seed region or at nucleotide 13 of the antisense strand
of the siRNA duplex. siRNAs have been named according to the
positioning of the GP modiﬁcations from the 50 end of the intended
guide strand. In psiCHECK-HBx, the viral target sequence was lo-
cated in the Renilla transcript but downstream of the reporter
ORF (Fig. 1A). Expression of Fireﬂy luciferase is constitutively ac-
tive to enable correction for variations in transfection efﬁciency.
The ratio of Renilla to Fireﬂy luciferase activity was used to assess
knockdown efﬁcacy. Compared to a scrambled siRNA control, anal-
ysis showed that the Fireﬂy luciferase activity was diminished by
approximately 70% when co-transfected with the unmodiﬁed siR-
NA (Fig. 1B). There was some variation in the efﬁcacy of the inhibi-
tion of reporter gene activity that was dependent on the position of
the chemically modiﬁed siRNAs. Knockdown efﬁcacy was weakest
Figure 1. Dual luciferase assay to determine efﬁcacy of GP antiHBV siRNAs. (A)
Schematic illustration of dual luciferase reporter plasmid. The HBx target sequence
was inserted downstream of the hRLuc ORF. Renilla luciferase activity was used as
an indicator of target silencing and efﬁcacy was determined relative to activity of
constitutively expressed Fireﬂy luciferase. (B) Ratio of Renilla to Fireﬂy luciferase
activity following cotransfection with indicated siRNAs together with dual lucifer-
ase reporter plasmid. Controls included a mock transfection in which inert plasmid
DNA was substituted for siRNA as well as a scrambled siRNA that did not have
complementary sequences to the HBx target. Data are represented as mean ratios of
Renilla to Fireﬂy luciferase activity (±SEM) and are normalised relative to the mock
treated cells. Differences were considered statistical signiﬁcant when the p value,
determined according to the Student’s 2 tailed paired t-test, was less than 0.05.
Figure 2. Inhibition of HBV replication by antiHBV siRNAs in cultured cells. A.
Illustration of the HBV replication competent plasmid, pCH-9/3091, which was used
to transfect liver-derived Huh7 cells in culture. (B) The concentration of HBsAg was
measured in cell culture supernatants following co-transfection GP-modiﬁed
siRNAs. Values are given as relative OD readings from the ELISA assay. Unmodiﬁed
siRNA did not include GP residues. Controls included a mock transfection in which
inert plasmid DNA was substituted for siRNA as well as a scrambled siRNA that did
not have complementary sequences to the HBx target. Data are represented as mean
ratios of Renilla to Fireﬂy luciferase activity (±SEM) and are normalised relative to
the mock treated cells. Differences were considered statistical signiﬁcant when the
p value, determined according to the Student’s 2 tailed paired t-test, was less than
0.05.
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tide 2 of the siRNA antisense sequence. siRNAs with the modiﬁca-
tion at positions 5 and 6 (GP5 siRNA3 and GP6 siRNA3) achieved
most effective knockdown of reporter gene expression which was
similar to that of the unmodiﬁed siRNA. A siRNA with the GP mod-
iﬁcation placed outside of the seed region at nucleotide 13 also
achieved knockdown of 75%. GP modiﬁcations in antiHBV siRNA
sequences are therefore compatible with effective target silencing,
but position within the seed of the antisense guide inﬂuences
efﬁcacy.
2.4. Inhibition of HBV surface antigen (HBsAg) secretion from
transfected cells by GP-modiﬁed siRNAs
To assess efﬁcacy against HBV replication in vitro, Huh7 liver-
derived cells were co-transfected with siRNAs together with the
pCH-9/3091 HBV replication competent target plasmid
(Fig. 2A).28 Compared to HBsAg concentration in the culture super-
natant of cells treated with scrambled siRNA, knockdown of up to
85% of viral antigen secretion was achieved by GP-modiﬁed siRNAs
(Fig. 2B). The unmodiﬁed siRNA was slightly less effective than the
siRNAs containing GP moieties. Of the modiﬁed siRNAs, positioning
of the GP residue at nucleotides 5 or 6 (GP5 siRNA3 and GP6 siR-
NA3) resulted in the most effective suppression of HBsAg secretion
(approximately 90%). These data correlate with observations using
the reporter gene knockdown assay. Interestingly, GP2 siRNA3
inhibited HBsAg secretion from transfected cells more effectively
than it did Renilla luciferase activity. The reason for this differenceis unclear but may result from better GP2 siRNA3 target accessibil-
ity in the context of the natural HBV transcripts. Overall, these data
support the notion that seed region GP modiﬁcations are compat-
ible with target silencing that is similar or more effective than
unmodiﬁed siRNAs.
2.5. Stability of GP-modiﬁed siRNAs in 80% FCS
siRNAs containing GP modiﬁcations were incubated in the pres-
ence or absence of 80% foetal calf serum (FCS) for time intervals of
0–24 h to assess their stability (Fig. 3). siRNAs were detected using
polyacrylamide gel electrophoresis and staining with ethidium
bromide. Bands corresponding to siRNAs were quantiﬁed to deter-
mine stability and FCS resistance. Analysis revealed that unmodi-
ﬁed siRNA3 was stable for 24 h when maintained in DMEM
tissue culture medium that did not include FCS. However, rapid
degradation of siRNA occurred in the presence of FCS, and approx-
imately 10% of the input siRNA remained at 5 h. Analysis of stabil-
ity of GP2 siRNA3, GP3 siRNA3, GP4 siRNA3, GP5 siRNA3 and GP6
siRNA3 showed a similar rapid degradation. When the GP modiﬁ-
cations were placed further from the 50 end of the antisense strand
of the siRNA (GP7 siRNA3, GP8 siRNA3 and GP13 siRNA3) slower
degradation of the siRNAs was observed. With these siRNAs, at
the time point of 5 h approximately 40% of the input siRNA re-
mained intact. Stability is therefore improved by including GP
Figure 3. Assessment of stability of GP-modiﬁed siRNAs. The panel of GP-modiﬁed
siRNAs was incubated with DMEM alone, or DMEM with 80% foetal calf serum, for
times ranging from 0 to 24 h. Thereafter degradation of siRNAs was assessed using
polyacrylamide gel electrophoresis with ethidium bromide staining.
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the siRNAs is important to confer this property.
3. Discussion
Successful preparation of GP phosphoramidite nucleosides for
incorporation into siRNAs presents a novel approach to utilising
chemical modiﬁcation for enhancement of efﬁcacy of synthetic siR-
NAs. Ideally, for gene silencing sequences to be therapeutically
applicable they should be stable, amenable to efﬁcient delivery
to target tissues, effective and speciﬁc to their targets. Alterations
to siRNAs have typically involved 20-OH modiﬁcation of the ribose
groups (11 and reviewed in Refs. 4,5). Changes at this site are useful
for improving overall siRNA efﬁcacy for several reasons. The 20-OH
may cause nucleophilic attack and removal of the hydroxyl group
limits susceptibility of siRNAs to degradation. Alterations at the
20-OH of ribose may also attenuate toxic innate immune responses
of duplex RNA by preventing interaction with intracellular Toll Like
Receptors (TLRs). Furthermore, 20-OH modiﬁcation may inﬂuence
nucleotide stacking to enhance interaction of the siRNA guide with
its target. Alterations to the 20-OH that have been reported to date
have included 20-F, 20-methoxy ribosyl (20-OMe) and locked nucleic
acid modiﬁcations.5,11 Recently a 20-azido modiﬁcation was re-
ported, that not only replaces the 20-OH group but can also be used
for postsynthetic labelling of RNA.29 Although improvements in
siRNA stability, efﬁcacy and immunostimulatory effects have been
reported, difﬁculties with efﬁcient regulation of nucleic acid deliv-
ery remain. The GP modiﬁcation reported here presents a novel ap-
proach that has distinct properties that potentially have
advantages over previously described 20-OH modiﬁcations. The
three amino groups of the GP moiety together with the three car-
bon atom propyl linker provide a ﬂexible charge-neutralising
group.
Chemical synthesis of GP-modiﬁed nucleosides is straightfor-
ward and comprises the following crucial steps. Cyanoethylationbased on Michael addition of suitably protected nucleosides with
acrylonitrile. The following Raney-Ni reduction results in the pro-
pylamino derivatives that are ﬁnally guanidinylated by triﬂylgua-
nidine. Different chemical structures of each of the bases require
that the protecting group strategies differ slightly between the four
nucleosides. Standard phosphitylation provides the appropriate
phosphoramidites 1d–4d, which are ready for solid phase oligonu-
cleotide synthesis (see Tables 1 and 2). Using this reaction se-
quence, this is the ﬁrst time that a full set of phosphoramidites
modiﬁed with guanidino groups at the 20 position is provided for
incorporation in synthetic oligonucleotides. Synthesis of modiﬁed
oligonucleotides was carried out under standard conditions of
phosphoramidite chemistry. Moreover coupling efﬁciency of the
GP-modiﬁed phosphoramidites was as good as for the unmodiﬁed
phosphoramidites.
An additional advantage of the synthetic procedures described
here is that it is possible to introduce diversiﬁcation at the
20-O-aminopropyl site of our compounds. With common peptide-
coupling reagents, such as carbodiimides and 1-hydroxybenzo-
triazoles, the 20-O-aminopropyl group can readily be modiﬁed with
carboxylic acid derivatives. These include amino acids, fatty acids
or carboxy-modiﬁed spermine to obtain more cationic or more
lipophilic oligonucleotides.24 Also, protection of the amino group
with a triﬂuoroacetyl group during oligonucleotide solid phase
synthesis would enable postsynthetic labelling with amino-reac-
tive ﬂuorophore derivatives (e.g., NHS-esters or isothiocyanates)
or reaction with cross linkers to connect nucleic acids to carrier
molecules, for example, cell penetrating peptides.
The melting behaviour of the duplex oligonucleotides showed
that the melting temperature was independent of the placement
and number of GP modiﬁcations (Table 2). For this analysis, we
chose a 12-mer with a sequence that was identical to the seed se-
quence of our siRNA. This shorter sequence, with a Tm of approxi-
mately 55 C, was better for demonstrating smaller changes in
melting properties. The results concur with hybridization analysis
of oligonucleotides containing 20-O-aminopropyl (AP) groups.30
Incorporation of one AP unit at the 30-end or in the middle of an oli-
gomer reduces the Tm of a RNA duplex. Duplex stabilization was
observed in RNA containing AP groups at adjacent sites or within
an entire strand. Molecular dynamic and NMR data indicate that
no strong electrostatic interaction or hydrogen bonding is formed
as a result of ﬂexibility of aminoalkyl chains.30 Another possibility
that has been proposed is that some stabilizing effect might be
conferred by hydration of the AP.31,32 For the guanidino group re-
ported here, there are three nitrogen atoms in a plane which are
protonated over a wide pH range. The individual contributions of
GP-RNA to thermodynamic stability are not clear yet but nanosec-
ond molecular modelling points to high ﬂexibility in water. (Villa
and Stock, unpublished)
When investigating the potential therapeutic utility of a new
chemical modiﬁcation to siRNAs, it is desirable to verify that
silencing is maintained in a clinically relevant model. In this study,
we assessed the efﬁcacy in a model of HBV infection. Persistence of
HBV is an important global cause of public health problems (re-
viewed in Ref. 33). Cirrhosis and liver cancer, which are potentially
fatal complications of HBV persistence, occur frequently. There is a
need to develop more effective antiHBV treatments to eliminate
these problems and harnessing the RNAi pathway to counter the
infection has shown promise.34 To assess silencing by GP-modiﬁed
siRNAs, a panel of silencing sequences was tested against a previ-
ously described susceptible HBV target.27 Evidence from this study
shows that incorporation of GP groups at the 20 ribose position en-
hances HBV silencing, while also improving stability. Interaction of
sequences within the guide seed region and the target are critically
important to effect silencing. Chemical modiﬁcation in the guide
seed potentially compromises the interaction of the guide with
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tended target is retained after incorporating the GP residues into
each of the nucleotides comprising the guide strand seed. This
observation is in accordance with previous reports showing mini-
mal attenuation of intended target silencing caused by modiﬁca-
tion in the seed region.35,36 Complete base pair matching within
the remainder of the siRNA guide and intended target compensates
for disruption that may occur in the seed.
The novel 20-GP modiﬁcation that is described here potentially
has several advantages for therapeutic application. Our data dem-
onstrate that changes in single nucleotides achieve enhanced
silencing efﬁcacy and stability of siRNAs. Modiﬁcation of more
than one nucleotide in a siRNA is feasible and multiple PG moieties
could further augment the efﬁcacy of therapeutic sequences. Cur-
rent investigations are addressing this as well as the role of GP
modiﬁcations on off target seed interaction and improvement in
in vivo delivery of GP-modiﬁed siRNA by non-viral vectors.4. Experimental
4.1. Material and methods
All reagents were of analytical reagent grade, obtained from
commercial resources and used without further puriﬁcation. For
synthesis, solvents with quality pro analysis were used. Dry
solvents were kept over molecular sieve and for column chroma-
tography technical solvents were distiled before use.
All NMR spectra were measured on Bruker AM250
(1H: 250 MHz, 13C: 63 MHz), AV300 (1H: 300 MHz, 13C: 75 MHz,
31P: 121 MHz) and AV400 (1H: 400 MHz, 13C: 101 MHz, 31P:
162 MHz) instruments. Chemical shifts (d) are reported in parts
per million (ppm). The following annotations were used with peak
multiplicity: s, singlet; d, doublet; t, triplet; q, quartet; m, multi-
plet; b, broadened. J values are given in Hz.
MALDI mass spectra were recorded on a Fisons VG Tofspec spec-
trometer and ESI mass spectra on a Fisons VG Plattform II spec-
trometer. High resolution mass spectra were acquired on a
Thermo MALDI Orbitrap XL.
UV-melting curves were measured on a JASCO V-650 spectro-
photometer. Melting proﬁles of the RNA duplexes were recorded
in a phosphate buffer containing NaCl (100 mM, pH 7) at oligonu-
cleotide concentrations 2 lM for each strand at wavelength
260 nm. Each melting curve was determined triply. The tempera-
ture range was 5–95 C with a heating rate 0.5 C. The thermody-
namic data were extracted from the melting curves by means of
a two state model for the transition from duplex to single strands.
Statistical analysis: Data have been expressed as the
mean ± standard error of the mean. Statistical difference was con-
sidered signiﬁcant when P <0.05 and was determined according to
the student’s t-test and calculated with the GraphPad Prism soft-
ware package (GraphPad Software Inc., CA, USA).
4.2. Chemistry
4.2.1. Synthesis of the 20-O-guanidinopropyl adenosine
phosphoramidite
30,50-O-(Tetraisopropyldisiloxane-1,3-diyl)-N6-dimethylamino-
methylene adenosine (1a) was synthesised as previously
described.16
4.2.1.1. N6 -Dimethylaminomethylene-20-O-cyanoethyl-30,50-O-
(tetraisopropyldisiloxane-1,3-diyl)-adenosine (1e). To a
solution of compound 1a (3.0 g, 5.31 mmol) in tert-butanol
(25 mL), freshly distiled acrylonitrile (6.7 mL, 102 mmol) and
cesium carbonate (1.6 g, 4.9 mmol) were added. The mixture wasstirred vigorously at room temperature for 3 h. The reaction mix-
ture was ﬁltered and the residue was washed with dichlorometh-
ane. The ﬁltrate was evaporated and the residue was puriﬁed using
column chromatography with ethyl acetate/methanol (99:1–95:5,
v/v) to give 3.28 g (87%) of the product. 1H NMR (400 MHz,
DMSO-d6) d [ppm] 8.90 (s, 1H, admidine-H), 8.34 (s, 1H, H2 or
H8), 8.32 (s, 1H, H2 or H8), 6.02–6.01 (m, 1H, H10), 5.05–5.01 (m,
1H, H30), 4.64–4.62 (m, 1H, H20), 4.08–3.84 (m, 5H, H40, 2  H50,
O–CH2–CH2–CN), 3.20 (s, 3H, N–CH3), 3.13 (s, 3H, N–CH3), 2.83–
2.80 (m, 2H, O–CH2–CH2–CN), 1.10–1.00 (m, 28H, tetraisopropyl-
CH and -CH3); MS (ESI) was calculated to be 618.3 for C28H48N7O5-
Si2 (M+H+), and found to be 618.8.
4.2.1.2. 20-O-Cyanoethyl-30,50-O-(tetraisopropyldisiloxane-1,3-
diyl)-adenosine (1b). N6-Dimethylaminomethylene-20-O-
cyanoethyl-30,50-O-(tetraisopropyldisiloxane-1,3-diyl)-adenosine
(1e) (1.0 g, 1.62 mmol) was dissolved in methanol (20 mL) then
hydrazine hydrate (H2N–NH2H2O; 500 lL, 10.3 mmol) was added.
The reaction solution was stirred at room temperature for 3 h. The
solvents were evaporated and the residue was puriﬁed using a sil-
ica gel column with ethylacetate as eluent to give 773 mg (87%) of
1b. 1H NMR (400 MHz, DMSO-d6) d [ppm] 8.21 (s, 1H, H2 or H8),
8.07 (s, 1H, H2 or H8), 7.33 (bs, 2H, NH2), 5.98–5.96 (m, 1H, H10),
5.03–4.99 (m, 1H, H30), 4.59–4.57 (m, 1H, H20), 4.08–3.83 (m, 5H,
H40, 2  H50, O–CH2–CH2–CN), 2.84–2.80 (m, 2H, O–CH2–CH2–
CN), 1.09–0.97 (m, 28H, tetraisopropyl-CH and -CH3); 13C NMR
(101 MHz, DMSO-d6) d [ppm] 156.01, 152.41 (C2 or C8), 148.46,
139.26 (C2 or C8), 119.20, 118.83, 87.47 (C10), 81.11 (C20), 80.45
(C40), 70.04 (C30), 65.62 (O–CH2–CH2–CN), 60.09 (C50), 18.38 (O–
CH2–CH2–CN), {17.20, 17.06, 17.05, 17.01, 16.98, 16.85, 16.81,
16.71} (tetraisopropyl-CH3), {12.60, 12.28, 12.09, 12.04} (tetraiso-
propyl-CH); MS (MALDI) was calculated to be 563.8 for
C25H43N6O5Si2 (M+H+) and found to be 564.0.
4.2.1.3. 20-O-Aminopropyl-30,50-O-(tetraisopropyldisiloxane-1,3-
diyl)-adenosine (1f). Compound 1b (1.0 g, 1.78 mmol) was
dissolved in 10 mL of methanol in a glass tube suitable for use in
an autoclave. Approximately 0.5 mL of the Raney-nickel slurry
was rinsed thoroughly with dry methanol and then washed into
the glass tube with the solution of 1b. After addition of 5 mL meth-
anol saturated with ammonia, the mixture was stirred for 1 h at
room temperature under a hydrogen atmosphere (30 bar). The
reaction mixture was ﬁltered and the catalyst was washed several
times with methanol. The ﬁltrate was evaporated and the residue
was puriﬁed using column chromatography with ethyl acetate/
methanol/triethylamine (70:25:5, v/v/v) to yield 503 mg (50%) of
the desired compound. When this reaction was repeated, the crude
product was used for the next step without further puriﬁcation. 1H
NMR (400 MHz, DMSO-d6) d [ppm] 8.20 (s, 1H, H2 or H8), 8.07 (s,
1H, H2 or H8), 7.32 (bs, 2H, NH2), 5.95–5.94 (m, 1H, H10), 4.95–4.90
(m, 1H, H30), 4.41–4.39 (m, 1H, H20), 4.08–3.90 (m, 3H, H40,
2  H50), 3.86–3.70 (m, 2H, O–CH2–CH2–CH2–NH2), 2.66–2.61 (m,
2H, O–CH2–CH2–CH2–NH2), 1.65–1.58 (m, 2H, O–CH2–CH2–CH2–
NH2), 1.08–0.96 (m, 28H, tetraisopropyl-CH and -CH3); MS (MALDI)
was calculated to be 567.9 for C25H47N6O5Si2 (M+H+), and found to
be 567.9.
4.2.1.4. 20-O-(N,N0-Di-boc-guanidinopropyl)-30,50-O-(tetra-
isopropyldisiloxane-1,3-diyl)-adenosine (1c). N,N0-Di-boc-
N00-triﬂyl guanidine (280 mg, 0.72 mmol) was dissolved in 5 mL
dichloromethane then triethylamine (100 lL) was added. After
cooling to 0 C, 20-O-aminopropyl-30,50-O-(tetraisopropyldisilox-
ane-1,3-diyl)-adenosine (1f) (400 mg, 0.71 mmol) was added and
the mixture was stirred for 1 h at 0 C then for 1 h at room temper-
ature. The reaction was diluted with dichloromethane and washed
with saturated sodium bicarbonate solution and brine. The organic
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residue was puriﬁed using column chromatography with dichloro-
methane/methanol (98:2, v/v) to give a yield of 402 mg (70%) of 1c.
1H NMR (400 MHz, DMSO-d6) d [ppm] 11.50 (s, 1H, NH-boc), 8.45–
8.41 (m, 1H, NH–CH2–), 8.17 (s, 1H, H2 or H8), 8.06 (s, 1H, H2 or
H8), 7.31 (bs, 2H, NH2), 6.02–5.99 (m, 1H, H10), 4.96–4.91 (m, 1H,
H30), 4.43–4.40 (m, 1H, H20), 4.06–3.70 (m, 5H, H40, 2  H50, O–
CH2–CH2–CH2–NH–), 3.51–3.32 (m, 2H, O–CH2–CH2–CH2–NH–),
1.84–1.78 (m, 2H, O–CH2–CH2–CH2–NH–), 1.44 (s, 9H, C(CH3)3),
1.37 (s, 9H, C(CH3)3), 1.07–0.99 (m, 28H, tetraisopropyl-CH and -
CH3); 13C NMR (101 MHz, DMSO-d6) d [ppm] 163.00, 156.00,
155.07, 152.40 (C2 or C8), 151.96, 148.48, 139.04 (C2 or C8),
119.21, 87.69 (C10), 82.70, 81.26 (C20), 80.41 (C40), 77.87, 69.99
(C30), 69.63 (O–CH2–CH2–CH2–NH–), 60.13 (C50), 38.41 (O–CH2–
CH2–CH2–NH–), 28.71 (O–CH2–CH2–CH2–NH–), 27.85 (C(CH3)3),
27.44 (C(CH3)3), {17.19, 17.05, 17.03, 17.00, 16.95, 16.82, 16.74,
16.68} (tetraisopropyl-CH3), {12.59, 12.28, 12.09, 12.01} (tetraiso-
propyl-CH); MS (MALDI) was calculated to be 810.1 for
C36H65N8O9Si2 (M+H+), and found to be 808.3.
4.2.1.5. N6 -Dimethylaminomethylene-20-O-(N,N0-di-boc-guani-
dinopropyl)-30,50-O-(tetraisopropyldisiloxane-1,3-diyl)-adeno-
sine (1g). Compound 1c (500 mg, 0.61 mmol) was dissolved
in methanol (5 mL) and N,N-dimethylformamide dimethyl acetale
(500 lL, 3.7 mmol) was added. The reaction was stirred at room
temperature overnight and the solvents were evaporated. The
crude product was used for further reactions without puriﬁcation.
4.2.1.6. N6 -Dimethylaminomethylene-20-O-(N,N0-di-boc-guani-
dinopropyl)-adenosine (1h). Compound 1g (500 mg, 0.58
mmol) was dissolved in tetrahydrofurane (5 mL) and triethylam-
monium trihydroﬂuoride (Et3N3HF; 330 lL, 2.0 mmol) was added.
The mixture was stirred at room temperature for 1.5 h, then the
solvent was evaporated. The residue was puriﬁed by column chro-
matography with ethyl acetate/methanol (98:2–9:1, v/v) giving
300 mg (83%) of the desired product. 1H NMR (400 MHz, DMSO-
d6) d [ppm] 11.47 (s, 1H, NH-boc), 8.92 (s, 1H, N6 = CH–NMe2),
8.50 (s, 1H, H2 or H8), 8.41 (s, 1H, H2 or H8), 8.33–8.29 (m, 1H,
NH–CH2–), 6.11–6.09 (m, 1H, H10), 5.28–5.24 (m, 1H, 50-OH),
5.18–5.16 (m, 1H, 30-OH), 4.46–4.43 (m, 1H, H20), 4.36–4.32 (m,
1H, H30), 4.01–3.98 (m, 1H, H40), 3.72–3.46 (4H, 2  H50, O–CH2–
CH2–CH2–NH–), 3.33–3.28 (m, 2H, O–CH2–CH2–CH2–NH–), 3.20
(s, 3H, N–CH3), 3.13 (s, 3H, N–CH3), 1.74–1.68 (m, 2H, O–CH2–
CH2–CH2–NH–), 1.45 (s, 9H, C(CH3)3), 1.37 (s, 9H, C(CH3)3); 13C
NMR (101 MHz, DMSO-d6) d [ppm] 162.97, 159.22, 157.97
(N6 = CH–NMe2), 155.09, 151.89, 151.77 (C2 or C8), 151.00,
141.08 (C2 or C8), 125.70, 85.91 (C10), 85.74 (C40), 82.72, 81.02
(C20), 77.99, 68.72 (C30), 67.88 (O–CH2–CH2–CH2–NH–), 61.04
(C50), 40.56 (N–CH3), 37.86 (O–CH2–CH2–CH2–NH–), 34.45 (N–
CH3), 28.57 (O–CH2–CH2–CH2–NH–), 27.87 (C(CH3)3), 27.51
(C(CH3)3); MS (MALDI) was calculated to be 622.7 for C27H44N9O8
(M+H+), and found to be 624.6.
4.2.1.7. N6 -Dimethylaminomethylene-20-O-(N,N0-di-boc-guani-
dinopropyl)-50-O-(4,40-dimethoxytrityl)-adenosine
(1i). Compound 1h (1.0 g, 1.6 mmol) was dissolved in dry pyr-
idine (20 mL). 4,40-Dimethoxytrityl chloride (660 mg, 1.95 mmol)
was added and the reaction was stirred at room temperature over-
night. The solution was diluted with dichloromethane and washed
with saturated sodium bicarbonate solution. After evaporation of
the solvents the residue was puriﬁed on a silica gel column with
dichloromethane/methanol (98:2, v/v) containing 0.5% triethyl-
amine, and 1.32 g (90%) of the tritylated compound was obtained.
1H NMR (400 MHz, DMSO-d6) d [ppm] 11.48 (s, 1H, NH-boc), 8.90
(s, 1H, N6 = CH–NMe2), 8.38–8.34 (m, 3H, H2, H3, NH–CH2–),
7.37–7.34 (m, 2H, DMTr), 7.27–7.17 (m, 7H, DMTr), 6.84–6.79(m, 4H, DMTr), 6.14–6.13 (m, 1H, H10), 5.18–5.15 (m, 1H, 30-OH),
4.57–4.54 (m, 1H, H20), 4.47–4.42 (m, 1H, H30), 4.14–4.08 (m, 1H,
H40), 3.72–3.71 (m, 6H, 2  OCH3), 3.70–3.56 (m, 2H, O–CH2–
CH2–CH2–NH–), 3.37–3.32 (m, 2H, O–CH2–CH2–CH2–NH–), 3.24–
3.21 (m, 2H, 2  H50), 3.19 (s, 3H, N–CH3), 3.12 (s, 3H, N–CH3),
1.77–1.70 (m, 2H, O–CH2–CH2–CH2–NH–), 1.44 (s, 9H, C(CH3)3),
1.35 (s, 9H, C(CH3)3); 13C NMR (101 MHz, DMSO-d6) d [ppm]
162.98, 159.15, 157.97, 157.94, 157.91, 157.85 (N6 = CH–NMe2),
155.09, 151.88 (C2 or C8), 151.06, 144.73, 141.18 (C2 or C8),
135.44, 135.37, {129.60, 129.56, 127.64, 127.59, 126.53} (DMTr),
125.70, 112.99 (DMTr), 86.14 (C10), 85.34, 82.97 (C40), 82.70,
80.36 (C20), 77.96, 69.08 (C30), 68.21 (O–CH2–CH2–CH2–NH–),
63.40 (C50), 54.88 (OCH3), 40.54 (N–CH3), 37.97 (O–CH2–CH2–
CH2–NH–), 34.44 (N–CH3), 28.56 (O–CH2–CH2–CH2–NH–), 27.84
(C(CH3)3), 27.50 (C(CH3)3); MS (MALDI) was calculated to be
925.1 for C48H62N9O10 (M+H+), and found to be 924.9.
4.2.1.8. N6 -Dimethylaminomethylene-20-O-(N,N0-di-boc-guani-
dinopropyl)-50-O-(4,40-dimethoxytrityl)-adenosine 30-(cyano-
ethyl)-N,N-diisopropyl phosphoramidite (1d). N6-Dimeth-
ylaminomethylene-20-O-(N,N0-di-boc-guanidinopropyl)-50-O-(4,40-
dimethoxytrityl)-adenosine (1i) (320 mg, 346 lmol) was dissolved
in dichloromethane (8 mL). 2-cyanoethyl N,N,N0,N0-tetraisopro-
pylamino phosphane (132 lL, 415 lmol) and 4,5-dicyanoimidaz-
ole (47 mg, 398 lmol) were added. The mixture was stirred at
room temperature. After 3 h, TLC revealed that some starting mate-
rial did not react. An additional 0.6 equiv of the phosphitylating
agent as well as the catalyst were therefore added. After 4 h the
reaction was complete. The mixture was diluted with dichloro-
methane, washed with saturated sodium bicarbonate solution
and the organic layer was dried over MgSO4. The solvent was evap-
orated and the residue dissolved in a small amount of dichloro-
methane (ca. 5 mL). This solution was added dropwise into a
ﬂask with hexane (500 mL) to form a white precipitate. Two thirds
of the solvent were evaporated and the remaining solvent was dec-
anted from the solid. The precipitated product was redissolved in
benzene and lyophilised to give 329 mg (84%) of 1d as a white
powder. 1H NMR (300 MHz, acetone-d6) d [ppm] 11.65 (s, 1H,
NH-boc) 8.95–8.93 (m, 1H, N6 = CH–NMe2), 8.42–8.27 (m, 3H, H2,
H3, NH–CH2–), 7.50–7.46 (m, 2H, DMTr), 7.38–7.17 (m, 7H, DMTr),
6.87–6.80 (m, 4H, DMTr), 6.28–6.26 (m, 1H, H10), 4.96–4.79 (m, 2H,
H20, H30) 4.45–4.37 (m, 1H, H40), 4.05–3.35 (m, 16H), 3.25 (s, 3H, N–
CH3), 3.18 (s, 3H, N–CH3), 2.85 (m, 1H, cyanoethyl), 2.64–2.60 (m,
1H, cyanoethyl), 1.90–1.82 (m, 2H, O–CH2–CH2–CH2–NH–), 1.50–
1.49 (m, 9H, C(CH3)3), 1.42–1.40 (m, 9H, C(CH3)3), 1.25–1.10 (m,
12H, iPr-CH3); 31P NMR (121 MHz, acetone-d6) d [ppm] 149.6,
149.3; MS (ESI) was calculated to be 1125.3 for C57H79N11O11P
(M+H+), and found to be 1125.7.
4.2.2. Synthesis of the 20-O-guanidinopropyl cytidine
phosphoramidite
N4-Dimethylaminomethylene-30,50-O-(tetraisopropyldisilox-
ane-1,3-diyl)-cytidine (2a) was synthesised according to a previ-
ously described procedure.37
4.2.2.1. N4 -Dimethylaminomethylene-20-O-cyanoethyl-30,50-O-
(tetraisopropyldisiloxane-1,3-diyl)-cytidine (2e). Com-
pound 2a (4 g, 7.39 mmol) was dissolved in acrylonitrile (8 mL,
122 mmol) and tert-Butanol (35 mL). Cesium carbonate (1.8 g,
5.52 mmol) was added and the reaction was stirred for 2.5 h at
room temperature. The mixture was ﬁltered over celite, the sol-
vents evaporated, and then the residue was puriﬁed using column
chromatography. Ethyl acetate was initially used as solvent then
changed to ethyl acetate/methanol (9:1, v/v) after the unpolar
impurities had passed through the column. A yield of 3.78 g
(86%) of the product were obtained. 1H NMR (400 MHz,
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J = 7.3 Hz, H6), 5.90 (d, 1H, J = 7.3 Hz, H5), 5.65 (s, 1H, H10), 4.22–
3.91 (m, 7H), 3.17 (s, 3H, N–CH3), 3.04 (s, 3H, N–CH3), 2.86–2.82
(m, 2H, O–CH2–CH2–CN), 1.07–0.96 (m, 28H, tetraisopropyl-CH
and -CH3); 13C NMR (101 MHz, DMSO-d6) d [ppm] 171.21 (C4),
157.77 (N4 = CH–NMe2), 154.57 (C2), 140.61 (C6), 118.86 (O–
CH2–CH2–CN), 101.14 (C5), 88.99 (C10), 81.42, 80.69, 67.83, 65.22
(O–CH2–CH2–CN), 59.39 (C50), 40.79 (N–CH3),34.71 (N–CH3),
18.18 (O–CH2–CH2–CN), {17.22, 17.11, 17.04, 16.97, 16.84, 16.72,
16.69, 16.61} (tetraisopropyl-CH3), {12.60, 12.20, 11.88} (tetraiso-
propyl-CH); MS (ESI) was calculated to be 594.9 for C27H48N5O6Si2
(M+H+) and found to be 594.9.
4.2.2.2. 20-O-Cyanoethyl-30,50-O-(tetraisopropyldisiloxane-1,3-
diyl)-cytidine (2b). N4-Dimethylaminomethylene-20-O-cya-
noethyl-30,50-O-(tetraisopropyldisiloxane-1,3-diyl)-cytidine (2e)
(1.0 g, 1.68 mmol) was dissolved in methanol (10 mL) and hydra-
zine hydrate (500 lL, 10.3 mmol) was added. The mixture was stir-
red for 1 h at room temperature and then the solvents were
evaporated. The residue was puriﬁed on a silica gel column with
ethyl acetate/methanol (95:5, v/v) to give 745 mg (82%) of 2b. 1H
NMR (400 MHz, DMSO-d6) d [ppm] 7.69 (d, 1H, J = 7.4 Hz, H6),
7.21 (s, 2H, NH2), 5.69 (d, 1H, J = 7.4 Hz, H5), 5.61 (s, 1H, H10);
4.19–3.90 (m, 7H), 2.90–2.76 (m, 2H, O–CH2–CH2–CN), 1.07–0.97
(m, 28 H, tetraisopropyl-CH and -CH3); 13C NMR (101 MHz,
DMSO-d6) d [ppm] 165.70, 154.60, 139.36 (C6), 118.89, 93.30
(C5), 88.66 (C10), 81.55 (C20), 80.49, 67.92, 65.19 (O–CH2–CH2–
CN), 59.44 (C50), 18.20 (O–CH2–CH2–CN), {17.23, 17.11, 17.05,
16.98, 16.85, 16.73, 16.72, 16.63} (tetraisopropyl-CH3), {12.62,
12.28, 12.21, 11.88} (tetraisopropyl-CH); MS (ESI) was calculated
to be 539.8 for C24H43N4O6Si2 (M+H+) and found to be 540.0.
4.2.2.3. 20-O-Aminopropyl-30,50-O-(tetraisopropyldisiloxane-1,3-
diyl)-cytidine (2f). Compound 2b (500 mg, 928 lmol) was
dissolved in 10 mL of methanol in a glass tube. Approximately
0.5 mL of the Raney-nickel sediment was washed thoroughly with
dry methanol and was rinsed into the glass tube with the solution
of 2b. After addition of 5 mL methanol saturated with ammonia,
the mixture was stirred for 1 h at room temperature under a
hydrogen atmosphere (30 bar). The reaction mixture was ﬁltered
through celite and the catalyst was washed several times with
methanol. The solvent was evaporated and the residue was puri-
ﬁed on a silica gel column using ethyl acetate/methanol/triethyl-
amine (60:35:5) to give 251 mg (50%) of the product. When this
procedure was repeated, the crude material after ﬁltration and
evaporation was used in further reactions without puriﬁcation.
1H NMR (400 MHz, DMSO-d6) d [ppm] 7.69 (d, 1H, J = 7.2 Hz, H6),
7.18 (bs, 2H, ar. NH2), 5.68 (d, 1H, J = 7.5 Hz, H5), 5.60 (s, 1H,
H10), 4.18–3.76 (m, 7H), 2.70–2.66 (m, 2H, O–CH2–CH2–CH2–
NH2), 1.68–1.61 (m, 2H, O–CH2–CH2–CH2–NH2), 1.07–0.95 (m, 28
H, tetraisopropyl-CH and -CH3); MS (MALDI) was calculated to be
643.8 for C24H47N4O6Si2 (M+H+) and found to be 544.6.
4.2.2.4. 20-O-(N,N0-Di-boc-guanidinopropyl)-30,50-O-(tetra-
isopropyldisiloxane-1,3-diyl)-cytidine (2c). N,N0-Di-boc-N00-
triﬂyl guanidine (360 mg, 920 lmol) was dissolved in 5 mL dichlo-
romethane and triethylamine (125 lL) then added. After cooling to
0 C, compound 2f (500 mg, 922 lmol) was added and the solution
was stirred for 1 h at 0 C and then 1 h at room temperature. The
reaction was diluted with dichloromethane and washed with satu-
rated sodium bicarbonate solution and brine. The combined organ-
ic layers were dried over Na2SO4 and after evaporating the solvent
the residue was puriﬁed using column chromatography with
dichloromethane/methanol (98:2–95:5, v/v) to give 434 mg (60%)
of 2c. 1H NMR (400 MHz, DMSO-d6) d [ppm] 11.48 (s, 1H, NH-
boc), 8.38–8.35 (m, 1H, NH–CH2–), 7.67 (d, 1H, J = 7.4 Hz, H6),7.19 (bs, 2H, NH2), 5.68 (d, 1H, J = 7.4 Hz, H5), 5.63 (s, 1H, H10),
4.17–3.78 (m, 7H), 3.49–3.33 (m, 2H, O–CH2–CH2–CH2–NH–),
1.84–1.77 (m, 2H, O–CH2–CH2–CH2–NH–), 1.45 (m, 9H, C(CH3)3),
1.38 (m, 9H, C(CH3)3), 1.06–0.96 (m, 28 H, tetraisopropyl-CH and
-CH3); 13C NMR (101 MHz, DMSO-d6) d [ppm] 165.61, 162.99,
155.04, 154.52, 151.94, 139.45 (C6), 93.21 (C5), 88.97 (C10),
82.66, 81.76 (C20), 80.36 (C40), 77.86, 69.11 (O–CH2–CH2–CH2–
NH–), 68.27 (C30), 59.51 (C50), 38.28 (O–CH2–CH2–CH2–NH–),
28.61 (O–CH2–CH2–CH2–NH–), 27.86 (C(CH3)3), 27.44 (C(CH3)3),
{17.22, 17.10, 17.03, 16.96, 16.83, 16.70, 16.68, 16.60} (tetraisopro-
pyl-CH3), {12.59, 12.26, 12.21, 11.87} (tetraisopropyl-CH); MS
(MALDI) was calculated to be 786.1 for C35H65N6O10Si2 (M+H+)
and found to be 786.4.
4.2.2.5. N4 -Benzoyl-20-O-(N,N0-di-boc-guanidinopropyl)-30,50-O-
(tetraisopropyldisiloxane-1,3-diyl)-cytidine (2g). Com-
pound 2c (1.0 g, 1.27 mmol) was dissolved in dry pyridine
(10 mL) and the solution was cooled in an ice bath. Benzoyl chlo-
ride (240 lL, 2.06 mmol) was added and the reaction solution
was stirred at 0 C for 1 h. The reaction was quenched with water
and ammonia (25% in water; 3 mL) was added. The mixture was
then stirred for 30 min at room temperature. The solvents were
evaporated and the residue was dissolved in dichloromethane
and washed with saturated sodium bicarbonate solution. The or-
ganic layer was dried over Na2SO4 and after evaporating the sol-
vent, the residue was puriﬁed by column chromatography using
dichloromethane/methanol (98:2, v/v) and 950 mg (84%) of the
product were obtained. 1H NMR (400 MHz, DMSO-d6) d [ppm]
11.50 (s, 1H, NH), 11.31 (s, 1H, NH), 8.40–8.37 (m, 1H, NH–CH2–),
8.15 (d, 1H, J = 7.3 Hz, H6), 8.03–7.99 (m, 2H, benzoyl), 7.65–7.60
(m, 1H, benzoyl), 7.53–7.49 (m, 2H, benzoyl), 7.38 (d, 1H,
J = 7.3 Hz, H5), 5.73 (s, 1H, H10), 4.24–4.13 (m, 3H, H30, H40, H50),
4.02–4.03 (m, 1H, H20), 3.97–3.92 (m, 1H, H50), 3.87–3.83 (m, 2H,
O–CH2–CH2–CH2–NH–), 3.52–3.35 (m, 2H, O–CH2–CH2–CH2–NH–
), 1.87–1.80 (m, 2H, O–CH2–CH2–CH2–NH–), 1.45 (m, 9H,
C(CH3)3), 1.38 (m, 9H, C(CH3)3), 1.08–0.95 (m, 28H, tetraisopro-
pyl-CH and -CH3); 13C NMR (101 MHz, DMSO-d6) d [ppm] 167.21,
163.14, 163.00, 155.06, 154.01, 151.97, 143.37 (C6), 132.97,
132.64, 128.31, 95.61 (C5), 89.46 (C10), 82.67, 81.30 (C20), 80.86
(C40), 77.86, 69.26 (O–CH2–CH2–CH2–NH–), 67.95 (C30), 59.38
(C50), 38.28 (O–CH2–CH2–CH2–NH–), 28.62 (O–CH2–CH2–CH2–
NH–), 27.86 (C(CH3)3), 27.43 (C(CH3)3), {17.22, 17.11, 17.04,
16.97, 16.89, 16.73, 16.71, 16.66} (tetraisopropyl-CH3), {12.56,
12.29, 12.22, 11.86} (tetraisopropyl-CH); MS (ESI) was calculated
to be 890.2 for C42H69N6O11Si2 (M+H+), and found to be 890.4.
4.2.2.6. N4-Benzoyl-20-O-(N,N0-di-boc-guanidinopropyl)-cytidine
(2h). N4-Benzoyl-20-O-(N,N0-di-boc-guanidinopropyl)-30,50-O-
(tetraisopropyldisiloxane-1,3-diyl)-cytidine (2g) (900 mg,
1.01 mmol) was dissolved in tetrahydrofurane (20 mL). Triethyl-
amine trihydroﬂuoride (Et3N3HF; 560 lL, 3.54 mmol) was added
and the solution was stirred at room temperature for 2 h. The sol-
vent was evaporated and the residue was puriﬁed using column
chromatography with dichloromethane/methanol (98:2–97:3, v/
v) to give 607 mg (93%) of the product as a pale yellow foam. 1H
NMR (300 MHz, DMSO-d6) d [ppm] 11.50 (s, 1H, NH), 11.28 (bs,
1H, NH), 8.57 (d, 1H, J = 7.5 Hz, H6), 8.40–8.35 (m, 1H, NH–CH2–),
8.02–7.98 (m, 2H, benzoyl), 7.66–7.60 (m, 1H, benzoyl), 7.54–
7.48 (m, 2H, benzoyl), 7.34 (d, 1H, J = 7.2 Hz, H5), 5.86–5.85 (m,
1H, H10), 5.24 (t, 1H, J = 5.0 Hz, 50-OH), 4.98 (d, 1H, J = 6.8 Hz,
30-OH), 4.12–3.60 (m, 7H), 3.44–3.37 (m, 2H, O–CH2–CH2–CH2–
NH–), 1.85–1.76 (m, 2H, O–CH2–CH2–CH2–NH–), 1.46 (m, 9H,
C(CH3)3), 1.38 (m, 9H, C(CH3)3); 13C NMR (75 MHz, acetone-d6) d
[ppm] 169.22, 165.59, 164.82, 157.83, 156.15, 154.80, 147.10
(C6), 135.58, 134.60, 130.46, 130.05, 97.67 (C5), 91.39 (C10),
86.19 (C40), 84.69 (C(CH3)3), 84.62 (C20), 79.88 (C(CH3)3), 70.71
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CH2–CH2–NH–), 30.86 (O–CH2–CH2–CH2–NH–), 29.46 (C(CH3)3),
29.14 (C(CH3)3); HRMS (MALDI) was calculated to be 647.3035
for C30H43N6O10 (M+H+), and found to be 647.3031.
4.2.2.7. N4-Benzoyl-20-O-(N,N 0-di-boc-guanidinopropyl)-50-O-
(4,40-dimethoxytrityl)-cytidine (2i). N4-Benzoyl-20-O-(N,N0-
di-boc-guanidinopropyl)-cytidine (2h) (516 mg, 798 lmol) was
dissolved in dry pyridine (20 mL) and the solution was cooled in
an ice bath. 4,40-Dimethoxytrityl chloride (515 mg, 1.52 mmol)
was added and the mixture was stirred overnight while the bath
came up to room temperature. The reaction was quenched with
methanol (10 mL) and the solvents were evaporated. The residue
was puriﬁed by column chromatography using dichloromethane/
methanol (99:1–98:2, v/v). The column was packed with solvent
containing 1% triethylamine to yield 715 mg (94%) of the product
as a pale yellow foam. 1H NMR (400 MHz, DMSO-d6) d [ppm]
11.50 (s, 1H, NH), 11.29 (bs, 1H, NH), 8.43–8.37 (m, 2H, H6, NH–
CH2–), 8.02–7.99 (m, 2H, benzoyl), 7.65–7.60 (m, 1H, benzoyl),
7.54–7.50 (m, 2H, benzoyl), 7.43–7.25 (m, 9H, DMTr), 7.18–7.15
(m, 1H, H5), 6.94–6.91 (m, 4H, DMTr), 5.88 (s, 1H, H10), 5.04 (d,
1H, J = 7.3 Hz, 30-OH), 4.34–4.28 (m, 1H, H30), 4.13–4.10 (m, 1H,
H40), 3.94–3.87 (m, 2H, H20, 1  O–CH2–CH2–CH2–NH–), 3.76 (s,
6H, 2  OCH3), 3.76–3.70 (m, 1H, 1  O–CH2–CH2–CH2–NH–),
3.46–3.36 (m, 4H, 2  H50, O–CH2–CH2–CH2–NH–), 1.86–1.80 (m,
2H, O–CH2–CH2–CH2–NH–), 1.42 (m, 9H, C(CH3)3), 1.36 (m, 9H,
C(CH3)3); 13C NMR (75 MHz, DMSO-d6) d [ppm] 167.19, 163.02,
158.11, 158.08, 155.12, 154.07, 151.93, 144.24 (C6), 135.47,
135.11, 133.06, 132.62, 129.70, 129.55, 128.35, 127.85, 127.73,
126.78, 113.19, 95.93 (C5), 88.99 (C10), 85.90, 82.67 (C(CH3)3),
81.93 (C20), 81.44 (C40), 77.94 (C(CH3)3), 68.44 (O–CH2–CH2–CH2–
NH–), 67.62 (C30), 61.36 (C50), 54.91 (OCH3), 54.90 (OCH3), 38.17
(O–CH2–CH2–CH2–NH–), 28.59 (O–CH2–CH2–CH2–NH–), 27.87
(C(CH3)3), 27.48 (C(CH3)3); HRMS (MALDI) was calculated to be
971.4161for C51H60N6O12Na (M+Na+), and found to be 971.4181.
4.2.2.8. N4-Benzoyl-20-O-(N,N 0-di-boc-guanidinopropyl)-50-O-
(4,40-dimethoxytrityl)-cytidine 30-(cyanoethyl)-N,N-diisopropyl
phosphoramidite (2d). Compound 2i (683 mg, 720 lmol)
was dissolved in dichloromethane (15 mL). 2-cyanoethyl
N,N,N0,N0-tetraisopropylamino phosphane (274 lL, 864 lmol) and
4,5-dicyanoimidazole (98 mg, 828 lmol) were added. After stirring
at room temperature for 5 h, TLC revealed that some starting mate-
rial had not reacted. Therefore 10 mg of 4,5-dicyanoimidazole and
30 lL of the phosphitylation agent were added and the reaction
was stirred at room temperature overnight. The solution was di-
luted with dichloromethane and washed with saturated sodium
bicarbonate solution. After drying the organic layer over MgSO4
the solvent was evaporated and the residue was dissolved in a
small amount (5 mL) of dichloromethane. This solution was
dripped into a ﬂask with hexane (500 mL) to form a white precip-
itate. Two thirds of the solvent was evaporated and the residual
solvent was decanted carefully. The precipitate was redissolved
in benzene and lyophilised to give 738 mg (89%) of 2d. According
to 31P NMR spectrum the product was still containing a small
amount of the hydrolysed phosphitylation reagent but this did
not interfere with the oligonucleotide synthesis. 1H NMR
(400 MHz, DMSO-d6) d [ppm] 11.50–11.48 (m, 1H, NH), 11.25
(bs, 1H, NH), 8.52–8.45 (m, 1H, H6), 8.39–8.34 (m, 1H, NH–CH2–),
8.01–7.98 (m, 2H, benzoyl), 7.66–7.61 (m, 1H, benzoyl), 7.53–
7.49 (m, 2H, benzoyl), 7.45–7.25 (m, 9H, DMTr), 7.13–7.09 (m,
1H, H5), 6.93–6.89 (m, 4H, DMTr), 5.95–5.92 (m, 1H, H10), 4.56–
4.38 (m, 1H, H30), 4.31–4.28 (m, 1H, H40), 4.07–3.29 (m, 17H),
2.90–2.57 (m, 2H, cyanoethyl), 1.86–1.78 (m, 2H, O–CH2–CH2–
CH2–NH–), 1.40–1.35 (m, 18H, 2  C(CH3)3), 1.20–0.93 (m, 12H,
iPr-CH3); 31P NMR (162 MHz, DMSO-d6) d [ppm] 148.4, 148.0(The signal of the hydrolysed phosphitylation reagent appears at
13.9 ppm); HRMS (MALDI) was calculated to be 1149.5421 for
C60H78N8O13P (M+H+), was found to be 1149.5447.
4.2.3. Synthesis of the 20-O-guanidinopropyl uridine
phosphoramidite
N3-Benzoyl-30,50-O-(tetraisopropyldisiloxane-1,3-diyl)-uridine
(3a) was synthesised according to a previously described
procedure.22
4.2.3.1. N3-Benzoyl-20-O-cyanoethyl-30,50-O-(tetraisopropyl-
disiloxane-1,3-diyl)-uridine (3b). Compound 3a (1.14 g,
1.93 mmol) was dissolved in 9.6 mL of tert-butanol. Freshly dist-
iled acrylonitrile (2.5 mL, 38.6 mmol) was added. After addition
of cesium carbonate (645 mg, 1.98 mmol) the reaction was stirred
for 4 h at room temperature. The reaction solution was ﬁltered
over celite. The residue was washed with 100 mL of dichlorometh-
ane. The ﬁltrate was evaporated in vacuum. Puriﬁcation via
column chromatography in dichloromethane/ethyl acetate
(99:1–95:5, v/v) yielded 746 mg (60%) of the desired product as
a white powder. 1H NMR (250 MHz, acetone-d6) d [ppm] 8.03–
7.99 (m, 3H, H6, benzoyl), 7.79–7.72 (m, 1H, benzoyl), 7.61–7.55
(m, 2H, benzoyl), 5.80–5.74 (m, 2H, H5, H10), 4.50–3.94 (m, 7H),
2.80–2.75 (m, 2H, O–CH2–CH2–CN), 1.17–1.07 (m, 28H, tetraiso-
propyl-CH and -CH3); 13C NMR (63 MHz, acetone-d6) d [ppm]
171.11, 163.78, 151.06, 141.48, 136.94, 133.92, 132.20, 131.13,
119.80, 102.75, 91.47, 84.05, 83.69, 70.65, 68.08, 61.60, 20.35,
18.92, 18.91, 18.75, 18.73, 18.64, 18.50, 18.46, 18.40, 15.23,
14.79, 14.72, 14.43; HRMS (XXX) was calculated to be 666.2637
for C31H45N3O8Si2Na (M+Na+) and found to be 666.2647.
4.2.3.2. 20-O-(Aminopropyl)-30,50-O-(tetraisopropyldisiloxane-
1,3-diyl)-uridine (3e). Compound 3b (500 mg, 0.78 mmol)
was dissolved in 10 mL of methanol in a glass tube suitable for
the applied autoclave. Approximately 0.5 mL of the Raney-nickel
slurry was put on a glass ﬁlter, washed thoroughly with dry meth-
anol and rinsed into the glass tube with the solution of 3b. After
addition of 5 mL methanol saturated with ammonia, the mixture
was stirred for 1 h at room temperature in an autoclave under a
hydrogen atmosphere (30 bar). The reaction solution was decanted
from the catalyst into a glass ﬁlter. The catalyst was washed sev-
eral times with methanol and the solvent was removed from the
combined ﬁltrates under reduced pressure. The product was puri-
ﬁed on a silica gel column initially using dichloromethane/ethyl
acetate (7:3–0:1, v/v) and thereafter ethyl acetate/methanol/tri-
ethylamine (6: 3.5: 0.5, v/v/v) to obtain 253 mg (60%) of a white
powder. When we repeated the reduction we used the crude prod-
uct after ﬁltration and evaporation for further derivatisation. 1H
NMR (250 MHz, acetone-d6) d [ppm] 7.81 (d, 1H, J = 8.1 Hz, H6),
5.71 (s, 1H, H10), 5.53 (d, 1H, J = 8.1 Hz, H5), 4.39–4.34 (m, 1H,
H30), 4.28–4.23 (m, 1H, H50), 4.14–4.03 (m, 3H, H20, H40, H50),
3.97–3.81 (m, 2H, O–CH2–CH2–CH2–NH2), 3.37–3.25 (m, 2H, O–
CH2–CH2–CH2–NH2), 1.92–1.82 (m, 2H, O–CH2–CH2–CH2–NH2),
1.14–1.05 (m, 28H, tetraisopropyl-CH and -CH3); 13C NMR
(63 MHz, acetone-d6) d [ppm] 167.18, 164.59, 151.93, 141.033,
102.82, 91.15, 83.77, 83.50, 70.88, 70.85, 61.78, 49.36, 33.03,
18.91, 18.90, 18.74, 18.61, 18.49, 18.47, 18.40, 15.19, 14.82,
14.71, 14.41; HRMS (MALDI) was calculated to be 544.2869 for
C24H46N3O7Si2 (M+H+), and found to be 544.2880.
4.2.3.3. 20-O-(N,N 0-Di-boc-guanidinopropyl)-30,50-O-(tetra-
isopropyldisiloxane-1,3-diyl)-uridine (3c). N,N0-Di-boc-N00-
triﬂyl guanidine (320 mg, 0.82 mmol) was dissolved in 3.6 mL
dichloromethane and triethylamine (150 lL) was added. The solu-
tion was cooled in an ice bath and 20-O-(aminopropyl)-30,50-O-(tet-
raisopropyldisiloxane-1,3-diyl)-uridine (3e) (490 mg, 0.9 mmol)
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the ice bath was and stirred for 2.5 h at room temperature. The
reaction solution was washed with saturated sodium bicarbonate
solution and brine. After drying over Na2SO4 the solvent was evap-
orated in vacuum. The crude product was puriﬁed using column
chromatography with dichloromethane/methanol (96:4–94:6, v/
v). 410 mg (58%) of compound 3c were obtained. 1H NMR
(400 MHz, DMSO-d6) d [ppm] 11.49 (s, 1H, NH), 11.37 (m, 1H,
NHuridine), 8.40–8.37 (m, 1H, NH–CH2–), 7.64 (d, 1H, J = 7.9 Hz,
H6), 5.64 (s, 1H, H10), 5.53 (d, 1H, J = 7.9 Hz, H5), 4.25–4.22 (H30),
4.13–4.09 (m, 1H, H50), 4.06–4.05 (m, 1H, H20), 4.03–4.00 (m, 1H,
H40), 3.93–3.89 (m, 1H, H50), 3.84–3.70 (m, 2H, O–CH2–CH2–CH2–
NH–), 3.49–3.32 (m, 2H, O–CH2–CH2–CH2–NH–), 1.83–1.77 (m,
2H, O–CH2–CH2–CH2–NH–), 1.45 (s, 9H, C(CH3)3), 1.38 (s, 9H,
C(CH3)3), 1.06–0.97 (m, 28H, tetraisopropyl-CH and -CH3); HRMS
(MALDI) was calculated to be 808.3955 for C35H63N5O11Si2Na
(M+Na+), and found to be 808.3991.
4.2.3.4. 20-O-(N,N0-Di-boc-guanidinopropyl)-uridine (3f). To
a solution of compound 3c (910 mg, 1.16 mmol) and triethylamine
(240 lL) in 13 mL tetrahydrofurane NEt33HF (700 lL, 4.3 mmol)
was added. The reaction mixture was stirred for 1 h at room
temperature. The solvents were evaporated and the residue was
puriﬁed on a silica gel column using dichloromethane/methanol
(93:7–92:8, v/v) to give 629 mg (97%) of a white foam. 1H NMR
(250 MHz, acetone-d6) d [ppm] 11.67 (bs, 1H, NH), 10.03 (bs, 1H,
NH), 8.46–8.41 (m, 1H, NH–CH2–), 8.10 (d, 1H, J = 8.2 Hz, H6),
5.99–5.97 (m, 1H, H10), 5.58 (d, 1H, J = 8.2 Hz, H5), 4.39–3.46 (m,
11H), 1.95–1.85 (m, 2H, O–CH2–CH2–CH2–NH–), 1.51 (s, 9H,
C(CH3)3), 1.43 (s, 9H, C(CH3)3); 13C NMR (63 MHz, acetone-d6) d
[ppm] 165.64, 164.59, 157.88, 154.86, 152.37, 142.33, 103.31,
89.82, 86.67, 84.77, 84.74, 84.39, 79.91, 70.73, 70.69, 62.45,
40.20, 30.96, 29.51, 29.19; MS (ESI) was calculated to be 566.2
for C23H37N5O10Na (M+Na+), and found to be 567.0.
4.2.3.5. 20-O-(N,N 0-Di-boc-guanidinopropyl)-50-O-(4,40-dime-
thoxytrityl)-uridine (3g). 20-O-(N,N0-Di-boc-guanidinopro-
pyl)-uridine (3f) (588 mg, 1.08 mmol) was dissolved in 11.4 mL of
dry pyridine and 4,40-dimethoxytrityl chloride (460 mg, 1.36 mmol)
was added. The reaction solution was stirred at room temperature
for 5 h. The reaction mixture was quenched with water and the sol-
vents were evaporated. The residue was dissolved in dichlorometh-
ane, washed twice with saturated sodium bicarbonate solution
(2  50 mL) and then twice with brine (2  50 mL). The organic
layer was dried over Na2SO4 and the solvent was removed under re-
duced pressure. After puriﬁcation using column chromatography
with dichloromethane/methanol (97:3, v/v) containing 0.5% trieth-
ylamine, 785 mg (86%) of a yellowpowderwas obtained. The yellow
impurity could not be separated on the column. 1H NMR (250 MHz,
DMSO-d6) d [ppm] 11.49 (s, 1H, NH), 11.37 (m, 1H, NH), 8.41–8.36
(m, 1H, NH–CH2–), 7.75 (d, 1H, J = 8.1 Hz, H6), 7.40–7.23 (m, 9H,
DMTr), 6.92–6.88 (m, 4H, DMTr), 5.83–5.82 (m, 1H, H10), 5.29–
5.25 (m, 1H, H5), 5.09–5.06 (m, 1H, 30-OH), 4.23–3.88 (m, 3H),
3.74 (s, 6H, 2  O–CH3), 3.68–3.63 (m, 2H), 3.43–3.20 (m, 4H),
1.82–1.72 (m, 2H, O–CH2–CH2–CH2–NH–), 1.44 (s, 9H, C(CH3)3),
1.37 (s, 9H, C(CH3)3); HRMS (MALDI) was calculated to be
846.3920 for C44H56N5O12 (M+H+), and found to be 846.3946.
4.2.3.6. 20-O-(N,N 0-Di-boc-guanidinopropyl)-50-O-(4,40-dime-
thoxytrityl)-uridine 30-(cyanoethyl)-N,N-diisopropyl phospho-
ramidite (3d). 20-O-(N,N0-Di-boc-guanidinopropyl)-50-O-
(4,40-dimethoxytrityl)-uridine (3g) (770 mg, 0.9 mmol) was dis-
solved in dichloromethane (11 mL). To this solution, 2-cyanoethyl
N,N,N0,N0-tetraisopropylamino phosphane (400 lL, 1.26 mmol)
and 4,5-dicyanoimidazole (130 mg, 1.1 mmol) were added. The
reaction progress was observed with TLC (dichloromethane/ethylacetate 1:1 (v:v), containing 0.5% triethylamine). Because the reac-
tion was not complete after 2 h, an additional 0.3 equiv of the re-
agents were added and the reaction was completed after
additional 40 min. The resulting solution was washed twice with
saturated sodium bicarbonate solution (2  100 mL) and once with
brine (200 mL). After drying over Na2SO4, the solvent was evapo-
rated and the residue was puriﬁed on a silica gel column with
dichloromethane/ethyl acetate (6:4–1:1, v/v) containing 0.5% tri-
ethylamine. The mixture of the two diastereomers was obtained
as a light yellow foam (762 mg, 83%). 1H NMR (400 MHz, DMSO-
d6) d [ppm] 11.50–11.48 (m, 1H, NH), 11.35 (bs, 1H, NH), 8.39–
8.33 (m, 1H, NH–CH2–), 7.87–7.80 (m, 1H, H6), 7.41–7.22 (m, 9H,
DMTr), 6.91–6.86 (m, 4H, DMTr), 5.86–5.84 (m, 1H, H10), 5.23–
5.18 (m, 1H, H5), 4.46–4.32 (m, 1H), 4.21–4.16 (m, 1H), 4.09–4.03
(m, 1H), 3.83–3.26 (m, 16H), 2.80–2.59 (m, 2H, –O–CH2–CH2–CN),
1.81–1.74 (m, 2H, O–CH2–CH2–CH2–NH–), 1.42–1.36 (m, 18H,
C(CH3)3), 1.13–0.94 (m, 12H, iPr-CH3); 31P NMR (121 MHz, DMSO-
d6) d [ppm] 150.0, 148.6; HRMS (MALDI) was calculated to be
1046,4999 for C53H73N7O13P (M+H+), and found to be 1046,5021.
4.2.4. Synthesis of the 20-O-guanidinopropyl guanosine
phosphoramidite
O6-(2,4,6-Triisopropylbenzenesulfonyl)-30,50-O-di-tert-buty-
lsilanediyl guanosine (4a) was synthesised according to a previ-
ously described procedure.21
4.2.4.1. 20-O-(2-Cyanoethyl)-30,50-O-di-tert-butylsilanediyl gua-
nosine (4b). Compound 4a (2.28 g, 3.3 mmol) was dissolved
in tert-butanol (17 mL). Freshly distiled acrylonitrile (4.25 mL,
66 mmol) and cesium carbonate (1.16 g, 3.3 mmol) were added
to the solution. After vigorous stirring at room temperature for
2–3 h, the mixture was ﬁltered through celite. The solvent and ex-
cess reagents were removed in vacuum. The crude material was
used for the next reaction without further puriﬁcation. The residue
was dissolved in 4 mL of a mixture of formic acid/dioxane/water
(70:24:6, v/v/v). After stirring at room temperature for 1 h, water
(150 mL) was added to the mixture and the solution extracted with
dichloromethane. The organic layer was dried over Na2SO4 and the
solvent was evaporated. The residue was puriﬁed using column
chromatography with dichloromethane/methanol (9:1, v/v) to give
1.1 g (70% over two steps) of 4b as a colourless foam. 1H NMR
(250 MHz, DMSO-d6) d [ppm] 10.71 (bs, 1H, NH), 7.89 (s, 1H, H8),
6.45 (bs, 2H, NH2), 5.81 (s, 1H, H10), 4.45–4.33 (m, 3H), 4.05–3.81
(m, 4H), 2.83–2.76 (m, 2H, O–CH2–CH2–CN), 1.06 (s, 9H, C(CH3)3),
1.01 (s, 9H, C(CH3)3); 13C NMR (63 MHz, DMSO-d6) d [ppm]
156.51, 153.69, 150.50, 135.36, 118.71, 116.53, 87.25, 80.31,
76.35, 73.80, 66.64, 65.14, 27.12, 26.80, 22.07, 19.82, 18.29; MS
(ESI) was calculated to be 477.2 for C21H33N6O5Si (M+H+), and
found to be 477.5.
4.2.4.2. 20-O-(2-Aminopropyl)-30,50-O-di-tert-butylsilanediyl
guanosine (4e). Compound 4b (500 mg, 1.06 mmol) was dis-
solved in dry methanol (5 mL). Raney nickel (ca. 0.5 mL of the
methanol-washed sediment) and methanol (5 mL) saturated with
ammonia were then added. The mixture was hydrogenated at
30 bar hydrogen-pressure for 1 h at room temperature. Thereafter
the mixture was ﬁltered through a glass ﬁlter and the catalyst was
washed several times with methanol and a methanol/water mix-
ture. The solvents were evaporated from the ﬁltrate and the resi-
due was used without further puriﬁcation for the next reaction.
MS (ESI) was calculated to be 481.3 for C21H37N6O5Si (M+H+),
and found to be 481.8.
4.2.4.3. 20-O-(N,N0-Di-boc-guanidinopropyl)-30,50-O-di-tert-buty-
lsilanediyl guanosine (4c). N,N0-Di-boc-N00-triﬂyl guanidine
(163 mg, 0.415 mmol) was dissolved in dichloromethane (2.1 mL)
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in an ice bath and then 20-O-(2-Aminopropyl)-30,50-O-di-tert-buty-
lsilanediyl guanosine (4e) (200 mg, 0.42 mmol) was added. After
30 min the reaction mixture was removed from the ice bath then
stirred for an additional 30 min at room temperature. The reaction
solution was washed with saturated sodium bicarbonate solution
and brine. After drying over Na2SO4 the solvent was evaporated.
The residue was puriﬁed by column chromatography using dichlo-
romethane/methanol (9:1, v/v) to give 270 mg (89%) of 4c. 1H NMR
(400 MHz, DMSO-d6) d [ppm] 11.49 (bs, 1H, NH), 10.66 (bs, 1H,
NH), 8.56–8.53 (m, 1H, NH–CH2–), 7.87 (s, 1H, H8), 6.39 (bs, 2H,
NH2), 5.86 (s, 1H, H10), 4.42–4.38 (m, 1H, H30), 4.30–4.27 (m, 2H,
H20, H50), 4.06–3.93 (m, 3H, H40, H50, ½  O–CH2–CH2–CH2–NH–),
3.72–3.67 (m, 1H, ½  O–CH2–CH2–CH2–NH–), 3.51–3.30 (m, 2H,
O–CH2–CH2–CH2–NH–), 1.84–1.77 (m, 2H, O–CH2–CH2–CH2–NH–
), 1.46 (s, 9H, –CO–C(CH3)3), 1.39 (s, 9H, –CO–C(CH3)3), 1.06 (s,
9H, –Si–C(CH3)3), 0.97 (s, 9H, –Si–C(CH3)3); HRMS (MALDI) was
calculated to be 723.3856 for C32H55N8O9Si (M+H+), and found to
be 723.3880.
4.2.4.4. N2-Isobutyryl-20-O-(N,N0-di-boc-guanidinopropyl)-30,50-
O-di-tert-butylsilanediyl guanosine (4f) and N2-Isobutyryl-20-
O-(N,N 0-di-boc-N00-isobutyryl-guanidinopropyl)-30,50-O-di-tert-
butylsilanediyl guanosine (4f⁄). A solution of compound 4c
(400 mg, 0.55 mmol) in 3.6 mL of pyridine was cooled in an ice
bath and isobutyryl chloride (145 lL, 1.37 mmol) was then added
dropwise. The mixture was stirred at 0 C for 1 h, then at room
temperature for 1 h and evaporated to dryness. The residue was
dissolved in 40 mL dichloromethane and washed twice with sat-
urated sodium bicarbonate solution (2  60 mL) and once with
brine (60 mL). The organic phase was dried over Na2SO4 and the
solvent was evaporated. The residue was puriﬁed by column
chromatography using dichloromethane/methanol (95:5–90:10,
v/v) to give 318 mg (ca. 70%) of a mixture of mono- and di-isobu-
tyryl derivative. 1H NMR (250 MHz, DMSO-d6) d [ppm] 12.12 (s,
1H, NH), 11.57–11.51 (m, NH, NH-boc), 10.53 (s, NH-boc⁄),
8.54–8.49 (m, 20-O–CH2–CH2–CH2–NH–), 8.25–8.22 (m, 1H, H8),
5.90–5.88 (m, 1H, H10), 4.42–3.42 (m, 9H), 2.85–2.72 (m, 1.5H, –
CH(CH3)2), 1.99–1.73 (m, 2H, 20-O–CH2–CH2–CH2–NH–), 1.47–
1.33 (m, 18H, 2  –CO–C(CH3)3), 1.15–0.99 (m, 27H, 2  –Si–
C(CH3)3, –CH(CH3)2, –CH(CH3)2⁄). As a result of the mixture com-
prising mono- and diisobutyryl derivatives, some of the integrals
could not be given as whole numbers. Thus, signals that depend
only on the diisobutyryl compound are marked with an asterisk.
MS (ESI) was calculated to be 793.4 for C36H61N8O10Si (M+H+),
and found to be 794.6.
4.2.4.5. N2-Isobutyryl-20-O-(N,N 0-di-boc-guanidinopropyl)-gua-
nosine (4g) and N2-Isobutyryl-20-O-(N,N0-di-boc-N 00-isobutyryl-
guanidinopropyl)-guanosine (4g⁄). A mixture of N2-Isobuty-
ryl-20-O-(N,N0-di-boc-guanidinopropyl)-30,50-O-di-tert-buty-
lsilanediyl guanosine (4f) and N2-Isobutyryl-20-O-(N,N0-di-boc-N00-
isobutyryl-guanidinopropyl)-30,50-O-di-tert-butylsilanediyl guano-
sine (4f⁄) (490 mg, ca. 592 lmol) was dissolved in dry tetrahydro-
furane (7 mL). Triethylamine (165 lL, 1.11 mmol) and Et3N3HF
(352 lL, 2.16 mmol) were then added. After stirring at room tem-
perature for 1 h the solvent was evaporated. The residue was puri-
ﬁed using column chromatography with dichloromethane/
methanol (9:1, v/v) to give 322 mg (ca. 79%) of a mixture of N2-iso-
butyryl-20-O-(N,N0-di-boc-guanidinopropyl)-guanosine and N2-Iso-
butyryl-20-O-(N,N0-di-boc-N00-isobutyryl-guanidinopropyl)-guano-
sine as white foam. A small sample of the mixture was separated
for NMR spectroscopy. NMR data is given for the mono-isobutyryl
compound. 1H NMR (400 MHz, DMSO-d6) d [ppm] 12.08 (s, 1H,
NH), 11.65 (s, 1H, NH), 11.46 (s, 1H, NH), 8.29 (s, 1H, H8), 8.28–
8.25 (m, 1H, NH–CH2–), 5.91 (d, 1H, J = 6.0 Hz, H10), 5.16 (d, 1H,J = 4.8 Hz, 30-OH), 5.06–5.03 (m, 1H, 50-OH), 4.36–4.29 (m, 2H,
H20, H30), 3.95–3.93 (m, 1H, H40), 3.67–3.46 (m, 4H, 2  H50, O–
CH2–CH2–CH2–NH–), 3.33–3.28 (m, 2H, O–CH2–CH2–CH2–NH–),
2.77 (sep, 1H, J = 6.8 Hz, –CH(CH3)2), 1.75–1.67 (m, 2H, O–CH2–
CH2–CH2–NH–), 1.45 (s, 9H, –CO–C(CH3)3), 1.37 (s, 9H, –CO–
C(CH3)3), 1.12 (d, 6H, J = 6.8 Hz, –CH(CH3)2); 13C NMR (63 MHz,
CDCl3) d [ppm] 178.72, 163.52, 156.12, 155.16, 153.39, 147.73,
147.05, 138.81, 122.49, 88.47, 86.74, 83.65, 82.28, 79.58, 70.69,
69.87, 62.66, 38.87, 36.39, 29.32, 28.28, 28.11, 18.96, 18.89; HRMS
(MALDI) was calculated to be 653.3253 for C28H45N8O10 (M+H+),
and found to be 653.3274.
4.2.4.6. N2-Isobutyryl-20-O-(N,N 0-di-boc-guanidinopropyl)-50-O-
(4,40-dimethoxytrityl)-guanosine (4h) and N2-Isobutyryl-20-O-
(N,N 0-di-boc-N00-isobutyryl-guanidinopropyl)-50-O-(4,40-dime-
thoxytrityl)-guanosine (4h⁄). A mixture of N2-Isobutyryl-20-
O-(N,N0-di-boc-guanidinopropyl)-guanosine (4g) and N2-Isobuty-
ryl-20-O-(N,N0-di-boc-N00-isobutyryl-guanidinopropyl)-guanosine
(4g⁄) (400 mg, ca. 583 lmol) was dissolved in dry pyridine (11 mL).
4,40-Dimethoxytrityl chloride (280 mg, 0.82 mmol) was added and
the solution was stirred for 3 h at room temperature. TLC revealed
that some starting material remained at this time and an additional
0.3 equiv of 4,40-Dimethoxytrityl chloride were therefore added.
When TLC demonstrated that the starting material had been con-
sumed, the reaction was quenched with water and the solvents
evaporated. The residue was puriﬁed by column chromatography
using dichloromethane/methanol (98:2, v/v) containing 0.5% tri-
ethylamine to give 427 mg (ca. 74%) of the desired products. 1H
NMR (400 MHz, DMSO-d6) d [ppm] 12.09 (s, 1H, NH), 11.58 (s,
1H, NH), 11.47 (s, 0.5H, NH-boc), 10.50 (s, 0.5H, NH–boc⁄), 8.33–
8.30 (m, 0.5H, 20-O–CH2–CH2–CH2–NH–), 8.15–8.12 (m, 1H, H8),
7.35–7.18 (m, 9H, DMTr), 6.84–6.80 (m, 4H, DMTr), 5.97–5.94
(m, 1H, H10), 5.15–5.13 (m, 1H, 30-OH), 4.42–4.37 (m, 1H, H20),
4.35–4.30 (m, 1H, H30), 4.09–4.03 (m, 1H, H40), 3.72 (s, 6H,
2  O–CH3), 3.69–3.47 (m, 2H, 20-O–CH2–CH2–CH2–NH–), 3.37–
3.26 (m, 3H, 20-O–CH2–CH2–CH2–NH–, H50), 3.17–3.13 (m, 1H,
H50), 2.79–2.73 (m, 1.5H, –CH(CH3)2), 1.77–1.67 (m, 2H, 20-O–
CH2–CH2–CH2–NH–), 1.43–1.35 (m, 18H, 2  –CO–C(CH3)3), 1.13–
1.10 (m, 6H, –CH(CH3)2), 1.00–0.98 (m, 3H, –CH(CH3)2⁄). As a result
of the mixture comprising mono- and diisobutyryl derivatives,
some of the integrals could not be given as whole numbers. Thus,
signals that depend only on the diisobutyryl compound are marked
with an asterisk. MS (ESI) was calculated to be 955.5 for
C49H63N8O12 (M+H+), and found to be 956.5.
4.2.4.7. N2 -Isobutyryl-20-O-(N,N0-di-boc-guanidinopropyl)-50-O-
(4,40-dimethoxytrityl)-guanosine 30-(cyanoethyl)-N,N-diisopro-
pyl phosphoramidite (4d) and N2-Isobutyryl-20-O-(N,N0-di-
boc-N00-isobutyryl-guanidinopropyl)-50-O-(4,40-dimethoxytrityl)-
guanosine 30-(cyanoethyl)-N,N-diisopropyl phosphoramidite
(4d⁄). A mixture of compounds 4h and 4h⁄ (380 mg, ca.
384 lmol) was dissolved in dichloromethane (8 mL), then 2-cya-
noethyl N,N,N0,N0-tetraisopropylamino phosphane (160 lL,
0.52 mmol) and 4,5-dicyanoimidazole (57 mg, 0.5 mmol) were
added. After 2 h TLC showed complete consumption of the starting
material. The reaction solution was then washed twice with satu-
rated sodium bicarbonate solution (2  50 mL) and once with
brine (100 mL). After drying over Na2SO4 the solvent was evapo-
rated and the residue was puriﬁed using column chromatography
with dichloromethane/ethyl acetate (8:2, v/v) containing 0.5% tri-
ethylamine to give 350 mg (ca. 76%) of the two diastereomers of
4d and 4d⁄. 1H NMR (400 MHz, DMSO-d6) d [ppm] 12.11 (bs, 1H,
NH), 11.61–11.57 (m, 1H, NH), 11.46–11.44 (m, 0.5H, NH-boc),
10.50–10.46 (m, 0.5H, NH-boc⁄), 8.31–8.27 (m, 0.5H, 20-O–CH2–
CH2–CH2–NH–), 8.18–8.14 (m, 1H, H8), 7.36–7.19 (m, 9H, DMTr),
6.85–6.80 (m, 4H, DMTr), 5.97–5.88 (m, 1H, H10), 4.64–4.61 (m,
J. Brzezinska et al. / Bioorg. Med. Chem. 20 (2012) 1594–1606 16051H, H20), 4.44–4.37 (m, 1H, H30), 4.27–4.12 (m, 1H, H40), 3.79–3.18
(m, 10H), 3.72 (s, 6H, 2  OCH3), 2.81–2.70 (m, 2.5H, –CH(CH3)2),
2.60–2.47 (m, 2H, –P–O–CH2–CH2–CN), 1.75–1.65 (m, 2H, 20-O–
CH2–CH2–CH2–NH–), 1.41–1.34 (m, 18H, 2  –CO–C(CH3)3), 1.15–
1.10 (m, 18H, –N((CH(CH3)2)2, –CO–CH(CH3)2), 1.00–0.96 (m, 3H,
–CH(CH3)2⁄); 31P NMR (162 MHz, DMSO-d6) d [ppm] 149.59,
149.44, 149.52, 149.19. As a result of the mixture comprising
mono- and diisobutyryl derivatives, some of the integrals could
not be given as whole numbers. Thus, signals that depend only
on the diisobutyryl compound are marked with an asterisk. MS
(ESI) was calculated to be 1155.6 for C58H80N10O13P (M+H+), and
found to be 1157.3.
4.3. Oligonucleotide synthesis
Modiﬁed oligonucleotides were synthesised on 500 Å CPG
material on an Expedite 8909 synthesiser using phosphoramidite
chemistry. The GP modiﬁed nucleosides were inserted into the
HBV antisense strand (intended guide, 50 UUG AAG UAU GCC
UCA AGG UCG 30) at each of positions 2, 3, 4, 5, 6, 7 and 13 from
the 50 end. The sense strand oligonucleotide (50 ACC UUG AAG
CAU ACU UCA ATT 30) did not include modiﬁcations. The duplex
HBV siRNA3 targeted HBV genotype A coordinates 1693 to 1711.
Control siRNA with scrambled unmodiﬁed sequences comprised
50-UAUUGGGUGUGCGGUCACGGT-30 (antisense) and 50-CGU-
GACCGCACACCCAAUATT-30 (sense). 5-Ethylthio-1H-tetrazole
(0.25 M in acetonitrile) was used as activator. Unmodiﬁed 20-
TBDMS-phorphoramidites were benzoyl- (A), isobutyryl- (G) or
acetyl- (C) protected. Coupling time for the modiﬁed phosphorami-
dites was 25 min. After completion of synthesis, 30 min of depro-
tection in 3% trichloroacetic acid in dichloromethane was carried
out to ensure complete cleavage of the boc groups. The RNA oligo-
mers were cleaved from the controlled-pore-glass (CPG) support
by incubation at 40 C for 24 h using an ethanol:ammonia solution
(1:3). The 20-TBDMS groups were deprotected by incubation for
90 min at 65 C with a triethylamine, N-methylpyrrolidinone and
Et3N3HF mixture. RNA oligomers were precipitated with BuOH
at 80 C for 30 min and puriﬁed by anion exchange HPLC using a
Dionex DNA-Pac 100 column(1 M LiCl, water, gradient: 0–70% LiCl
solution in 40 min, ﬂow: 1 mL/min). Oligonucleotides were
desalted in a subsequent reverse phase HPLC step (colunm: phe-
nomenex Jupiter 4u Proteo 90A 250 mm  15 mm, 0.1 M triethyl-
ammonium acetate pH 7, acetonitrile, gradient: 0% acetonitrile
for 2 min, 0–37% acetonitrile in 28 min). Identity was conﬁrmed
by mass spectroscopy on a Bruker micrOTOF-Q.
4.4. Biological experiments
4.4.1. Cell culture, transfection, dual luciferase assay and
measurement of HBV surface antigen (HBsAg) concentrations
Huh7 and HEK293 cells were cultured in DMEM (Lonza, Basel,
Switzerland) supplemented with 5% foetal calf serum (Gibco BRL,
UK). Cells were seeded in 24-well plates at a conﬂuency of 40%
on the day before transfection, and were then maintained in anti-
biotic-free medium for at least an hour prior to transfection. To as-
sess target knockdown when using the luciferase reporter assay,
Lipofectamine 2000 (Invitrogen, Carlsbad, CA) was employed to
transfect HEK293 cells with 100 ng psiCHECK-HBx20 and 32.5 ng
siRNA (5 nM ﬁnal concentration) at ratios of 1:1 and 1:3 (ml:mg),
respectively. The psiCHECK-HBx reporter vector contains the HBx
target sequence downstream of the Renilla ORF within the psi-
CHECK 2.2 (Promega, WI, USA) and has been described previ-
ously.20 Forty-eight hours after transfection, cells were assayed
for luciferase activity using the Dual-Luciferase Reporter Assay
System (Promega, WI, USA) and the ratio of Renilla luciferase to
Fireﬂy luciferase activity was calculated. Similarly, to assess knock-down of HBV replication in a liver-derived line, Huh7 cells were
transfected with 100 ng pCH-9/309128 and 32.5 ng siRNA. Forty-
eight hours after transfection, growth medium was harvested
and HBsAg concentration was measured by ELISA using the MON-
OLISA HBs Ag ULTRA kit (Bio-Rad, CA, USA). Each experiment was
repeated at least in triplicate.
4.4.2. siRNA serum stability assessment
Annealed siRNAs were diluted in 80% FCS to a ﬁnal concentra-
tion of 5 lM and incubated at 37 C. At time points ranging from
1 to 24 h, aliquots were removed and snap frozen using liquid
nitrogen. Twenty picomoles of the samples were subjected to elec-
trophoresis through a 10% denaturing polyacrylamide gel then
stained with ethidium bromide.
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 Chapter 13 
 Use of Guanidinopropyl-Modifi ed siRNAs 
to Silence Gene Expression 
 Maximilian  C.R.  Buff ,  Stefan  Bernhardt ,  Musa  D.  Marimani , 
 Abdullah  Ely ,  Joachim  W.  Engels , and  Patrick  Arbuthnot 
 Abstract 
 Silencing gene expression by harnessing the RNA interference (RNAi) pathway with short interfering 
RNAs (siRNAs) has useful analytical and potentially therapeutic application. To augment silencing effi cacy 
of siRNAs, chemical modifi cation has been employed to improve stability, target specifi city, and delivery to 
target tissues. siRNAs incorporating guanidinopropyl (GP) moieties have demonstrated enhanced target 
gene silencing in cell culture and in vivo models of hepatitis B virus replication. Here we describe the syn-
thesis of GP-modifi ed siRNAs and use of 5′ rapid amplifi cation of cDNA ends (5′ RACE) to verify an 
RNAi-mediated mechanism of action of these novel chemically modifi ed siRNAs. 
 Key words  siRNA ,  RNAi ,  RNA ,  Oligonucleotide synthesis ,  Guanidinopropyl ,  HBV ,  5′ RACE 
1  Introduction 
 Since discovery of the RNA interference (RNAi) pathway, there 
has been widespread interest in using exogenous sequences to 
silence a variety of gene targets. RNAi naturally occurs in cells of a 
variety of organisms, which include mammals, fungi, and plants 
(reviewed in [ 1 ]. The pathway typically involves expression and 
processing of RNA comprising hairpin motifs that are processed to 
form short duplex microRNAs (miRNAs) that comprise approxi-
mately 23 base pairs. One of the two strands of the mature miRNA 
is selected to serve as a guide sequence for mRNA inactivation by 
the RNA-Induced Silencing Complex (RISC). Complete pairing 
between the guide and target leads to Ago2-mediated cleavage of 
the mRNA ( see Chapter  1 ). However partial complementarity 
between the seed region of miRNA guide strands and their targets 
naturally occurs more commonly to cause mRNA destabilization 
and translational suppression [ 2 ]. 
218
 Exogenous RNA sequences used to reprogramme RNAi simulate 
intermediates of the pathway, and their guide strands are often 
designed to mediate silencing by causing cleavage of completely 
complementary target mRNA [ 3 ]. Synthetic short interfering 
RNAs (siRNAs), which mimic mature miRNAs, as well as DNA 
cassettes that express artifi cial pri-miRNAs and pre-miRNAs have 
been used widely to silence target gene expression. Since siRNAs 
are considerably smaller than pri-miRNA- or pre-miRNA- encoding 
DNA cassettes, delivery to target cells and better dose regulation 
are easier to achieve. Nevertheless, susceptibility of siRNAs to deg-
radation, nonspecifi c gene silencing, and inadequate delivery to 
target cells remain problematic. Chemical modifi cation of siRNAs 
offers the means of addressing these diffi culties [ 4 ]. Several dif-
ferent approaches have been employed, which include addition 
of various groups to the 2′ and 4′ carbons of ribose, changes to the 
phosphodiester linkage and substitution of ribose with other 
sugars [ 5 ,  6 ]. 
 In earlier studies, our groups have shown that incorporating 
2′- O -guanidinopropyl (GP) moieties can be used successfully to 
improve stability, effi cacy, and specifi city of siRNAs that target the 
 HBx open reading frame of hepatitis B virus (HBV) [ 7 ,  8 ]. Detailed 
analysis, which entailed incorporation of GP substitutions at posi-
tions 2 to 21 of the intended siRNA guide, demonstrated that 
modifi cations to nucleotides in the seed region limited off target 
silencing. Melting point analysis showed that the GP modifi cations 
caused only minimal destabilization of the duplexes. An added 
potential benefi t of introducing a positive charge within the GP 
residue is that the overall neutralization of the negative charge of 
the siRNAs facilitates their delivery to target cells. Using murine 
hydrodynamic tail vein injection to administer siRNAs resulted in 
highly effective knock down of viral replication markers in vivo. 
Collectively these positive features indicate that GP modifi cation of 
siRNAs has potential utility for gene silencing. 
 Here we describe our improved and now standard synthesis 
procedures for the generation of GP-modifi ed nucleosides and 
their incorporation into siRNAs. Importantly, one of the changes 
involved replacing the isobutyryl group to a dimethylformamidine 
group at the N 2 -position of guanosine, thus avoiding formation of 
a mixture of mono- and di-isobutyryl substituted compounds 
during the synthesis. This alteration in procedure improved the 
product yields considerably. Production of each of the adenosine 
(A), cytidine (C), and uridine (U) derivatives follows an analo-
gous chemical protecting scheme, while the protecting groups of 
the guanosine (G) derivative was changed slightly to improve 
yields and purity (Scheme  1 ). Each synthesis started with simul-
taneous protection of 5′- and 3′-OH-groups with either 1,1,3,3-
tetraisopropyldisiloxane- 1,3-diyl (TIPS) for adenosine ( 1 ), cyti-
dine ( 2 ), and uridine ( 3 ) or di- tert- butylsilanediyl (DTBS) for 
Maximilian C.R. Buff et al.
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guanosine ( 4 ). The latter was chosen to improve the reported 
selectivity for the subsequent 2,4,6-triisopropylbenzenesulfonyl 
(TPS) protection at the  O 6 -position of guanosine ( 4a ) [ 9 ]. The 
exocyclic amino functions of A and C were protected with dimeth-
ylaminomethylene groups employing standard conditions and a 
benzoyl group was attached to  N 3 -position of U [ 10 ]. The fi rst 
key step follows Michael addition of acrylonitrile in  tert- butanol 
 Scheme 1  Synthesis of the 2′ -O- guanidinopropyl adenosine-, cytidine- uridine- and guanosine- 
phosphoramidites for oligoribonucleotide synthesis. (i) acrylonitrile, CsCO 3 ,  tert- butyl alcohol, rt; (ii) 
H 2 N-NH 2 · H 2 O, methanol, rt (adenosine and cytidine derivative); formic acid (70 %), dioxane/water (guanosine 
derivative); no deprotection of the uridine derivative; (iii) H 2 (30 bar), Raney-Nickel, NH 3 , methanol, 30–60 min, 
rt; (iv)  N , N' -di-Boc- N'' -trifl ylguanidine, Et 3 N, CH 2 Cl 2 , 0 °C (30 min) to rt (30 min); (v) DMF-dimethyl diacetale, 
methanol, rt (adenosine and guanosine derivative); benzoyl chloride, pyridine, 0 °C (30 min) to rt (30 min) 
(cytidine derivative); no protection group was applied to the uridine derivative; (vi) Et 3 N · 3HF, THF, rt; (vii) 
4,4′-dimethoxytrityl chloride, pyridine, rt; (viii) 2-cyanoethyl  N,N,N',N' -tetraisopropylphosphane, 4,5-dicyano-
imidazole, CH 2 Cl 2 , rt 
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with Cs 2 CO 3 as base to 2′ -O -cyanoethyl [ 11 ]. Deprotection of 
dimethylaminomethylene groups of the A and C with hydrazine 
yielded  1b and  2b . This additional deprotection step was neces-
sary to avoid formation of mixtures of dimethylaminomethylene-
protected and unprotected derivatives. The TPS-group from the 
O 6 -position of the guanosine derivative was cleaved with a mix-
ture of formic acid (70 %), dioxane, and water ( 4b ). For produc-
tion of the uridine derivative, this extra step was not necessary. In 
the next key step, the nitrile to amine transformation was achieved 
by reduction with hydrogen (30 bar) and using Raney-nickel in 
ammonia and methanol as catalyst [ 12 ]. The hydrogenation step 
was found to be sensitive to subtle variations in the reaction con-
ditions, which include the mass ratio of starting material to cata-
lyst, the size of the autoclave and the reaction time. Under optimal 
conditions we were able to produce yields of about 50 % for each 
nucleoside. Despite intensive washings with methanol, critical loss 
of the desired amino compound occurred as a result of adsorption 
onto the catalyst. To minimize this, we introduced the guanidino 
groups directly. Thus  N , N' -di-Boc- N'' -trifl ylguanidine, now 
commercially available [ 13 ], was added as guanidinylation agent. 
Our previous studies showed that two boc groups are suffi cient in 
RNA solid phase synthesis, although they are cleaved after repeti-
tive acid deprotection using TBDMS-phosphoramidite protocols. 
The guanidino group does not seem to undergo side reactions 
during the solid phase synthesis. Yields after guanidinylation were 
70 % for  1c (A), 60 % for  2c (C), around 60 % for  3c (U) and 
approximately 90 % for  4c (G).
 Established standard reaction conditions were applied to syn-
thesize the desired phosphoramidites ( 1d –  4d ). The A and G 
derivatives were protected with dimethylaminomethylene at the 
 N 6 - or  N  2  -positions, and the exocyclic amino function of the C 
derivative was protected with a benzoyl group. For U derivative, 
no further protection of the base was necessary. Finally we accom-
plished the synthesis of all four 2′ -O- guanidinopropyl phosphora-
midites by removal of silyl protecting groups with Et 3 N · 3HF. Then 
the 5′-OH-group was protected with a 4,4′-dimethoxytrityl group 
and in a last step the 3′-OH group was converted to a phosphorami-
dite using 2-cyanoethyl  N,N,N',N' -tetraisopropylaminophosphane 
and 4,5-dicyanoimidazole as activator. Starting with the adenos-
ine, cytidine, uridine, and guanosine nucleosides, synthesis of the 
2′ -O- guanidinopropyl phosphoramidites took place in  6–8 steps 
and routinely provided overall yields of 16–17 % ( 1d ), 13–14 % 
( 2d ), 14–15 % ( 3d ) and 16–17 % ( 4d ). 
 To incorporate GP-containing nucleotides into the oligonu-
cleotides constituting the siRNAs, standard phosphoramidite syn-
thetic procedures with a prolonged coupling time of 30 min were 
employed. Control siRNA3 without GP moieties, referred to in 
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this study as being unmodifi ed, were also synthesized. The siRNAs 
contain the classical two dT residues at the 3′ end of the sense 
strand to improve stability. In addition to the detailed description 
of the methods for synthesis of GP-modifi ed siRNAs, procedures 
for verifying Ago2-mediated target HBV mRNA cleavage by 
GP-modifi ed siRNAs, using 5′ rapid amplifi cation of cDNA ends 
(RACE), are presented. 
2  Materials 
 The syntheses of the GP-modifi ed phosphoramidites are performed 
with standard chemicals and solvents suitable for chemical synthe-
sis. Chemicals were purchased from  Sigma-Aldrich ,  TCI ,  Acros 
Organics , and  ChemGenes among other suppliers.
  1.  Chemicals and solvents for syntheses: adenosine, cytidine, 
uridine, guanosine, 1,3-dichloro-1,1,3,3-tetraisopropyldisi-
loxane, di- tert- butylsilyl ditrifl ate,  tert- butanol, acrylonitrile 
(freshly distilled), cesium carbonate, hydrazine hydrate (H 2 N–
NH 2 · H 2 O), Raney-Nickel (activated nickel catalyst), methanol 
saturated with ammonia, hydrogen (H 2 , compressed in a steel 
cylinder), triethylamine,  N,N' -di-boc- N'' -trifl yl guanidine, 
 N,N -dimethylformamide dimethylacetale, triethylammonium 
trihydrofl uoride (Et 3 N · 3HF), 4,4′-dimethoxytrityl chloride, 
2-cyanoethyl- N,N,N',N' -tetraisopropylamino phosphane, 4,5-
dicyanoimidazole, benzoyl chloride, ammonium hydroxide 
solution (25–33 % in water), sodium carbonate, tetrabutylam-
monium bromide, 4-( N,N -dimethylamino)pyridine (DMAP), 
2,4,6-triisopropylbenzenesulfonyl chloride, formic acid, diox-
ane, ethanol, acetone, benzene, pyridine, toluene. 
  2.  Water-free solvents for syntheses (bottled with septum and 
molecular sieve): dichloromethane, dimethylformamide, 
methanol, pyridine, tetrahydrofurane. 
  3.  Solutions and desiccants for workup: saturated sodium bicar-
bonate solution, saturated sodium chloride solution (brine), 
anhydrous magnesium sulfate, or sodium sulfate, celite. 
  4.  Solvents for extractions and column chromatography: dichlo-
romethane, ethyl acetate, hexane, methanol. (We used techni-
cal grade solvents that were redistilled before usage to avoid 
contamination of the purifi ed products with nonvolatile impu-
rities of the solvents.) 
  5.  Solid-phase material for column chromatography: silica gel 60 
with grain size of 0.04–0.063 mm (e.g. from  Merck KGaA or 
 Macherey-Nagel GmbH&Co.KG ), TLC plates: silica gel 60 on 
aluminum foil with fl uorescence indicator (254 nm). 
2.1  Synthesis 
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  1.  Empty synthesis columns fi tting to your synthesizer (e.g. from 
 Glen Research or  ChemGenes ) 
  2.  Ribonucleoside functionalized solid support (LCAA-support, 
500 Å, e.g. from  ChemGenes ):
 N-Bz-5′ -O- DMTr-2′(3′)-Ac-adenosine-LCAA-CPG 
 N-ibu-5′ -O- DMTr-2′(3′)-Ac-guanosine-LCAA-CPG 
 N-Ac-5′ -O- DMTr-2′(3′)-Ac-cytidine-LCAA-CPG 
 5′ -O- DMTr-2′(3′)-Ac-uridine-LCAA-CPG 
 Commercially available prepacked synthesis columns may also 
be used. 
  3.  Ribonucleoside phosphoramidites for unmodifi ed positions 
(e.g. from  SAFC/Proligo or  ChemGenes or  Glen Research ): 
 N-Bz-5′ -O- DMTr-2′ -O- TBDMS-adenosine-3′ -O-N,N' -
diisopropyl(2-cyanoethyl)phosphoramidite 
 N-ibu-5′ -O- DMTr-2′ -O- TBDMS-guanosine-3′ -O-N,N' -
diisopropyl(2-cyanoethyl)phosphoramidite 
 N-Ac-5′ -O- DMTr-2′ -O- TBDMS-cytidine-3′ -O-N,N' -
diisopropyl(2-cyanoethyl)phosphoramidite 
 5 ′  -O-  DMTr-2 ′  -O-  TBDMS-ur id ine -3 ′  -O-N,N'  -
diisopropyl(2-cyanoethyl)phosphoramidite 
  4.  Reagents and solvents required for the synthesizer (e.g. from 
 SAFC/Proligo ): anhydrous acetonitrile, deblock solution (3 % 
trichloroacetic acid in dichloromethane), activator (0.35 M 
5-ethylthiotetrazole (ETT) in acetonitrile ( see  Note 1 )), Cap A 
(acetic anhydride/tetrahydrofurane 9.1/90.9 (v/v)), Cap B 
(Tetrahydrofurane/N-Methylimidazole/Pyridine 8/1/1 
(v/v/v)), oxidizer (0.1 M iodine in tetrahydrofurane/pyri-
dine/water (75:20:2 v/v/v)) 
  5.  Amidite diluent: anhydrous acetonitrile (100 mL, bottled with 
septum, e.g. from  SAFC/Proligo ) 
  1.  Oligonucleotide cleavage: For cleavage from solid support and 
removal of the cyanoethyl groups and exocyclic amino protect-
ing groups of the bases we use a 3:1 mixture of ammonium 
hydroxide solution (25–33 % in water) and ethanol. 
  2.  Cleavage of the 2′ -O- TBDMS-groups: Et 3 N · 3HF/1-methyl- 
2-pyrrolidone/Et 3 N (6:3:4, v/v/v) 
  3.  DEPC-water: Diethylpyrocarbonate (DEPC) is dissolved in 
distilled or deionized water (0.1 % DEPC). The solution is 
kept overnight at room temperature and then autoclaved at 
120 °C for 20 min to deactivate the DEPC. 
  4.  For RNA-precipitation: n-Butanol 
  5.  LiCl-Buffer: 1 M lithium chloride in DEPC-water, adjusted 
to pH 8. 
  6.  Triethylammonium acetate buffer: 0.1 M triethylammonium acetate 
in DEPC-water. We prepare a 1 M solution of triethylammonium 
2.2  Solid-Phase 
Oligonucleotide 
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Purifi cation, 
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acetate and dilute it 1:9 with DEPC-water before usage. For the 1 M 
solution acetic acid (60.05 g, 57.2 mL, 1 mol) is dissolved in 700 mL 
DEPC-water. Triethylamine (101.2 g, 138.6 mL, 1 mol) is added in 
small portions while the solution is stirred vigorously. Caution: As a 
result of the enthalpy of the neutralization reaction, the solution heats 
up, so cooling may be required. After the solution has cooled down to 
room temperature, the volume is adjusted to 1,000 mL with DEPC- 
water and the pH is adjusted to pH 7 with acetic acid or 
triethylamine. 
  7.  Anion-exchange HPLC-column:  Dionex DNA Pac PA-100 
(9 mm × 250 mm) 
  8.  Reverse-phase HPLC-column:  Phenomenex Jupiter 4u Proteo 
90 Å 250 mm × 15 mm. 
  9.  Chemicals: acetic acid, triethylamine, lithium chloride, 
1-methyl-2-pyrrolidone. 
  1  Stock solutions of target and reporter plasmids (100 ng/μL) 
prepared using anion-exchange resins (e.g. Qiagen Plasmid 
Maxi Kit, MD, USA): pCH-9/3091  14 , pCI-neo-eGFP  15 
( see  Note 2 ). 
  2  Lipofectamine ® -2000 and Opti MEM ® (Invitrogen, CA, USA). 
  3  Tri Reagent ® (Sigma, MO, USA). 
  4  Diethyl pyrocarbonate-treated water ( see above). 
  5  GeneRacer™ Kit (Invitrogen, CA, USA). 
  6  Thermocycler (e.g. T100™ Instrument from BioRad, CA, USA) 
  7  MinElute Gel Extraction kit (Qiagen, MD, USA) 
  8  Reverse transcriptase gene-specifi c primers: HBx RT 
5′-AGGGTCGATGTCCATGCCCC-3′ (Integrated DNA 
Technologies, IA, USA) ( see  Note 3 ). 
3  Methods 
 Syntheses of the GP-modifi ed phosphoramidites have previously 
been described for A, C, and U 7 and separately for G 8 . Since many 
reagents are sensitive to hydrolysis, it is highly recommended to 
work under inert gas atmosphere (nitrogen or argon) and use 
anhydrous solvents for the reactions ( see  Note 4 ). 
  1.  Synthesis of N 6 -Dimethylaminomethylene-2′ -O -cyanoethyl- 3 ′,
5′ -O- (tetraisopropyldisiloxane-1,3-diyl)-adenosine ( 1e ). To a 
solution of N 6 -Dimethylaminomethylene-3′,5′ -O- (tetraisopro-
pyldisiloxane-1,3-diyl)-adenosine ( 1a ) (3.0 g, 5.31 mmol) in 
 tert- butanol (25 mL), freshly distilled acrylonitrile (6.7 mL, 
102 mmol) and cesium carbonate (1.6 g, 4.9 mmol) are added. 
2.4  Analysis 
of RNAi- Mediated 
Target Cleavage by 
GP-Modifi ed siRNAs 
Using 5′ RACE
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2′- O -GP- Modifi ed 
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The mixture is stirred vigorously at room temperature for 3 h. 
The reaction mixture is fi ltered and the residue is washed 
with dichloromethane. The fi ltrate is evaporated and the resi-
due is purifi ed using column chromatography with ethyl 
acetate/methanol (99:1–95:5, v/v) to give 3.28 g (87 %) of N 6 -
Dimethylaminomethylene-2′ -O -cyanoethyl-3′, 5′ -O- (tetraiso-
propyldisiloxane-1,3-diyl)-adenosine ( 1e ).  1 H NMR (400 MHz, 
DMSO- d  6  )  δ [ppm] 8.90 (s, 1H, amidine- H ), 8.34 (s, 1H,  H 2 
or  H 8), 8.32 (s, 1H,  H 2, or  H 8), 6.02–6.01 (m, 1H,  H 1′), 
5.05–5.01 (m, 1H,  H 3′), 4.64–4.62 (m, 1H,  H 2′), 4.08–3.84 
(m, 5H,  H 4′, 2×  H 5′, O–C H 2 –CH 2 –CN), 3.20 (s, 3H, N–C H 3 ), 
3.13 (s, 3H, N–C H 3 ), 2.83–2.80 (m, 2H, O–CH 2 –C H 2 –CN), 
1.10–1.00 (m, 28H, tetraisopropyl- C H and -C H 3 ); MS (ESI) 
was calculated to be 618.3 for C 28 H 48 N 7 O 5 Si 2 (M + H + ), and 
found to be 618.8. 
  2.  Synthesis of  2′ -O -cyanoethyl-3′, 5′ -O- (tetraisopropyldisiloxane- 1,
3-diyl)-adenosine ( 1b ).  N 6 -Dimethylaminomethylene-2′ -O -
cyanoethyl - 3 ′, 5′ -O- (tetraisopropyldisiloxane-1,3-diyl)-adenosine 
( 1e ) (1.0 g, 1.62 mmol) is dissolved in methanol (20 mL) then 
hydrazine hydrate (H 2 N-NH 2 · H 2 O; 500 μL, 10.3 mmol) is 
added. The reaction solution is stirred at room temperature for 
3 h. The solvents are evaporated and the residue is purifi ed using 
a silica gel column with ethyl acetate as eluent to give 773 mg 
(87 %) 2′ -O -cyanoethyl-3′,5′ -O- (tetraisopropyldisiloxane-1,3-
diyl)-adenosine ( 1b ).  1 H NMR (400 MHz, DMSO- d  6  )  δ [ppm] 
8.21 (s, 1H,  H 2, or  H 8), 8.07 (s, 1H,  H 2, or  H 8), 7.33 (bs, 
2H, N H 2 ), 5.98–5.96 (m, 1H,  H 1′), 5.03–4.99 (m, 1H,  H 3′), 
4.59–4.57 (m, 1H,  H 2′), 4.08–3.83 (m, 5H,  H 4′, 2×  H 5′, 
O-C H 2 –CH 2 –CN), 2.84–2.80 (m, 2H, O–CH 2 –C H 2 –CN), 
1.09–0.97 (m, 28H, tetraisopropyl-C H and -C H 3 ); MS (MALDI) 
was calculated to be 563.8 for C 25 H 43 N 6 O 5 Si 2 (M + H + ) and 
found to be 564.0. 
  3.  Synthesis of  2′ -O- Aminopropyl-3′,5′ -O- (tetraisopropyldisiloxane-
1,3-diyl)-adenosine ( 1f ) ( see  Notes 5 and  6 ). 2′ -O -cyanoethyl-
3′,5′ -O- (tetraisopropyldisiloxane-1,3- diyl)-adenosine ( 1b ) (1.0 g, 
1.78 mmol) is dissolved in 10 mL of methanol in a glass tube 
suitable for use in an autoclave. Approximately 0.5 mL of 
Raney-nickel slurry are rinsed thoroughly on a glass fi lter ( see 
 Note 7 ) with dry methanol and then washed into the glass tube 
containing the solution of 2′ -O -cyanoethyl-3′, 5′ -O-
 (tetraisopropyldisiloxane-1,3-diyl)-adenosine ( 1b ). After addi-
tion of 5 mL methanol saturated with ammonia, the mixture is 
stirred for 1 h at room temperature under a hydrogen atmo-
sphere (30 bar). The reaction mixture is fi ltered and the catalyst 
is washed three times with methanol. The fi ltrate is evaporated 
and the residue is purifi ed using column chromatography with 
ethyl acetate/methanol/triethylamine (70:25:5, v/v/v) to yield 
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503 mg (50 %) of 2′ -O- Aminopropyl-3′,5′ -O- (tetraisopro-
pyldisiloxane-1,3-diyl)-adenosine ( 1f ). If no NMR or MS anal-
ysis is needed, the crude product can be used for the next step 
without chromatographic purifi cation.  1 H NMR (400 MHz, 
DMSO- d  6  )  δ [ppm] 8.20 (s, 1H,  H 2, or  H 8), 8.07 (s, 1H,  H 2, 
or  H 8), 7.32 (bs, 2H, N H 2 ), 5.95–5.94 (m, 1H,  H 1′), 4.95–
4.90 (m, 1H,  H 3′), 4.41–4.39 (m, 1H,  H 2′), 4.08–3.90 (m, 
3H,  H 4′, 2×  H 5′), 3.86–3.70 (m, 2H, O–C H 2 –CH 2 –CH 2 –
NH 2 ), 2.66–2.61 (m, 2H, O–CH 2 –CH 2 –C H 2 –NH 2 ), 1.65–
1.58 (m, 2H, O–CH 2 –C H 2 –CH 2 –NH 2 ), 1.08–0.96 (m, 28H, 
tetraisopropyl-C H and -C H 3 ); MS (MALDI) was calculated to 
be 567.9 for C 25 H 47 N 6 O 5 Si 2 (M + H + ), and found to be 567.9. 
  4.  Synthesis of 2′ -O- ( N,N' -Di-boc-guanidinopropyl)-3′,5′ -O-
 (tetraisopropyldisiloxane-1,3-diyl)-adenosine ( 1c ).  N,N' -Di-
boc- N '' -trifl yl guanidine (280 mg, 0.72 mmol) is dissolved in 
5 mL dichloromethane then triethylamine (100 μL) is added. 
After cooling to 0 °C, 2′ -O- aminopropyl-3′, 5′ -O- (tetraisopro-
pyldisiloxane-1,3-diyl)-adenosine ( 1f ) (400 mg, 0.71 mmol) is 
added and the mixture is stirred for 1 h at 0 °C then for 1 h at 
room temperature. The reaction is diluted with dichlorometh-
ane and washed with saturated sodium bicarbonate solution 
and brine. The organic layer is dried over Na 2 SO 4 and the sol-
vent is evaporated. The residue is purifi ed using column chro-
matography with dichloromethane/methanol (98:2, v/v) to 
give a yield of 402 mg (70 %) of 2′ -O- ( N, N' -Di-boc-
guanidinopropyl)-3′, 5′ -O- (tetraisopropyldisiloxane-1,3-diyl)-
adenosine ( 1c ).  1 H NMR (400 MHz, DMSO- d  6  )  δ [ppm] 11.50 
(s, 1H, N H -boc), 8.45–8.41 (m, 1H, N H –CH 2 –), 8.17 (s, 1H, 
 H 2, or  H 8), 8.06 (s, 1H,  H 2 or  H 8), 7.31 (bs, 2H, N H 2 ), 6.02–
5.99 (m, 1H,  H 1′), 4.96–4.91 (m, 1H,  H 3′), 4.43–4.40 (m, 1H, 
 H 2′), 4.06–3.70 (m, 5H,  H 4′, 2×  H 5′, O–C H 2 –CH 2 –CH 2 –
NH–), 3.51–3.32 (m, 2H, O–CH 2 –CH 2 –C H 2 –NH–), 1.84–
1.78 (m, 2H, O–CH 2 –C H 2 –CH 2 –NH–), 1.44 (s, 9H, C(C H 3 ) 3 ), 
1.37 (s, 9H, C(C H 3 ) 3 ), 1.07–0.99 (m, 28H, tetraisopropyl-C H 
and -C H 3 ); MS (MALDI) was calculated to be 810.1 for 
C 36 H 65 N 8 O 9 Si 2 (M + H + ), and found to be 808.3. 
  5.  Synthesis of N 6 -Dimethylaminomethylene-2′ -O- ( N,N' -di-
boc- guanidinopropyl)-3′,5′ -O- (tetraisopropyldisiloxane-1,3-
diyl)-adenosine ( 1g ). 2′ -O- ( N,N' -Di-boc-guanidinopropyl)-3′,
5′ -O- (tetraisopropyldisiloxane-1,3-diyl)-adenosine ( 1c ) (500 mg, 
0.61 mmol) is dissolved in methanol (5 mL) and  N,
N - dimethylformamide dimethyl acetal (500 μL, 3.7 mmol) is 
added. The reaction is stirred at room temperature overnight 
and the solvents are evaporated. The crude product is used for 
further reactions without purifi cation. 
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  6.  Synthesis of N 6 -Dimethylaminomethylene-2′ -O- ( N,N' -di-boc- 
guanidinopropyl)-adenosine ( 1h ). N 6 -Dimethylaminomethylene- 
2′ -O- ( N,N' -di-boc- guanidinopropyl)-3′,5′ -O- (tetraiso-
propyldisiloxane-1,3-diyl)-adenosine ( 1g ) (500 mg, 0.58 mmol) 
is dissolved in tetrahydrofurane (5 mL) and triethylammonium 
trihydrofl uoride (Et 3 N · 3HF; 330 μL, 2.0 mmol) is added. The 
mixture is stirred at room temperature for 1.5 h, and then the 
solvent is evaporated. The residue is purifi ed by column chroma-
tography with ethyl acetate/methanol (98:2–9:1, v/v) giving 
300 mg (83 %) of N 6 -Dimethylaminomethylene-2′ -O- ( N,N' -di-
boc- guanidinopropyl)-adenosine ( 1h ).  1 H NMR (400 MHz, 
DMSO- d  6  )  δ [ppm] 11.47 (s, 1H, N H -boc), 8.92 (s, 1H, 
N 6 = C H –NMe 2 ), 8.50 (s, 1H,  H 2, or  H 8), 8.41 (s, 1H,  H 2, or 
 H 8), 8.33–8.29 (m, 1H, N H –CH 2 –), 6.11–6.09 (m, 1H,  H 1′), 
5.28–5.24 (m, 1H, 5′–O H ), 5.18–5.16 (m, 1H, 3′–O H ), 4.46–
4.43 (m, 1H,  H 2′), 4.36–4.32 (m, 1H,  H 3′), 4.01–3.98 (m, 
1H,  H 4′), 3.72–3.46 (4H, 2×  H 5′, O–C H 2 –CH 2 –CH 2 –NH–), 
3.33–3.28 (m, 2H, O–CH 2 –CH 2 –C H 2 –NH–), 3.20 (s, 3H, N–
C H 3 ), 3.13 (s, 3H, N–C H 3 ), 1.74–1.68 (m, 2H, O–CH 2 –C H 2 –
CH 2 –NH–), 1.45 (s, 9H, C(C H 3 ) 3 ), 1.37 (s, 9H, C(C H 3 ) 3 ); 
MS (MALDI) was calculated to be 622.7 for C 27 H 44 N 9 O 8 
(M + H + ), and found to be 624.6. 
  7.  Synthesis of N 6 -Dimethylaminomethylene-2′ -O- ( N,N' -di-boc-
 guanidinopropyl)-5′ -O- (4,4′-dimethoxytrityl)-adenosine ( 1i ). 
N 6 -Dimethy laminomethy lene-2 ′  -O-  (  N,N'  -d i -boc- 
guanidinopropyl)-adenosine ( 1g ) (1.0 g, 1.6 mmol) is dis-
solved in dry pyridine (20 mL). 4,4′-Dimethoxytrityl chloride 
(660 mg, 1.95 mmol) is added and the reaction is stirred at 
room temperature overnight. The solution is diluted with 
dichloromethane and washed with saturated sodium bicarbon-
ate solution. After evaporation of the solvents the residue is 
purifi ed on a silica gel column with dichloromethane/methanol 
(98:2, v/v) containing 0.5 % triethylamine ( see  Note 8 ), and 
1.32 g (90 %) of N 6 -Dimethylaminomethylene-2′ -O- ( N,N' -di-
boc- guanidinopropyl)-5′ -O- (4,4′-dimethoxytrityl)-adenosine 
( 1i ) can be obtained.  1 H NMR (400 MHz, DMSO- d  6  )  δ 
[ppm] 11.48 (s, 1H, N H -boc), 8.90 (s, 1H, N 6 = C H –NMe 2 ), 
8.38–8.34 (m, 3H,  H 2,  H 3, N H –CH 2 –), 7.37–7.34 (m, 2H, 
DMTr), 7.27–7.17 (m, 7H, DMTr), 6.84–6.79 (m, 4H, 
DMTr), 6.14–6.13 (m, 1H,  H 1′), 5.18–5.15 (m, 1H, 3′–
O H ), 4.57–4.54 (m, 1H,  H 2′), 4.47–4.42 (m, 1H,  H 3′), 
4.14–4.08 (m, 1H,  H 4′), 3.72–3.71 (m, 6H, 2× OC H 3 ), 
3.70–3.56 (m, 2H, O–C H 2 –CH 2 –CH 2 –NH–), 3.37–3.32 (m, 
2H, O–CH 2 –CH 2 –C H 2 –NH–), 3.24–3.21 (m, 2H, 2×  H 5′), 
3.19 (s, 3H, N–C H 3 ), 3.12 (s, 3H, N–C H 3 ), 1.77–1.70 (m, 
2H, O–CH 2 –C H 2 –CH 2 –NH–), 1.44 (s, 9H, C(C H 3 ) 3 ), 1.35 
(s, 9H, C(C H 3 ) 3 ); MS (MALDI) was calculated to be 925.1 for 
C 48 H 62 N 9 O 10 (M + H + ), and found to be 924.9. 
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  8.  Synthesis of N 6 -Dimethylaminomethylene-2′ -O- ( N,N' -di-
boc- guanidinopropyl)-5′ -O- (4,4′-dimethoxytrityl)-adenosine 
3′-(cyanoethyl)- N,N -diisopropyl phosphoramidite ( 1d ).  N 6 -
Dimethylaminomethylene - 2 ′ -O- ( N,N' -di-boc- guanidino-
propyl)-5′ -O- (4,4′-dimethoxytrityl)-adenosine ( 1i ) (320 mg, 
346 μmol) is dissolved in dichloromethane (8 mL). 2-cyano-
ethyl  N,N,N',N' -tetraisopropylamino phosphane (132 μL, 
415 μmol) and 4,5-dicyanoimidazole (47 mg, 398 μmol) are 
added. The mixture is stirred at room temperature. After 3 h, 
TLC checks completion of the reaction. In the event that some 
starting material did not react, an additional 0.6 equivalents of 
the phosphitylating agent as well as the catalyst are added and 
the reaction is stirred at room temperature for additional 4 h. 
After completion of the reaction, the mixture is diluted with 
dichloromethane, washed with saturated sodium bicarbonate 
solution and the organic layer is dried over MgSO 4 . The sol-
vent is evaporated and the residue dissolved in a small amount 
of dichloromethane (ca. 5 mL). This solution is added drop 
wise into a fl ask with hexane (500 mL) to form a white precipi-
tate. Two thirds of the solvent is evaporated and the remaining 
solvent is decanted from the solid ( see  Note 9 ). The precipi-
tated product is redissolved in benzene and lyophilized ( see 
 Note 10 ) to give 329 mg (84 %) of N 6 -Dimethylaminomethylene- 
2 ′  -O-  (  N,N'  -d i -boc -  guan id inopropy l ) -5 ′  -O-  (4 ,4 ′ -
dimethoxytrityl)-adenosine 3′-(cyanoethyl)- N,N -diisopropyl 
phosphoramidite ( 1d ) as a white powder ( see  Note 11 ).  1 H 
NMR (300 MHz, acetone- d  6  )  δ [ppm] 11.65 (s, 1H, N H -
boc) 8.95–8.93 (m, 1H, N 6 = C H –NMe 2 ), 8.42–8.27 (m, 3H, 
 H 2,  H 3, N H –CH 2 –), 7.50–7.46 (m, 2H, DMTr), 7.38–7.17 
(m, 7H, DMTr), 6.87–6.80 (m, 4H, DMTr), 6.28–6.26 (m, 
1H,  H 1′), 4.96–4.79 (m, 2H,  H 2′,  H 3′) 4.45–4.37 (m, 1H, 
 H 4′), 4.05–3.35 (m, 16H), 3.25 (s, 3H, N–C H 3 ), 3.18 (s, 
3H, N–C H 3 ), 2.85 (m, 1H, cyanoethyl), 2.64–2.60 (m, 1H, 
cyanoethyl), 1.90–1.82 (m, 2H, O–CH 2 –C H 2 –CH 2 –NH–), 
1.50–1.49 (m, 9H, C(C H 3 ) 3 ), 1.42–1.40 (m, 9H, C(C H 3 ) 3 ), 
1.25–1.10 (m, 12H,  i Pr-C H 3 );  31 P NMR (121 MHz, acetone-
 d  6  )  δ [ppm] 149.6, 149.3; MS (ESI) was calculated to be 
1,125.3 for C 57 H 79 N 11 O 11 P (M + H + ), and found to be 1,125.7. 
  1.  Synthesis of N 4 -Dimethylaminomethylene-2′ -O -cyanoethyl- 3 ′,
5′ -O- (tetraisopropyldisiloxane-1,3-diyl)-cytidine ( 2e ). N 4 -
Dimethylaminomethylene- 3′, 5′ -O- (tetraisopropyldisiloxane-
1,3-diyl)-cytidine ( 2a ) (4 g, 7.39 mmol) is dissolved in 
acrylonitrile (8 mL, 122 mmol) and  tert- Butanol (35 mL). 
Cesium carbonate (1.8 g, 5.52 mmol) is added and the reac-
tion is stirred for 2.5 h at room temperature. The mixture is 
fi ltered over celite, the solvents are evaporated and the residue 
is purifi ed using column chromatography. Ethyl acetate is ini-
3.2  Synthesis 
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tially used as solvent then changed to ethyl acetate/methanol 
(9:1, v/v) after the nonpolar impurities have passed through the 
column. A yield of 3.78 g (86 %) of N 4 -Dimethylaminomethylene- 
2′ -O -cyanoethyl-3′,5′ -O- (tetraisopropyldisiloxane-1,3-diyl)-
cytidine ( 2e ) can be obtained.  1 H NMR (400 MHz, DMSO- d  6  ) 
 δ [ppm] 8.62 (s, 1H, N 4 = C H –NMe 2 ), 7.88 (d, 1H, J = 7.3 Hz, 
 H 6), 5.90 (d, 1H, J = 7.3 Hz,  H 5), 5.65 (s, 1H,  H 1′), 4.22–
3.91 (m, 7H), 3.17 (s, 3H, N–C H 3 ), 3.04 (s, 3H, N–C H 3 ), 
2.86–2.82 (m, 2H, O–CH 2 –C H 2 –CN), 1.07–0.96 (m, 28H, 
tetraisopropyl- C H and -C H 3 ); MS (ESI) was calculated to be 
594.9 for C 27 H 48 N 5 O 6 Si 2 (M + H + ) and found to be 594.9. 
  2.  Synthesis of 2′ -O -cyanoethyl-3′,5′ -O- (tetraisopropyldisiloxane- 
1,3-diyl)-cytidine ( 2b ).  N  4  -Dimethylaminomethylene-2′ -O -
cyanoethyl - 3 ′,5′ -O- (tetraisopropyldisiloxane-1,3-diyl)-cytidine 
( 2e ) (1.0 g, 1.68 mmol) is dissolved in methanol (10 mL) and 
hydrazine hydrate (500 μL, 10.3 mmol) is added. The mixture 
is stirred for 1 h at room temperature and then the solvents are 
evaporated. The residue is purifi ed on a silica gel column with 
ethyl acetate/methanol (95:5, v/v) to give 745 mg (82 %) of 
2′ -O -cyanoethyl-3′,5′ -O- (tetraisopropyldisiloxane-1,3-diyl)-
cytidine ( 2b ).  1 H NMR (400 MHz, DMSO- d  6  )  δ [ppm] 7.69 
(d, 1H, J = 7.4 Hz,  H 6), 7.21 (s, 2H, N H 2 ), 5.69 (d, 1H, 
J = 7.4 Hz,  H 5), 5.61 (s, 1H,  H 1′); 4.19–3.90 (m, 7H), 2.90–
2.76 (m, 2H, O–CH 2 –C H 2 –CN), 1.07–0.97 (m, 28 H, 
tetraisopropyl- C H and -C H 3 ); MS (ESI) was calculated to be 
539.8 for C 24 H 43 N 4 O 6 Si 2 (M + H + ) and found to be 540.0. 
  3.  Synthesis of 2′ -O- Aminopropyl-3′,5′ -O- (tetraisopropyldisiloxane-
1,3-diyl)-cytidine ( 2f ) ( see  Notes 5 and  6 ). 2′ -O -cyanoethyl-
3′,5′ -O- (tetraisopropyldisiloxane-1,3- diyl)-cytidine ( 2b ) (500 mg, 
928 μmol) is dissolved in 10 mL of methanol in a glass tube. 
Approximately 0.5 mL of Raney- nickel sediment is washed 
thoroughly with dry methanol on a glass fi lter ( see  Note 7 ) and 
is rinsed with methanol into the glass tube containing the solu-
tion of 2′ -O -cyanoethyl-3′,5′ -O- (tetraisopropyldisiloxane-1,3-
diyl)-cytidine ( 2b ). After addition of 5 mL methanol saturated 
with ammonia, the mixture is stirred for 1 h at room tempera-
ture under a hydrogen atmosphere (30 bar). The reaction 
mixture is then fi ltered through celite and the catalyst is washed 
several times with methanol. The solvent is evaporated and the 
residue is purifi ed on a silica gel column using ethyl acetate/
methanol/triethylamine (60:35:5) to give 251 mg (50 %) of 
2′ -O- Aminopropyl-3′,5′ -O- (tetraisopropyldisiloxane-1,3-
diyl)-cytidine ( 2f ). If no NMR or MS analysis is needed, the 
crude product can be used for the next step without chromato-
graphic purifi cation.  1 H NMR (400 MHz, DMSO- d  6  )  δ [ppm] 
7.69 (d, 1H, J = 7.2 Hz,  H 6), 7.18 (bs, 2H, ar. N H 2 ), 5.68 (d, 
1H, J = 7.5 Hz,  H5 ), 5.60 (s, 1H,  H 1′), 4.18–3.76 (m, 7H), 
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2.70–2.66 (m, 2H, O–CH 2 –CH 2 –C H 2 –NH 2 ), 1.68–1.61 (m, 
2H, O–CH 2 –C H 2 –CH 2 –NH 2 ), 1.07–0.95 (m, 28 H, tetraiso-
propyl-C H and -C H 3 ); MS (MALDI) was calculated to be 
543.8 for C 24 H 47 N 4 O 6 Si 2 (M + H + ) and found to be 544.6. 
  4.  Synthesis of 2′ -O- ( N,N' -Di-boc-guanidinopropyl)-3′,5′ -O-
 (tetraisopropyldisiloxane-1,3-diyl)-cytidine ( 2c ).  N,N' -Di-
boc- N '' -trifl yl guanidine (360 mg, 920 μmol) is dissolved in 
5 mL dichloromethane and triethylamine (125 μL) is then 
added. After cooling to 0 °C, 2′ -O- Aminopropyl-3′,5′ -O-
 (tetraisopropyldisiloxane-1,3-diyl)-cytidine ( 2f ) (500 mg, 
922 μmol) is added and the solution is stirred for 1 h at 0 °C 
and then 1 h at room temperature. The reaction is diluted with 
dichloromethane and washed with saturated sodium bicarbon-
ate solution and brine. The combined organic layers are dried 
over Na 2 SO 4 and after evaporating the solvent the residue is 
purifi ed using column chromatography with dichlorometh-
ane/methanol (98:2–95:5, v/v) to give 434 mg (60 %) 
2′ -O- ( N,N' -Di-boc-guanidinopropyl)-3′,5′ -O- (tetraiso-
propyldisiloxane- 1,3-diyl)-cytidine ( 2c ).  1 H NMR (400 MHz, 
DMSO- d  6  )  δ [ppm] 11.48 (s, 1H, N H -boc), 8.38–8.35 (m, 
1H, N H –CH 2 –), 7.67 (d, 1H, J = 7.4 Hz,  H 6), 7.19 (bs, 2H, 
N H 2 ), 5.68 (d, 1H, J = 7.4 Hz,  H5 ), 5.63 (s, 1H,  H 1′), 4.17–
3.78 (m, 7H), 3.49–3.33 (m, 2H, O–CH 2 –CH 2 –C H 2 –NH–), 
1.84–1.77 (m, 2H, O–CH 2 –C H 2 –CH 2 –NH–), 1.45 (m, 9H, 
C(C H 3 ) 3 ), 1.38 (m, 9H, C(C H 3 ) 3 ), 1.06–0.96 (m, 28 H, tet-
raisopropyl-C H and -C H 3 ); MS (MALDI) was calculated to be 
786.1 for C 35 H 65 N 6 O 10 Si 2 (M + H + ) and found to be 786.4. 
  5.  Synthesis of N 4 -Benzoyl-2′ -O- ( N,N' -di-boc-guanidinopropyl)-
3′,5′ -O- (tetraisopropyldisiloxane-1,3-diyl)-cytidine ( 2g ). 2′ -O-
 ( N,N' -Di-boc-guanidinopropyl)-3′,5′ -O- (tetraisopropyldisiloxane-
1,3-diyl)-cytidine ( 2c ) (1.0 g, 1.27 mmol) is dissolved in dry 
pyridine (10 mL) and the solution is cooled in an ice bath. 
Benzoyl chloride (240 μL, 2.06 mmol) is added and the reac-
tion solution is stirred at 0 °C for 1 h. The reaction is quenched 
with water, and then ammonia (25 % in water; 3 mL) is added. 
The mixture is stirred for 30 min at room temperature. 
The solvents are evaporated and the residue is dissolved in 
dichloromethane and washed with saturated sodium bicarbonate 
solution. The organic layer is dried over Na 2 SO 4 and after 
evaporating the solvent, the  residue is purifi ed by column 
chromatography using dichloromethane/methanol (98:2, 
v/v) and 950 mg (84 %) of N 4 -Benzoyl-2′ -O- ( N,N' -di-boc-
guanidinopropyl)-3′,5′ -O- (tetraisopropyldisiloxane-1,3-diyl)-
cytidine ( 2g ) can be obtained.  1 H NMR (400 MHz, DMSO- d  6  ) 
 δ [ppm] 11.50 (s, 1H, N H ), 11.31 (s, 1H, N H ), 8.40–8.37 
(m, 1H, N H –CH 2 –), 8.15 (d, 1H, J = 7.3 Hz,  H 6), 8.03–7.99 
(m, 2H, benzoyl), 7.65–7.60 (m, 1H, benzoyl), 7.53–7.49 
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(m, 2H, benzoyl), 7.38 (d, 1H, J = 7.3 Hz,  H 5), 5.73 (s, 1H, 
 H 1′), 4.24–4.13 (m, 3H,  H 3′,  H 4′,  H 5′), 4.02–4.03 (m, 1H, 
 H 2′), 3.97–3.92 (m, 1H,  H 5′), 3.87–3.83 (m, 2H, O–C H 2 –
CH 2 –CH 2 –NH–), 3.52–3.35 (m, 2H, O–CH 2 –CH 2 –C H 2 –
NH–), 1.87–1.80 (m, 2H, O–CH 2 –C H 2 –CH 2 –NH–), 1.45 (m, 
9H, C(C H 3 ) 3 ), 1.38 (m, 9H, C(C H 3 ) 3 ), 1.08–0.95 (m, 28H, 
tetraisopropyl-C H and -C H 3 ); MS (ESI) was calculated to be 
890.2 for C 42 H 69 N 6 O 11 Si 2 (M + H + ), and found to be 890.4. 
  6.  Synthesis of N 4 -Benzoyl-2′ -O- ( N,N' -di-boc-guanidinopropyl)-
cytidine ( 2h ).  N  4  -Benzoyl-2′ -O- ( N,N' -di-boc- guanidinopropyl)-
3′,5′ -O- (tetraisopropyldisiloxane-1,3-diyl)-cytidine ( 2g ) (900 mg, 
1.01 mmol) is dissolved in tetrahydrofurane (20 mL). Triethy-
lamine trihydrofl uoride (Et 3 N · 3HF; 560 μL, 3.54 mmol) is 
added and the solution is stirred at room temperature for 2 h. 
The solvent is evaporated and the residue is purifi ed using 
column chromatography with dichloromethane/methanol 
(98:2–97:3, v/v) to give 607 mg (93 %) of N 4 -Benzoyl-2′ -O-
 ( N,N' -di-boc-guanidinopropyl)-cytidine ( 2h ) as a pale yellow 
foam.  1 H NMR (300 MHz, DMSO- d  6  )  δ [ppm] 11.50 (s, 1H, 
N H ), 11.28 (bs, 1H, N H ), 8.57 (d, 1H, J = 7.5 Hz,  H 6), 
8.40–8.35 (m, 1H, N H –CH 2 –), 8.02–7.98 (m, 2H, benzoyl), 
7.66–7.60 (m, 1H, benzoyl), 7.54–7.48 (m, 2H, benzoyl), 
7.34 (d, 1H, J = 7.2 Hz,  H 5), 5.86–5.85 (m, 1H,  H 1′), 5.24 
(t, 1H, J = 5.0 Hz, 5′–O H ), 4.98 (d, 1H, J = 6.8 Hz, 3′–O H ), 
4.12–3.60 (m, 7H), 3.44–3.37 (m, 2H, O–CH 2 –CH 2 –C H 2 –
NH–), 1.85–1.76 (m, 2H, O–CH 2 –C H 2 –CH 2 –NH–), 1.46 
(m, 9H, C(C H 3 ) 3 ), 1.38 (m, 9H, C(C H 3 ) 3 ); HRMS (MALDI) 
was calculated to be 647.3035 for C 30 H 43 N 6 O 10 (M + H + ), and 
found to be 647.3031. 
  7.  Synthesis of N 4 -Benzoyl-2′ -O- ( N,N' -di-boc-guanidinopropyl)-
5′ -O- (4,4′-dimethoxytrityl)-cytidine ( 2i ).  N  4  -Benzoyl-2′ -O-
 ( N,N' -di-boc-guanidinopropyl)-cytidine ( 2h ) (516 mg, 
798 μmol) is dissolved in dry pyridine (20 mL) and the solu-
tion is cooled in an ice bath. 4,4′-Dimethoxytrityl chloride 
(515 mg, 1.52 mmol) is added and the mixture is stirred over-
night while the bath comes up to room temperature. The reac-
tion is quenched with methanol (10 mL) and the solvents are 
evaporated. The residue is purifi ed by column chromatography 
using dichloromethane/methanol (99:1–98:2, v/v) (The col-
umn is packed with solvent containing 1 % triethylamine ( see 
 Note 8 )) to yield 715 mg (94 %) N 4 -Benzoyl-2′ -O- ( N,N' -di-
boc- guanidinopropyl)-5′ -O- (4,4′-dimethoxytrityl)-cytidine 
( 2i ) as a pale yellow foam.  1 H NMR (400 MHz, DMSO- d  6  )  δ 
[ppm] 11.50 (s, 1H, N H ), 11.29 (bs, 1H, N H ), 8.43–8.37 
(m, 2H,  H 6, N H –CH 2 –), 8.02–7.99 (m, 2H, benzoyl), 7.65–
7.60 (m, 1H, benzoyl), 7.54–7.50 (m, 2H, benzoyl), 7.43–
7.25 (m, 9H, DMTr), 7.18–7.15 (m, 1H,  H 5), 6.94–6.91 
(m, 4H, DMTr), 5.88 (s, 1H,  H 1′), 5.04 (d, 1H, J = 7.3 Hz, 
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3′–O H ), 4.34–4.28 (m, 1H,  H 3′), 4.13–4.10 (m, 1H,  H 4′), 
3.94–3.87 (m, 2H,  H 2′, 1× O–C H 2 –CH 2 –CH 2 –NH–), 3.76 
(s, 6H, 2× OC H 3 ), 3.76–3.70 (m, 1H, 1× O–C H 2 –CH 2 –
CH 2 –NH–), 3.46–3.36 (m, 4H, 2×  H 5′, O–CH 2 –CH 2 –C H 2 –
NH–), 1.86–1.80 (m, 2H, O–CH 2 –C H 2 –CH 2 –NH–), 1.42 
(m, 9H, C(C H 3 ) 3 ), 1.36 (m, 9H, C(C H 3 ) 3 ); HRMS (MALDI) 
was calculated to be 971.4161 for C 51 H 60 N 6 O 12 Na (M + Na + ), 
and found to be 971.4181. 
  8.  Synthesis of N 4 -Benzoyl-2′ -O- ( N,N' -di-boc-guanidinopropyl)-
5′ -O- (4,4′-dimethoxytrityl)-cytidine 3′-(cyanoethyl)- N,N - 
diisopropyl phosphoramidite ( 2d ). N 4 -Benzoyl-2′ -O- ( N,N' -
di-boc-guanidinopropyl)-5′ -O- (4,4′-dimethoxytrityl)-cytidine 
( 2i ) (683 mg, 720 μmol) is dissolved in dichloromethane 
(15 mL). 2-cyanoethyl  N,N,N',N' -tetraisopropylamino phos-
phane (274 μL, 864 μmol) and 4,5-dicyanoimidazole (98 mg, 
828 μmol) are added. After stirring at room temperature for 
5 h, completion of the reaction is checked by TLC. In the 
event that some starting material did not react, an additional 
0.5 equivalents of the phosphitylating agent as well as the cata-
lyst are added and the reaction is stirred at room temperature 
for additional 4 h. After completion of the reaction the solu-
tion is diluted with dichloromethane and washed with satu-
rated sodium bicarbonate solution. After drying the organic 
layer over MgSO 4 the solvent is evaporated and the residue is 
dissolved in a small amount (5 mL) of dichloromethane. This 
solution is added dropwise into a fl ask with hexane (500 mL) 
to form a white precipitate. Two thirds of the solvent is evapo-
rated and the residual solvent is decanted carefully ( see  Note 9 ). 
The precipitate is redissolved in benzene and lyophilized ( see 
 Note 10 ) to give 738 mg (89 %) of N 4 -Benzoyl- 2′ -O- ( N,N' -
di-boc-guanidinopropyl)-5′ -O- (4,4′-dimethoxytrityl)-cytidine 
3′-(cyanoethyl)- N,N -diisopropyl phosphoramidite ( 2d ) ( see 
 Note 11 ).  1 H NMR (400 MHz, DMSO- d  6  )  δ [ppm] 11.50–
11.48 (m, 1H, N H ), 11.25 (bs, 1H, N H ), 8.52–8.45 (m, 1H, 
 H 6), 8.39–8.34 (m, 1H, N H –CH 2 –), 8.01–7.98 (m, 2H, 
benzoyl), 7.66–7.61 (m, 1H, benzoyl), 7.53–7.49 (m, 2H, 
benzoyl), 7.45–7.25 (m, 9H, DMTr), 7.13–7.09 (m, 1H, 
 H 5), 6.93–6.89 (m, 4H, DMTr), 5.95–5.92 (m, 1H,  H 1′), 
4.56–4.38 (m, 1H,  H 3′), 4.31–4.28 (m, 1H,  H 4′), 4.07–3.29 
(m, 17H), 2.90–2.57 (m, 2H, cyanoethyl), 1.86–1.78 (m, 
2H, O–CH 2 –C H 2 –CH 2 –NH–), 1.40–1.35 (m, 18H, 2× 
C(C H 3 ) 3 ), 1.20–0.93 (m, 12H,  i Pr–C H 3 );  31 P NMR 
(162 MHz, DMSO- d  6  )  δ [ppm] 148.4, 148.0 (The signal of 
the hydrolyzed phosphitylation reagent appears at 13.9 ppm); 
HRMS (MALDI) was calculated to be 1,149.5421 for 
C 60 H 78 N 8 O 13 P (M + H + ), was found to be 1,149.5447. 
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  1.  Synthesis of N 3 -Benzoyl-2′ -O -cyanoethyl-3′,5′ -O- (tetraisopro-
pyldisiloxane-1,3-diyl)-uridine ( 3b ). N 3 -Benzoyl- 3′,5′ -O-
 (tetraisopropyldisiloxane-1,3-diyl)-uridine ( 3a ) (1.14 g, 1.93 
mmol) is dissolved in 9.6 mL of  tert- butanol. Freshly distilled 
acrylonitrile (2.5 mL, 38.6 mmol) is added. After addition of 
cesium carbonate (645 mg, 1.98 mmol) the reaction is stirred 
for 4 h at room temperature. The reaction solution is fi ltered 
over celite. The residue is washed with 100 mL of dichloro-
methane. The fi ltrate is evaporated in a vacuum. Purifi cation 
via column chromatography in dichloromethane/ethyl acetate 
(99:1–95:5, v/v) yields 746 mg (60 %) of N 3 -Benzoyl-2′ -O -
cyanoethyl-3′,5′ -O- (tetraisopropyldisiloxane-1,3-diyl)-uridine 
( 3b ) as a white powder.  1 H NMR (250 MHz, acetone- d  6  )  δ 
[ppm] 8.03–7.99 (m, 3H,  H 6, benzoyl), 7.79–7.72 (m, 1H, 
benzoyl), 7.61–7.55 (m, 2H, benzoyl), 5.80–5.74 (m, 2H, 
 H 5,  H 1′), 4.50–3.94 (m, 7H), 2.80–2.75 (m, 2H, O–CH 2 –
C H 2 –CN), 1.17–1.07 (m, 28H, tetraisopropyl-C H and -C H 3 ); 
HRMS (MALDI) was calculated to be 666.2637 for 
C 31 H 45 N 3 O 8 Si 2 Na (M + Na + ) and found to be 666.2647. 
  2.  Synthesis of 2′ -O- (Aminopropyl)-3′,5′ -O- (tetraisopropyl-
disiloxane-1,3-diyl)-uridine ( 3e ) ( see  Notes 5 and  6 ). N 3 -
Benzoyl-2′ -O -cyanoethyl-3′,5′ -O- (tetraisopropyldisiloxane-
1,3-diyl)-uridine ( 3b ) (500 mg, 0.78 mmol) is dissolved in 
10 mL of methanol in a glass tube suitable for the applied 
autoclave. Approximately 0.5 mL of Raney-nickel slurry is put on 
a glass fi lter, washed thoroughly with dry methanol ( see  Note 7 ) 
and rinsed into the glass tube containing the solution of N 3 -
Benzoyl-2′ -O -cyanoethyl-3′,5′ -O- (tetraisopropyldisiloxane-1,
3-diyl)-uridine ( 3b ). After addition of 5 mL methanol satu-
rated with ammonia, the mixture is stirred for 1 h at room 
temperature in an autoclave under a hydrogen atmosphere 
(30 bar). The reaction solution is decanted from the catalyst 
into a glass fi lter. The catalyst is washed several times with 
methanol and the solvent is removed from the combined fi l-
trates under reduced pressure. The product is purifi ed on a 
silica gel column initially using dichloromethane/ethyl acetate 
(7:3–0:1, v/v) and thereafter ethyl acetate/methanol/triethyl-
amine (6:3.5:0.5, v/v/v) to obtain 253 mg (60 %) of 
2′ -O- (Aminopropyl)-3′,5′ -O- (tetraisopropyldisiloxane-1,3-
diyl)-uridine ( 3e ) as a white powder. If no NMR or MS analy-
sis is needed, the crude product can be used for the next step 
without chromatographic purifi cation.  1 H NMR (250 MHz, 
acetone- d  6  )  δ [ppm] 7.81 (d, 1H, J = 8.1 Hz,  H 6), 5.71 (s, 
1H,  H 1′), 5.53 (d, 1H, J = 8.1 Hz,  H 5), 4.39–4.34 (m, 1H, 
 H 3′), 4.28–4.23 (m, 1H,  H 5′), 4.14–4.03 (m, 3H,  H 2′,  H 4′, 
 H 5′), 3.97–3.81 (m, 2H, O–C H 2 –CH 2 –CH 2 –NH 2 ), 3.37–
3.25 (m, 2H, O–CH 2 –CH 2 –C H 2 –NH 2 ), 1.92–1.82 (m, 2H, 
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O–CH 2 –C H 2 –CH 2 –NH 2 ), 1.14–1.05 (m, 28H, tetraisopropyl-
C H and -C H 3 ); HRMS (MALDI) was calculated to be 544.2869 
for C 24 H 46 N 3 O 7 Si 2 (M + H + ), and found to be 544.2880. 
  3.  Synthesis of 2′ -O- ( N,N' -Di-boc-guanidinopropyl)-3′,5′ -O-
 (tetraisopropyldisiloxane-1,3-diyl)-uridine ( 3c ).  N,N' -Di-boc- 
N '' -trifl yl guanidine (320 mg, 0.82 mmol) is dissolved in 
3.6 mL dichloromethane and triethylamine (150 μL) is added. 
The solution is cooled in an ice bath and 2′ -O- (Aminopropyl)-
3′,5′ -O- (tetraisopropyldisiloxane-1,3-diyl)-uridine ( 3e ) (490 mg, 
0.9 mmol) is added. After 15 min the reaction mixture is 
removed from the ice bath and is stirred for 2.5 h at room 
temperature. The reaction solution is washed with saturated 
sodium bicarbonate solution and brine. After drying over 
Na 2 SO 4 the solvent is evaporated. The crude product is puri-
fi ed using column chromatography with dichloromethane/
methanol (96:4–94:6, v/v). A yield of 410 mg (58 %) of 2′ -O-
 ( N,N' -Di-boc-guanidinopropyl)-3′,5′ -O- (tetraisopro-
pyldisiloxane- 1,3-diyl)-uridine ( 3c ) can be obtained.  1 H NMR 
(400 MHz, DMSO- d  6  )  δ [ppm] 11.49 (s, 1H, N H ), 11.37 
(m, 1H, N H uridine ), 8.40–8.37 (m, 1H, N H –CH 2 –), 7.64 (d, 
1H, J = 7.9 Hz,  H 6), 5.64 (s, 1H,  H 1′), 5.53 (d, 1H, J = 7.9 Hz, 
 H 5), 4.25–4.22 ( H 3′), 4.13–4.09 (m, 1H,  H 5′), 4.06–4.05 
(m, 1H,  H 2′), 4.03–4.00 (m, 1H,  H 4′), 3.93–3.89 (m, 1H, 
 H 5′), 3.84–3.70 (m, 2H, O–C H 2 –CH 2 –CH 2 –NH–), 3.49–
3.32 (m, 2H, O–CH 2 –CH 2 –C H 2 –NH–), 1.83–1.77 (m, 2H, 
O–CH 2 –C H 2 –CH 2 –NH–), 1.45 (s, 9H, C(C H 3 ) 3 ), 1.38 (s, 
9H, C(C H 3 ) 3 ), 1.06–0.97 (m, 28H, tetraisopropyl-C H and 
-C H 3 ); HRMS (MALDI) was calculated to be 808.3955 for 
C 35 H 63 N 5 O 11 Si 2 Na (M + Na + ), and found to be 808.3991. 
  4.  Synthesis of 2′ -O- ( N,N' -Di-boc-guanidinopropyl)-uridine 
( 3f ). To a solution of 2′ -O- ( N,N' -Di-boc-guanidinopropyl)-
3′,5′ -O- (tetraisopropyldisiloxane-1,3-diyl)-uridine ( 3c ) 
(910 mg, 1.16 mmol) and triethylamine (240 μL) in 13 mL 
tetrahydrofurane, NEt 3 · 3HF (700 μL, 4.3 mmol) is added. 
The reaction mixture is stirred for 1 h at room temperature. 
The solvents are evaporated and the residue is purifi ed on a 
 silica gel column using dichloromethane/methanol (93:7–92:8, 
v/v) to give 629 mg (97 %) 2′ -O- ( N,N' -Di-boc- guanidinopropyl)-
uridine ( 3f ) as a white foam.  1 H NMR (250 MHz, acetone- d  6  ) 
 δ [ppm] 11.67 (bs, 1H, N H ), 10.03 (bs, 1H, N H ), 8.46–8.41 
(m, 1H, N H –CH 2 –), 8.10 (d, 1H, J = 8.2 Hz,  H 6), 5.99–5.97 
(m, 1H,  H 1′), 5.58 (d, 1H, J = 8.2 Hz,  H 5), 4.39–3.46 (m, 
11H), 1.95–1.85 (m, 2H, O–CH 2 –C H 2 –CH 2 –NH–), 1.51 (s, 
9H, C(C H 3 ) 3 ), 1.43 (s, 9H, C(C H 3 ) 3 ); MS (ESI) was calcu-
lated to be 566.2 for C 23 H 37 N 5 O 10 Na (M + Na + ), and found to 
be 567.0. 
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  5.  Synthesis of 2′ -O- ( N,N' -Di-boc-guanidinopropyl)-5′ -O- (4,
4′-dimethoxytrityl)-uridine ( 3g ). 2′ -O- ( N,N' -Di-boc- guani-
dinopropyl)-uridine ( 3f ) (588 mg, 1.08 mmol) is dissolved in 
11.4 mL of dry pyridine and 4,4′-Dimethoxytrityl chloride 
(460 mg, 1.36 mmol) is added. The reaction solution is stirred 
at room temperature for 5 h. The reaction mixture is quenched 
with water and the solvents are evaporated. The residue is dis-
solved in dichloromethane, washed twice with saturated 
sodium bicarbonate solution (2 × 50 mL) and then twice with 
brine (2 × 50 mL). The organic layer is dried over Na 2 SO 4 and 
the solvent is removed under reduced pressure. After purifi ca-
tion using column chromatography with dichloromethane/
methanol (97:3, v/v) containing 0.5 % triethylamine ( see  Note 
8 ), 785 mg (86 %) of 2′ -O- ( N,N' -Di-boc-guanidinopropyl)-
5′ -O- (4,4′-dimethoxytrityl)-uridine ( 3g ) (yellow powder) can 
be obtained. There may be a yellow impurity that cannot be 
separated on the column.  1 H NMR (250 MHz, DMSO- d  6  )  δ 
[ppm] 11.49 (s, 1H, N H ), 11.37 (m, 1H, N H ), 8.41–8.36 
(m, 1H, N H –CH 2 –), 7.75 (d, 1H, J = 8.1 Hz,  H 6), 7.40–7.23 
(m, 9H, DMTr), 6.92–6.88 (m, 4H, DMTr), 5.83–5.82 (m, 
1H,  H 1′), 5.29–5.25 (m, 1H,  H 5), 5.09–5.06 (m, 1H, 
3′-O H ), 4.23–3.88 (m, 3H), 3.74 (s, 6H, 2× O–C H 3 ), 3.68–
3.63 (m, 2H), 3.43–3.20 (m, 4H), 1.82–1.72 (m, 2H, O–
CH 2 –C H 2 –CH 2 –NH–), 1.44 (s, 9H, C(C H 3 ) 3 ), 1.37 (s, 9H, 
C(C H 3 ) 3 ); HRMS (MALDI) was calculated to be 846.3920 
for C 44 H 56 N 5 O 12 (M + H + ), and found to be 846.3946. 
  6.  Synthesis of 2′ -O- ( N,N' -Di-boc-guanidinopropyl)-5′ -O- (4,
4′-dimethoxytrityl)-uridine 3′-(cyanoethyl)- N,N -diisopropyl 
phosphoramidite ( 3d ). 2′ -O- ( N,N' -Di-boc-guanidinopropyl)-
5′ -O- (4,4′-dimethoxytrityl)-uridine ( 3g ) (770 mg, 0.9 mmol) 
is dissolved in dichloromethane (11 mL). To this solution, 
2-cyanoethyl  N,N,N',N' -tetraisopropylamino phosphane 
(400 μL, 1.26 mmol) and 4,5-dicyanoimidazole (130 mg, 
1.1 mmol) are added. The reaction progress is observed with 
TLC (dichloromethane/ethyl acetate 1:1 (v:v), containing 
0.5 % triethylamine). In the event that after 2 h some starting 
material did not react, an additional 0.3 equivalents of the 
 phosphitylating agent as well as the catalyst are added and the 
reaction is stirred at room temperature for additional 2 h. After 
completion of the reaction the reaction mixture is washed 
twice with saturated sodium bicarbonate solution (2 × 100 mL) 
and once with brine (200 mL). After drying over Na 2 SO 4 , the 
solvent is evaporated and the residue is purifi ed on a silica gel 
column with dichloromethane/ethyl acetate (6:4–1:1, v/v) 
containing 0.5 % triethylamine ( see  Note 8 ). 2′ -O- ( N,N' -Di-
boc- guanidinopropyl)-5′ -O- (4,4′-dimethoxytrityl)-uridine 
3′-(cyanoethyl)- N,N -diisopropyl phosphoramidite ( 3d ) is 
obtained as a light yellow foam (762 mg, 83 %).  1 H NMR 
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(400 MHz, DMSO- d  6  )  δ [ppm] 11.50–11.48 (m, 1H, N H ), 
11.35 (bs, 1H, N H ), 8.39–8.33 (m, 1H, N H –CH 2 –), 7.87–
7.80 (m, 1H,  H 6), 7.41–7.22 (m, 9H, DMTr), 6.91–6.86 (m, 
4H, DMTr), 5.86–5.84 (m, 1H,  H 1′), 5.23–5.18 (m, 1H, 
 H 5), 4.46–4.32 (m, 1H), 4.21–4.16 (m, 1H), 4.09–4.03 (m, 
1H), 3.83–3.26 (m, 16H), 2.80–2.59 (m, 2H, − O– CH 2 –
C H 2 –CN), 1.81–1.74 (m, 2H, O–CH 2 –C H 2 –CH 2 –NH–), 
1.42–1.36 (m, 18H, C(C H 3 ) 3 ), 1.13–0.94 (m, 12H,  i Pr–
C H 3 );  31 P NMR (121 MHz, DMSO- d  6  )  δ [ppm] 150.0, 148.6; 
HRMS (MALDI) was calculated to be 1,046.4999 for 
C 53 H 73 N 7 O 13 P (M + H + ), and found to be 10,046.5021. 
  1.  Synthesis of 2′ -O- (2-cyanoethyl)-3′,5′ -O- di- tert- butylsilane-
diylguanosine ( 4b ).  O 6 -(2,4,6- Triisopropylbenzenesulfonyl)-
3′,5′ -O- di- tert- butylsilanediylguanosine ( 4a ) (2.28 g, 
3.3 mmol) is dissolved in  tert- butanol (17 mL). Freshly dis-
tilled acrylonitrile (4.25 mL, 66 mmol) and cesium carbonate 
(1.16 g, 3.3 mmol) are added to the solution. After vigorous 
stirring at room temperature for 2–3 h, the mixture is fi ltered 
through celite. The solvent and excess reagents are removed in 
vacuo. The crude material is used for the next reaction without 
further purifi cation: The residue is dissolved in 4 mL of a mix-
ture of formic acid/dioxane/water (70:24:6, v/v/v). After 
stirring at room temperature for 1 h, water (150 mL) is added 
to the mixture and the solution is extracted with dichloro-
methane. The organic layer is dried over Na 2 SO 4 and the sol-
vent is evaporated. The residue is purifi ed using silica gel 
column chromatography with dichloromethane/methanol 
(9:1, v/v) to give 1.1 g (70 % over 2 steps) of 2′ -O- (2-
cyanoethyl)-3′,5′ -O- di- tert- butylsilanediylguanosine ( 4b ) as a 
colorless foam.  1 H NMR (250 MHz, DMSO- d  6  )  δ [ppm] 
10.71 (bs, 1H, N H ), 7.89 (s, 1H,  H 8), 6.45 (bs, 2H, N H 2 ), 
5.81 (s, 1H,  H 1′), 4.45–4.33 (m, 3H), 4.05–3.81 (m, 4H), 
2.83–2.76 (m, 2H, O–CH 2 –C H 2 –CN), 1.06 (s, 9H, C(C H 3 ) 3 ), 
1.01 (s, 9H, C(C H 3 ) 3 ); MS (ESI) was calculated to be 477.2 
for C 21 H 33 N 6 O 5 Si (M + H + ), and found to be 477.5. 
  2.  Synthesis of 2′ -O- (2-Aminopropyl)-3′,5′ -O- di- tert- butylsilane-
diylguanosine ( 4e ) ( see  Notes 5 and  6 ). 2′ -O- (2- cyanoethyl)-
3′,5′ -O- di- tert- butylsilanediylguanosine ( 4b ) (500 mg, 
1.06 mmol) is dissolved in dry methanol (5 mL). Raney nickel 
(ca. 0.5 mL of the methanol-washed sediment ( see  Note 7 )) 
and methanol (5 mL) saturated with ammonia are then added. 
The mixture is hydrogenated at 30 bar hydrogen- pressure for 
1 h at room temperature. Thereafter the mixture is fi ltered 
through a glass fi lter and the catalyst is washed several times 
with methanol and a methanol/water mixture. The solvents 
are evaporated from the fi ltrate and the residue is used without 
further purifi cation for the next reaction. MS (ESI) was calculated 
to be 481.3 for C 21 H 37 N 6 O 5 Si (M + H + ), and found to be 481.8. 
3.4  Synthesis of the 
2′- O -GP- Modifi ed 
Guanosine-
phosphoramidite
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  3.  Synthesis of 2′ -O- ( N,N' -Di-tert- butoxycarbonylguanidino-
propyl)-3′,5′ -O- di- tert- butylsilanediylguanosine ( 4c ).  N,N' -
Di-boc- N'' -trifl ylguanidine (163 mg, 0.415 mmol) is dissolved 
in dichloromethane (2.1 mL) and triethylamine (54 μL) is 
then added. The solution is cooled in an ice bath and 2′ -O- (2-
Aminopropyl)-3′,5′ -O-di- tert - butylsilanediylguanosine ( 4e ) 
(200 mg, 0.42 mmol) is added. After 30 min the reaction mix-
ture is removed from the ice bath and stirred for additional 
30 min at room temperature. The reaction solution is washed 
with saturated sodium bicarbonate solution and brine. After 
drying over Na 2 SO 4 the solvent is evaporated. The residue is 
purifi ed by column chromatography using dichloromethane/
methanol (9:1, v/v) to give 270 mg (89 %) of 2′ -O- ( N,N' -Di-
ter t- butoxycarbonylguanidinopropyl)-3′,5′ -O- di- ter t- 
butylsilanediylguanosine ( 4c ).  1 H NMR (400 MHz, 
DMSO- d  6  ) δ [ppm] 11.49 (bs, 1H, N H ), 10.66 (bs, 1H, N H ), 
8.56–8.53 (m, 1H, N H –CH 2 –), 7.87 (s, 1H,  H 8), 6.39 (bs, 
2H, N H 2 ), 5.86 (s, 1H,  H 1′), 4.42–4.38 (m, 1H,  H 3′), 4.30–
4.27 (m, 2H,  H 2′,  H 5′), 4.06–3.93 (m, 3H,  H 4′,  H 5′, ½× 
O–C H 2 –CH 2 –CH 2 –NH–), 3.72–3.67 (m, 1H, ½× O–C H 2 –
CH 2 –CH 2 –NH–), 3.51–3.30 (m, 2H, O–CH 2 –CH 2 –C H 2 –
NH–), 1.84–1.77 (m, 2H, O–CH 2 –C H 2 –CH 2 –NH–), 1.46 (s, 
9H, −CO–C(C H 3 ) 3 ), 1.39 (s, 9H, −CO–C(C H 3 ) 3 ), 1.06 (s, 
9H, −Si–C(C H 3 ) 3 ), 0.97 (s, 9H, −Si–C(C H 3 ) 3 ); HRMS 
(MALDI) was calculated to be 723.3856 for C 32 H 55 N 8 O 9 Si 
(M + H + ), and found to be 723.3880. 
  4.  Synthesis of  N  2  -Dimethylformamidine-2′ -O- ( N,N' -di-tert- 
butoxycarbonylguanidinopropyl)-3′,5′ -O- di- tert- butylsilane-
diylguanosine ( 4f ). 2′ -O- ( N,N' -Di- tert- butoxycarbonylguani-
dinopropyl)-3′,5′ -O-di - tert - butylsilanediylguanosine ( 4c ) 
(1.12 g, 1.55 mmol) is dissolved in 25 mL dry methanol.  N,N -
dimethylformamide dimethyl acetal (1.0 mL, 7.76 mmol) is 
added and the solution is stirred at room temperature over-
night. After a reaction time of 12 h the solvents are removed in 
vacuo and the residue is purifi ed by silica gel column chroma-
tography using dichloromethane/methanol (19:1, v/v) to 
give 1.14 g (94 %) of  N 2 -Dimethylformamidine - 2 ′ -O- ( N,N' -
di-tert- butoxycarbonylguanidinopropyl)-3′,5′ -O- di- tert- 
butylsilanediylguanosine ( 4f ).  1 H NMR (400 MHz, DMSO- d  6  ) 
 δ [ppm] 11.51 (s, 1H, N 1 H ), 11.40 (s, 1H, N H -boc), 8.54 (s, 
1H, −N = C H –N(CH 3 ) 2 ), 8.47 (m, 1H, 2′ -O –CH 2 –CH 2 –
CH 2 –N H –), 7.99 (s, 1H,  H -8), 5.98 (s, 1H,  H 1′), 4.48–4.45 
(m, 1H,  H 5′), 4.41–4.39 (m, 1H,  H 2′), 4.33–4.30 (m, 1H, 
 H 5′), 4.07–3.99 (m, 2H,  H 3′ und  H 4′), 3.98–3.77 (m, 2H, 
2′ -O –C H 2 –CH 2 –CH 2 –NH–), 3.48–3.37 (m, 2H, 2′ -O –CH 2 –
CH 2 –C H 2 –NH–), 3.14 (s, 3H, N–C H 3 ), 3.04 (s, 3H, N–
C H 3 ), 1.87–1.78 (m, 2H, 2′ -O –CH 2 –C H 2 –CH 2 –NH–), 1.47 
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(s, 9H, −CO–C(C H 3 ) 3 ), 1.37 (s, 9H, −CO–C(C H 3 ) 3 ), 1.06 (s, 
9H, −Si–C(C H 3 ) 3 ), 1.00 ppm (s, 9H, −Si–C(C H 3 ) 3 ); HRMS 
(MALDI) was calculated to be 800.4097 for C 35 H 59 N 9 O 9 SiNa 
(M + Na + ), and found to be 800.4124. 
  5.  Synthesis of  N  2  -Dimethylformamidine-2′ -O- ( N,N' -di-tert-
butoxycarbonylguanidinopropyl)-guanosine ( 4g ).  N 2 -Dimethyl-
formamidine - 2 ′ -O- ( N,N' -di-tert- butoxycarbonylguanidinopropyl)-
3′,5′ -O- di- tert- butylsilanediylguanosine ( 4f ) (1.24 g, 1.59 mmol) 
is dissolved in dry tetrahydrofurane (17 mL). Triethylamine 
(470 μL, 3.18 mmol) and Et 3 N · 3HF (943 μL, 5.79 mmol) are 
then added. After stirring at room temperature for 1 h the solvent 
is evaporated. The residue is purifi ed using silica gel column chro-
matography with dichloromethane/methanol (9:1, v/v) to give 
840 mg (83 %) of  N  2  -Dimethylformamidine-2′ -O- ( N,N' -di- tert-
 butoxycarbonylguanidinopropyl)-guanosine ( 4g ) as a white foam. 
 1 H NMR (400 MHz, DMSO- d  6  )  δ [ppm] 11.50 (s, 1H, N 1 H ), 
11.34 (s, 1H, N H -boc), 8.54 (s, 1H, −N = C H –N(CH 3 ) 2 ), 8.35 
(m, 1H, 2′ -O –CH 2 –CH 2 –CH 2 –N H –), 8.10 (s, 1H,  H 8), 5.95–
5.94 (m, 1H,  H 1′), 5.14–5.12 (m, 1H, 3′–O H ), 5.08–5.05 (m, 
1H, 5′–O H ), 4.31–4.30 (m, 2H,  H 2′,  H 3′), 3.95–3.93 (m, 1H, 
 H 4′), 3.67–3.56 (m, 4H, 2×  H 5′, O–C H 2 –CH 2 –CH 2 –NH–), 
3.36–3.33 (m, 2H, O–CH 2 –CH 2 –C H 2 –NH–), 3.16 (s, 3H, N–
C H 3 ), 3.04 (s, 3H, N–C H 3 ), 1.77–1.74 (m, 2H, O–CH 2 –C H 2 –
CH 2 –NH–), 1.47 (s, 9H, −CO–C(C H 3 ) 3 ), 1.37 (s, 9H, 
−CO–C(C H 3 ) 3 ); HRMS (MALDI) was calculated to be 660.3076 
for C 27 H 43 N 9 O 9 Na (M + Na + ), and found to be 660.3087. 
  6.  Synthesis of  N  2  -Dimethylformamidine-2′ -O- ( N,N' -di-tert- 
butoxycarbonylguanidinopropyl)-5′ -O- (4,4′-dimethoxytrityl)-
guanosine ( 4h ).  N  2  -Dimethylformamidine-2′ -O- ( N,N' -di-
tert- butoxycarbonylguanidinopropyl)-guanosine ( 4g ) (840 mg, 
1.32 mmol) is dissolved in dry pyridine (30 mL). 4,4′-
Dimethoxytrityl chloride (670 mg, 1.98 mmol) is added and 
the solution is stirred for 3 h at room temperature. After the 
reaction is complete as assessed by TLC, the reaction is 
quenched with methanol and the solvents are evaporated. The 
residue is purifi ed by silica gel column chromatography using 
dichloromethane/methanol (100:0 → 95:5, v/v; the column is 
packed with dichloromethane containing 0.5 % triethylamine 
( see  Note 8 )) to give 1.08 g (87 %) of  N 2 -Dimethylformamidine- 
2 ′ -O- ( N,N' -di- tert- butoxycarbonylguanidinopropyl)-5′ -O-
 (4,4′-dimethoxytrityl)-guanosine ( 4h ).  1 H NMR (400 MHz, 
DMSO- d  6  )  δ [ppm] 11.51 (s, 1H, N 1 H ), 11.38 (s, 1H, N H - 
boc), 8.50 (s, 1H, −N = C H –N(CH 3 ) 2 ), 8.40 (m, 1H, 2′ -O –
CH 2 –CH 2 –CH 2 –N H –), 7.94 (s, 1H,  H 8), 7.38–7.20 (m, 9H, 
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DMTr), 6.86–6.82 (m, 4H, DMTr), 6.01–6.00 (m, 1H,  H 1′), 
5.16–5.13 (m, 1H, 3′–O H ), 4.35–4.30 (m, 2H,  H 2′,  H 3′), 
4.08–4.05 (m, 1H,  H 4′), 3.73 (s, 6H, 2× O–C H 3 ), 3.71–3.61 
(m, 2H, 2′ -O –C H 2 –CH 2 –CH 2 –NH–), 3.40–3.35 (m, 2H, 2′ -
O –CH 2 –CH 2 –C H 2 –NH–), 3.28–3.16 (m, 2H, 2×  H 5′), 3.09 
(s, 3H, N–C H 3 ), 3.02 (s, 3H, N–C H 3 ), 1.80–1.74 (m, 2H, 
2′ -O –CH 2 –C H 2 –CH 2 –NH–), 1.44 (s, 9H, −CO–C(C H 3 ) 3 ), 
1.34 (s, 9H, −CO–C(C H 3 ) 3 ); HRMS (MALDI) was calculated 
to be 962.4383 for C 48 H 61 N 9 O 11 Na (M + Na + ), and found to 
be 962.4408. 
  7.  Synthesis of  N  2  -Dimethylformamidine-2′ -O- ( N,N' -di-tert- 
butoxycarbonylguanidinopropyl)-5′ -O- (4,4′-dimethoxytrityl)-
guanosine 3′-(cyanoethyl)- N,N -diisopropylphosphoramidite 
( 4d ).  N  2  -Dimethylformamidine-2′ -O- ( N,N' -di-tert- utoxycar-
bonylguanidinopropyl)-5′ -O- (4,4′-dimethoxytrityl)-
guanosine ( 4h ) (1.08 g, 1.15 mmol) is dissolved in 
dichloromethane (25 mL), then 2-cyanoethyl- N,N,N',N' - 
tetraisopropylaminophosphane (590 μL, 1.76 mmol) and 
4,5-dicyanoimidazole (199 mg, 1.69 mmol) are added. After 
4 h the reaction progress is checked by TLC. In the event that 
some starting material did not react, an additional 0.3 equiva-
lents of the phosphitylating agent as well as the catalyst are 
added and the reaction is stirred at room temperature for addi-
tional 4 h. After completion of the reaction the reaction solu-
tion is washed twice with saturated sodium bicarbonate 
solution and once with brine. After drying over Na 2 SO 4 the 
solvent is evaporated and the residue is purifi ed using silica gel 
column chromatography with dichloromethane/acetone/
methanol (4:0:1 → 3:0:2 → 2:1:2 → 2:2:1, v/v, the column is 
packed with eluent containing 0.5 % triethylamine ( see 
 Note 8 )). The residue is dissolved in a small amount (5 mL) of 
dichloromethane. This solution is added dropwise into a fl ask 
with  hexane (500 mL) to form a white precipitate. Two thirds 
of the solvent is evaporated and the residual solvent decanted 
carefully ( see  Note 9 ). The precipitate is redissolved in benzene 
and lyophilized ( see  Note 10 ) to give 1.01 g (77 %) of 
 N  2 - D i m e t h y l f o r m a m i d i n e  -  2  ′  - O -  (  N , N '  - d i - t e r t - 
butoxycarbonylguanidinopropyl)-5′ -O- (4,4′-dimethoxytrityl)-
guanosine 3′-(cyanoethyl)- N,N -diisopropylphosphoramidite 
( 4d ) ( see  Note 11 ).  1 H NMR (400 MHz, DMSO- d  6  )  δ [ppm] 
11.50–11.48 (m, 1H, N H ), 11.39 (s, 1H, N H ), 8.44–8.42 
(m, 1H, −N = C H –N(CH 3 ) 2 ), 8.39–8.34 (m, 1H, 2′ -O –CH 2 –
CH 2 –CH 2 –N H –), 7.96 (s, 1H,  H 8), 7.37–7.19 (m, 9H, 
DMTr), 6.85–6.78 (m, 4H, DMTr), 6.07–6.05 (m, 1H,  H 1′), 
4.64–4.58 (m, 1H,  H 3′), 4.48–4.44 (m, 1H,  H 2′), 4.26–4.19 
(m, 1H,  H 4′), 3.80–3.23 (m, 10H), 3.73–3.70 (m, 6H, 2× 
OC H 3 ), 3.07 (s, 3H, N–C H 3 ), 3.02 (s, 3H, N–C H 3 ), 2.77–
2.74 (m, 1H, −P– O –CH 2 –C H 2 –CN), 2.55–2.52 (m, 1H, 
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−P– O –CH 2 –C H 2 –CN),1.80–1.72 (m, 2H, 2′ -O –CH 2 –C H 2 –
CH 2 –NH–), 1.44–1.34 (m, 18H, 2× –CO–C(C H 3 ) 3 ), 1.20–
0,93 (m, 12H, −N((CH(C H 3 ) 2 ) 2 );  31 P NMR (121 MHz, 
DMSO- d  6  )  δ [ppm] 149.21, 148.93. 
 The solid-phase syntheses of the GP-modifi ed oligonucleotides are 
carried out according to the phosphoramidite method. We used an 
EXPEDITE Perseptive Biosystems 8909 synthesizer for the syn-
thesis of our GP-modifi ed oligonucleotides and performed our 
syntheses in a 1 μmol scale. A more comprehensive description of 
the synthesis of 2′ -O- modifi ed oligonucleotides has previously 
been reported [ 16 ].
  1.  Check your synthesizer: Refi ll all reagent bottles and required 
solvents or replace empty bottles, check Argon supply, check 
waste. 
  2.  Dissolve the applied phosphoramidites with amidite diluent 
(anhydrous acetonitrile) and attach them to the synthesizer 
according to manufacturer’s information. 
  3.  Program your synthesizer as specifi ed by the manufacturer. 
Use the standard RNA cycle for unmodifi ed nucleotides. Use 
a prolonged coupling time of 25 min for GP-modifi ed phos-
phoramidites. After synthesis is completed, an additional 
deprotection step with deblock solution (3 % trichloroacetic 
acid in dichloromethane) for 20 min has to be applied ( see 
 Note 12 ). 
  4.  Fill the synthesis column with an appropriate amount of solid- 
phase material and attach the column to your synthesizer (or 
use prefi lled synthesis columns). 
  5.  Start synthesis. 
  6.  (optional, see  step 3 ): If an additional deprotection step with 
deblock solution after completion of the synthesis cannot be 
programmed, it is necessary to apply this step by manual oper-
ation of the synthesizer ( see  Note 12 ): When the synthesis is 
fi nished, fl ush the synthesis column with deblock solution and 
let it act on the column for 20 min. Then thoroughly purge 
the synthesis column with acetonitrile and dry it with the 
applied inert gas. 
 After deprotection, the RNA is sensitive to RNase degradation. 
Therefore it is recommended to work under RNase-free conditions 
from then on ( see  Note 13 ).
  1.  The solid-phase material is transferred to an appropriate vial. 
  2.  To the solid-phase material 1 mL of a 3:1 mixture of ammo-
nium hydroxide solution (25–33 %) and ethanol is added and 
the mixture is kept at 40 °C for 24 h. This cleaves the RNA 
3.5  Automated 
Solid-Phase Synthesis 
of GP-Modifi ed 
Oligonucleotides
3.6  Deprotection 
of GP-Modifi ed 
Oligonucleotides
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from the solid support and also removes the cyanoethyl groups 
and the protecting groups of the exocyclic amino functions. 
  3.  The supernatant is transferred into a 4 mL vial. The solid-phase 
material is washed with an additional 0.5 mL of the ammonia/
ethanol mixture. After sedimentation the supernatant is again 
transferred into the new vial and the RNA-solution is dried in 
a centrifugal evaporator. 
  4.  The dried RNA is treated with 300 μL of a mixture from 
Et 3 N · 3HF/1-methyl-2-pyrrolidone/Et 3 N (6:3:4, v/v/v) 
and incubated at 60 °C for 90 min. This step removes the 
2′ -O- TBDMS-groups. 
  5.  RNA-precipitation: After cooling to room temperature  n - 
butanol (1.4 mL) is added and the solution is cooled to −80 °C 
for 60 min to facilitate precipitation. 
  6.  The solution is centrifuged at 0 °C for 30 min. 
  7.  The supernatant is discarded and the RNA-pellet is kept for 
further purifi cation. 
 For a more comprehensive description of purifi cation and analytics 
of 2′ -O- modifi ed oligonucleotides we refer again to a previously 
published article [ 16 ].
  1.  Anion-exchange HPLC: The pellet of the deprotected RNA 
(from 3.6) is dissolved in 1-methyl-2-pyrrolidone (200 μL) 
and DEPC-water (200 μL) and purifi ed by AE-HPLC using a 
 Dionex DNA-Pac 100 column (9 mm × 250 mm) (1 M LiCl- 
buffer, DEPC-water, gradient: 0–70 % LiCl-solution in 40 min, 
fl ow: 5 mL/min, column oven: 80 °C). The fraction of the 
desired RNA-oligomer is collected and dried in a centrifugal 
evaporator ( see  Note 14 ). 
  2.  Reverse-phase HPLC: The dried RNA fraction is dissolved in 
DEPC-water (1.5 mL) and purifi ed by RP-HPLC using a 
 Phenomenex Jupiter 4u Proteo 90 Å (15 mm × 250 mm) (0.1 M 
triethylammonium acetate pH 7, acetonitrile, gradient: 0 % 
acetonitrile for 2 min, 0–37 % acetonitrile in 28 min, fl ow: 
6 mL/min). The fraction with the purifi ed RNA is collected 
and dried in a centrifugal evaporator. The RNA is redissolved 
in DEPC- water (500 μL) and dried again, to remove any traces 
of triethylammonium acetate. 
  3.  Quantifi cation: The RNA is dissolved in a specifi c volume of 
DEPC-water. The OD (optical density) is measured in a con-
ventional UV spectrophotometer or with a NanoDrop 
Instrument at 260 nm. For appropriate values of the OD, the 
RNA-solution may need to be diluted. The concentration of 
the RNA-solution is calculated by the formula:  c = OD 260 / ε ×  d , 
where  ε is the extinction coeffi cient of the oligonucleotide and 
3.7  Purifi cation 
and Analytics 
of GP-Modifi ed 
Oligonucleotides
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 d is the length of the light path through the sample. The 
extinction coeffi cient of the RNA oligonucleotides was calcu-
lated using the nearest neighbor method. 
  4.  Identity of the RNA was confi rmed by mass spectrometry. We 
used  Bruker micrOTOF-Q II. Four hundred picomoles of 
RNA was diluted with DEPC-water to a sample volume of 
20 μL. The sample was applied to the mass spectrometer by the 
use of an attached HPLC-system. The measuring procedure 
included an integrated desalting step on a short RP-column 
previous to injection into the ion source. 
 Procedures to defi ne the exact site of cleavage by a siRNA that is 
perfectly matched to its target cognate are illustrated schematically 
in  Fig.  1 .
3.8  Analysis 
of RNAi- Mediated 
Target Cleavage by 
GP-Modifi ed siRNAs 
Using 5′ RACE
 Fig. 1  Schematic illustration of the 5′ RACE protocol. After transfection of cells 
with siRNA sequences, total RNA is isolated approximately two days later. 
Ligation of the RNA oligonucleotide to the 5′ end of the cleaved target is followed 
by reverse transcription using a gene specifi c reverse primer. The cDNA is then 
used as template for PCR amplifi cation with a primer specifi c to the ligated RNA 
oligonucleotide-derived sequence and a reverse gene specifi c primer. The ampli-
cons are then inserted into a plasmid and a representative number of positive 
clones, approximately 10, subjected to sequencing analysis 
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 A day before transfection, seed Huh7 cells in 24-well plates at a 
confl uency of 40 %. Cells should be cultured in Dulbecco’s modi-
fi ed essential medium (DMEM, Lonza, Basel, Switzerland) supple-
mented with 10 % FCS (Gibco BRL, UK). Incubation is in a 
humidifi ed atmosphere at 37 °C with 5 % CO 2 . siRNAs are trans-
fected at a fi nal concentration of 10 nM. For a single well of a 
24-well plate prepare transfection mixes as follows: mix 100 ng of 
target plasmid (pCH-9/3091), 100 ng of marker plasmid (pCI-
neo- eGFP) and 20 pmol of the respective siRNA duplex (approxi-
mately 32.5 ng) and add Opti MEM ® up to a volume of 
50 μL. Dilute 0.3 μL of Lipofectamine ® 2000 in 50 μL of Opti 
MEM ® . The ratio of Lipofectamine to plasmid DNA is 1:1 
(mL:mg), while that of Lipofectamine to siRNAs is 3:1 (mL:mg). 
Mix the nucleic acid/Opti MEM ® and the Lipofectamine/Opti 
MEM ® by vortexing and incubate at room temperature for 5 min. 
Add 50 μL of the Lipofectamine/Opti MEM ® solution to 50 μL 
of the nucleic acid/Opti MEM ® , briefl y vortex and incubate at 
room temperature for 35 min. Transfections are typically carried 
out in triplicate and transfection mixes are scaled-up accordingly. 
For transfection, dispense 100 μL of the transfection mix to each 
well. Gently mix by shaking and incubate for 48 h. For all studies, 
include unmodifi ed and scrambled siRNAs as positive and negative 
controls, respectively. 
 Perform the 5′ RACE technique using reagents from the 
GeneRacer™ kit (Invitrogen, CA, USA) and procedures described 
by the supplier. Add 7 μL of total RNA (100 ng/μL) to a tube 
containing the aliquot of lyophilized GeneRacer™ RNA Oligo 
(0.25 μg), mix thoroughly, collect the solution by brief centrifuga-
tion and incubate at 65 °C for 5 min. Thereafter, place on ice for 
2 min, add 1 μL of Ligase Buffer (10×), 1 μL ATP (10 mM), 1 μL 
RNaseOut™ (40 U/μL), 1 μL of T4 RNA ligase (5 U/μL) and 
incubate at 37 °C for 1 h. 
 After incubation, add 90 μL of nuclease-free water, 100 μL 
phenol-chloroform and mix vigorously by vortexing for 30 s. 
Centrifuge the mixture at 15,000 ×  g for 5 min at room tempera-
ture. Transfer the upper aqueous phase (about 100 μL) to a fresh 
tube. Add 2 μL of mussel glycogen (10 mg/mL) and 10 μL 3 M 
sodium acetate (pH 5.2) and mix gently. Add 220 μL of 95 % etha-
nol, mix and incubate overnight at −20 °C. Collect the RNA by 
centrifugation at 15,000 ×  g for 20 min at 4 °C and discard the 
supernatant. Wash the pellet with 500 μL of 70 % ethanol and cen-
trifuge at 15,000 ×  g for 2 min. Gently remove the ethanol, air-dry 
the pellet at room temperature for 2 min, resuspend the ligated 
RNA in 10 μL nuclease-free water and keep at −70 °C until required. 
 Unless otherwise indicated all reagents were supplied with the 
GeneRacer™ kit (Invitrogen, CA, USA). To tubes containing 
10 μL of ligated RNA add 1 μL of the reverse gene specifi c primer 
3.8.1  Cell Culture, 
Transfection, and RNA 
Extraction
3.8.2  Ligation of RNA 
to GeneRacer™ RNA Oligo
3.8.3  Reverse 
Transcription of Ligated 
RNA
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(10 μM, 5′-AGGGTCGATGTCCATGCCCC-3′, Integrated 
DNA Technologies, Iowa, USA ( see  Note 3 ), 1 μL dNTP mix (at 
10 mM each) and 1 μL of nuclease-free water. Incubate the mix-
ture at 65 °C for 5 min then place on ice for 2 min. Subsequently, 
add 4 μL of First Strand Buffer (5×), 1 μL (0.1 M DTT), 1 μL 
RNaseOut™ (40 U/μL) and 1 μL SuperScript™ III RT (200 U/
μL) and incubate at 55 °C for 1 h. Inactivate the reaction by incu-
bating at 70 °C for 15 min then place on ice for 2 min. Add 1 μL 
of RNase H (2 U) and incubate at 37 °C for 20 min. Prepare 
10 μL aliquots of each cDNA sample and store at −20 °C until 
required for use. 
 Amplify the cDNA template using Platinum ®  Taq High Fidelity 
DNA Polymerase (Invitrogen, CA, USA). Make up the reaction 
mix in a total volume of 25 μL comprising 2.5 μL High Fidelity 
PCR Buffer (10×), 0.5 μL dNTP solution (at 10 mM each), 1.5 μL 
of the forward GeneRacer™ primer (10 μM, 5′-CGACTGGA
GCACGAGGACACTGA-3′), 0.5 μL of the reverse gene specifi c 
PCR primer (10 μM, 5′-CAAGAGATGATTAGGCAGAGGTG-3′, 
Integrated DNA Technologies, Iowa, USA), 0.25 μL Platinum ® 
 Taq High Fidelity DNA Polymerase (5 U/μL), 1.25 μL cDNA and 
18.5 μL of nuclease- free water. Perform amplifi cation reactions 
using a PCR thermocycler (T100™ Thermal Cycler, BIORAD, 
CA, USA) with the following cycling conditions: one cycle of 
94 °C for 3 min (initial denaturation), 35 cycles of 94 °C for 30 s 
(denaturation), 63 °C for 30 s (annealing) and 72 °C for 1 min 
(extension). Perform the fi nal extension step at 72 °C for 10 min 
( see  Note 15 ). Electrophorese 10 μL of the samples on a 2 % aga-
rose gel at 100 V for approximately 30 min and visualize the ampli-
fi ed PCR products under UV transillumination (Syngene G:Box, 
SYNGENE, UK) (Fig.  2 ).
 Purifi cation of the PCR products is carried out according to proce-
dures recommended by the supplier of the MinElute Gel Extraction 
kit (Qiagen, MD, USA) with minor modifi cations. Briefl y, cut the 
band containing the PCR product from the gel using a clean sharp 
blade. Weigh the gel slice and add 3 volumes of QG buffer. Melt 
the agarose by incubating the tube at 55 °C for approximately 
5 min. Add an equal gel volume of isopropanol, mix and apply to 
the spin column. Centrifuge for 1 min at room temperature then 
discard the fl ow through. Apply 500 μL of QG buffer to the col-
umn and centrifuge at 10,000 ×  g . Discard the fl ow through and 
then wash with 750 μL of PE buffer. After discarding the fl ow 
through, recentrifuge for 1 min at 10,000 ×  g . Place the column in 
a fresh 1.7 mL tube and add 50 μL of water to the column matrix. 
Incubate for 2 min at room temperature then elute the DNA by 
centrifugation. 
3.8.4  Amplifi cation 
of cDNA by 5′ RACE-PCR
3.8.5  Gel Extraction 
of PCR Products 
and Inserting Them into 
the pTZ57R/T Plasmid
Synthesis of Guanidinopropyl-Modifi ed siRNAs
244
 Ligate the purifi ed PCR products to the pTZ57R/T plasmid 
(Thermo Scientifi c, MA, USA) in a total reaction volume of 30 μL 
comprising 6 μL Ligation Buffer (5×), 1 μL T4 DNA ligase 
(Thermo Scientifi c, MA, USA) (5 U/μL), 3 μL of pTZ57R/T 
plasmid (0.17 pmol ends), 5 μL of purifi ed 5′ RACE PCR product 
and 15 μL nuclease-free water. Incubate overnight at 
14 °C. Transform 100 μL of chemically competent bacteria (e.g. 
DH5α, Invitrogen, CA, USA) with 10 μL of ligation reaction and 
spread on ampicillin-containing Luria Bertani agar plates impreg-
nated with 5-bromo-4-chloro-3-indolyl-β- D -galactopyranoside 
(X-gal) (US BIOLOGICAL Life Sciences, MA, USA) and Isopropyl 
β- D -1-thiogalactopyranoside (IPTG) (Sigma, MO, USA). Incubate 
 Fig. 2  Representative data from 5′ RACE analysis of RNA targeted by siRNA modifi ed with a GP residue in 
position 3 from the 5′ end of the guide strand GP3 siRNA3. The GP3 siRNA3 targeted a sequence within the 
 HBx region of HBV. ( a ) Agarose gel resolution of DNA amplifi ed after reverse transcription of RNA comprising 
the RNA linker oligonucleotide ligated to the downstream target RNA. The reverse primer was specifi c to the 
HBV target sequence and the forward primer hybridized to complementary sequences of the oligonucleotide 
linker. Controls to verify specifi city of the reaction included RNA extracted from cells that had been transfected 
with unmodifi ed siRNA3 targeting the HBV sequence, a scrambled siRNA that did not target any known gene 
and no template cDNA. ( b ) Sequence of the HBV target region with sequence complementary to GP3 siRNA3 
indicated in  italic font . Sequence of the RNA oligonucleotide and amplicon are indicated  below . The junction of 
the oligonucleotide and target sequence indicates the site of cleavage mediated by GP3 siRNA3 
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overnight at 37 °C then pick ten individual white colonies using 
sterile procedures. Inoculate each into 10 mL of ampicillin-con-
taining Luria Bertani broth and incubate overnight at 37 °C with 
shaking. Perform standard mini preparations of each cloned 
plasmid. 
 Screen for positive clones by digesting with  ApaL I restriction 
enzyme ( see  Note 16 ) in a total reaction volume of 20 μL compris-
ing 2 μL of Fast Digest Buffer (10×), 2 μL Fast Digest  ApaL I 
(1 U/μL) (Thermo Scientifi c, MA, USA), 5 μL of plasmid DNA 
(200 ng/μL) and 11 μL of water. Incubate the samples at 37 °C 
for about 30 min. Electrophorese 10 μL of each sample on a 2 % 
agarose gel at 100 V for approximately 30 min and visualize under 
UV transillumination (Syngene G:Box, SYNGENE, UK). Presence 
of two DNA fragments of 1,859 bp and 1,246 bp indicates suc-
cessful cloning of the PCR products into pTZ57R/T ( see  Note 
16 ). Select the positive plasmid clones for automated sequencing. 
Presence of sequences derived from both the ligated GeneRacer™ 
RNA oligonucleotide and predicted mRNA cleavage product 
indicates specifi c RNAi-mediated cleavage of the target by 
GP-containing siRNAs (see example shown in Fig.  2 ). 
4  Notes 
  1.  We purchased solid 5-ethylthiotetrazole (e.g. from  Azco Biotech 
Inc. ) to be able to make our own solution with a particular 
concentration of 0.35 M. There are also ready-to-use solutions 
available with a 5-ethylthiotetrazole concentration of 
0.25 M. These solutions can also be used, maybe with slightly 
less coupling effi ciency for the modifi ed phosphoramidites. 
  2.  Plasmids are selected according to the specifi c requirements of 
the assay. In the example here we used an HBV replication- 
competent target plasmid (pCH-9/3091) [ 14 ] in conjunction 
with a GFP reporter plasmid [ 15 ] to verify transfection 
effi ciency. 
  3.  Gene-specifi c primers should be designed according to the 
sequence of the gene under investigation. They should com-
plement a sequence at least 200 bases downstream of the 
intended siRNA cleavage site and the Tm suitable for use dur-
ing reverse transcription at 42 °C. Short primers of 16–20 
bases are typically preferred. 
  4.  For the chemical syntheses it is necessary to use anhydrous 
solvents and to work with an inert gas atmosphere, because 
many of the reagents are sensitive to hydrolysis. 
  5.  Reduction with activated Ni-catalyst and hydrogen. The 
hydrogenation step is sensitive to reaction conditions such as 
3.8.6  Screening 
for Positive Clones Using 
ApaLI
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the ratio of amount of starting material to catalyst, the size of 
the employed autoclave and reaction time. Under optimized 
conditions, yields for reduction of each nucleotide derivative 
were moderate (about 50 %). A loss of the desired product was 
also confi rmed by the observation that part of the amino com-
pound was not released from the catalyst during fi ltration, 
despite being subjected to several washes with methanol. To 
minimize losses the crude unpurifi ed 2′ -O- aminopropyl com-
pounds were used to introduce the guanidino groups in the 
next synthesis step. 
  6.  There might be an alternative way of reducing the 2′ -O -
cyanoethyl groups, if there is no autoclave available or to avoid 
the application of hazardous H 2 and the pyrophoric nickel cat-
alyst. The original procedure was published here [ 17 ,  18 ]. We 
tested this reaction only with the guanosine derivative and with 
2′ -O- cyanomethyl-3′,5′ -O- (tetraisopropyldisiloxane- 1,3-diyl)-
uridine but it may also work with the other nucleosides. The 
yield was only moderate (ca. 30 %). Typical procedure: To 
obtain dry nickel(II)chloride, NiCl 2 · 6H 2 O was placed in a 
round bottom fl ask and was heated carefully under reduced 
pressure with a heat gun until the solid turns golden yellow. 
The nucleoside (3 mmol) was dissolved in anhydrous ethanol 
under inert gas atmosphere and the solution was cooled to 
0 °C. To the stirred solution dry NiCl 2 (3 mmol) was added 
and the sodium borohydride (9 mmol) was added in small por-
tions. A black precipitate is formed. After 1 h the progress of 
the reaction is monitored by TLC and if the conversion is not 
complete, some more sodium borohydride is added. The reac-
tion is stopped by addition of diethylenetriamine (30 mmol) 
and is stirred for another 30 min. The solvent is evaporated 
and the residue is dissolved in ethylacetate, washed twice with 
saturated sodium bicarbonate solution (2 × 80 mL). The 
organic phase is dried over magnesium sulfate, evaporated and 
the residue is purifi ed by silica gel column chromatography 
with dichloromethane/methanol (5:1 (v/v)). 
  7.  When the activated nickel catalyst (Raney-Nickel) is washed 
with methanol, it is important that the catalyst does not com-
pletely dry, because of its pyrophoric properties. Also, take 
great care when opening the autoclave because of the adsorbed 
H 2 in the catalyst. 
  8.  The slightly acidic reaction of silica gel may cause a partial 
deprotection of the DMTr-group during purifi cation. To cir-
cumvent this problem the addition of 0.5 % triethylamine to 
the eluent is recommended. If eluent with 0.5 % triethylamine 
is used for purifi cation of phosphoramidites it is very important 
to completely remove the triethylamine from the purifi ed 
product, because residual triethylamine will deprotonate the 
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5-ethylthiotetrazole in the activator solution of the synthesizer 
and will thereby reduce or completely extinguish coupling effi -
ciency of your phosphoramidite. We only use 0.5 % triethyl-
amine in the solvent used for packing the column while elution 
is performed without triethylamine. 
  9.  The forming precipitate will largely adhere to the glass wall of 
the used fl ask or vessel, so decanting is easy. You have to make 
sure to thoroughly redissolve the entire adhering product for 
purifi cation. 
  10.  Lyophilization can be performed by dissolving the phosphora-
midite in a round bottom fl ask, freezing the solution by dip-
ping and slightly rotating the fl ask in liquid nitrogen. Finally 
the fl ask is connected to a vacuum pump with an intercon-
nected cooling trap. To avoid the use of benzene, it is also 
possible to use dioxane for lyophilization. The dioxane must 
be checked for contamination with peroxides before use, 
because peroxides will oxidize the phosphoramidite to a 
phosphoramidate. 
  11.  In some cases after precipitation (and even after column chro-
matography) the phosphoroamidite still contains some traces 
of hydrolysed phosphorylation agent (H-phosphonate). 
According to our experience, this does not interfere with solid-
phase synthesis. The amount of the impurity can be reduced by 
several consecutive precipitations but this will slightly reduce 
yield. The signal of the H-phosphonate can be observed in  31 P-
NMR at approximately 14 ppm. 
  12.  The function of the additional deprotection step is the cleav-
age of the boc-protecting groups ( tert- butoxycarbonyl-) from 
the guanidino moiety. This is especially required, if the 
GP-modifi cation is introduced at the very end of the oligonu-
cleotide and only few or no consecutive synthesis cycles includ-
ing deprotection will follow. 
  13.  After cleavage from solid support and removal of protecting 
groups, the RNA is sensitive to RNase digestion. To prevent 
the RNA from degradation it is recommended to wear gloves 
and to use RNase-free labware. DEPC-water and RNase-free 
reagents and solutions should be used. For long term storage 
the RNA-solution should be kept at −80 °C. Alternatively the 
RNA can be precipitated or lyophilized again. 
  14.  If a complete 1 μmol synthesis batch of siRNA is purifi ed with 
a  Dionex DNA-Pac 100 column (9 mm × 250 mm), the signals 
will suffer signifi cant signal broadening due to column over-
load. To avoid this problem the siRNA can be purifi ed in 
smaller portions or a bigger column can be used. 
  15.  Thermal cycling conditions vary according to the specifi c 
properties of the sequences to be analyzed. Importantly, the 
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primers should form stable and specifi c pairs with their cognates 
under the cycling conditions that are selected. Protocols giving 
advice on optimizing PCR conditions are widely available and 
a detailed discussion is beyond the scope of this article. 
  16.  Selection of appropriate restriction enzymes for screening of 
plasmid clones should be made according to how the positions 
of their recognition sites relative to the inserted sequence will 
be most informative. The sizes of the electrophoretically 
resolved bands will also be dependent on the positions of the 
restriction sites of the cloned plasmids. 
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SUPPLEMENTARY METHODS: 
7.5.1. Detection of siRNA-mediated HBV cleavage by 5’ RACE 
7.5.1.1. Generation of positive control for 5’ RACE 
The in vitro transcribed RNA was designed to have the same sequence as that of the predicted 
cleaved mRNA product in vitro and served as a positive control for 5’ RACE analysis (Fig. 
7.5A). The template for in vitro transcription was designed to contain the T7 promoter 
immediately upstream of the predicted siRNA3-mediated cleavage product. In vitro 
transcription using T7 RNA polymerase would therefore generate the predicted cleavage 
product. All reagents used for PCR were from Thermo Scientific (Thermo Scientific, MA, 
USA), unless otherwise stated. The in vitro transcribed template was prepared by amplifying 
the target region within pCH-9/3091 (100 ng/µl) with 10 pmol each of the following primer 
pair (Integrated DNA Technologies, IA, USA): forward siRNA3 TF 5’-
GCTAGCTAATACGACTCACTATAGGGAGGCATACTTCAAAGACTGTTTGTT-3’ and 
reverse siRNA3 TR 5’-GCGGCCGCAGGGTCGATGTCCATGCCCCA-3’.  
 
All PCR amplifications were performed in a PCR thermocycler comprised of the following 
cycling conditions: one cycle of 94°C for 3 minutes (initial denaturation), 35 cycles of 94°C 
for 30 seconds (denaturation), 63°C for 30 seconds (annealing) and 72°C for 1 minute 
(extension). The final extension step was performed at 72°C for 10 minutes. Amplified PCR 
products of about 257 bp were subjected to electrophoresis on a 2% agarose gel at 100 volts 
for 45 minutes and visualised under UV transillumination. The PCR products were subjected 
to MinElute Gel Extraction and subsequent cloning into pTZ57R/T plasmid, as described in 
Supplementary Methods Section 5.4.3. Positive clones were identified after digesting 
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plasmids (1 µg) with PvuII (40 U, Thermo Scientific, MA, USA) and NotI (10 U, Thermo 
Scientific, MA, USA) (Fig. 7.5A). Samples were incubated at 37°C for 2 hours and subjected 
to electrophoresis on a 2% agarose gel at 100 volts for 45 minutes and visualised under UV 
transillumination. Generation of three DNA fragments (of approximately 2513 bp, 375 bp 
and 257 bp) indicated successful cloning of PCR products into pTZ57R/T. Sequences of 
positive clones were confirmed by DNA sequencing using the M13 primer pair (Inqaba 
Biotech Industries, South Africa): forward 5’-GTAAAACGACGGCCAGT-3’ and reverse 
5’-CAGGAAACAGCTATGAC-3’. 
 
7.5.1.2. Preparation of in vitro transcribed RNA 
ScaI and HindIII (Thermo Scientific, MA, USA) digestion was performed to produce the 
template for in vitro transcription (Fig. 7.5B). This reaction was performed using DNA (1 
µg), HindIII (40 U) and ScaI (20 U). Samples were incubated for 2 hours at 37°C, resolved 
on a 2% agarose gel at 100 volts for about 45 minutes and visualised under UV 
transillumination. Digestion with HindIII and ScaI produced two DNA fragments of about 
1759 bp and 1386 bp. Thereafter, the smaller fragment of approximately 1386 bp was 
purified using the MinElute Gel Extraction as described in Supplementary Methods Section 
5.4.3.  
 
Samples were subjected to in vitro transcription using the TranscriptAid T7 High Yield 
Transcription Kit (Thermo Scientific, MA, USA) (Fig. 7.5B). This was conducted using 
NTPs (100 mM each), TranScriptAid
TM
 Enzyme Mix and DNA template (1 µg). The reaction 
mixture was briefly centrifuged at 12 000 × g at 4°C for 20 seconds. The sample was 
resolved on a 2% agarose gel at 80 volts for 30 minutes and visualised under UV 
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transillumination. The generated RNA transcripts were purified using the phenol-chloroform 
extraction method as described in Supplementary Methods Section 5.4.1.  
 
7.5.1.3. Detection of siRNA-mediated mRNA cleavage product in vitro by 5’ RACE 
The 5’-RLM-RACE technique was employed to specifically detect the cleaved mRNA 
product in cells transfected with unmodified or GP-modified siRNAs. For this experiment, 
Huh7 cells were maintained, seeded and co-transfected with 100 ng of pCH-9/3091 target 
plasmid, 100 ng pCI-eGFP and 10 nM siRNA (32.5 ng), as described in Supplementary 
Methods Section 4.1. A combination of siRNAs containing a single, double, triple or 
quadruplicate number of GP residues were employed and included: unmodified siRNA3, GP3 
siRNA3, GP4 siRNA3, GP5 siRNA3, GP2.3 siRNA3, GP2.3.17 siRNA3, GP2.5.17.20 
siRNA3 and scrambled siRNA (Table 7.1). The different combinations of GP modifications 
were employed to investigate whether the position or number of GP residues within the 
siRNA would alter the mRNA cleavage site. Total RNA extraction was performed using Tri 
Reagent
®
 at 24-hours post-transfection as described in Supplementary Methods Section 
4.2. Subsequently, ligation and reverse transcription were performed as described in 
Supplementary Methods Section 5.4.1-5.4.2. 
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Table 7.1: The siRNAs employed for 5’ RACE analysis in vitro 
 
7.5.1.4. Amplification of cDNA by 5’ RACE-PCR, cloning and DNA sequencing 
The generated cDNA template was amplified by 5’ RACE-PCR using the Platinum® Taq 
DNA Polymerase High Fidelity kit (Life Technologies, CA, USA). The PCR was performed 
using dNTP solution (10 mM each), 10 pmol each of the forward GeneRacer
TM
 5’ primer (5’-
CGACTGGAGCACGAGGACACTGA-3’; Life Technologies, CA, USA), reverse gene-
specific PCR primer (5’-CAAGAGATGATTAGGCAGAGGTG-3’; Integrated DNA 
Technologies, IA, USA), 0.25 µl Platinum
®
Taq DNA Polymerase High Fidelity (5 U/µl) and 
1.25 µl cDNA template (100 ng/µl). All PCR amplification reactions were performed in a 
thermocycler using the following cycling conditions: one cycle of 94°C for 3 minutes (initial 
denaturation), 35 cycles of denaturation at 94°C for 30 seconds, annealing at 63°C for 30 
seconds and extension at 72°C for 1 minute. The final extension step was performed at 72°C 
Name of siRNA Antisense siRNA sequence 
Unmodified siRNA3 5’-UUG AAG UAU GCC UCA AGG UCG-3’ 
GP3 siRNA3 5’-UUGGP AAG UAU GCC UCA AGG UCG-3’ 
GP4 siRNA3 5’-UUG AGPAG UAU GCC UCA AGG UCG-3’  
GP5 siRNA3 5’-UUG AAGPG UAU GCC UCA AGG UCG-3’  
GP2.3 siRNA3 5’-UUGPGGP AAG UAU GCC UCA AGG UCG-3’ 
GP2.3.17 siRNA3 5’-UUGPGGP AAG UAU GCC UCA AGGPG UCG-3’ 
GP2.5.17.20 siRNA3 5’-UUGPG AAGPG UAU GCC UCA AGGPG UCGPG-3’ 
Scrambled siRNA 5’-GCG AAG UGA CCA GCG AAU AC dT-3’ 
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for 10 minutes. Amplified PCR products were subjected to electrophoresis on a 2% agarose 
gel at 100 volts for 30 minutes and visualised under UV transillumination (Appendix 7.3.1) 
[223]. This was followed by purification of PCR products, cloning into pTZ57R/T plasmid 
and DNA sequencing using the M13 reverse primer, as described in Supplementary 
Methods Section 5.4.3. The positive 5’ RACE product was verified by the presence of 
sequences derived from the ligated GeneRacer
TM
 RNA oligonucleotide and predicted mRNA 
cleavage product (Appendix 7.3.2) [223]. Diagrammatic illustration of the 5’ RACE protocol 
is shown in a study conducted by Buff et al., 2015 [223]. 
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    Generation of 5’ RACE positive control:   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.5A. Generation of positive control for 5’ RACE 
The 5’ RACE positive control was generated by amplifying the region of pCH-9/3091 where 
siRNA-mediated cleavage was predicted to occur. After PCR amplification, the products 
were cloned into pTZ57R/T, followed by screening with PvuII and NotI and positive clones 
confirmed by DNA sequencing.  
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Figure 7.5B. Preparation of in vitro transcribed RNA  
Following cloning into pTZ57R/T, screening with PvuII and NotI, and DNA sequencing, 
positive clones were digested with ScaI and HindIII to produce the template for in vitro 
transcription. Subsequently, samples were subjected to in vitro transcription to generate an 
RNA template possessing the same sequence as that of the predicted mRNA cleavage product 
for use as a positive control for 5’ RACE analysis.  
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